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____________________________________ 
Primary brain tumors are a diverse group of 
malignancies, arising from different cell types 
within the central nervous system (CNS). They 
display a large heterogeneity, both between 
patients as within one tumor. Because of this heterogeneity, more than 100 different 
(sub)types of brain tumors have been identified. Until recently, CNS tumor classification was 
based mainly on histopathological features 1. However, it was recognized that genetic and 
epigenetic aberrations should be added to the 2007 classification as findings from large-scale 
genomic studies and epigenetic profiling have identified human glioblastoma genes and core 
pathways involved in glioma genesis 2–6. This has resulted in the renewed 2016 WHO 
classification where schemes for the diagnosis of CNS tumors include genetic and epigenetic 
signatures and diagnosis is based on a layered, morphological-molecular diagnostic approach 
7,8. Besides heterogeneity between patients, there is also a great intra-tumoral 
heterogeneity. This is reflected already by the old name of the most common primary brain 
tumor, glioblastoma multiforme (GBM), in which multiform indicated the many different 
aspects which are presented in these tumors 4,9–13. Treatment of patients is hampered by this 
heterogeneous appearance of the tumors, as well as by the location of the tumor within the 
delicate brain tissue. Also, intrinsic and acquired resistance to treatment and the presence 
of the blood-brain-barrier (BBB) represent major challenges in the treatment of these 
patients.  
 
In this thesis, we focus on improving therapy of pediatric medulloblastoma and diffuse 
intrinsic pontine glioma and adult glioblastoma by novel treatment strategies. In order to 
quantify and visualize the tumor progression, advanced imaging tools were used to monitor 
therapeutic efficacy. 
 
 
____________________________________ 
Brain tumors are the most common solid 
tumors in children accounting for the majority 
of cancer related deaths in this age group. Most 
pediatric brain tumors are primary tumors, 
thus originating in the CNS. Childhood brain tumors frequently appear in different locations 
and behave differently than brain tumors in adults. In children, 15.1% of the brain tumors 
are  located in the cerebellum, and a proportion of 10.1% of the tumors is located in the brain 
stem 14. The most common pediatric brain tumors are embryonic tumors: In order of 
increasing age, the most prominent ones are medulloblastoma in children age 0-4 years; 
pilocytic astrocytoma at ages 5-9 years and malignant glioma in age group 10-14 years 15. 
INTRODUCTION 
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Treatment options vary between tumor type and are strongly influenced by the age of the 
child. Although, in some occasions the prognosis for children with brain tumors is much 
better than for adults with similar conditions, adverse side effects of the anti-cancer therapy 
could limit treatment efficacy, especially in young children. Unfortunately, for a subset of 
childhood tumors, such as pediatric high grade gliomas (pHGG), patient outcome is still 
dismal as 70-90% of these patients die within 2 years of diagnosis 15–19 
 
Diffuse pontine glioma 
Diffuse pontine glioma (DIPG) is a high-grade glioma in the brainstem, mostly in children. 
With the new 2016 WHO classification, these tumors are included in the group of diffuse 
midline glioma. However, because this new nomenclature is not common practice yet, the 
old name, DIPG, will still be used throughout this thesis. Although DIPG is rare, approximately 
10 children per year in The Netherlands, this disease is the most deadly pediatric neoplasm, 
with a 5 years survival approaching to zero percent 20,21. The symptoms of DIPG usually 
develop rapidly before diagnosis, thus reflecting the fast growth and location of these 
tumors. These symptoms include problems in controlling eye movements, speech, chewing 
and swallowing; weakness in arms and legs and subsequent problems with walking and 
coordination. The diagnosis is based on MRI, but conventional MRI cannot predict survival in 
childhood DIPG 22. In 2012, several genomic studies of DIPG tissue have identified mutations 
in genes encoding histone 3 6,23. These H3K27 alterations appeared as the founding event in 
DIPG. Two main histone H3 variants can be identified which drive two distinct oncogenic 
programmes: The H3.3-K27M-mutated DIPG -which has a proneural/oligodendroglial 
phenotype and a pro-metastatic gene expression with PDGFRA activation-, and the H3.1-
K27M-mutated DIPG -which exhibit a mesenchymal/astrocytic phenotype and a pro-
angiogenic/hypoxic signature-.  Patients with tumors harboring the K27M mutation in H3.3 
(H3F3A) have an even worse clinical response as those with a mutation in H3.1 (HIST1H3b/C). 
The patients with the H3F3A variant relapsed significantly earlier and exhibited more 
metastatic recurrences than those patients with H3.1  variant 4,24,25.  
Because DIPG is incurable, most treatments are mainly palliative. There are no strict 
guidelines for the treatment of DIPG, resulting in individualized therapy and a heterogeneous 
application of treatment schedules. Most DIPG patients are treated with radiotherapy or by 
combined radiotherapy/chemotherapy. The most widely prescribed chemotherapeutic 
agents are temozolomide and vincristine/carboplatin. 20. Surgical resection is not possible 
due to the location of the tumor.  With current therapies, the median overall survival is only 
9.5 months. 
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Medulloblastoma   
Medulloblastomas, a highly aggressive WHO-grade IV embryonal tumor, located in the 
cerebellum, are mainly occurring in the first decade of life, with a peak incidence between 0 
and 4 years of age. Medulloblastomas constitute 15-20% of all childhood brain malignancies. 
Currently risk stratification into high- and standard risk groups primarily depended on 
variables such as age, presence of metastasis, extent of resection and histological subtypes 
26,27. More recently, molecular characterization showed that medulloblastomas can be 
classified into four subgroups: WNT-activated, SHH-activated, Group 3 and Group 4. The 
SHH-activated subgroup can be divided further into TP53-mutant and TP53-wildtype 
subgroups 8–10,28–30. These classifications allow the definition of risk groups based on current 
survival rates. Patients with WNT-activated subtype have the best prognosis (>90% survival) 
whereas patients of Group 3 with metastasis and patients of SHH-activated with PT53-
mutations have the worst prognosis of all subtypes with a 5-year overall survival of 50% 26.  
Treatment consists of surgical removal of as much of the tumor as feasible, followed by 
craniospinal radiation and adjuvant chemotherapy. Based on the age of the child, extent of 
surgical resection and metastasis, a patient is assigned to either the standard risk group or 
the high-risk group. Standard risk patients are treated with reduce-dose radiation (23.4 Gy) 
whereas high risk patients are treated with a higher radiation dose (36 Gy). Adjuvant 
chemotherapy consists of different combinations of therapeutic agents, including cisplatin, 
lomustine, vincristine, cyclophosphamide and etoposide 31,32.  Very young children, generally 
defined as those less than 3 years of age, are typically not treated by radiotherapy due to the 
devastating neurocognitive outcome associated with this treatment. Patients in this age 
group  are treated by chemotherapy only,  to delay or avoid the radiotherapy 17,33–35. Other 
means to limit exposure of healthy tissue to the harmful radiation include technical 
advantages in radiation equipment such as stereotactic radiosurgery and strategies to 
enhance radiotherapeutic efficacy by so called radiosensitizers, including quercetin and 
protein kinase inhibition such as the WEE1 or MRK/ZAK pathways 36–39. With current 
therapies, 70-80% of children with average risk medulloblastoma have a 5 years progression 
free survival. And even in high-risk patients, long term PFS is 60-65% 34. New understanding 
of the biology of medulloblastoma and the classification into distinct molecular subtypes will 
further facilitate the stratification of patients to the optimal treatment options.  
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    ____________________________________ 
Glioblastoma (GBM) is the most common and 
aggressive primary brain tumor in adults. GBM 
can develop both de novo or via progression 
from primary low-grade glioma (LGG). Median 
age of diagnosis of primary GBMs is 62 years whereas secondary GBMs are often diagnosed 
in younger patients at a median age of 44 years 8. The incidence is slightly higher in males 
than in females (ratio 1.6 to 1). GBMs are generally located in the cerebral hemispheres and 
show an infiltrative growth. The tumors are histologically characterized by nuclear atypia, 
mitoses, endothelial proliferation and/or necrosis 40. Within one tumor, many different 
aspects could be present simultaneously. This heterogeneity might be represented by area-
specific chromosome aberrations, mutations and gene-expression profiles 41–43. Three key 
signaling pathways are deregulated, namely the RB (retinoblastoma), p53 and 
RTK/RAS/PI(3)K pathways 2. Amplification of the epidermal growth factor receptor (EGFR) 
gene is the most frequent genetic change associated with GBM, which results in over-
expression of the transmembrane tyrosine kinase receptor. The amplified EGFR frequently 
expresses EGFRvIII, a truncated variant of the receptor which is constitutive activated 
without necessity of ligand binding.  EGFRvIII has been shown to increase proliferation and 
migration of GBM cells. Cells expressing EGFRvIII cause wild-type EGFR-expressing cells to 
accelerate their proliferation by upregulation of IL-6. Furthermore, EGFRvIII can promote 
angiogenesis by activation of the src oncogene 44–46.  
In the 2016 CNS WHO classification, glioblastomas are divided into IDH-wildtype and IDH-
mutant. The IDH-wildtype are about 90% of the GBM cases and corresponds closely to 
primary GBM. Patients in this subgroup have a median survival of 15 months after treatment 
with surgery, radiotherapy and chemotherapy.  Commonly found mutations are in the TERT 
promotor (72%), TP53 (27%), EGFR amplification (35%) and PTEN mutations. IDH-mutant 
GBM corresponds closely to secondary GBMs. Median survival of these patients is 31 months 
after treatment. Typical genetic alterations include ATRX mutations (71%), TP53 mutations 
(81%). Patients with GBM are treated by a combination of surgery, radiation and 
chemotherapy. Due to the delicate region and infiltrative nature of GBM, radical surgery is 
never possible and inevitably some tumor cells will remain behind, which will give rise to 
tumor recurrence. The introduction of radiotherapy after surgical resection improved brain 
cancer treatment. In the case of GBM, radiotherapy was the first postsurgical adjuvant 
therapy that consistently demonstrated efficacy, typically doubling median survival from 4 – 
6 months to 10 – 11 months 47. Adding temozolomide (TMZ) chemotherapy has resulted in a 
further increase of median survival to 15.6 months after diagnosis. The current standard of 
care for GBM treatment is surgical resection to the maximal extent feasible, followed by 
radiotherapy concomitantly with temozolomide (TMZ) therapy and followed by six additional 
cycles of adjuvant TMZ alone 48,49. TMZ is an alkylating/methylating agent of DNA. This 
ADULT BRAIN 
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methylation damages the DNA which causes death of the cell. Unfortunately, TMZ therapy 
delays tumor relapse and consequent improvement of survival in only a part of the GBM 
patient population. One explanation for this therapy resistance is the presence of a DNA 
repair mechanism in the treated cells, such as expression of O-6-alkylguanine DNA alkyl 
transferase (AGT) which is encoded by the methylguanine-DNA methyltransferase (MGMT) 
gene. AGT removes the alkyl groups from the O6 position of guanine residues, thus 
decreasing the therapeutic efficacy of TMZ. Epigenetic silencing of the MGMT promoter by 
methylation diminishes AGT expression and has been associated with longer survival of 
patients treated with alkylating agents. This methylation status of the MGMT promoter has 
shown to be a predictor of TMZ efficacy. However, this MGMT status is not the only factor 
involved in therapy resistance, paving the way for additional research to improve current 
therapies 50,51. 
 
 
 
____________________________________ 
Many chemotherapies which are effective in non-
CNS malignancies, are ineffective in brain tumor 
treatment. One obstacle to brain tumor 
treatment is the existence of the blood-brain 
barrier. Under normal circumstances, this barrier functions as a ‘filter’ to protect the brain 
from harmful substances. However, this barrier also prevents chemotherapy and other drugs 
to reach the brain in patients, thereby rendering the tumor resistant to therapy. One way to 
circumvent this BBB and allow effective delivery of pharmaceuticals at the tumor location is 
by convection-enhanced delivery (CED). With this technique, the pharmaceutical compound 
is administered under constant pressure into the tumor, and adjacent brain tissue. The 
volume of CED, and the placement of the catheters through which the compound is injected, 
are chosen such that the compound will reach the whole tumor core 52,53. Besides a means 
to pass the BBB, CED is also useful for compounds which have severe systemic toxic effects. 
Due to the direct administration into the brain tumor, high local concentrations will be 
achieved whereas systemic levels are minimal 54,55. Other methods which are explored to 
deliver compounds across the BBB into a brain tumor are the use of PEGylated vesicles  and 
the use of viruses as delivery vehicle 56–58. Also, ways to temporarily disrupt the BBB, thus 
allowing the compounds to pass this BBB, are evaluated. These include the use of 
microbubbles which can be activated locally by ultrasound to disrupt the BBB as well as 
methods such as TNF injections or high osmotic fluids which will open the BBB temporarily 
59–63. 
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Currently, most therapies, including radiotherapy and TMZ chemotherapy are mainly 
targeted towards dividing cells. But cancer cells are not solely dividing cells. Cascades of 
aberrant signals within the cancer cells promote survival, accelerate growth, recruit blood 
vessels, enhance nourishment (Warburg effect), educate the immune system towards a pro-
tumorigenic environment and lead to other effects which sustain life of the cancer cell 64,65. 
Consequently, many of these aspects are potential targets for therapies in the treatment of 
cancer. An example of this is anti-angiogenic therapy. As GBMs are highly vascularized, it was 
postulated that inhibition of angiogenic factors, particularly VEGF, would be an effective way 
to control this disease. VEGF is upregulated in response to hypoxia, although overexpression 
of oncogenes (Src, ras) or the absence of tumor suppressor genes (p53) can also upregulate 
VEGF expression. Several strategies to target VEGF have been developed. Reduction of the 
amount of available extracellular VEGF is accomplished by anti-VEGF antibodies like 
bevacizumab or the use of soluble receptors like aflibercept. Other strategies are directed 
towards the VEGF-receptor, such as vandetanib and sunitinib. Also, methods to target the 
VEGF induced intracellular signaling pathways such as phosphatidylinositol-3-kinase (PI3K), 
Akt and ERK pathways. Although anti-angiogenic therapies were effective in some glioma 
animal models, experiences with anti-angiogenic mono-therapies were disappointing. This 
might be due to the fact that tumors may use alternative ways, such as vessel co-option, to 
obtain blood supply  or the fact that even single GBM cells have the capacity to migrate, thus 
escaping hypoxic areas 66–69. Anti-angiogenesis treatment may also lead to ischemic stress 
which attracts and activates pro-tumorigenic macrophages. 
 
Besides the BBB and angiogenesis, other factors play a role in the poor response of brain 
tumors to treatment. Intratumoral heterogeneity, which is the presence of multiple, 
epigenetically and genetically different subpopulations of cells within a single tumor, might 
contribute largely to treatment failure 70. This heterogeneity may result in tumors where 
multiple driver receptor tyrosine kinase (RTK) amplifications are presented and activated in 
adjacent tumor cells. Similarly, intercellular heterogeneous expression of the MGMT DNA 
repair gene has been shown in pediatric medulloblastoma where MGMT positive and MGMT 
negative cells were intermingled 71. Transfer of these driver mutations or transfer of MGMT 
repair system from therapy resistant cells towards more sensitive cells plays a role in 
treatment failure. This tumor heterogeneity prompts for the use of combinations of 
treatments against several targets, either simultaneous or consecutive. As therapy resistance 
can be transferred from one cell to another 72–74, novel ways to block this transfer of 
resistance are being explored to enhance therapy efficacy. 
 
Another major factor in tumor progression is the role of the immune system. In normal 
situations, the immune system removes abnormal cells before they transform into cancer 
cells. However, tumor cells have not only escaped this immune surveillance, but merely 
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educated the immune cells to enhance tumor growth 75–77. In GBM, up to 30% of the tumor 
bulk consists of tumor associated macrophages/microglia (TAMs). These TAMs stimulate 
angiogenesis and drive the T-cells towards an anti-inflammatory Th2 response 78,79. In 
preclinical research, reduction of the number of TAMs by engagement of CSF-1R was 
effective in delaying tumor progression, but also other immune therapeutically approaches 
are being explored in the context of brain tumor therapy 76,80,81. 
 
 
 
____________________________________ 
 Cancer cell lines are pivotal to study biochemical 
pathways in vitro. With the use of human and 
animal cancer cell lines, many fundamental 
questions about tumor development and 
progression have been raised, and answered. However, when one wants to study the 
complex interplay of tumor cells and their micro-environment, effects of the blood-brain-
barrier or adverse effects on a organism, animal models are inevitable. These animal models 
are tools to translate knowledge from in vitro research towards clinical practice as they 
provide means to characterize physiological interactions where in vitro systems are 
insufficient to answer these interactions 82. Animal models are used to address scientific 
questions, evaluate pharmacokinetics, efficacy and safety of novel therapeutics, and 
biomarker discovery. These models include chicken embryo chorioallantoic membrane 
(CAM) assay, zebrafish , dogs, rat and mouse models 83–85. Ideally animal models for brain 
tumor research should recapitulate the complexity of the human body and brain, and reflect 
all aspects of human brain tumors including initiation and progression of tumor, migration of 
tumor cells, presence of relevant tumor markers, and interaction with the micro-
environment, thus covering the diversity of all human brain tumor types and furthermore 
reflecting the intratumoral heterogeneity as seen in humans 86,87. 
 
For most preclinical animal research, the mouse is the experimental model of choice. Great 
advantages of the mouse as experimental models are the highly developed methodology for 
genetic manipulation, and the wide availability of mouse specific reagents, such as 
antibodies. Moreover, the possibility to use immune deficient mice with xenografts of human 
tissues makes mouse models particularly attractive for oncology research. These arguments 
already recapitulate two of the most used strategies to reproduce brain tumors in animals 
which will be described below namely genetically-engineered mouse models and (xenograft) 
transplantation models. 
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Genetically-engineered mouse models (GEMMs) 
Genetically-engineered mouse models (GEMMs) include transgenic-, knockout- and knockin 
mouse models. GEMMs are a valuable tool for determining target function, verifying 
selectivity, predicting toxicity and drug discovery 88. These models have the advantages of 
defined genetic modifications that are known to be involved in human malignancies. 
Furthermore, GEMMs develop reliably tumors at the correct anatomical site, and have 
properties very similar to those of their human counterpart 89. Development of the first 
patented animal, the OncoMouse 90, made it possible to study the role of oncogenes and 
environmental stimuli which are necessary for tumor development and progression. Since 
the introduction of technologies to culture mouse blastocyst cells and the genetic 
modification technologies in the 1980s, thousands of models have been generated. Another 
important milestone in the development of GEMMs was the Cre/LoxP system 91,92. This 
technique offers the advent of inducible transgenic systems, thus allowing temporal and 
spatial regulation of gene-expression. At that time, appropriate engineering of these genetic 
models was still cumbersome and time consuming. Nowadays, much faster production of 
transgenic animals can be obtained by current genetic modification techniques using 
CRISPR/Cas9 or TALENs-mediated genome editing 93,94.  
Despite the aforementioned advantages, GEMMs do not cover all aspects of brain tumors. 
GEMMs are generated for only a single, known target or at most a limited combination of 
targets. Furthermore, GEMMS do not reflect the tumor heterogeneity found in human 
cancers.  One approach to reflect better the initiation of cancer is by a less targeted way of 
tumor induction. For instance by injection of tumorigenic viruses into the brain or by injection 
of chemicals 95,96.  This will result in a more random tumor induction and may present better 
the natural tumor initiation. Due to this more random tumor initiation, likely an 
inhomogeneous tumor will develop which reflects biological tumor heterogeneity. 
 
Transplantation models 
Xenograft transplantation of patient derived tumor material into immune compromised mice 
give tumors that partially retain histological features and molecular characteristics of human 
cancer. Tumor cells of different types or subtypes of brain tumors can be injected into 
immune compromised animals, thus giving raise of human tumors. When primary cells, e.g. 
directly obtained from biopsy, autopsy or surgery are used, part of the intratumoral 
heterogeneity will be covered by the full grown xenografted tumor 97. Traditionally, new 
treatments were often assessed in subcutaneous tumor models (heterotopic) due to their 
convenience, low costs and wide availability 98–100.  But, as recognized already long ago, to 
duplicate in vivo conditions even better, brain tumors should be transplanted into the brains 
of mice 101,102. These orthotopic xenografts have proven to be valuable for identification of 
new therapeutic strategies in many occasions.  
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Most often, xenograft studies are performed in immune deficient nude or scid mice. 
However, a disadvantage of immune compromised mice is the lack or altered tumor 
immunology and the absence of a natural microenvironment.  Although human xenograft 
models in immune competent mice has been described to be feasible and it was shown that 
these models recapitulates glioblastoma-microenvironment interactions 103, more often 
syngeneic murine models are being used to study immunological interactions and 
immunotherapy 104,105. In these syngeneic mouse models, murine cancer cells are injected 
into immune competent mice which allows the evaluation of immunological based therapies. 
Alternatively, the use of humanized mice could be considered to study the role of immune 
therapeutically approaches 106,107. 
 
 
____________________________________ 
Beyond advancing our knowledge about basic 
cancer biology, mouse tumor models also 
comprise a stringent means to evaluate the in 
vivo efficacy of therapeutic intervention 
strategies. As described by De Jong et al, translation of in vitro research to clinical practice is 
mainly a two-step procedure. During the first step, where translation from laboratory 
findings towards preclinical models takes place, imaging tools such as bioluminescent 
imaging, fluorescent imaging and intravital microscopy play a major role. During the second 
step, where preclinical in vivo findings are translated to clinical findings, a more prominent 
role is given to imaging techniques which are also being used in the clinic 82. The most 
efficient way of utilizing mouse models is through longitudinal studies. Through application 
of a suite of imaging techniques, it is now possible to measure a broad range of tumor-
relevant parameters in a single animal at different time points. The greatest advantages of 
preclinical imaging techniques include the reduction of biological variability along with the 
substantial reduction in the number of animals required for a particular study, fully 
complying with 3R (Replacement, Reduction and Refinement) policies 108,109.  
 
To visualize and quantify progression of disease, numerous techniques are available for 
preclinical imaging, including positron emitting tomography (PET), computed tomography 
(CT), magnetic resonance imaging (MRI), bioluminescence imaging (BLI) and intravital 
microscopy (IVM). Except for IVM and BLI, these imaging modalities are also widely used in 
clinical applications where these are routinely used for diagnosis and follow-up of human 
diseases (Figure 1). This use of translational imaging techniques facilitates the correlation 
between preclinical and clinical data (bench-to-bedside model).  
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Every imaging technique has its own limitations and advantages. Each imaging modality has 
its strengths and weaknesses which define its use in visualization of different stages of 
disease or in drug development process (Table 1).  For example, MRI and CT are in general 
label free and are well suited for visualization of anatomical detail. However, they lack 
molecular specificity whereas the nuclear imaging techniques PET and SPECT allow functional 
imaging of tumor biology 82. PET is more sensitive than SPECT, whereas SPECT can be used 
to visualize multiple nuclear tracers simultaneous. Techniques such as PET, MRI, CT, SPECT 
and ultrasound (US) have great translational capabilities as these techniques are already used 
in the clinic. 
 
Bioluminescence imaging (BLI) 
Bioluminescence is the production of light by a living organism. Many bacteria can produce 
light as over 700 strains of luminous bacteria are isolated. But also other organisms such as 
fireflies, jellyfish and squids are capable of bioluminescence. Several luciferase genes were 
isolated and cloned from these organisms, including firefly luciferase (Fluc), gaussia 
luciferase (Gluc) and renilla luciferase 110–113. Introduction of these genes into cancer cells 
allows to study biological events such as intracranial tumor development, treatment efficacy, 
and to monitor metastasis 114, because the luminescent signal corresponds highly with tumor 
burden and predicts animal survival 115,116. A major advantage of the use of these luciferase 
genes is the absolute lack of background signal. As only these genetically modified cells will 
emit light in the presence of the luciferin substrate, BLI shows higher sensitivity as compared 
to imaging techniques such as PET or MRI, allowing detection of small number of cells 117. 
Because this technique is inexpensive, fast, sensitive and simple to operate, BLI is efficient 
for longitudinal studies and drug discovery research. A disadvantage of BLI is that this 
technique does not allow real quantification of data. Because visible light is highly quenched 
by tissues and erythrocytes, as well as by bone structures and fur of the animals, signal 
intensity is largely dependent on the location and depth of the cells to be visualized and 
therefore not proportionally related to the number of bioluminescent cells.  
 
Intravital microscopy (IVM) 
Light microscopy provide means to visualize cellular and even subcellular details.  Intravital 
microscopy makes use of such light microscopes to observe biological systems at high spatial, 
and temporal resolution in a living animal. The use of optical imaging for in vivo imaging is 
still mainly limited to preclinical imaging, largely because of the limited penetration depth of 
visible light into intact tissue. However, advances in instrumentation, especially the use of 
longer wavelengths for multiphoton microscopy, have improved light penetration and will 
probably continue to do so. Furthermore the potential of translating optical imaging towards 
the clinic has been shown by recent studies of fluorescence-guided surgery 118,119 and label 
free imaging by using second- and third harmonic imaging 120 . Intravital fluorescence 
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microscopy can be performed non-invasive on superficial structures 121–124. If deeper tissues, 
or tissues covered by bones or tissues in the skull have to be visualized by intravital 
microscopy, optical windows are needed to visualize cellular and vascular processes 115,125–
130. Limitations of intravital imaging are the small field of view and limited imaging depth. 
Imaging depth is limited due to absorption and reflection of photons. The use of higher 
wavelengths, as in multiphoton imaging and by the use of near-infrared dyes, has improved 
imaging depth, but still it is under 2 mm 131,132. 
 
Positron Emitting Tomography (PET) 
Small animal PET-imaging was boosted by the development of dedicated small animal PET 
scanners, which became available during the 1990’s 133–135 . Preclinical PET-imaging is 
increasingly used to assess efficacy of therapeutic interventions and to validate applications 
of current and novel radiotracers for translation to human applications. Due to developments 
such as thinner scintillator sizes and smaller bore sizes, preclinical devices have a reduction 
in spatial resolution of approximately 3-fold as compared to the clinical scanners. But still, 
this improvement in resolution is insufficient to create an equal sampling size in mice and 
humans because a human is about 3000 times the size of a mouse. Although sensitivity is low 
compared to BLI and spatial resolution is far less as compared to MRI, PET-imaging has its 
own advantages. Positron emitting radionuclides can be coupled to many different types of 
molecules. This allows imaging of biological processes such as proliferation, DNA damage and 
repair and angiogenesis thus allowing to get functional, quantitative information about 
physiological processes in tissues or organs 136,137. 
 
Computed Tomography (CT) 
X-ray imaging makes use of electromagnetic radiation (X-rays) and the differential absorption 
of these X-rays by water, bone, fat and air to make cross-sections of the body. Computational 
combination of X-rays taken from different angles allows 3D reconstruction of the scanned 
object. The main advantage of CT is the high contrast between bone and soft tissues. Soft 
tissues have often similar densities of contrast as their surrounding tissues, which makes CT 
less suitable for imaging of soft tissues. Although contrast agents are available to enhance 
contrast, the use of iodinated contrast agents to discern organs and vessels in mice is 
challenging. Because mice have a physiological heart rate between 500-620 bpm, these 
contrast agents are cleared quickly from the circulation. Moreover, image resolution of CT 
images is limited to about 50 µm, making the visualization of minute structures such as 
vessels in small animal models difficult 138. CT imaging is often used for anatomical 
localization of tumors in combination with other imaging modalities such as PET or BLI, and 
for image-guided stereotactic cranial irradiation 139,140. 
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Magnetic Resonance Imaging (MRI) 
The ability of MRI to confer anatomic detail are unmatched. However, overall it is low in 
throughput, is labor intensive, time-consuming and requires expensive instrumentation. MR 
in preclinical brain tumor imaging is most used to screen and monitor tumor growth and to 
correlate imaging phenotypes with tumor histology 103,141. High spatial resolution (down to 
25 µm) is obtained by applying high strength magnetic fields, up to 15.2 Tesla, but for 
characterization of the growth of preclinical tumor models, low-field (1T) magnetic 
resonance imaging, which gives a spatial resolution of 100 µm,  is often sufficient 142,143. MRI 
can be used to study blood-brain-barrier integrity with the use of MRI contrast agents such 
as gadolinium 144. 
 
Ultrasound (US) / Photo-Acoustic (PA) imaging 
Ultrasound (US) imaging uses registration of reflected high-frequency sound waves which 
are translated into 2D and 3D images. Preclinical ultrasound devices are specifically 
developed for small animal research, with frequencies ranging from 9 MHz to 80 MHz. Due 
to its high data capturing rate, up to 1000 frames per second, US is capable to visualize blood 
flow in vivo. 
Photo-acoustic imaging (PA) is a special type of acoustic imaging where a laser delivers 
energy to biological tissues. This energy is absorbed and converted to heat which results in 
the production of a high-frequency sound wave which can be registered with an ultrasound 
probe. As the energy absorption is associated on properties such as oxygen saturation of 
hemoglobulin, PA imaging can be applied to visualize oxygenation levels in a tumor 145.  Both 
US and PA have limited penetration trough bone tissues. Imaging of brain tissues or tumors 
is therefore limited to the more superficial areas. Alternatively imaging windows have to be 
created, or part of the skull has to be removed to allow imaging of deeper located brain areas 
126,128. 
 
Figure 1. (next page) Overview of various imaging techniques for preclinical brain tumor research. a Positron 
emission tomography (PET) image of the distribution of 89Zr-bevacizumab in mice. b T1 weighed magnetic resonance 
image (MRI) of a mouse xenografted with U251FM GBM cells. c T2-weighed MRI. d Computed tomography (CT) 
image. e Ultrasound (US) image of a mouse with GBM8FM brain tumor. f Photo-acoustic (PA) image of the same 
region. g Bioluminescent light imaging (BLI) of a mouse with an intracranial E98FM tumor and some drop-metastasis 
in the spinal cord. h Intravital microscopy of diffuse growing GBM8FM cells in the brain of a mouse. i Superficial 
blood vessels imaged by intravital microscopy through a cranial window. j Immunohistology; lectin labeled blood 
vessels (green) and GBM8 tumor cells (red). k Hematoxylin & eosin stained GBM8 tissue. l Co-registration of 89Zr-
bevacizumab PET scan with anatomical CT data. m Co-registration of GBM8FM BLI data with 3D X-ray anatomical 
data. n 3D brain vasculature of a health mouse of CLARITY cleared tissue. 
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Figure 1 (legend see previous page) 
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Ex vivo: 3D microscopy 
Microscopical imaging has been indispensable in tumor diagnosis and research. Up to now, 
cancer diagnosis depends largely on histological analysis of formalin-fixed, paraffin-
embedded (PPFE) tissue slides. To visualize cells or structures, the tissues are usually stained 
by chemical procedures, such as hematoxylin and eosin (H&E) staining, or histochemical 
staining using antibodies against specific targets. Traditional histological assessment of 
tissues limits proper insight in 3D tissues structure. Imaging of serial sections and subsequent 
3D reconstruction has been developed successfully, but its application remained limited to 
small volumes of tissue 146–150. Furthermore, mechanical slicing and manual aligning of tissue 
slides is a time-consuming and error-prone procedure.  This has led to the development of 
methods for optical slicing avoiding mechanical slicing of tissue. Optical slicing has become 
feasible because of developments in microscope, laser, optics and detector technologies, 
such as improved confocal microscopes with long working distance objects, multiphoton 
laser scanning microscopes and light sheet microscopes 151–153. Because light scattering and 
absorbance hinders proper imaging of large samples, samples need to be cleared by optical 
tissue clearing (OTC) to render transparent tissues. Many OTC's have been developed, 
including BABB,  Scale, 3Disco, ClearT, SeeDB, CLARITY, CUBIC, PACT/PARS, iDISCO, ACT-
PRESTO 149,154–157, reviewed by Azaripour 158. Other advantages which allowed 3D imaging of 
cells and structures in optical cleared tissues are developments of stable and strong 
fluorescent labels such as Alexa Fluor and Dylight labels, and animals which express 
endogenous fluorescence. Major advances for 3D imaging of larger pieces of tissues are 
being expected from more efficient labeling of the structures of interest 159–163. 
Table  1: Main characteristics of preclinical imaging modalities. Information partly sourced from 164–167 Spatial 
resolution=minimum distance between two objects that can be distinguished separately  MRI: Magnetic Resonance 
Imaging, US: Ultrasound, BLI: Bioluminescence Imaging, FLUOR: Fluorescence imaging, IVM: Intravital microscopy, 
CT: Computed Tomography, SPECT: single-photon emission computed tomography, PET: Positron emitting 
tomography 
Imaging 
Modality
Spatial 
Resolution
Acquisition 
time
Imaging 
depth
Contrast agents /
 molecular probes
Clinical
translational
Quantitative
degree
Morphological 
imaging Key use
MRI 25 - 100 µm mins to hours no limit gadolinium, iron particles yes ++ +++
anatomical imaging
(soft tissues)
US 30 - 50 µm mins  mm - cms microbubbles, nanoparticles yes + to ++ +++ vascular imaging
BLI 1 - 10 mm secs to mins 1 - 2 cm luciferases no - to +/- - research
FLUOR 0.2 - 10 mm secs to mins 1 - 2 cm fluorecent labels yes - to +/- - research
IVM 5 µm secs to hours 1 - 2 mm fluorescent labels no - to +/- +/- research
CT 30 - 50 µm mins no limit iodine yes + to ++ ++
anatomical imaging
(bone tissues)
SPECT 1 - 2 mm mins to hour no limit isotopes (99m Tc, 123I, 125I, 67Ga) yes +++ + metabolic imaging
PET 1 - 2 mm mins to hour no limit isotopes (18F, 89Zr, 68Ga) yes +++ + metabolic imaging
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The general aim of the research presented in 
this thesis is to explore novel therapeutic 
strategies for the treatment of high grade brain 
cancer. To this end we have used brain tumor 
models in mice, which we used to study the efficacy of several therapeutics or administration 
routes. The focus was on imaging tumor progression and therapy efficacy. 
In the first part of this thesis we pay attention to treatment and imaging options in DIPG, a 
pediatric high-grade tumor in the brainstem. In chapter 2 we describe a method for delivery 
of carmustine directly into a brainstem tumor by convection-enhanced delivery. The safety 
and efficacy of this CED-method was evaluated by histological and bioluminescence imaging 
in tumor bearing mice.   
 
This CED technique which was further explored to test feasibility of local delivery of 
doxorubicin to treat pediatric DIPG and thalamic high-grade glioma is described in chapter 3. 
 
As high-grade tumors are highly angiogenic, anti-angiogenic therapies could be beneficial in 
the treatment of these tumors. In chapter 4, we use PET-imaging and distribution studies in 
orthotopic (intracranial) and heterotopic (subcutaneous) DIPG and high-grade glioma animal 
models to study whether VEGF-expression is dependent on the tumor microenvironment.   
 
In chapter 5, we screened a library of chemical compounds to identify possible 
radiosensitizers in order to study, in an orthotopic xenograft model for medulloblastoma, 
whether administration of the radiosensitizer quercetin around the time of radiation 
increases the radiation efficacy and prolonged survival in this preclinical animal model. 
 
Chapter 6 addresses a novel way to inhibit tumor progression. Because extracellular vesicles 
(EVs) are important in tumor progression, we identify chemokine receptors on the tumor 
cells which are involved in EV interaction. Next, we evaluate if therapeutic intervention 
inhibits the EV-interactions and their consequent effects on tumor progression and the 
prevention of temozolomide resistance.   
 
Finally, in chapter 7, we describe a method for 3D-histology of the brain and the use of this 
technique to visualize, and quantify blood-vessels in healthy brain and the topological 
orientation of tumor cells towards the vasculature in tumors.  
 
Chapter 8 discusses the results of these studies and the use of preclinical imaging models in 
the field of brain tumor research, concluding with the implications for future research to 
improve treatment strategies of brain cancer. 
THESIS OUTLINE 
 23 
 
 
 24 
 
  
 25 
 
 
 
 
 
CHAPTER 2 |  
CONVECTION-ENHANCED DELIVERY OF 
CARMUSTINE TO THE MURINE 
BRAINSTEM: A FEASIBILITY STUDY 
 
 
 
 
 
 
 
 
 
Tonny Lagerweij*, A. Charlotte P. Sewing*, Viola Caretti*, Pepijn 
Schellen, Marc H.A. Jansen, Dannis G. van Vuurden, Sander Idema, 
Carla F.M. Molthoff, W. Peter Vandertop, Gertjan J.L. Kaspers, 
David P. Noske, Esther Hulleman 
 
Published in: J. Neurosci. Methods 2014;238:88-94. 
 
*  These authors contributed equally to this work 
  
 26 
 
___________________________________ 
Systemic delivery of therapeutic agents 
remains ineffective against diffuse intrinsic 
pontine glioma (DIPG), possibly due to an 
intact blood–brain-barrier (BBB) and to 
dose-limiting toxicity of systemic 
chemotherapeutic agents. Convection-enhanced delivery (CED) into the brainstem 
may provide an effective local delivery alternative for DIPG patients. 
 
The aim of this study is to develop a method to perform CED into the murine 
brainstem and to test this method using the chemotherapeutic agent carmustine 
(BiCNU). To this end, a newly designed murine CED catheter was tested in vitro and 
in vivo. After determination of safety and distribution, mice bearing VUMC-DIPG-3 
and E98FM-DIPG brainstem tumors were treated with carmustine dissolved in 5% 
dextrose (DW) or carmustine dissolved in 10% ethanol. 
 
Our results show that CED into the murine brainstem is feasible and well tolerated 
by mice with and without brainstem tumors. CED of carmustine dissolved in 5% DW 
increased median survival of mice with VUMC-DIPG-3 and E98FM-DIPG tumors with 
35% and 25% respectively. Dissolving carmustine in 10% ethanol further improved 
survival to 45% in mice with E98FM-DIPG tumors. 
  
ABSTRACT 
CARMUSTINE 
27 
 
   ____________________________________ 
Diffuse intrinsic pontine glioma (DIPG) is a fatal 
brain malignancy in children, for which 
prognosis has not improved in the last 40 years 
168,169. Although recent in vitro studies have 
shown DIPG cells to be sensitive to both classic chemotherapeutic drugs and novel targeted 
agents 170, multiple clinical trials have so far been unsuccessful 169. A possible reason for this 
failure is the inability of therapeutic agents to reach tumor cells, due to a relatively intact 
blood–brain-barrier (BBB) 171,172. The BBB constitutes a physiological barrier to safeguard the 
central nervous system from exposure to both endogenous and exogenous toxins, thereby 
also preventing effective delivery of chemotherapy to the tumor parenchyma 173. Therefore, 
convection-enhanced delivery (CED), a local drug delivery method, may be a promising 
delivery approach to more effectively treat DIPG patients 174,175. CED relies on a continuous 
hydrostatic pressure gradient, which propels therapeutic agents over relevant anatomical 
volumes, at a speed several orders of magnitude greater than simple diffusion 176. Local drug 
concentrations achieved by CED can be up to 10,000-fold higher as compared to intravenous 
drug administration, while minimizing systemic exposure 177. Because of a wider distribution, 
CED could be preferred over intrathecal-, intraventricular- and intra-arterial drug 
administration or polymer-wafer implantation in brain tumor patients 178–180. The use of CED 
as a treatment strategy for DIPG patients has matured from preclinical studies showing 
feasibility in rats 181,182, to safety and distribution studies in non-human primates 183,184 and 
phase I/II clinical trials in children 185. To our current knowledge, four studies have been 
published, describing follow up of five pediatric patients treated with CED in the brainstem, 
four of which were suffering from a DIPG 53,186–188. These studies have shown CED in DIPG to 
be feasible and safe but have yet to show a survival benefit. To further improve CED for more 
(pre-clinical) research is needed. 
 
Even though the safety and efficacy of CED in the brainstem has been assessed in rat non-
tumor 181 and non-DIPG brainstem tumor models in rats 182, no study has shown the feasibility 
of CED in the murine brainstem. Since true primary DIPG-xenograft and genetically-
engineered models of DIPG are currently only available in mice 189,190, we decided to conduct 
a safety and efficacy study of CED in the murine brainstem using the chemotherapeutic agent 
carmustine (BiCNU, 1,3-bis-(chloroethyl)- 1-nitrosourea). Carmustine is an alkylating agent 
with a clear differential toxicity to pediatric high grade glioma and DIPG cells in vitro 
compared to astrocytes 170. Dose-limiting systemic toxicity makes carmustine unsuitable for 
intravenous therapy in brain tumor patients 191, but its efficacy against glioma cells and the 
lack of toxicity to astrocytes at clinically relevant concentrations 170, makes it an excellent 
candidate for local therapy. Currently, carmustine is the only FDA-approved treatment for 
intracerebral chemotherapy of adult glioblastoma 168,192. In addition, interstitial carmustine 
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administration by wafers has shown to be safe in pediatric brain tumor patients 193,194. In this 
study we evaluated carmustine dissolved in 5% dextrose (DW) which is known to be safe in 
rats. Subsequently, we tested the safety of 10% ethanol administration to the murine 
brainstem, because dissolving carmustine in 10% ethanol could improve distribution and 
allows for a better translation into the clinic 195. As a final test we studied the in vivo efficacy 
of local delivery of carmustine via CED dissolved in both vehicles (5% DW and 10% ethanol). 
For this purpose we employed our recently developed VUMC-DIPG-3 196 model and our 
previously established E98-Fluc-mCherry (E98-FM) DIPG model 197. 
 
__________________________________ 
Convection-enhanced delivery in vitro 
The CED-system was tested in vitro by 
performing CED of trypan blue in 0.6% 
agarose gel, which has been previously 
described as a reliable model to simulate CED in the brain parenchyma 198. CED was 
performed at a speed of 0.5 µl/min for 30 min. Total infusion volume was 15 µl. Five 
minutes after the end of the procedure, the inner cannula was withdrawn and after 
1 min the guide was also withdrawn at a speed of 1 mm/min. Distribution and 
backﬂow were assessed by observing trypan blue distribution in the agarose gel. 
 
Carmustine 
For the in vivo experiments carmustine (BiCNU), (Bristol-Myers- Squibb, Princeton, 
NJ), was resuspended to a concentration of 3.3 mg/ml in either 5% DW (pH <4), or 
10% ethanol. Carmustine dose was measured in vitro before and after the CED 
procedure using HPLC–UV in both vehicles. 
 
Animals used for convection-enhanced delivery experiments 
Animal experiments were performed in accordance with the Dutch law on animal 
experimentation and the protocol was approved by the committee on animal 
experimentation of the VU University Medical Center (VUMC). All tumor models (E98FM-
DIPG, total n = 31, VUMC-DIPG 3, total n = 12) were established in immune deficient 6-
week-old athymic nude-foxn1nu mice to allow for adequate engraftment. Toxicity 
studies of 10% ethanol infusion (total n = 15) were performed on 6-week-old balb/c 
mice with an intact immune system to study the full scope of possible tissue reactions. 
All mice were housed under specific pathogen-free conditions in a 12-h light–dark 
cycle and were offered food and water ad libitum. Weights were measured, and 
clinical scores were assigned daily after the CED procedure (toxicity and efficacy 
studies). Clinical scores ranged from 0 to 4 and referred to 0: normal active 
behavior, 1: subtle inactivity or subtle neurological symptoms, 2: mild to moderate 
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inactivity or neurological symptoms, 3: severe neurological symptoms, inactivity, loss 
of reﬂexes, inadequate grooming, 4: dead. Half point scores were assigned to mice 
that were behaving in between two scores. 
 
Orthotopic DIPG mouse models 
A single-cell suspension was prepared after harvesting subcutaneous E98-FM and 
VUMC-DIPG-3 tumors. E98-FM cells were originally isolated from an adult GBM patient 
197 and the genotypic murine-DIPG model: VUMC-DIPG-3 was established after injection 
of DIPG material collected during autopsy 196,199.  E98-FM cells and VUMC-DIPG 3 cells 
were injected as previously described 197, Coordinates from lambda for tumor-cell 
injections were: −1.0 mm X, −0.8 mm Y, 4.5 mm Z. Coordinates were based on “The 
mouse brain in stereotaxic coordinates” by Franklin and Paxinos, 3rd edition 200.  For 
the DIPG-E98-FM model, tumor growth was monitored twice weekly by 
bioluminescence imaging (BLI), as previously reported 197.  
 
 
Convection-enhanced delivery in vivo 
Before the CED-procedure, animals were injected subcutaneously with the analgesic 
buprenorphine 0.05–1 mg/kg and then anesthetized with isoflurane 2.5–3% in 100% 
oxygen. After placing the animals in a stereotactic frame on a heated platform, the 
CED- catheter was introduced into the pons (coordinates from lambda: −1.0 mm X, 
−0.8 mm Y, 4.5 mm Z) and the drug was infused (15 µl in 30 min). After the procedure, 
the catheter was removed, and the animals were returned to their cages to recover 
and resumed normal active behavior within 3–12 h. 
 
Convection-enhanced delivery efficacy studies 
At day five (VUMC-DIPG-3) or day seven to nine, depending on bioluminescence signal 
in E98-FM, after intracranial injection of tumor cells for the establishment of 
orthotopic pontine tumors, mice were stratified on the basis of BLI signal intensities 
into different treatment groups (E98-FM) or randomly assigned to one of the two 
groups (VUMC-DIPG-3). Animals were assigned to receive CED with carmustine in DW 
5% (VUMC-DIPG-3 and E98FM-DIPG) or 10% ethanol (E98FM-DIPG) or only DW 5% or 
10% ethanol vehicle. Researchers were blinded as to which treatment group mice 
belonged to. Follow-up included daily observations and weight measurement and 
measurement of BLI signal twice a week (E98-FM). Clinical scores were assigned 
ranging from 0 (normal active behavior) to 4 (dead). Endpoints were defined as 
weight loss more than 15%, severe neurological symptoms or severe inactivity. Mice 
were sacrificed via pentobarbital overdose. Brains were removed and fixed in 3.7% 
formaldehyde solution in PBS (phosphate buffered saline). Blood was withdrawn from 
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the tail vein before CED and a week thereafter, allowing the monitoring of alanine 
aminotransferase (ALAT), aspartate aminotransferase (ASAT) and creatinine levels 
using standard laboratory techniques used at the VUMC. 
 
Tissue staining and histological scoring of mice receiving convection-enhanced 
delivery with 10% ethanol 
Hematoxylin and eosin (H&E) staining was performed on 5 µm formalin-fixed, paraffin-
embedded tissue sections cut in the coronal plane from non-tumor baring balb/c mice 
2 or 21 days after CED with 10% ethanol or distilled water, using a standard H&E 
protocol. Sections were selected at the site of the needle tract and 100 µm both 
rostrally and posteriorly. Two researchers and an independent neuropathologist 
performed assessment of tissue damage and inflammation. They were blinded to the 
experimental procedure that the animals underwent. 
 
Statistics 
Differences in survival were analyzed by Kaplan–Meier curves and log rank tests for 
significance in the efficacy studies. Non-parametric Kruskal–Wallis test followed by a 
Dunn’s posthoc test was used to determine differences in ALAT, ASAT and creatinine 
levels and differences in BLI signal. The weight loss of mice treated with 10% ethanol 
was analyzed using a generalized linear model (GLM) and carmustine dose measured 
before and after CED in 10% ethanol and 5% DW was analyzed using a two-tailed t-test. A 
p < 0.05 was considered statistically significant. 
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    ____________________________________ 
Convection-enhanced delivery in vitro 
provides a symmetrical distribution with 
minimal backﬂow 
A stepped design catheter was developed incorporating an inner cannula (Hamilton 
Comp., Reno, NV) into an outer needle (Fig. 1a and b). The use of a stepped design 
reduces the risk of backﬂow or mechanical tissue injury and allows for a higher 
infusion rate 53 (Fig. 1a and b). The cannula has an outer and inner diameter of 0.24 
and 0.11 mm, respectively; the outer guide has an outer and inner diameter of 0.52 
and 0.26 mm, respectively. This catheter was connected via a tubing system (Fig. 1c) to 
a 300 µl disposable syringe inserted into a syringe pump (PHD 2000, Harvard Apparatus 
Inc., Holliston, MA). A pressure transducer was put in place to assure continuous 
pressure during the infusion and prompt detection of any issues in delivery (Fig. 1c). 
The inner cannula was inserted 2.5 mm into the agarose and further lowered to 4.5 
mm using a dedicated screw system to ensure the inner cannula followed a straight 
line minimizing backﬂow and damage to the brainstem (Fig. 1a). The CED catheter was 
tested in vitro by performing CED of trypan blue in 0.6% agarose gel. Rate of infusion 
(0.5 µl/min) and total volume (15 µl) were chosen based on previous pre-clinical 
studies201, clinical relevance (size of pons in relation to volume infused), and presumed 
feasibility (supplemental Table 1). Only minor leakage could be detected due to 
needle- and guide withdrawal and trypan blue was distributed as a symmetrical 
sphere in the agarose gel (Fig. 1d). 
 
Convection-enhanced delivery into the murine brainstem is feasible and safe 
Next, using the same settings, CED of trypan blue was performed in vivo to confirm 
proper infusate delivery. Mice were sacrificed after surgery to confirm infusion at the 
correct anatomical location (Fig. 1e and f). Trypan blue could be identified in the 
brainstem area (Fig. 1e and f). To assess safety of CED with carmustine in the 
brainstem, vehicle solution (5% DW) or carmustine (3.3 mg/kg in 5% DW) was infused 
in balb/c mice using the same settings as previously described. Mice recovered 
promptly from the surgery and no acute or chronic toxicities were observed during a 
two months follow-up. 
 
10% ethanol can be safely administered to the brainstem via convection-enhanced 
delivery 
To exclude toxicity of 10% ethanol infused directly in the brainstem by CED, non-
tumor bearing mice were treated with 15 µl of 10% ethanol or vehicle. One vehicle-
treated mouse died during the procedure due to a technical problem (inaccurately 
fixed catheter). Both 10% ethanol and vehicle-treated mice showed a transient 
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clinical deterioration and increase in weight loss after the CED procedure.  All mice 
recovered completely, and no significant difference could be detected in clinical score 
or weight loss between treatment groups (Fig. 2a and b and supplemental Table 1, 
supplemental Figure 1). Histological evaluation of H&E stained brain sections from 
three separate locations around the needle tract showed substantial early tissue 
damage at day two (Fig. 2c and Table 1) and more subtle late changes at day 21 (Fig. 
2d and Table 1). There were no differences between 10% ethanol and vehicle-treated 
brain tissues. 
Figure  1 (a) Stepped design CED catheter with separate parts shown (b) stepped design CED 
catheter 3D image (c) CED setup for in vivo convection-enhanced delivery. Legend (a–c): 1: 
inner cannula (32G needle, OD 0.24 mm, ID 0.11 mm); 2: guide needle (25G, OD 0.52 
mm, ID 0.26 mm); 3: nuts (for fixation in the stereotactic frame); 4: blocking screw; 5: 
adjusting screw (part one); 6: flexible catheter; 7: adjusting screw (part two); 8: infusion 
pump; 9: pressure transducer; 10 stereotactic frame; 11 stepped catheter (d) CED of 
trypan blue in 0.6% agarose gel. The arrowhead indicates minimal backﬂow of trypan blue 
after termination of CED. Scale bar: 1 mm. (e) Anatomy of the mouse brainstem at the 
level of the pons from Franklin & Paxinos: the mouse brain in stereotaxic coordinates200. 
(f) Image of the brainstem of a balb/c mouse sacrificed directly after CED of trypan blue
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counterstained with eosin corresponding to (e) Asterisk shows needle-track (e) dotted line 
shows infused area in (e and f). The area infused contains intended pontine regions 
including the pontine reticular nucleus, motor and sensory nucleus of the trigeminal nerve, 
superior olivary complex and to a lesser extend areas outside the pons including the 
superior cerebellar peduncles and bordering on the periaqueductal gray matter200. 
Contrast in this picture was enhanced using Adobe Photoshop Elements 11. 
Dissolving carmustine in 10% ethanol increases its efficacy in vivo 
To enable translation to the clinic, we investigated whether this significantly increased 
survival could be further improved by dissolving carmustine in 10% ethanol and used 
the well-established E98FM-DIPG orthotopic mouse model. Accordingly, we injected 
E98-FM cells into the murine pons as previously described 197. Some mice experienced 
transient clinical symptoms after injection of E98-FM cells, but no differences were 
detected between groups (Fig. 3e–h). At day seven to nine, depending on BLI signal, 
mice bearing E98FM tumors were treated with either carmustine dissolved in 5% DW 
or vehicle (5% DW) or carmustine dissolved in 10% ethanol or vehicle (10% ethanol). 
It should be noted that the differences in BLI between the groups were relatively large, 
despite not being statistically significant (Table 2). Due to the CED procedure, clinical 
scores rose transiently in some animals (Fig. 3e–h) and in vehicle treated groups, mice 
rapidly deteriorated due to tumor growth, starting at day 14 (Fig. 3e and f). Mice 
treated with CED of carmustine dissolved in ethanol demonstrated a significant 
decrease in tumor growth two weeks after CED, measured by bioluminescent imaging 
(p < 0.05) (Fig. 3i and j). CED of carmustine dissolved in 5% DW significantly increased 
median survival time with 25% compared to CED of 5% DW only (p < 0.01) (Fig. 3k). 
In comparison, CED of carmustine dissolved in 10% ethanol increased median survival 
time by 45% (p < 0.01) and resulted in one animal without any clinical symptoms or 
measurable BLI signal after 60 days of follow up (Fig. 3k). Dissolving carmustine in 
10% ethanol instead of DW 5% increased survival by 36% (p < 0.05). CED with 10% 
ethanol vehicle itself did not increase survival significantly compared to CED with 5% 
DW (p = 0.15). HPLC–UV measurements before and after CED in both vehicles showed 
availability of carmustine to be 30% higher when using 10% ethanol compared to 5% 
DW as vehicle (p < 0.05). Carmustine concentration was similar when measured after 
the CED procedure, suggesting chemical stability in both vehicles (supplemental figure 
2). 
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Figure  2 Maximal clinical scores (a) and maximal weight loss (b) two days after CED in balb/c 
mice treated with CED of 15 µl 10% ethanol or vehicle (distilled water). (c) H&E staining 
from a 5 µm brain section cut in the coronal plane approximately 100 µm posterior from 
the needle tract two days after CED of 15 µl 10% ethanol in an 8 weeks old Balb/c non-
tumor bearing mouse. Higher magnification shows loss of tissue and necrotic nuclei. (d) 
Section in the coronal plane 50 µm posteriorly from the needle tract, 3 weeks after CED 
of 15 µl 10% ethanol. Changes include glial scaring, macrophage influx and some loss of 
tissue. Scale bars are equal to 100 µm. 
Table 1: Histological findings 2 or 21 days after CED with 10% ethanol or vehicle 
Acute (day 2 after CED) Chronic (day 21 after CED) 
Ethanol 10% Necrosis, oedema and loss of tissue around the 
needle tract (N=4) 
Inflammation (macrophages), glial scaring, some loss of 
tissue around needle tract (N=4) 
Vehicle Necrosis, oedema and loss of tissue around the 
needle tract (N=3) 
Severe necrosis and tissue loss (N=1) 
Inflammation (macrophages), glial scaring, some loss of 
tissue around needle tract (N=4) 
CARMUSTINE 
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Figure  3 Kaplan–Meier survival curves of mice bearing VUMC-DIPG-3 tumors treated with 
CED of carmustine 5% dextrose (red) or vehicle 5% dextrose (blue) Arrow indicates day of 
treatment with CED; **p < 0.01 (b–d) ALAT, ASAT, and creatinine blood values from all 
mice bearing VUMC-DIPG-3 tumors at the day of CED treatment and seven days later, n.s. 
= not significant. Error bars indicate standard error of the mean (SEM). (e–h) Clinical 
scores of a representative group (total n = 14) of E98FM bearing mice treated with CED 
from day 0 (before implantation of E98FM cells) until day 28. Clinical scores refer to 0: 
normal active behavior, 1: subtle inactivity or subtle neurological symptoms, 2: mild to 
moderate inactivity or neurological symptoms, 3: severe neurological symptoms, 
inactivity, loss of reﬂexes, inadequate grooming, 4: dead. Transient symptoms after IC-
injection of E98FM cells and CED, clinical score rapidly increasing from day 12 in vehicle 
groups. No increase of clinical score in carmustine-treated animals. No difference in CED-
associated clinical scores between treatment groups. (i) Fireﬂy luciferase bioluminescence 
imaging of E98-FM DIPG tumor bearing mice treated with CED of carmustine (dissolved 
in 10% ethanol or 5% DW) or vehicle over time; *p < 0.05, Kruskal–Wallis nonparametric 
test. (j) Representative bioluminescence images of E98-FM DIPG tumor bearing mice 
treated with either Carmustine 5% DW or 5% DW. Color bar represents photons/second. 
(k) Kaplan–Meier survival curves of mice bearing E98FM-DIPG tumors treated with CED of
carmustine 5% DW (red), carmustine 10% ethanol (purple) or vehicle 5% DW (blue) or 10%
ethanol (cyan). Arrow indicates day of treatment with CED; **p < 0.01.
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In this study, we show for the first time that
CED in the mouse brainstem is 
reproducible, safe and has potential to 
show a significant survival benefit. The 
methods and results presented here set the foundation for future preclinical studies in 
orthotopic DIPG mouse models, including efficacy and distribution studies using 
different therapeutic agents and drug carrier systems such as liposomes. As stated 
earlier, no significant improvement in survival has been achieved for children affected 
by DIPG in the last 40 years. Unlike other gliomas that present a leaky BBB, the 
permanence of an intact BBB could in part explain DIPG resistance to therapeutic 
agents delivered systemically 202.  Whether potential chemotherapeutic agents actually 
reach the tumor after systemic delivery is largely unknown and should be further 
studied using advanced molecular imaging techniques such as positron emission 
tomography (PET) scans or experimental systems. When therapeutic levels of agents, 
shown to  be  effective  in  vitro,  cannot be established in the tumor due to the effects 
of the BBB or dose-limiting toxicity, CED may overcome these issues 175,179.  Therefore, 
CED is anticipated to play an important role in future potentially successful treatment 
regimens, intensifying the need for in vivo techniques to study CED in the brainstem. 
Currently, clinical CED is performed in phase I/II clinical trials in children with DIPG. 
Lonser et al. treated a four-year-old DIPG patient with fusion protein interleukin 13 – 
pseudomonas exotoxin (IL-13-PE) (volume 1.4 ml in 6 h with infusion rate 0.5–10 µl/min) 
at time of progression. The patient showed only transient worsening of symptoms and 
died four month after infusion 53. Anderson et al. treated two children age ﬁve and six 
years with topotecan (volume 6.04 or 5.3 ml in ± 100 h, infusion rate between 0.3 
and 2 µl/min). Both children did show only transient worsening of neurological 
symptoms after the CED procedure 186. Follow-up MRI showed a slight decrease of 
tumor size, but the patients did not experience prolonged survival. Barua et al. 
reported treating a 5-year-old DIPG patient with CED of carboplatin (volume 9 ml in 
20 h, five times in nine days, with infusion rate 0.5–10 µl/min) at tumor progression. 
One month after treatment the patient showed mild clinical improvement and MRI 
changes that could be attributed to tumor necrosis. The patient died two month 
after CED from tumor progression outside the field of infusion 187. Even though 
clear progress has been made in demonstrating the feasibility of CED in DIPG 
patients, many questions remain that could be answered by in vivo studies. Although 
our preclinical CED setup was designed to mimic the clinical situation as accurately as 
possible, infusion time difference varies significantly between clinical CED and 
preclinical CED as presented here. This difference is caused by limitations in the 
acceptable duration of anesthesia in mice. Implanting flexible catheters that remain 
DISCUSSION 
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in the brain parenchyma of the mice would allow for continuous administration 
without anesthesia. This infusion technique has been performed in the rat brainstem 
2 0 3, but due to the size of the murine brainstem this will be technically challenging. 
It could be argued that the small size of the murine brainstem also limits studying the 
benefits of convection in CED, because small molecules can, in time, diffuse over 
relative anatomical distances in this model. However, since the biological half-life of 
carmustine is relatively short, our method still poses an unique opportunity to study 
the efficacy of drugs such as carmustine in vivo orthotopically. 
 
 
Table 2: Median BLI of E98FM-DIPG at start CED 
 
We show CED with carmustine using 5% DW as a vehicle to be effective in a primary 
model of DIPG, however carmustine dissolved in ethanol 10% proved significantly 
more effective. Adequate distribution of a therapeutic agent is key to the efficacy of 
locally delivered therapy. Chemical structure (large molecules) and solvability 
(lipophilicity) of the infused compound can negatively influence volume of 
distribution in tissue after CED 201. Carmustine is a lipophilic drug that, for intravenous 
use and for local delivery, including into brain tumors, has long been dissolved in 
100% ethanol to improve delivery 195. Using 100% ethanol allowed for safe intra-
tumoral injection up to a carmustine concentration of 60 mg/ml in GBM patients, 
although adverse events of 100% ethanol were reported when used for intra-arterial 
delivery 195. Currently it is thought that a minimum of 10% ethanol or 5% DW solution 
with pH <4, can be used as a vehicle for carmustine, up to a maximum concentration 
of 3.3 mg/ml 195. Both vehicles will maintain the stability of the drug, however the 
safety and efficacy of CED with 10% ethanol in the brainstem is unknown. It has 
been noted that carmustine in 5% DW remains a suspension, possibly influencing 
the distribution of the compound and thereby its efficacy. In this study efficacy 
significantly improved upon dissolving carmustine in 10% ethanol. This improvement 
is likely due to a better solvability and sub-sequential availability of the drug and is 
 
  
  
Median BLI at start CED   Days after IC - injection   Total N   
Ethanol 10%   1.10E+06   7  -   8   8   
Dextrose 5%   6.59E+04   7  -   9   7   
CAR in Ethanol 10%   5.91E+05   7  -   8   8   
CAR in Dextrose 5%   9.44E+04   7  -   9   8   
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therefore of preference in a clinical setting. Of note in this respect, 10% ethanol could 
be administered to the normal murine brainstem without additional clinical or 
histological abnormalities. Murine studies like these will enable faster and more 
effective translation to the clinic and our results encourage exploring the possibility of 
a clinical trial studying CED of carmustine in DIPG. 
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Pediatric high-grade gliomas (pHGGs) including
diffuse intrinsic pontine gliomas (DIPGs) are 
primary brain tumors with high mortality and 
morbidity. Because of their poor brain 
penetrance, systemic chemotherapy regimens have failed to deliver satisfactory results; 
however, convection-enhanced delivery (CED) may be an alternative mode of drug delivery. 
Anthracyclines are potent chemotherapeutics that have been successfully delivered via CED 
in preclinical supratentorial glioma models. This study aims to assess the potency of 
anthracyclines against DIPG and pHGG cell lines in vitro and to evaluate the efficacy of CED 
with anthracyclines in orthotopic pontine and thalamic tumor models. 
The sensitivity of primary pHGG cell lines to a range of anthracyclines was tested in vitro. 
Preclinical CED of free doxorubicin and PEGylated liposomal doxorubicin (PLD) to the 
brainstem and thalamus of naïve nude mice was performed. The maximum tolerated dose 
(MTD) was determined based on the observation of clinical symptoms, and brains were 
analyzed after H&E staining. Efficacy of the MTD was tested in adult glioma E98-FM-DIPG 
and E98-FM-thalamus models and in the HSJD-DIPG-007-Fluc primary DIPG model. 
Both pHGG and DIPG cells were sensitive to anthracyclines in vitro. Doxorubicin was selected 
for further preclinical evaluation. Convection-enhanced delivery of the MTD of free 
doxorubicin and PLD in the pons was 0.02 mg/ml, and the dose tolerated in the thalamus 
was 10 times higher (0.2 mg/ml). Free doxorubicin or PLD via CED was ineffective against 
E98-FM-DIPG or HSJD-DIPG-007-Fluc in the brainstem; however, when applied in the 
thalamus, 0.2 mg/ml of PLD slowed down tumor growth and increased survival in a subset of 
animals with small tumors. 
Local delivery of doxorubicin to the brainstem causes severe toxicity, even at doxorubicin 
concentrations that are safe in the thalamus. As a consequence, the authors could not 
establish a therapeutic window for treating orthotopic brainstem tumors in mice. For tumors 
in the thalamus, therapeutic concentrations to slow down tumor growth could be reached. 
These data suggest that anatomical location determines the severity of toxicity after local 
delivery of therapeutic agents and that caution should be used when translating data from 
supratentorial CED studies to treat infratentorial tumors. 
ABSTRACT 
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    ____________________________________ 
Diffuse intrinsic pontine glioma (DIPG) and 
thalamic glioma are diffusely infiltrating midline 
gliomas, often harboring histone H3K27M 
mutations and most frequently observed in 
childhood 204. These tumors have very high mortality and morbidity as effective treatment 
strategies still do not exist 205,206,  despite significant progress in understanding the biological 
processes that play a role in the development and progression of these tumors 23,24,125,207–
209. Tumor cells are highly resistant to chemo- and radiotherapy, and the presence of the 
blood-brain barrier (BBB) prevents drugs from reaching the bulk tumor and infiltrating tumor 
cells in sufficient concentrations 22,210.  
None of the clinical trials performed in DIPG and pediatric high-grade glioma (pHGG), which 
have used a large number of different chemotherapeutic agents such as cytostatic agents, 
targeted antibodies, and small-molecule inhibitors, has yet to show a clear benefit that can 
be translated to standard clinical practice 209,211. Recently, preclinical research has identified 
pHGG and DIPG cell lines to be sensitive to a number of “classic” cytostatic agents, especially 
some anthracycline drugs 170. Anthracyclines are the cornerstones of many 
chemotherapeutic treatment regimens in a wide variety of cancer types in both adults and 
children 212. They are, despite their assumed value, associated with serious adverse events, 
including debilitating or even life-threatening cardiotoxicity 213. Almost all anthracyclines 
have been identified as strong substrates of ATP-binding cassette transporters (ABC 
transporters), P-gP, MRP1, and BCRP, causing limited brain penetration 214,215. The limited 
brain penetrance of anthracyclines in brain tumors with an intact BBB, such as diffuse 
gliomas, may also explain these agents' lack of efficacy when used in the treatment of pHGG 
including DIPG. 
Convection-enhanced delivery (CED) is a local delivery technique that is being considered a 
potential drug delivery strategy in DIPG and other brain tumors as it circumvents the BBB 
53,63,186,187,201,216. Drug distribution is facilitated by a pressure gradient at the tip of the infusion 
catheter, resulting in bulk flow through the interstitial spaces of the brain 217,218. However, 
choosing the right drug to administer via CED is difficult: it should be effective against pHGG 
cells, have favorable chemical properties to enable adequate distribution, and give no or 
limited toxicity in healthy brain tissue 187,201,218. Using liposomal formulations of a drug can 
potentially improve distribution, bioavailability, biological half-life, and efficacy after CED, as 
suggested by several preclinical studies 219–222.  
In the present study, we aimed to investigate the translational potential of anthracyclines in 
the treatment of DIPG and pHGG using CED. Preclinical animal studies have already shown 
the potential for local delivery of anthracyclines to treat brain tumor models, but no study 
has investigated the administration of these chemotherapeutic drugs directly to the pons or 
thalamus 220,221. We studied the efficacy of different anthracyclines in vitro and determined 
INTRODUCTION 
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the feasibility of delivering these agents to delicate brain areas such as the brainstem and 
thalamus. Subsequently, we investigated the efficacy of nanoliposomal and free 
anthracyclines in treating orthotopic high-grade tumors in the brainstem and thalamus in 
vivo. 
____________________________________ 
Expression of Topoisomerase Type IIA in DIPG
and pHGG 
Because topoisomerase Type IIA (TOPIIA)
expression is associated with a good clinical 
response to treatment with anthracyclines in a number of cancer types 223,224, TOPIIA mRNA 
expression in DIPG (n = 27) 225 and pHGG (n = 53) 226 was determined in silico by using publicly 
available data sets and compared with a data set of nonmalignant brain tissue (44 tissue 
samples) 227, low-grade brainstem glioma (LG-BSG; 6 samples) 225, and adult HGG (284 
samples)228. These data sets included tumor material from biopsy (adult and pediatric HGG 
and DIPG), resection (adult and pediatric HGG), and autopsy (DIPG). All expression analyses 
were performed using R2, a web-based microarray analysis and visualization platform 
(http://r2.amc.nl). 
Processing of Tumor Material and Cell Cultures 
Single-cell cultures were established from biopsy samples derived from pediatric 
glioblastoma multiforme (GBM), anaplastic astrocytoma, anaplastic oligodendroglioma, and 
DIPG. Informed consent was obtained according to institutionally approved protocols. Tumor 
pieces were collected into DMEM (PAA Laboratories GmbH) and washed twice with 
phosphate-buffered saline (PBS) to remove blood clots. Samples were sliced into small (3–5 
mm3) pieces and either mechanically dissociated by filtering through a cell strainer (BD 
Falcon Biosciences) or dissociated by incubation with Accutase (PAA Laboratories GmbH). 
Single cells were seeded in DMEM-F12 constituted with stable glutamine, 10% fetal bovine 
serum (Perbio Science Nederland B.V.), 1% penicillin-streptomycin (PAA Laboratories GmbH), 
and 0.5% sodium pyruvate. For primary astrocytes, 15% fetal bovine serum was used. Cells 
were grown at 37°C in a 5% CO 2  humidified atmosphere. Primary cell cultures were 
genetically characterized using karyotyping or array comparative genomic hybridization 
(CGH), as previously described by Veringa et al 170. The primary HSJD-DIPG-007 cell line was 
established from DIPG material obtained at Hospital Sant Joan de Déu (Barcelona, Spain) 
from a 6-year-old patient after autopsy and was confirmed to have an H3F3A (K27M) and 
ACVR1 (R206H) mutation 229. The HSJD-DIPG-007-Fluc was cultured in serum-free tumor 
stem medium, as previously described230.  
MATERIALS and 
METHODS 
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Drug Treatment 
The primary pediatric glioma and astrocyte cultures were exposed to different anthracycline 
drugs (idarubicin, epirubicin, mitoxantrone, doxorubicin, and daunorubicin) at 
concentrations ranging from 0.01 to 1000 nM. A total of 1500 cells were seeded per well in 
96-well tissue culture plates. After 96 hours, cell survival was assessed with the Acumen eX3 
laser cytometer (TTO Labtech) using 300 mM of DAPI (Sigma-Aldrich) as readout. Results 
were analyzed using Acumen Explorer software, calculating the survival percentage for each 
compound tested in the assay. Each experiment was performed at least 4 times. 
 
Drugs 
Clinical formulations of the idarubicin, epirubicin, and daunorubicin used for the in vitro drug 
screens were supplied by the Department of Pharmacology of the VU University Medical 
Center (VUMC). Free and PEGylated liposomal doxorubicin (PLD) were supplied by 2-BBB 
Medicines BV. The PLD was prepared according to the commercial doxil/caelyx preparation 
method, that is, using active doxorubicin loading against an ammonium sulfate gradient, as 
previously described 231.  Mean liposome size was 95 nm and contained 2 mg/ml of 
doxorubicin, more than 90% of which was encapsulated in the liposomes. The liposomes 
were stored in liposome buffer (9.4% sucrose with histidine, 1.55 mg/ml; Sigma-Aldrich) at 
4°C for no longer than 3 months after production. The vehicle was previously shown to be 
nontoxic in mice 231. For details on the stability of doxorubicin and its liposomal formulation, 
we refer to previously published data by Barenholz and Gaillard et al. 231,232  
 
Animals  
Animal experiments were performed in accordance with the Dutch law on animal 
experimentation, and the protocol was approved by the committee on animal 
experimentation of the VUMC. Athymic nude-foxn1nu mice (6 weeks old, total of 112 mice 
used in all experiments) were purchased from Harlan, were kept under filter top conditions, 
and received food and water ad libitum. 
 
Orthotopic DIPG Mouse Models 
The E98 adult GBM cell line233 was transduced to express firefly luciferase (Fluc) and mCherry 
(E98-FM cells) and cultured in DMEM supplemented with 10% fetal calf serum and penicillin-
streptomycin. These cells were injected subcutaneously into female athymic nude mice (6–
8 weeks of age, 1 mouse per batch of intracranially injected cells) to expand the number of 
cells 197. When the subcutaneous tumor reached a diameter of 1 cm, the tumor was 
removed, and a single-cell suspension was prepared by mechanical disruption through a 100-
μm nylon cell strainer. The HSJD-DIPG-007-Fluc cells were injected directly from culture after 
mechanical dissociation and counting. The cells were washed once with PBS and 
concentrated to 105 cells/μl (both E98-FM and HSJD-DIPG-007-Fluc). Mice were 
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stereotactically injected with 5 − 105 cells in a final volume of 5 μl into either the pons (x: 
−1.0 mm, y: −0.8 mm, and z: 4.5 mm from the lambda) or the thalamus (x: 1.5, y: −2, and z:
−3.2 from the bregma). Coordinates were based on The Mouse Brain in Stereotaxic
Coordinates by Franklin and Paxinos 200 and were previously validated using injections of
trypan blue (data not shown).
Convection-Enhanced Delivery in vivo 
The CED procedure was performed using a stepped catheter specifically designed for this 
purpose (Fig. 1A), as we have described elsewhere 234. In vivo targeting of the brainstem was 
determined by infusion of trypan blue via CED (Fig. 1C), and MRI was performed after infusion 
of 15 μl of gadolinium 5 μM (Dotarem, Guerbet; Fig. 1D). Imaging was performed on 3 mice 
anesthetized with isoflurane inhalation (1.5 L O 2 /min and 2.5% isoflurane) using a 
preclinical PET-MRI system (nanoScan system, Mediso Medical Imaging Systems). The T1-
weighted images were acquired and analyzed using MIPAV software (Medical Image 
Processing, Analysis, and Visualization, version 7.2.0, National Institutes of Health). To 
perform in vivo CED, animals were injected with buprenorphine 0.05–1 mg/kg and 
anesthetized with isoflurane 2%–3% in 100% O 2 . After placing the animals in a 
stereotactic frame on a heated platform (37°C), we introduced the CED catheter into the 
pons (30 mice for toxicity studies, 24 mice for efficacy studies) or thalamus (9 mice for toxicity 
studies, 24 mice for efficacy studies; Fig. 1B). The coordinates used for CED were the same 
as those used for intracranial injections. During 30 minutes, a total of 15 μl of free 
doxorubicin, PLD, or vehicle was infused in the murine brain with a flow velocity of 0.5 μl/min. 
After the procedure, animals were returned to their cages to recover and resumed normal 
active behavior within 3–12 hours. 
Toxicity Study 
Convection-enhanced delivery toxicity (3 mice per dose and location) of 0.02 mg/ml (35 μM, 
pons), 0.2 mg/ml (345 μM, pons and thalamus), or 2 mg/ml (3448 μM, pons) of doxorubicin 
or PLD was determined based on clinical observations, including weight loss and clinical 
score. Clinical scores ranged from 0 to 4 and referred to normal active behavior (0); subtle 
inactivity or subtle neurological symptoms (1); mild to moderate inactivity or neurological 
symptoms (2); severe neurological symptoms, inactivity, loss of reflexes, and inadequate 
grooming (3); and death (4). Half-point scores were assigned to mice that were behaving in 
a manner between 2 scores. End points due to toxicity were defined as weight loss more 
than 15%, severe neurological symptoms, or severe inactivity. When none of these clinical 
end points were met, mice were euthanized 6 weeks after CED to determine histological 
toxicity. The maximum tolerated dose (MTD) was selected based on clinical features after 
treatment of 3 mice (no end point reached in all 3 animals, no clinical score > 2). 
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Figure 1. Schematic overview of preclinical CED including CED catheter (A) and stereotactic infusion 
setup (B). Infusion of 15 μl of trypan blue to the selected stereotactic coordinates (C, upper) and in 
agarose gel (C, lower). T1-weighted MR images (D) obtained directly after infusion of 15 μl of 
gadolinium. Panels A, B, and C reprinted from Sewing et al: J Neurosci Methods 238:88–94, 2014. 
 
Convection-Enhanced Delivery and Intravenous Efficacy Studies 
The start of treatment was determined by a rise in the bioluminescent imaging (BLI) signal, 
indicating tumor engraftment and growth. At Day 7 or 8 after intracranial injection of tumor 
cells to establish orthotopic brain tumors, mice were stratified on the basis of BLI signal 
intensities into different treatment groups. For the CED studies, animals harboring a pontine 
(E98-FM-DIPG or HSJD-DIPG-007-Fluc) or thalamic (E98-FM-thalamus) tumor were assigned 
to undergo CED of 0.02 mg/ml (35 μM) or 0.2 mg/ml (345 μM) of free doxorubicin or PLD, or 
vehicle (NaCl 0.9%; 4 mice for pons, 8 mice for thalamus per treatment group). For the 
intravenous studies, mice (4 per group) were assigned to receive PLD (18 mg/kg, once a week 
for 2 weeks) or vehicle (NaCl 0.9%) injected intravenously into the tail vein (3 mice/treatment 
group). Dosing was performed at the previously described MTD 235. Follow-up included daily 
observations, assignment of clinical scores, and weight measurement as well as twice weekly 
measurement of the BLI signal (E98-FM). End points were defined as weight loss more than 
15%, severe neurological symptoms, or severe inactivity. Researchers were blinded to 
treatment group. Mice were euthanized via pentobarbital overdose. Brains were removed 
and fixed in 3.7% PBS-buffered formaldehyde. Differences in survival were analyzed with 
Kaplan-Meier curves and log-rank tests for significance. Nonparametric Kruskal-Wallis test 
followed by Dunn's post hoc test was used to determine differences in the BLI signal. A p 
value < 0.05 was considered statistically significant. 
 
  
A CED catheter B in vivo CED setup D T1 CED gadoliniumC Trypan blue
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Tissue Staining and Histological Scoring 
Hematoxylin and eosin (H & E) staining was performed on 4-μm formalin-fixed, paraffin-
embedded tissue sections cut in the coronal plane, using a standard H & E protocol. To 
determine histological toxicity in non–tumor-bearing animals, sections were selected at the 
site of the needle tract and 100 μm both rostrally and posteriorly. Two researchers (A.C.P.S. 
and T.L.) and an independent neuropathologist (P.W.) assessed tissue damage and 
inflammation. They were blinded to the experimental procedure that the animals 
underwent. 
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    ____________________________________ 
Anthracyclines as Promising Drugs to Treat 
pHGG and DIPG 
Topoisomerase Type IIA was significantly 
overexpressed in pHGG and DIPG as compared 
with levels in LG-BSG and normal brain (p < 
0.01; Fig. 2A and B). Cytotoxicity of clinically available anthracyclines was tested in vitro 
against pHGG and DIPG primary cells and showed moderate to excellent sensitivity with half 
maximal inhibitory concentration (IC50) values ranging from 1 μM to 10 pM (Fig. 2C–G). 
Doxorubicin proved to be particularly active against DIPG cells (Fig. 2G). Next, the potency of 
doxorubicin was tested against E98-FM cells, used to establish orthotopic E98-FM-DIPG and 
E98-FM-thalamus models197,233, and normal human astrocytes, showing an excellent 
therapeutic window (Fig. 2H). For doxorubicin, used in subsequent in vivo experiments, IC50 
values ranged from 1 nM in the VUMC-DIPG-A cell line to 0.8 μM in the VUMC-HGG-05 cell 
line. HSJD-DIPG-007-Fluc had an intermediate sensitivity profile (IC50 40 nM; Supplemental 
Fig. 2). 
 
 
Clinical Toxicity of Doxorubicin Determined by Anatomical Location 
Convection-enhanced delivery of high-dose (2 mg/ml) doxorubicin and PLD to the pons led 
to severe clinical toxicity (Fig. 3A). Severe symptoms occurred later after the CED procedure 
in the PLD-treated animals (6 days) than in the animals treated with free doxorubicin (1–3 
days), and the difference in survival and weight loss was statistically significant (p < 
0.05; Table 1 and Supplemental Fig. 1). Eventually, all animals treated with high-dose 
doxorubicin in the brainstem had to be euthanized because of unacceptable toxicity. 
Symptoms consisted of weight loss (> 15%) and neurological deficits including paresis and 
loss of balance. 
 
Severe clinical toxicity still occurred with CED of medium-dose (0.2 mg/ml) doxorubicin to 
the pons. All animals in the free-doxorubicin group had to be euthanized. In the PLD group, 
1 animal had to be euthanized because of severe symptoms and 1 animal had clear 
neurological symptoms but remained active, with weight loss within acceptable limits (< 
15%); these neurological symptoms regressed after approximately 3 weeks (Table 1 and Fig. 
3B). 
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Figure 2. Expression of TOPIIA (A) in adult GBM, pHGG, DIPG, LG-BSG, and normal brain. TOPIIA 
expression (B) in DIPG, LG-BSG, and normal brainstem (individual cases plotted), as assessed by mining 
a publicly available database (http://r2.amc.nl). Sensitivity (IC50) of pHGG and DIPG cell lines to 
idarubicin (C), epirubicin (D), daunorubicin (E), mitoxantrone (F), and doxorubicin (G). Sensitivity of 
normal human astrocytes and E98-FM cells to doxorubicin (H). Numbers 1–8 refer to VUMC-HGG and 
VUMC-DIPG cell lines.  
None of the animals treated with low-dose (0.02 mg/ml) doxorubicin or PLD to the pons 
showed significant clinical toxicity, as illustrated by the absence of clinical symptoms after 
CED (data not shown). In our experience, weight loss or inadequate weight gain in the 
animals is a sensitive symptom of toxicity, and all animals treated with 0.02 mg/ml showed 
normal weight gain after treatment (Fig. 3C). To find out the MTD of doxorubicin for injection 
into the pons, mice were treated via CED with doses of 0.1 and 0.04 mg/ml as well. These 
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doses still caused intolerable symptoms that were beyond the criteria set for MTD (clinical 
end point reached > 1 animal, clinical score > 2, data not shown). 
Toxicity of CED of doxorubicin to the thalamus was significantly less pronounced. Medium-
dose (0.2 mg/ml) free doxorubicin and PLD could be delivered to the thalamus without any 
clinical symptoms or weight loss (Fig. 3D). Given the severe toxicity seen after treatment with 
2 mg/ml of doxorubicin to the pons, this dose level was not further assessed in the thalamus 
because of ethical considerations. 
 
 
 
 
Figure 3. Clinical symptoms of mice treated via CED of doxorubicin (Dox) in the brainstem and thalamus. 
Clinical scores (0–4) of mice treated with high-dose (A, 2 mg/ml) or intermediate-dose (B, 0.2 mg/ml) 
free doxorubicin (red), PLD (purple), or vehicle (blue) in the brainstem. Normalized weight gain of mice 
(C) treated with vehicle, 0.02 mg/ml of free doxorubicin, or 0.02 mg/ml PLD in the brainstem. 
Normalized weight gain of mice (D) treated with vehicle, 0.2 mg/ml of free doxorubicin, or 0.2 mg/ml 
of PLD in the thalamus.  
 
 
  
A CED Dox 2 mg/ml pons                       B           CED Dox 0.2 mg/ml pons                
C   CED Dox 0.02 mg/ml pons                     D       CED Dox 0.2 mg/ml thalamus
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Location Dose & Formulation 
Euthanized After CED  
(days) 
Pons 
High 
   Doxorubicin 1–3 
   PLD 5–6 
Middle 
   Doxorubicin 2–3 
   PLD 20–56 
Low 
   Doxorubicin 56 
   PLD 56 
Vehicle 56 
Thalamus 
Middle 
   Doxorubicin 56 
   PLD 56 
Vehicle 56 
Table 1. Number of days after CED that mice were euthanized 
because they reached the clinical end point or the end of 
follow-up 
Histological Toxicity of CED Related to Dose and Formulation of Doxorubicin 
After the mice were euthanized, their brains were histologically analyzed. Animals were 
euthanized 6 weeks after treatment unless they had to be euthanized at an earlier time point 
because of unacceptable clinical symptoms (CED to the pons with high- and medium-dose 
free doxorubicin and high-dose PLD; Table 1).In the pons tissues obtained 6 days after high-
dose (2 mg/ml) PLD treatment, we consistently noted a sharply demarcated lesion with 
incomplete necrosis, dispersed macrophages, and relative sparing of the microvessels (Fig. 
4A). In animals treated with high-dose free doxorubicin (2 mg/ml, clinical end point reached 
1–3 days after treatment), lesions were much less circumscribed and showed insipient 
necrosis of intervascular tissue and more widespread spongy changes of the neuropil (Fig. 
4B). 
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Figure 4. Black squares indicate enlarged areas. Brain slices from the 
pontine area of mice treated with 2 mg/ml of PLD (A), 2 mg/ml of free 
doxorubicin (B), 0.2 mg/ml of PLD (C), or 0.02 mg/ml of free doxorubicin 
(D). Brain slices from the thalamic area of mice treated via CED of 
intermediate-dose (0.2 mg/ml) free doxorubicin (E and F), PLD (G and H), 
or vehicle (I and J). H & E. Bar = 100 μm.  
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In brains treated with medium-dose (0.2 mg/ml) doxorubicin to the brainstem, the tissue 
damage was more variable. In sharp contrast to the functional neurological deficits 
demonstrated in these animals, histological abnormalities at 2–3 days after treatment were 
generally absent. After treatment with 0.2 mg/ml of PLD (brains analyzed 3–6 weeks after 
CED), some focal gliosis and deposition of iron pigment was found (Fig. 4C). Six weeks after 
treatment with low-dose (0.02 mg/ml) free doxorubicin, the brainstem showed only focal 
areas with more coarse texture, consistent with astrogliosis (Fig. 4D), similar to what was 
found in some of the animals treated with low-dose PLD or vehicle only. After 6 weeks of 
follow-up, brains treated with 0.2 mg/ml of free doxorubicin to the thalamus showed clear 
toxicity characterized by a variably circumscribed area of tissue decay, pericellular thickening 
of the walls of microvessels, some iron pigment deposition (partly in macrophages), and 
some proliferation of (myo)fibroblasts (Fig. 4E and F). Brains treated with 0.2 mg/ml of PLD 
still showed similar but less pronounced lesions (Fig. 4G and H). No histological abnormalities 
were detected in animals treated with vehicle to the thalamus (Fig. 4I and J). 
E98-FM Cells and the Formation of Diffuse Infiltrative High-Grade Tumors in the Pons and 
Thalamus 
Adult GBM-derived E98-FM cells have been described to grow as diffuse tumors in the pons, 
with histological and clinical features quite similar to human DIPG 197. To study CED in diffuse 
HGGs in the thalamus, we established thalamic tumors using E98-FM cells. To this end, we 
injected E98-FM cells into previously validated thalamic coordinates and followed in vivo 
tumor growth using BLI. A subset of mice injected with E98-FM to the thalamus and pons 
were euthanized at set time points, and their brains were analyzed to study the size and 
histological features of the tumors (Fig. 5A–C and G–I). Others were followed until the 
previously determined clinical end point (weight loss, severe neurological symptoms, or 
severe inactivity; Fig. 5M and N). Histological assessment showed diffuse infiltrative tumors 
located in the thalamus with tumor size proportionate to the bioluminescence signal. Median 
survival of mice with E98-FM-thalamus was 23.5 days (8 mice; Fig. 5M); for those with E98-
FM-DIPG, median survival was 22 days (6 mice; Fig. 5N). 
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Figure 5. Validation of the E98-FM tumor model in the pons and thalamus. Progression of E98-FM 
tumors after injection to the thalamus or pons at Days 7 (A and G), 14 (B and H), and 21 (C and I). 
Corresponding BLI signals (D and J, E and K, and F and L, respectively) and survival curves (M and N). 
Eight mice per tumor line listed. Bar = 100 μm. 
 
Treatment of E98-FM-DIPG and E98-FM-Thalamus with Free Doxorubicin or PLD 
Both E98-FM-DIPG and HSJD-DIPG-007-Fluc, and E98-FM-thalamus tumors were treated via 
CED of free doxorubicin, PLD, or vehicle at the MTD determined in the previous toxicity 
experiments. The treatment and follow-up schedule are depicted in Fig. 6. Median survival 
of E98-FM-DIPG and HSJD-DIPG-007-Fluc animals treated with free doxorubicin or PLD at a 
low dose (0.02 mg/ml) did not differ significantly from animals treated with vehicle (Fig. 7A 
and G), and the bioluminescence signal was not significantly different for the E98-FM-DIPG 
and HSJS-DIPG-007-Fluc groups, regardless of treatment (Fig. 7B and H). Of note, one mouse 
with HSJD-DIPG-007-Fluc treated with PLD survived beyond the 90 days of follow-up. In mice 
with E98-FM-thalamus tumors treated with a medium dose (0.2 mg/ml), the 
bioluminescence signal of the tumors was significantly lower in the mice treated with PLD 
than in those treated with vehicle or free doxorubicin (Fig. 7D). Survival did not differ 
significantly for the whole E98-FM-thalamus tumor group, regardless of treatment; however, 
2 of 8 animals treated with PLD had a prolonged decrease in BLI signal and prolonged survival 
(Fig. 7C). Treating mice with E98-FM-DIPG tumors with intravenous PLD did not significantly 
influence clinical course (Fig. 7E) or bioluminescence signal (Fig. 7F). 
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Figure 6. Schematic of the 
treatment and follow-up for 
E98-FM-DIPG and E98-FM-
thalamus (A) and HSJD-DIPG-
007-Fluc (B). 
Figure 7. Survival and corresponding BLI data of mice with E98-FM-DIPG (A and B) or E98-FM-thalamus 
(C and D) treated with free doxorubicin (red), PLD (purple), or vehicle (blue). Survival (E) and BLI (F) data 
of mice treated with intravenous (iv) PLD or vehicle. Survival (G) and BLI (H) data of HSJD-DIPG-007-
Fluc mice treated with 0.02 mg/ml of doxorubicin, PLD, or vehicle. *p < 0.05.  
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Influence of E98-FM Tumor Size on Efficacy of PLD Treatment via CED 
In the efficacy study using E98-FM-thalamus orthotopic tumors, we found a significant 
difference in the bioluminescence signal in the 1st week after treatment with 0.2 mg/ml PLD 
and noticed a survival benefit in a small proportion (2 of 8) of the mice. To determine whether 
this survival benefit was due to a true treatment-dependent decrease in tumor burden or 
just a random occurrence, we studied these animals in more detail. One noticeable 
difference in animals that responded to treatment was a relatively low bioluminescence 
signal at the start of treatment. Even though the median BLI signal was not significantly 
different between groups, there was great variation in the signal at the start of treatment 
(Fig. 8A, D, and G). We studied the response of each individual animal in relation to the 
bioluminescence signal at the start of treatment. Thereto, we stratified mice into low (< 
106photons/sec), medium (< 107 photons/sec), or high (> 107 photons/sec) tumor burden at 
the start of treatment. By doing so, we found that mice with E98-FM-thalamus tumors with 
a low tumor burden showed response to treatment with 0.2 mg/ml of PLD (Fig. 8F), while no 
responsive subgroup could be identified in the E98-FM-DIPG or HSJD-DIPG-007-Fluc tumors 
treated either via CED (PLD or doxorubicin; Fig. 8C and Supplemental Fig. 3) or intravenously 
(Fig. 8I). In these mice, the BLI signal rose exponentially without change, in a manner similar 
to that in vehicle-treated animals. This finding suggests that tumor size at the start of 
treatment has substantial influence on the efficacy of CED of PLD at the MTD in the thalamus 
but not in tumors in the pons treated at the MTD via CED or intravenously. 
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Figure 8. Bioluminescent imaging response at the start of CED for E98-FM-DIPG (A) or E98-FM-thalamus 
(D) or E98-FM-iv (G) treated with free doxorubicin (red), PLD (purple), or vehicle (blue). The BLI response 
of individual mice was related to the bioluminescent signal at the start of CED. E98-FM-DIPG treated
with vehicle (B) or low-dose doxorubicin (C), E98-FM-thalamus treated with vehicle (E) or intermediate-
dose PLD (F), or intravenous (iv) administration of vehicle (H) or PLD (18 mg/kg once a week for 2
weeks, I). 
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    ____________________________________ 
Using in silico and in vitro experiments, we 
identified anthracyclines as an interesting class 
of chemotherapeutics that could potentially be 
administered for the treatment of DIPG and 
pHGG. Topoisomerase Type IIA, previously 
shown to be correlated with anthracycline efficacy in patients 223,224, was highly expressed in 
both DIPG and pHGG compared with levels in normal brain and brainstem. Furthermore, we 
showed that pHGG and DIPG cells were sensitive to anthracyclines in vitro. The severity of 
toxicity after local delivery via CED, however, limits effective treatment in vivo. 
Anthracyclines' method of action has not been fully elucidated but is thought to be 
multifactorial. The best-known effect of anthracycline drugs is the inhibition of TOPII, which 
is necessary to avoid supercoiling of DNA in dividing cells. Inhibition of TOPII leads to double-
stranded breaks and subsequent cell death via apoptosis. Just a few clinical trials of 
anthracyclines have been conducted in children with pHGG, DIPG, or other recurrent or 
progressive brain tumors 235–237. Results have been variable thus far. In one study, 4 of 8 
patients with recurrent or progressive pHGG responded with stable disease for a period of 
9–48 weeks on a regimen of PLD and oral topotecan, but the toxicity of this systemic 
treatment was high 237. In another study, children with recurrent or progressive brain tumors 
were treated with liposomal daunorubicin, resulting in a treatment response in 6 of 14 
children, with relatively mild toxicities 236. Interestingly, our in vitro data showed that some 
DIPG cells (VUMC-DIPG-A) appeared to be ultrasensitive to 4 of 5 anthracyclines tested, with 
IC50 values well below those needed to treat all other cell lines in this panel and other glioma 
cell lines reported in the literature 238. Only this particular cell line carries a mutation in 
histone gene H3F3A at lysine 27 (K27M) 24, which can be found in approximately 60% of 
DIPGs 23. This mutation alters the organization of chromatin by the inability of EZH2 to 
trimethylate lysine 27. The absence of Lys27 trimethylation causes a more open chromatin 
structure and leads to gross changes in expression profiles of various cell types 6,239,240. It was 
recently discovered that certain anthracyclines, including doxorubicin and daunorubicin, can 
cause histone eviction, especially in chromatin regions with an absence in trimethylation at 
lysine 27 241. This mechanism could potentially add to the sensitivity of H3F3A-mutated DIPG 
cells to anthracyclines. Further experiments to elucidate the role of histone eviction are 
beyond the scope of this paper. Unfortunately, the VUMC-DIPG-A cell line does not engraft 
after inoculation in the brain of mice and thus could not be used to perform the in vivo 
efficacy experiment. Therefore, another H3F3A K27M mutated cell line (HSJD-DIPG-007-
Fluc), which was not part of our initial screen, was used. This cell line was intermediately 
sensitive to doxorubicin in vitro, but no efficacy of low-dose doxorubicin via CED could be 
established using our methods. 
DISCUSSION 
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Despite their potential, these compounds' limited penetration of the brain after systemic 
delivery greatly constricts their clinical use in the treatment of brain tumors. In this study, we 
investigated the feasibility of using CED for local delivery of doxorubicin in the brainstem and 
thalamus. To our surprise, doxorubicin showed an MTD that was 100 times lower than the 
dose previously described to be safe for local delivery in the rat striatum 220. In our 
experience, anatomical location clearly influenced clinical toxicity after CED. The tolerable 
dose when treating mice via CED of doxorubicin to the thalamus was 10 times higher than 
the MTD to the brainstem. Meanwhile, histological analysis of brains after CED showed 
similar tissue damage in the infused regions. Why this difference in toxicity occurs is not 
completely understood. We hypothesize that damage to the brainstem, including the pons, 
is more likely to produce functional deficits as compared with damage to structures in the 
thalamus, a phenomenon that is well known in human neurology. Of note, we only studied 
indirect distribution of doxorubicin by observing the spread of histological toxicity. In theory, 
it is possible that the distribution of free doxorubicin or PLD differs between the pons and 
the thalamus, causing differences in clinical presentation after CED. In this study, we also did 
not investigate more subtle defects in performance in mice treated with moderately high-
dose doxorubicin in the thalamus. In doing so, we may have observed functional deficits that 
escaped our attention using basic observations. The expected tolerable dose in the thalamus 
still differed 10-fold from safe concentrations delivered to the striatum of rats described in 
the literature. Although toxicity after CED appears to be related to concentration and not 
total dose 242, this finding could still be explained by the use of a relatively large volume (15 
μl) compared with the volume used in most CED studies using rats (average 20 μl). 
Furthermore, additional toxicity could be species or even strain related. 
Liposomal formulation of doxorubicin gave rise to clinical symptoms in mice much later than 
did the free doxorubicin, but despite this lag time, free and liposomal doxorubicin had similar 
MTDs. The distribution of PLD was more sphere-like, as illustrated by the circumscribed 
lesions found in the brains of animals treated with high doses. The high protein affinity of 
free doxorubicin (nearly 98%) could lead to poor distribution, and the PLD used in this study 
should have had a nearly ideal size (100 nm in diameter 231) for convection through the brain 
interstitial spaces 222. Our data imply that PLD indeed gives a more gradual release of 
doxorubicin and a wider area of distribution after CED. Both effects may enhance efficacy of 
CED in patients. 
The low-dose doxorubicin (MTD pons) was ineffective in treating a diffusely growing 
orthotopic DIPG model with a single delivery, suggesting that no therapeutic window could 
be reached and that a one-time infusion of doxorubicin via CED would most likely have no 
role in the treatment of DIPG. This result is contrasted by data from our in vitro experiments 
showing cytotoxicity at much lower in vitro IC50 values than those delivered to tumors in vivo 
(up to a theoretical million-fold difference) and a substantial difference in cell survival 
between E98-FM and normal human astrocytes (Fig. 2H). The difference between in vitro 
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efficacy and in vivo lack of efficacy could be attributable to inadequate coverage of the tumor 
due to inadequate distribution or fast efflux of doxorubicin from the brain by efflux pumps 
243, causing a much lower area under the curve than with in vitro treatment. When using the 
10-fold higher dose (MTD thalamus), PLD was effective in slowing down tumor growth in the 
thalamus. These findings suggest that data from supratentorial CED studies cannot be 
directly translated to design trials to treat infratentorial tumors and stress the need for 
selective agents to avoid excessive toxicity to healthy surrounding tissue, especially to treat 
tumors in delicate areas of the brain. One preclinical study has already shown that infusing 
the more targeted small-molecule inhibitors dasatinib, everolimus, and perifosine can be 
safely performed in the rat pons using long-term CED 244.  
Using our methods, we were able to infuse a substantial area of the pons, but even when 
treating this area, CED was only effective when tumors were still very small. This is 
particularly problematic considering the small size of the murine pons compared with the 
human pons. Translating this knowledge to a clinical setting would imply treating only small, 
very-early-stage tumors. Since this is not the clinical reality of DIPG and thalamic HGG, CED 
will require drugs with a very high therapeutic index or long-term continuous infusions with 
lower-concentration drugs. To achieve the latter, it will be necessary to apply more 
sophisticated techniques such as using multiple infusion catheters and computer modeling 
for targeted infusion 187,245 or brain-penetrating nanoparticles with regulated release 
222,244. These projects are ongoing, and results from clinical studies are eagerly awaited. To 
advance CED to an effective treatment strategy for pHGG including DIPG will be a clinical, 
biological, and technical challenge requiring a comprehensive multidisciplinary approach. 
 
Conclusions 
In vitro studies showed that anthracyclines, especially doxorubicin, are effective against 
pHGG and DIPG cells, while sparing normal human astrocytes. Convection-enhanced delivery 
can be used to achieve an adequate concentration of doxorubicin at the site of the tumor. 
However, preclinical evaluation of CED with free and liposomal doxorubicin showed that no 
therapeutic window could be reached in the pons to locally treat diffuse orthotopic 
brainstem tumors in mice because of excessive toxicity. The administration of higher-dose 
doxorubicin in orthotopic tumors within the thalamus was tolerated and effective in slowing 
down tumor growth. This preclinical study raises awareness that results obtained from 
supratentorial CED studies cannot be directly translated to the treatment of infratentorial 
tumors. 
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Supplementary Figures 
Supplemental Figure 1 (A) Kaplan-Meier curve of naïve mice treated with 2 mg/ml free doxorubicin 
(red), PLD (purple) or vehicle (blue) (B) Normalized weight curves of naïve mice treated with 2 mg/ml 
free doxorubicin (red), PLD (purple) or vehicle (blue) 
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Supplemental Figure 2. In vitro sensitivity of HSJD-DIPG-007-Fluc to 
doxorubicin 
 
 
 
Supplemental Figure 3. BLI data of HSJD-DIPG-007-Fluc treated with 
doxorubicin, PLD or vehicle, plotted for each individual mouse and 
showing one long-term survivor treated with PLD. 
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The role of the vascular endothelial growth
factor (VEGF)-inhibitor bevacizumab in the 
treatment of diffuse intrinsic pontine glioma 
(DIPG) in children is unclear. The aim of this 
study was to determine the biodistribution and uptake of zirconium-89 (89Zr)-labeled 
bevacizumab in DIPG mouse models.  
Human E98-FM, U251-FM glioma cells and HSJD-DIPG-07-FLUC DIPG primary cells were 
injected into the subcutis, pons, or striatum of athymic nude mice. Tumor growth was 
monitored by bioluminescence imaging (BLI) and visualized by Magnetic Resonance 
Imaging (MRI).  Seventy-two to 96 hours after intraperitoneal 89Zr-bevacizumab injections, 
mice were imaged by Positron Emitting Tomography (PET) and biodistribution was analyzed 
ex vivo.  
Data from a publicly available database showed up-regulation of VEGF expression in human 
DIPG and pediatric high-grade glioma (pHGG). However, in our preclinical tumor models no 
significant 89Zr-bevacizumab uptake could be detected in orthotopic gliomas located in the 
pons and striatum at an early or late stage of the disease. The E98-FM, and to a lesser 
extent the U251-FM and HSJD-DIPG-07 subcutaneous tumors, showed high accumulation 
of 89Zr-bevacizumab. VEGF expression could not be demonstrated in the intracranial 
tumors by in situ hybridization (ISH), but was clearly present in the perinecrotic regions of 
the subcutaneous E98-FM tumors. 
The poor uptake of 89Zr-bevacizumab in orthotopic diffuse infiltrative tumors in the pons 
and striatum and high uptake in subcutaneous E98-FM-tumors, suggests that VEGF 
targeting with bevacizumab has limited efficacy for diffuse infiltrative parts of glial brain 
tumors in mice. Translating these results to a clinical setting would imply that treatment 
with bevacizumab in children with DIPG is only justified after demonstrating the presence 
and targeting of VEGF in the tumor by applying techniques such as 89Zr-bevacizumab 
immuno-PET studies. We aim to confirm this observation in a clinical PET study with DIPG 
patients. 
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    __________________________________ 
Recent advances in molecular and cellular 
cancer biology have resulted in the 
identification of critical molecular tumor 
targets involved in the different phases of 
tumor growth and spreading. This knowledge has boosted the rational design of novel 
drugs, especially monoclonal antibodies and tyrosine kinase inhibitors. However, broad 
application of these targeted therapies to treat brain tumors has lagged behind in daily 
clinical practice. By using molecular positron emission tomography (PET) imaging, target 
expression, bio-distribution can be studied concurrently in a relatively non-invasive 
manner. It potentially allows the identification of those patients who may, or may not, 
benefit from targeted therapy. 
A disease that may benefit from molecular imaging is diffuse intrinsic pontine glioma 
(DIPG), a childhood malignancy located in the brainstem. In the past 40 years the outcome 
of patients with DIPG has remained unchanged, with less than 10% of the patients being 
alive two years from diagnosis 168,169. Given the lack of gadolinium uptake on MRI in DIPG 
tumors 22, it is plausible that the blood brain barrier (BBB) in DIPG often remains intact 
which might explain the resistance to systemic chemotherapy in these patients. 
A well-studied drug target in gliomas is the vascular endothelial growth factor (VEGF), a 
signal protein stimulating angiogenesis and increasing vessel permeability 246. 
Overexpression of VEGF-A, its receptor VEGFR2, or both, have been implicated as poor 
prognostic markers in various clinical studies 246,247. Bevacizumab is a recombinant 
humanized monoclonal antibody that selectively binds with high affinity to all isoforms of 
human VEGF-A, and neutralizes their biologic activity 246,248. Studies in adult patients with 
recurrent high-grade gliomas (HGG) reported high radiological response rates with 
bevacizumab treatment 248–250 but recently two large phase III randomized studies showed 
no improvement in overall survival with bevacizumab treatment in an upfront setting 251–
253.  Bevacizumab has been studied in a number of non-randomized trials in pediatric brain 
tumor patients. Efficacy in these trials has been variable, with a subset of patients showing 
clear radiological and/or clinical improvement.  The role of bevacizumab in the treatment 
of DIPG patients is even less clear, but is currently studied in several trials 254–257, 
(NCT00890786 and NCT01182350; clinicaltrials.gov; NTR2391 Trialregister.nl).  
No validated methods are available to identify patients who may potentially benefit from 
bevacizumab treatment. Lack of clinical effect may be due to either poor transport of 
bevacizumab into the tumor microenvironment due to an intact BBB, or a lack of VEGF 
expression. In this study, we analyzed VEGF(R) expression in adult and childhood high-
grade gliomas, including DIPG tumors. Furthermore, we studied bevacizumab distribution 
in vivo using molecular PET-imaging with 89Zirconium-labeled bevacizumab in murine DIPG 
models 197. 
INTRODUCTION 
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VEGF-A and VEGFR2 mRNA expression profiles 
VEGF-A and VEGFR2 (KDR) mRNA expression 
in DIPG (n=27) and pediatric high-grade 
glioma (pHGG) (n=53) were determined in 
silico, using publicly available datasets, and compared to a dataset of non-malignant brain 
tissue (n=44), low grade brainstem glioma (n= 6) and adult HGG (n=284).  These datasets 
include tumor material from biopsy, resection and autopsy (DIPG). Differences were 
analyzed by two-way ANOVA and a p < 0.01 was considered significant. As a validation of 
these findings, VEGF associated gene expression was studied in normal brain, low grade 
brainstem glioma (LG-BSG), DIPG and GBM by creating a heat map using K-means 
clustering. All expression analyses were performed using R2, a web-based microarray 
analysis and visualization platform (http://r2.amc.nl).  
 
Immunohistochemistry and in situ hybridization 
Formalin-fixed paraffin-embedded slides were sectioned from xenograft tumors and brain 
tissue and subjected to immunohistochemical (IHC) staining. Briefly, after deparaffinization 
and heat induced antigen retrieval, sections were incubated with primary mouse anti-Ki67 
antibodies (clone MIB-1, DAKO) overnight at 4°C. Thereafter slides were washed and 
incubated with HRP-conjugated EnVision (DAKO) and subsequently stained by DAB with 
hematoxylin counterstaining. 
For in situ hybridization (ISH), tumors were cut in 5 µm slices and incubated with VEGF 
probes against the human VEGF coding sequence using a previously described protocol 258. 
Samples were evaluated by microscopy with a Zeiss Axioskip microscope (HBO100W/Z), 
equipped with a Canon digital camera and imaging software (Canon PowerShot A640, 
Canon Utilities, ZoomBrowser Ex. 5.7, Canon Inc., Tokyo, Japan).  
 
Labeling and quality control of 89Zr-bevacizumab 
Bevacizumab was labeled with zirconium-89 using N-succinyl-desferrioxamine (N-suc-Df) 
as described previously 259. In short: the chelator, desferrioxamine, was succinylated to N-
suc-Df. Next, the hydroxamate groups were blocked with iron and the succinyl group was 
activated as its TFP-ester (Fe-N-suc-Df-TFP ester).  Bevacizumab (6 mg/mL) was reacted 
with two equivalents of Fe-N-suc-Df-TFP ester at pH 9 for 30 min at room temperature. 
Hereafter, iron was removed at pH 4.2-4.5 with an excess of ethylenediaminetetraacetic 
acid (EDTA) for 30 min at 35°C and N-suc-Df-bevacizumab was purified by size exclusion 
chromatography using a PD-10 column. Radiolabeling of N-suc-Df-bevacizumab was 
performed in HEPES buffer: to 200 μL 89Zr in 1M oxalic acid 90 μL 2M Na 2 CO 3  was 
added. After 3 min 300 μL 0.5 M HEPES, N-suc-Df-bevacizumab and 700 μL 0.5 M HEPES 
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were added. After 60 minutes reaction time 89Zr-N-suc-Df-bevacizumab was purified by 
PD10 using 5 mg/mL gentisic acid in 0.9% NaCl (pH 4.9-5.4) as the mobile phase.  
 
Radiochemical purity and antibody integrity were determined using instant thin-layer 
chromatography (iTLC), high-performance liquid chromatography (HPLC) and sodium 
dodecylsulfate-polyacrylamide gel electrophoresis followed by phosphor imager analysis. 
For analysis of immunoreactivity an ELISA based assay was used. iTLC analysis of 89Zr-
bevacizumab was performed on TEC control chromatography strips (Biodex). As the mobile 
phase, citrate buffer (20 mmol/L, pH 5.0) containing 10% acetonitrile was used. HPLC 
analyses of bevacizumab modification and radiolabeling were performed using a Jasco 
HPLC system equipped with a SuperdexTM 200 10/30 GL size exclusion column (GE 
healthcare Life sciences) using a mixture of 0.05 M sodium phosphate, 0.15 M sodium 
chloride (pH 6.8) and 0.01 M NaN 3  as the eluent at a flow rate of 0.5 mL/min. The 
radioactivity of the eluate was monitored using an inline NaI(Tl) radiodetector 
(RaytestSockett).  
 
Cell lines and animal models 
Animal experiments were performed in accordance with the European Community Council 
Directive 2010/63/EU for laboratory animal care and the Dutch Law on animal 
experimentation. The experimental protocol was validated and approved by the local 
committee on animal experimentation of the VU University Medical Center. Athymic Nude-
Foxn1nu mice (six weeks old) were purchased from Harlan/Envigo (Horst, The Netherlands) 
and kept under filter top conditions and received food and water ad libitum. 
 
The primary HSJD-DIPG-07 cell line was established from DIPG tumor material obtained 
after autopsy from a 6-year-old patient and was confirmed to have a H3F3A (K27M) and 
ACVR1 (R206H) mutation 260. The E98 cell line was obtained from Radboud University 
Medical Center Nijmegen 261, the  U251 glioma cell line from ATCC. All cell lines were 
transduced in our laboratory to express firefly luciferase (FLUC) and/or mCherry 261,262. Cell 
lines were mycoplasm negative and were authenticated by STR-analysis modified from De 
Weger et al. 263   
 
E98-FM cells were injected subcutaneously in female athymic nude mice (7-9 weeks of age) 
to expand the number of cells 197. When the subcutaneous tumor reached a diameter of 1 
cm, the tumor was removed and a single cell suspension was prepared by mechanical 
disruption through a 100 µm nylon cell strainer. HSJD-DIPG-07-FLUC was cultured in tumor 
stem medium (TSM) 24, U251-FM in DMEM supplemented with 10% FCS and penicillin/ 
streptomycin.  Shortly before stereotactic injection, cells were washed once with 
phosphate buffered saline (PBS) and concentrated to 1x105 cells per µl. Mice were 
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stereotactically injected with 5x105 cells in a final volume of 5 µL into either the pons or 
striatum, or injected subcutaneously with 3x106 cells in a final volume of 100 µl/flank. 
Coordinates used for intracranial injections were -1.0 mm X, -0.8 mm Y, 4,5 mm Z from the 
lambda for pontine tumors and 0.5 mm X, 2 mm Y, −2 mm Z from the bregma for the 
striatum tumors. Coordinates were previously validated and based on “The mouse brain in 
stereotaxic coordinates” by Franklin and Paxinos 200. Tumor engraftment was monitored by 
bioluminescence measurement of the Fluc signal. For E98-FM, early stage tumors in the 
pons (n=8), striatum (n=7) and s.c. xenografts (n=3) were allowed to grow for 18 days and 
late stage tumors (n=9, striatum; n=3, subcutaneous) for 35 days after xenograft injection.  
E98 xenograft tumors in the pons were not available 35 days post injection, because 
injection of E98FM cells in the pons would result in death of the mice due to tumor growth 
within three weeks. For HSJD-DIPG07-FLUC and U251-FM tumors (pons, striatum, 
subcutaneous) were evaluated, at days 78 and 22 respectively (Figure 2A) 
 
Two to three days before the endpoint of the study, mice were injected intraperitoneally 
(i.p.) with 89Zr-labeled bevacizumab (40 µg, 5 MBq for PET analysis and ex vivo 
biodistribution or 185 kBq for ex vivo biodistribution only).  
 
PET-imaging and ex vivo analysis 
The distribution of 89Zr-bevacizumab was determined 72 hours (ex vivo only) or 96 hours 
(PET followed by ex vivo analysis) after administration, as a minimum of 72 hours interval 
between injection and scanning has previously been shown to achieve optimal tumor-to-
nontumor ratios 264. Scanning of E98-FM tumors was performed using a LSO/LYSO double 
layer ECAT High-resolution Research Tomograph (HRRT, CTI/Siemens, Knoxville, TN, USA): 
a small animal and human brain 3-dimensional (3D) scanner with high spatial resolution 
(2.3–3.4 mm full width at half maximum) and high sensitivity 265. Mice were anesthetized 
by isoflurane inhalation anesthesia (1.5 L 0 2 /minute and 2.5% isoflurane) before 
positioning in the HRRT. A static transmission scan (6 min) using a rotating 740 MBq 137Cs 
point source was performed. Prior to positioning the mice in the HRRT, a canula was placed 
i.p. to enable later injection of 18F(-). Static images of 60 minutes acquisition time were 
obtained. Immediately thereafter 18F(-) was injected i.p (10 MBq/mouse) for co-localization 
of bone structures (static images of 60 minutes acquisition). Body temperature was 
controlled with a heated platform (kept at 37 °C).  
 
Mice with HSJD-DIPG07-FLUC or U251-FM tumors and where tumor growth was confirmed 
by increase of BLI signal were imaged using another, preclinical, PET system, (Nanoscan 
PET-CT, MEDISO, Budapest, Hungary), 72 hours after 89Zr-bevacizumab injection. PET 
images were analyzed using AMIDE software. (Amide’s a Medical Image Data Examiner, 
version 1.0.1) 266  
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Magnetic Resonance Imaging (MRI) 
Mice with representative HSJD-DIPG-07-FLUC or U251-FM tumors were selected for MRI 
based on the intensity of the bioluminescence signal. Gadolinium (750 µmol, Dotarem) was 
administered i.v. immediately before imaging. Mice were anesthetized by isoflurane 
inhalation anaesthesia (1.5 L 0 2 /minute and 2.5% isoflurane), placed in a preclinical PET-
MRI system (Nanoscan system, MEDISO, Budapest, Hungary) and T1 and T2 weighed 
images were acquired. MRI images were analyzed using MIPAV software (Medical Image 
Processing, Analysis, and Visualization, version 7.2.0). 
 
Ex vivo analysis 
Immediately after PET-imaging, animals were sacrificed for ex vivo tissue distribution 
analysis. Blood, urine, tumor and various tissues were excised, rinsed in PBS to remove 
residual blood, and weighed. Radioactivity in blood and tissues (in percentage injected dose 
per gram of tissue: % ID/g) was determined using an LKB 1282 gammacounter 
(Compugamma,LKB Wallac, Turku, Finland). Differences in the amount of radioactivity in 
healthy brain regions versus subcutaneous-, pontine-, and striatal tumors were analysed 
by Kruskal-Wallis test with Dunn's Multiple Comparison posthoc testing. A p<0.05 was 
considered statistically significant. 
 
 
Figure 1: Expression profiles of VEGF-A and VEGFR2  
1A: Box-plots representing relative median mRNA expression in diffuse intrinsic pontine glioma (DIPG) 
(n=27) and pediatric high grade glioma (pHGG) (n=53), versus datasets of normal brain tissue (n=44, 
blue), low grade brainstem glioma (n= 6) and adult HGG (n=284). VEGF-A overexpression is shown in 
DIPG compared to normal brain and compared to adult glioma. 1B: VEGFR2 is not overexpressed in 
DIPG and pediatric glioma compared to normal brain. * P<0.01, ANOVA 
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VEGF-A, VEGFR2 and VEGF associated gene
expression in DIPG A search in a publicly 
available mRNA expression database 
curated by the Amsterdam Medical Center 
(R2.amc.nl) revealed that VEGF-A mRNA is 
overexpressed in DIPG compared to normal brain and compared to low grade brainstem 
glioma (LG-BSG) and non-pontine adult- and pediatric HGG (Figure 1a; p<0.01, ANOVA). 
VEGFR2 (KDR) mRNA expression was low in both pediatric and adult glioma, compared to 
normal brain (Figure 1b; p<0.01, ANOVA).  A heatmap generated using K-means clustering 
of expression of VEGF-A associated genes confirmed an aberrant VEGF-A pathway to be 
more prominent in DIPG compared to LG-BSG. Most DIPG (red) samples clustered together 
with pediatric GBM (green) and LG-BSG (blue) clustered with normal brain tissue (purple) 
(supplemental Figure 1). 
Figure 2A: Schematic overview of the experiment. Cells are injected at day 0 in the pons, striatum or 
subcutis (early stage tumors) or the striatum and subcutis (late stage E98-FM tumors). Tumor 
progression was monitored by bioluminescent imaging. The time point for 89Zr-bevacizumab 
injection was dependent on the growth speed of used cell lines. This injection was done 72-96 hours 
before PET scanning. MRI, PET or PET/CT imaging was followed by ex vivo measurement of 89Zr-
bevacizumab accumulation in tissues (Bio-distribution) . 2B: Charged couple device (CCD) camera 
images of mice bearing E98-FM tumors. BLI images were obtained at the study endpoint, day 18 
(early stage, upper panel) and day 35 (late stage, lower panel).  
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Biodistribution of 89Zr-bevacizumab  
After tumor growth was confirmed by increase in bioluminescence (BLI) signal, 89Zr-
bevacizumab was injected in these animals. 72 – 96 hours after i.p. injection of 89Zr-
bevacizumab, animals were imaged by PET; a schematic overview of the experiment is 
given in Figure 2, with representative BLI figures of E98-FM engrafted mice shown in Figure 
2b.  89Zr-bevacizumab uptake was not visualized in the E98 gliomas located in the pons 
(only early stage, Figure 3a) or in the striatum at early or late stage. The rest of the brain 
showed no uptake of 89Zr-bevacizumab either, independently of the presence of a tumor. 
However, subcutaneous E98 tumors showed high accumulation of 89Zr-bevacizumab 
indicated by a red hotspot (Figure 3a).  
Figure 3A: 89Zr-PET combined with 18F- imaging of mice with an E98 tumor located in the pons (upper 
panels), or subcutaneous (bottom panels). White circles indicate expected location of intracranial 
tumors. While no uptake of 89Zr-bevacizumab is observed in the pontine tumor, the subcutaneous 
tumor shows a PET hot spot reflecting 89Zr-bevacizumab accumulation in the tumor (arrow). In all 
animals, high intensity (visualized by red color code)  is seen in the heart and liver of the mice, 
reflecting 89Zr-bevacizumab in the blood pool.. Images acquired with Siemens HRRT. 3B: Immuno-PET 
scanning of mice with HSJD-DIPG07-Fluc (upper and middle panels) or U251FM tumors (bottom 
panels) confirmed the lack of bevacizumab uptake in intracranial tumors. Image acquired with 
MEDISO Nanoscan PET-CT system. White circles indicate expected location of intracranial tumors.  Ex 
vivo tissue distribution measurements confirmed that no significant 89Zr-bevacizumab uptake was 
detected in the brain or brain tumor at any stage of disease, while there was high uptake in the 
subcutaneous tumor (p < 0.01)  (Figure 4a).  
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Besides accumulation in the subcutaneous tumor with an average level of 50% ID/g, 89Zr-
bevacizumab was measured in all animals (to a lesser extent) in the blood pool and in well-
perfused organs, such as the liver, spleen and lungs (Figure 5). Experiments using the two 
other cell lines (U251FM and HSJD-DIPG-07-FLUC) showed comparable results. Using these 
cell lines, no uptake of 89Zr-bevacizumab was visualized on PET in any of the xenografts 
(Figure 3b). Ex vivo biodistribution analysis showed higher 89Zr-bevacizumab uptake in 
subcutaneous HSJD-DIPG-07-FlUC tumors (p<0.05) as compared to brain (areas) without 
tumor (Figure 4b). The subcutaneous U251FM tumors showed no significant increase in 
89Zr-bevacizumab uptake (Figure 4c) as compared to non-tumor brain. Of note, both HSJD-
DIPG-07-FLUC and U251FM cells formed only very small subcutaneous tumors during the 
time window in which mice baring intracranial tumors had reached human endpoints (78 
vs. 22 days after tumor injection).                                                                 .  
Figure 4: 89Zr-bevacizumab measured ex vivo by a gamma-counter and normalized to counts found in 
healthy brain tissue (brain tissue of animals without xenografted brain tumors). 4A: Uptake is 
significantly higher in the subcutaneous E98-FM tumors (***p<0.01), but there is no significant 
difference in uptake in pontine or striatal xenografts at any stage of the disease compared to normal 
brain. 4B: Uptake in subcutaneous DIPG7-Fluc tumors is higher than in normal brain(*p<0.05). 4C: No 
significant differences between U251-FM tumors (s.c. or intracranial) versus normal brain. 
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Figure 5:  89Zr-bevacizumab uptake measured ex vivo by radioactivity of the specific organs and the 
tumor after dissection, expressed as percentage of the injected dose per gram tissue in E98-FM 
tumor bearing animals. Note the high uptake in subcutaneous tumors, compared to the negligible 
uptake in the intracerebral tumors. 
 
In situ-hybridization of VEGF 
To determine whether the differences in 89Zr-bevacizumab uptake in the subcutaneous and 
the intracranial tumors were due to an impaired distribution of 89Zr-bevacizumab into the 
brain or to a differential expression of its target (or both), VEGF expression was analyzed in 
the different xenografts. In situ hybridization confirmed expression of VEGF in the 
subcutaneous E98FM tumor (Figure 6a), while VEGF expression was absent in E98FM-brain 
tumors (Figure 6b) and brain tissue without a xenograft. Of note, in the subcutaneous 
tumors, VEGF was preferentially expressed in perinecrotic areas, while necrosis was absent 
in all of the striatal and pontine tumors. A Ki67 (Mib-1) staining was performed to confirm 
presence of proliferating tumor tissue (Figures 6c,d). In HSJD-DIPG-07-FLUC and U251FM 
tumors, VEGF mRNA expression was not detectable in striatal and pontine gliomas. The 
subcutaneous tumors were too small to adequately perform VEGF ISH and therefore no 
conclusions could be drawn regarding VEGF expression in these s.c. tumors.  
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Figure 6: VEGF expression in DIPG tumors as assessed by VEGF in situ hybridization (ISH).  6A: 
Positive VEGF staining in subcutaneous E98-FM tumor cells (magn. 20x, insert 2,5x). The tumor 
shows extensive necrosis surrounded by VEGF positive cells. 6B: No VEGF mRNA is detected in 
the E98-FM tumor tissue in the striatum (magn. 20x, insert 1.25x). 6C: Ki67 staining shows the 
presence of proliferating tumor cells in the subcutaneous tumor tissue (magn. 20x, insert 2.5x). 
6D: Ki67 positive tumor cells in the striatal E98-FM tumor (magn. 20x, insert 10x) 
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Magnetic Resonance Imaging. 
To visualize disruption of the blood-brain-barrier, mice with HSJD-DIPG07-FLUC and U251-
FM intracranial tumors were imaged by MRI after intravenous administration of 
gadolinium. In the diffusely growing HSJD-DIPG07-FLUC tumor, gadolinium enhancement 
on T1 weighed images was limited (Figure 7a, arrow), whereas gadolinium enhancement 
was clearly visible in the U251-FM tumor (Figure 7c, arrow). On T2 weighed images, tumors 
were not clearly visible (Figures 7b, d; arrow).  
 
 
Figure 7: MRI scans of pontine tumors. The 89Zr-bevacizumab uptake in the tumors 
of these two mice is presented as %ID/g. 7A: Limited gadolinium contrast 
enhancement in the tumor area (arrow) on T1 scan. 7B: HSJD-DIPG07-Fluc tumor is 
poorly visible on T2 weighed MRI image (arrow). 7C: Clear gadolinium contrast 
enhancement in the U251-FM tumor area (T1 weighed MRI scan) indicates disruption 
of the blood-brain-barrier. 7D: U251-FM tumor is visible on T2 weighed MRI scan. 
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The potential benefit of bevacizumab in the 
treatment of DIPG is unclear, as efficacy 
depends on expression of VEGF-A as well as 
appropriate drug distribution 267. We used 
molecular PET-imaging to study the influence of location and stage of disease on 
biodistribution of 89Zr-bevacizumab in three glioma mouse models (pontine, striatal, 
subcutaneous) using three different cell lines. The E98-FM pontine and striatal and HSJD-
DIPG-07 pontine xenograft models have previously been described to resemble the diffuse 
phenotype of human DIPG and other diffuse high grade gliomas 197,229,233. U251 has been 
described as an intracranial murine tumor model that recapitulates most of the key figures 
of adult GBM 268. We found no significant uptake of 89Zr-bevacizumab in the intracranial 
tumor models at any stage of the disease, nor in the normal/non-neoplastic surrounding 
brain. In contrast, high accumulation of 89Zr–bevacizumab was observed in the 
subcutaneous E98-xenograft and moderate uptake in the subcutaneous HSJD-DIPG07-
FLUC. 
We initially hypothesized that lack of 89Zr–bevacizumab uptake could be explained solely 
by poor distribution into the brain, as large molecules like monoclonal antibodies may not 
be able to pass the BBB. This hypothesis is supported by the absence of enhancement of 
the tumor on MRI after administration of gadolinium in animals with HSJD-DIPG-07-FLUC 
pontine tumors. However, MRI analysis of U251-FM tumors in the brainstem of mice 
showed clear gadolinium enhancement, which is indicative of “leaky” blood vessels in the 
tumor. Furthermore, VEGF expression of the E98FM glioma cells - analyzed by ISH – also 
differed between tumor locations: E98FM gliomas in both striatum and pons appeared 
VEGF-negative, while the s.c. E98FM tumors were partly VEGF-positive. The differences in 
VEGF expression of the tumors in distinct locations originating from the same cell line, 
confirms that the orthotopic microenvironment and the resulting growth pattern 
significantly influence gene expression in glioma cells, a phenomenon that has been 
described previously (19, 20). Moreover, it has been shown that in GBM, VEGF is 
predominantly overexpressed in hypoxic, perinecrotic cells 269,270. Indeed, in our study the 
VEGF expression in subcutaneous E98FM tumors was especially present around areas of 
necrosis, whereas in intracranial E98FM tumors necrosis and VEGF expression were lacking 
and this also coincided with lack of bevacizimab uptake studied ex vivo and by PET. Of note, 
bevacizumab does not bind to murine VEGF-A 271, but as typically the neoplastic cells are 
upregulating VEGF expression in tumor angiogenesis we consider it unlikely that stromal 
cell-derived mouse VEGF-A plays an important role in this particular xenograft model. 233 
In contrast to our preclinical findings, the in silico analysis that we performed in this study, 
indicates that human DIPG tumors have relatively high expression levels of VEGF mRNA. 
However, the majority of tumors (23 out of 27) used for the microarray experiments were 
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collected post-mortem 225,272 and therefore these samples represent the end-stage of the 
disease, and are post-radiation therapy. In the end-stage of the disease, DIPG is known to 
have necrotic areas with microvascular proliferations and blood-brain barrier disruption, 
compatible with the histology of a GBM, which is associated with high VEGF expression. 
Although the numbers are low, it is important to point out that VEGF-A expression levels in 
samples obtained pre-treatment were low compared to expression in post-mortem/end-
stage samples (supplemental Figure 2). In addition, biopsy samples that were included in 
the analysis are frequently directed at contrast-enhancing regions, and this 'biased 
sampling' may well lead to overestimation of the role of VEGF in the tumor as a whole. We 
are currently studying the differences in VEGF-A expression in autopsy-derived DIPG tissue 
between the perinecrotic areas and the more diffusely growing tumor parts without 
necrosis.  
Experimental and clinical research in both adult and pediatric high grade glioma and DIPG 
has suggested that there is a complex relation between a histologically diffuse growth 
pattern of tumors, VEGF expression and availability and BBB integrity 210,258,273–276. 
Traditionally, VEGF is viewed as the main cause of increased BBB permeability in CNS 
tumors as represented by contrast-enhancing lesions on MRI 277. More recently, anti-VEGF 
therapy is thought to potentially induce a more diffuse and distant spread of tumor cells 
210,274. In contrast to adult high grade gliomas, gadolinium contrast enhancement on MRI in 
DIPGs at diagnosis is generally limited, with 50% of the patients showing no enhancement 
at all 22. The lack of gadolinium enhancement suggests an intact BBB, at least for large 
molecules, in a substantial percentage of the patients, coinciding with low VEGF expression 
and inability of bevacizumab to target the tumor 211.  
Results from our preclinical PET, MRI with gadolinium contrast and ISH studies suggest that 
this relation is not so straightforward, pressing the need for studying VEGF targeting in 
patients treated with anti-VEGF therapy. One could however argue, whether high local 
tumor accumulation of bevacizumab is at all needed to obtain potential therapeutic effects 
in DIPG. Bevacizumab is capable of decreasing VEGF levels to undetectable range in less 
than 20 days in a large cohort of adult cancer patients 278, but only a subgroup of patients 
responded to anti-VEGF therapy. This suggest simply decreasing VEGF in the blood-pool is, 
at least for the tumor types studied, not sufficient to treat all tumors, and presence and 
targeting of VEGF should therefore be confirmed to identify those patients that will benefit 
from treatment 278–280.   
The results of immuno-PET-imaging and VEGF-ISH in these DIPG models are in line with the 
poor clinical response rates thus far obtained with bevacizumab in children with DIPG 254. 
The data presented suggest that no adequate uptake of bevacizumab will occur in diffusely 
growing gliomas, which present with BBB disruption but without drastically increased VEGF 
expression. Therefore we suggest that bevacizumab treatment is only justified if targeting 
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of VEGF by bevacizumab has been visualized by immuno-PET scan. We aim to confirm this 
hypothesis in a clinical PET study with DIPG patients.  
 
Future directions 
This study underlies the importance of using strong biological and biodistributional 
rationale before using any therapy in any patient. Following the results of this study, we 
developed a molecular drug imaging trial with 89Zr-bevacizumab in children with DIPG 
(study number NTR3518 www.trialregister.nl). This technique aims to further unravel the 
role of bevacizumab treatment in DIPG. Ideally, such molecular imaging is combined with 
VEGF-A and VEGFR2 expression analysis on tumor tissue originating from biopsies taken 
from several (contrast-enhancing and non-enhancing) parts of the tumor. Because DIPG 
can generally be diagnosed based on its typical radiological presentation and the delicate 
nature of the brain involved, taking biopsies from DIPGs is still no common practice and 
bioptic sampling of multiple regions is even more cumbersome. In general, integrating 
molecular imaging with radiolabelled drugs (classic cytostatic agents, small molecules, 
other monoclonal antibodies) in the treatment of childhood brain cancer provides an 
insight in drug targeting and might help to personalize treatment and thereby to avoid 
unnecessary side effects of drugs that do not reach the tumor. 
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Supplementary Figures 
 
Supplemental Figure 1: Heatmap of VEGF-A associated genes generated 
using Spearman’s rank correlation; LG-BSG samples (blue) in the disease 
type histology (upper legends) cluster with normal brain (purple). DIPG 
(red) clusters with GBM (green). DIPG (green), pHGG/GBM (red). 
Supplemental Figure 2: VEGF mRNA expression in DIPG in comparison to 
normal brain (n=31) as analyzed by R2 (R2.amc.nl), clustered by stage of 
disease; unknown (n=10), pretreatment (n=2) and postmortem (n=23)
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________________________________ 
Treatment of medulloblastoma in children fails 
in approximately 30% of patients, and is often 
accompanied by severe late sequelae. 
Therefore, more effective drugs are needed 
that spare normal tissue and diminish long-term side effects. Since radiotherapy plays a 
pivotal role in the treatment of medulloblastoma, we set out to identify novel drugs that 
could potentiate the effect of ionizing radiation selectively.   
A small molecule library, consisting of 960 chemical compounds, was screened for its ability 
to sensitize towards irradiation, using two independent read-out systems.  
 
This small molecule screen identified the flavonoid quercetin as a novel radiosensitizer and 
we show that quercetin can sensitize the medulloblastoma cell lines DAOY, D283-med, and, 
to a lesser extent, D458-med to ionizing radiation at low micromolar concentrations. 
Quercetin enhanced the in vitro radiation sensitivity of medulloblastoma cells in clonogenic 
survival assays at doses used in fractionated radiation schemes. Furthermore, quercetin did 
not affect the proliferation of neural precursor cells or normal human fibroblasts. DAOY and 
D283-med were identified as a SHH and a group 3 subtype medulloblastoma, respectively, 
which may indicate a subgroup-independent effect of quercetin on the radiation response. 
Importantly, in vivo experiments confirmed the radiosensitizing properties of quercetin, as 
administration of this flavonoid at the time of irradiation significantly prolonged survival in 
orthotopically xenografted mice.  
 
Together, these findings indicate that quercetin is a potent radiosensitizer for 
medulloblastoma cells that may be a promising lead for the treatment of medulloblastoma 
in patients.  
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         ____________________________________ 
Medulloblastoma, the most common malignant 
brain tumor in children, accounts for 
approximately 20% of all intracranial childhood 
tumors 281. Medulloblastomas are invasive 
neuroepithelial tumors that are thought to arise from the progenitor cells of the dorsal brain 
stem, or from precursor cells in the cerebellum 282,283. Currently, patients are stratified into 
two groups based on histological features and clinical criteria: the standard- and high-risk 
groups. Treatment of standard-risk medulloblastoma patients consists of surgery and 
reduced-dose craniospinal radiotherapy, followed by an additional boost aimed at the 
primary tumor site, and adjuvant chemotherapy. In high-risk patients, a higher craniospinal 
dose is used 284,285. Although such treatment has resulted in remarkable improvement in 
outcome, this therapy still fails in approximately 30% of medulloblastoma patients 286. 
Moreover, such therapy causes severe long-term side effects that significantly impact quality 
of life 16–18,33,287–289. There is a need for alternative therapies that allow to lower the total dose 
of irradiation or increase the radiation efficacy. Besides new radiotherapy techniques that 
limit the radiation doses to surrounding healthy tissues 290–292, new chemotherapeutics that 
specifically sensitize the tumor to irradiation may provide alternative therapies 293,294.  
We screened a commercially available small molecule library consisting of 960 compounds 
(ActiTarg-K960) with a diversity of chemical structures to identify radiosensitizers for 
medulloblastoma. Chemical structures represented by these compounds have been 
reported to exert kinase inhibitory functions and screening of these compounds would help 
in the identification of new chemical directions for hit optimization. However, to our surprise, 
we identified a known chemical compound, quercetin (3,3’,4’5,7-pentahydroxyflavone), a 
flavonoid found in fruits, vegetables and grains, as a radiosensitizer for human 
medulloblastoma cells. Quercetin treatment at low micromolar concentrations did not affect 
cell proliferation when used as monotherapy, while the combination with irradiation 
significantly decreased medulloblastoma cell growth. Importantly, this sensitizing effect was 
not found on neural precursor cells, or normal human fibroblasts. In addition, quercetin 
treatment enhanced the in vitro sensitivity of medulloblastoma cell lines in clonogenic 
survival assays. However, the radiosensitizing effect was not observed in two primary 
medulloblastoma cell cultures. Finally, we observed that quercetin administration to 
orthotopically xenograft mice around the time of irradiation significantly prolonged survival. 
Since quercetin sensitizes medulloblastoma cells in our experiments at doses used in 
fractionated radiation schemes, and the quercetin concentrations used can easily be 
achieved by oral administration, we suggest that the use of quercetin should be further 
evaluated in clinical trials in medulloblastoma patients in the near future.  
INTRODUCTION 
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Cell culture and lentiviral infections 
Mouse C17.2 neural precursor cells, human 
primary fibroblasts and D283-Med, D458-Med, 
DAOY medulloblastoma cell lines were cultured 
at 37°C in a 5% CO 2  humidified atmosphere in DMEM plus 10% fetal calf serum, 100IU/ml 
penicillin and 100µg/ml streptomycin (PAA Laboratories GmbH, Austria). Pools of D283-med 
FM/GC or DAOY FM/GC cells were generated by infection with lentiviral vectors, expressing 
the reporter gene combinations Firefly luciferase/mCherry (FM) or Gaussia 
luciferase/Cerulean (GC), as described previously 111. Fluorescence microscopy was used to 
assess the success rate of transductions and cell viability. For intracranial injections, cells 
were harvested and suspended in PBS at a concentration of 1x108 cells/ml. The cells used in 
this study were not authenticated. 
Primary cell culture VU371 was derived from tumor tissue, surgically removed from a patient 
diagnosed with medulloblastoma at the VU University Medical Center. Informed consent was 
obtained according to institutionally approved protocols. ICb-1299MB is a patient derived 
orthotopic xenograft mouse model of group 4 medulloblastoma 295 and the xenograft cells 
were kindly provided by Dr. Xiao-Nan Li and Dr. Mari Kogiso (Baylor College of Medicine, 
Houston, TX, USA). VU371 and ICb-1299MB were cultured at 37°C in a 5% CO 2 humidified 
atmosphere in NBM (NeuroBasal Medium)(Invitrogen) supplemented with neural stem cell 
supplement (NSCS), N2, stable glutamine (PAA), epidermal growth factor (EGF), and basic 
fibroblast growth factor (bFGF)(PeproTech). 
 
Chemicals 
The ActiTarg-K960 chemical library, consisting of 960 putative kinase inhibitory compounds, 
was obtained from TimTec (Newark, Delaware, USA). Ninety-one percent of these 
compounds conform to four Lipinski criteria and 97% to three Lipinski criteria, suggesting 
they have desirable pharmacologic properties 296. Quercetin dihydrate (Calbiochem, USA) 
was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, USA), with a final DMSO 
concentration of 0.1% for in vitro experiments or a final DMSO concentration of 5% for in 
vivo experiments.  
 
Chemical library screen 
Seven hundred and fifty DAOY cells were plated per well in 96-well plates. The next day, cells 
in each well were treated with a different compound from the ActiTarg-K960 library at a 1 
µM concentration. Treatment was performed with drugs in paired 96-well plates, where one 
plate was exposed to 4 Gy in a Gammacell® 220 Research Irradiator (MDS Nordion, Canada) 
30 minutes after addition of the compounds, and the other plate was a non-irradiated 
control. Four days later, cell survival was evaluated by measuring Gaussia luciferase (Gluc) 
MATERIALS and 
METHODS 
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activity 297, or by means of the Acumen eX3 laser scanning cytometer (TTP LabTech, UK). 
Results were analyzed using Acumen Explorer software, calculating the percentage survival 
for each compound tested with the assay. 
 
Survival assays   
Responsiveness of D283-med, D458-med (1,000 cells/well, or 1x104 cells/flask), or DAOY 
(1,500 cells/well) medulloblastoma cells to quercetin (1 µM) was determined in a cell 
proliferation assay by use of the Acumen eX3 laser scanning cytometer as described above, 
and confirmed by cell counts using a Bürker hemocytometer. Viability of primary cells, VU371 
and ICb-1299MB (2,000 cells/well), after treatment with 1 µM quercetin and 0.7 Gy 
irradiation was determined with Cell Titer Glo assay (Promega) according to manufacturer’s 
protocol. In addition, a clonogenic assay was performed with different doses of irradiation 
(0-3 Gy). Therefore, exponentially growing D283-med and D458-med cells were plated in 
triplicate in 6-well plates at concentrations ranging from 200-2,000 cells/well, and grown for 
14 days in MethoCult®H4001 with 0, 0.5, or 1 µM quercetin. Colonies were counted visually 
and plating efficiency (PE) was calculated by dividing the number of colonies counted by the 
number of cells plated. Surviving fractions (SF) were then calculated by dividing the PE by the 
PE of the non-irradiated control per drug concentration. Duplicate experiments were 
performed for each cell line. Analysis of inhibitory concentrations was performed using 
SigmaPlot 11.0 (Systat Software, Inc. San Jose, CA, USA).  
 
qRT-PCR 
Quantitative RT-PCR (qRT-PCR) analysis was performed to determine expression of the 
medulloblastoma subgroup classifiers WIF1, SFRP1, NPR3, and KCNA in medulloblastoma cell 
lines and a normal cerebellum sample. Total RNA was isolated using the TRIzol RNA isolation 
protocol (Invitrogen, Carlsbad, CA, USA) and equal amounts of RNA were converted to cDNA 
using the Omniscript kit (Qiagen). Primer sequences for WIF1, SFRP1, NPR3, and KCNA 
transcripts were previously described by Zhao et al. 298 and primers were manufactured by 
Biolegio (Nijmegen, The Netherlands). Gene expression of the subgroup classifiers in 
medulloblastoma cells was normalized to GAPDH expression levels and the Ct values were 
used to calculate the relative fold difference in mRNA levels (ΔΔCt method) compared to 
normal cerebellum. 
 
D283-med orthotopic xenograft mouse model 
Female athymic nude-Fox1nu mice (age 8-10 weeks; Harlan, Horst, The Netherlands) were 
maintained in accordance with the guidelines and regulations set out by the VU University 
committee on research animal care. For intracranial injections, mice were anesthetized with 
2.5% isoflurane in oxygen, and a volume of 5 µl (0.5x106 D283-med FM-GC cells) was injected 
stereotactically into the cerebellum at a rate of 2 µl per minute, using a Hamilton 10 µl 
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syringe with a 26G needle. Coordinates for injection were determined according to the 
mouse brain atlas 299: 2.0 mm lateral, 2.5 mm ventral of lambda, and at a 2.0 mm depth. 
Before start of the treatment (three weeks after injection of the tumor cells) tumor 
engraftment was determined by measuring Firefly luciferase (Fluc) activity. Based on this 
activity, mice were randomized into four treatment protocols: vehicle (5% DMSO), quercetin, 
DMSO/irradiation (4 Gy), and quercetin/irradiation (4 Gy). Mice without tumor engraftment 
(Fluc activity <80,000 photons/sec at three weeks after implantation) were excluded from 
the experiment. Quercetin (100 mg/kg) was administered intraperitoneally at six time points: 
30 and 60 minutes before-, or after irradiation, 0 hours, and 24 hours after irradiation. Mice 
not receiving quercetin were treated with the same volume of DMSO dissolved in PBS, at the 
same time intervals as the quercetin treated mice. To enable precise positioning of the 
radiation beam on the head and neck area of the mice, the animals were anesthetized with 
ketamine/xylazine. Mice that were not irradiated were anesthetized just before the zero 
hours’ time point. Tumor growth was monitored semi-weekly by bioluminescent imaging 
(BLI). In short, 150 µl D-luciferin (0.03 g/L, Gold Biotechnology, St. Louis, USA) was injected 
intraperitoneally and 10 minutes after administration mice were anesthetized with 
isoflurane inhalation anesthesia, positioned in the IVIS camera and the bioluminescence 
signal was determined with the IVIS Lumina CCD camera. In addition, the mice were 
monitored daily for discomfort and weight loss. When moderate to severe symptoms were 
present (weight loss of >20% or severe neurological deficits), animals were sacrificed and 
brains were removed and formalin-fixed.  
 
Statistical analysis 
A coefficient of variation (CV) and Z’ factor were calculated to assess the reproducibility and 
robustness of the small molecule screens, as described by Zhang et al. 300, where CV=SD/µ 
and Z’ = 1-(3σ c+ +3σ c- )/Iµ c+ -µ c- I. Statistical significance of treatment was 
assessed using the Mann-Whitney U test. Kaplan-Meier survival curves were generated with 
GraphPad Prism 5. Median survival of the groups was calculated and survival curves were 
compared with the Log-rank (Mantel-Cox) test. The p values <0.05 were considered 
statistically significant. 
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   ____________________________________ 
Identification of quercetin as a radiosensitizer 
for medulloblastoma  
In order to enable the identification of novel 
radiosensitizers for medulloblastoma, a small 
molecule screen was performed using DAOY 
medulloblastoma cells that were transduced with a lentiviral Gaussia luciferase (Gluc) vector 
co-expressing the fluorescent ‘Cerulean’ (CFP) reporter 111. Expression of these genes 
allowed to monitor cell survival by bioluminescent and fluorescent read-out of cell viability. 
To optimize screening conditions, the well-to-well and plate-to-plate variation, number of 
DAOY cells, and the dose of irradiation were determined. For the well-to-well and plate-to-
plate variation, aliquots of Gluc-conditioned medium were distributed over 96-well plates 
and assayed for luciferase activity as described previously 297. In four independent 
experiments a variation coefficient (CV) of < 7% was observed (Fig. 1A), indicating only 
minimal variation in pipetting errors, substrate stability and measurement errors. An even 
better CV of < 2% was observed (Fig. 1A) for the plates measured by Acumen technology, 
where equal numbers of cells were plated and detected by CFP expression. Robustness of 
the assays was determined by calculating the Z’ factor as described by Zhang et al. 300, where 
Z’=0.84 for the Gluc assay and Z’=0.56 for the Acumen screen. Since both assays allowed to 
monitor cell viability at different time points after treatment, we optimized our screening 
conditions – number of cells, dose of irradiation, and drug concentrations – by measuring 
Gluc secretion or cell numbers in time (Fig. 1B-D). This resulted in a four-day assay, using 750 
DAOY cells per well with 4 Gy irradiation. In addition, a drug concentration of 1 µM was 
chosen, since this showed good results in a pilot experiment using eight different, randomly 
chosen small molecules (Fig. 1D), and yielded positive hits in a drug screen performed 
previously by our group 297. Once all conditions were established, cells were seeded in 96-
well plates, and treated the next day with compounds from the ActiTarg-K960 drug library 
(TimTec) consisting of 960 putative kinase inhibitors, or with 0.1% DMSO as an internal 
control. The compounds were added in duplicate plates, where one set was irradiated to 
identify putative radiosensitizers, while the other set was left non-irradiated to assess 
cytotoxicity of the compounds as monotherapy. A reduction of >75% of cell growth after four 
days of incubation as compared to the DMSO controls was considered to be significant (Fig. 
2A). In four separate screens, a total of 23 compounds were identified that consistently 
inhibited cell growth or sensitized towards irradiation, with 12 compounds inducing cell 
death independently of irradiation, and 11 compounds functioning as radiosensitizers (Table 
1 and Supplementary Fig. S1). Cytotoxicity of these 23 compounds was subsequently 
determined on primary human fibroblasts and on C17.2 neuronal precursor cells (NPCs), to 
assess the therapeutic window (Table 1).  
RESULTS 
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Figure 1. Determination of screening conditions. A, reproducibility of Gluc measurements (upper panel) 
or cell counts as measured by Acumen technology (lower panel). Aliquots of Gluc-containing medium 
or equal numbers of cells were plated in 96-well plates in quadruplicate, and measured to assess plate-
to-plate and well-to-well variation (RLU=relative luciferase units). Data are presented as means ± SD. 
The corresponding coefficients of variation (CV) are depicted in the right-hand panels. B, growth curves 
of DAOY medulloblastoma cells. One hundred, 250, 500, 750, or 1000 cells were plated per well and 
set at 100%. Relative cell numbers were measured at different time points after plating as indicated in 
the figure. A plating density of 750 cells/well resulted in exponentially growing cells after 4 days of 
incubation that could be monitored without much variation. Data are presented as means ± SD (n=3). 
C, graphic representation of the irradiation response in DAOY cells. Growth of non-irradiated (NI) cells 
is set at 100%. For each irradiation dose 8 samples were measured. D, concentration curves of DAOY 
medulloblastoma cells treated for four days with 0, 0.5, 1, or 2 µM of different drugs. Compounds were 
chosen randomly from the TimTec library: ST027883 (-■-), ST004727 (-●-), ST053862 (-▲-), ST012157 
(-▼-), ST012256 (-♦-), ST029265 (-○-), ST036501 (-□-), ST052055 (--). A drug concentration of 1 µM 
was (red dotted line) was used for the final screen.  
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This smaller screen narrowed our list of putative novel compounds for use in 
medulloblastoma down to five: two radiosensitizing agents and three compounds that have 
been identified as inducers of cell death in DAOY cells independently of irradiation (Fig. 2B). 
The flavonoid quercetin was among the radiosensitizing compounds that has been shown to 
enhance radiation-induced cell death in rat hepatoma cells.301,302 Treatment with quercetin 
30 minutes prior to irradiation resulted in a 5-fold reduction in cell growth (~20% cell 
survival), while treatment with quercetin alone did not significantly affect cell viability 
compared to cells treated with the solvent DMSO (Fig. 2C). Irradiation without addition of 
quercetin resulted in a 2-fold reduction in cell numbers. As mentioned above, these results 
were not observed in primary human fibroblasts or neuronal precursor cells (Fig. 2C).  
 
Quercetin sensitizes medulloblastoma cells to radiation in vitro 
Since quercetin has been reported to effectively cross the blood-brain-barrier 303, we 
hypothesized that this compound could be an attractive agent for the treatment of 
medulloblastoma. Therefore, we investigated if similar effects could be observed in 
additional medulloblastoma cell lines. D283-med, D458-med, and DAOY cells were incubated 
with 1 µM quercetin 30 minutes prior to irradiation, and cell numbers were determined at 4 
days after treatment (Fig. 3A). Although the responses were less pronounced in the D458-
med cells, a radiosensitizing effect of quercetin was observed in all cell lines, while quercetin 
treatment by itself did not inhibit cell proliferation. To further confirm the radiosensitizing 
potential of quercetin, dose-dependent clonogenic survival assays were performed. DAOY 
cells appeared unfit for these experiments, since they did not form clones. However, 
treatment of D283-med and D458-med medulloblastoma cells with 0.5 µM or 1 µM 
quercetin showed radiosensitization in both cell lines (Fig. 3B), even at radiobiologically 
relevant irradiation doses of 1 Gy or 2 Gy used in fractionated radiation schemes. These 
results strengthen our hypothesis that quercetin is a putative radiosensitizer for 
medulloblastoma. Next, we tested the radiosensitizing effect of quercetin on two primary 
medulloblastoma cell cultures, VU371 and ICb-1299MB 298. Similar as for the cell lines, cells 
were treated with 1 µM quercetin 30 minutes prior to irradiation, and viability was 
determined four days after treatment (Fig. 3C). Again, quercetin by itself did not reduce cell 
viability, however, these cells are highly sensitive to radiation (data not shown). Therefore, 
cells were irradiated with the lowest technical dose possible, 0.7 Gy, which already 
significantly impaired viability. We did not observe an enhanced radiation response in 
combination with quercetin in these cells. Since medulloblastomas have been subclassified 
into four molecular subgroups 10, we determined to which subgroups the used cell lines 
belong. Expression of four subgroup classifier genes was assessed by qRT-PCR, which was 
previously described by Zhao et al. 298 (Supplementary Fig. S2A+B). DAOY was identified as a 
SHH medulloblastoma while D283-med, D458-med, and VU371 seem to belong to the group 
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3 subtype (Fig. 3D and Supplementary Fig. S2A+B). ICb-1299MB was previously classified as 
a group 4 medulloblastoma 298. 
 
Quercetin treatment improves radiation efficacy in a xenograft tumor model 
To further evaluate if quercetin can function as a novel agent in the treatment of 
medulloblastoma, we investigated the effect of this compound in an in vivo setting, using an 
orthotopic xenograft mouse model. Therefore, luciferase-expressing D283-med cells were 
implanted stereotactically into the left cerebellar hemisphere of nude mice. In two 
independent experiments, 31 out of 36 mice developed primary tumors, as judged by 
bioluminescent imaging (BLI) three weeks after implantation. These mice were then 
randomly assigned into four groups, and treated with vehicle (5% DMSO) or quercetin, either 
alone or in combination with irradiation. Since quercetin has a half-life of only 20 minutes in 
vivo 304, six consecutive injections with quercetin (100 mg/kg) were given at different time 
points around the time of irradiation (60 or 30 minutes before, 30 or 60 minutes after 
irradiation, 0 hours and 24 hours after irradiation). Quercetin treatment did not induce any 
neurological symptoms or other adverse events. Tumor growth was monitored twice a week 
by BLI. In addition, the mice were monitored daily for discomfort and weight loss. Although 
the BLI signal of the tumors did not differ between the various groups, survival analysis 
indicated a significant extension of the group that received ionizing radiation in combination 
with quercetin as compared to the vehicle-treated group (p=0.0052), the quercetin group 
(p<0.0001), or the group that only received radiotherapy (p=0.002; Fig. 4A). All animals 
treated with the combination of quercetin and irradiation survived for more than 24 days 
after treatment, with a median survival time of 32 days. Animals that did not receive 
irradiation (either vehicle- or quercetin-treated) had a median survival of only 12-17 days 
(Fig. 4B).  
 
Figure 2. (next page) A small molecule screen identifies quercetin as a radiosensitizer in 
medulloblastoma cells. A, example of a scatter plot of Gluc values (left panels) and Acumen read-out 
(right panels), representing cell survival after treatment of DAOY cells with 1 µM of the ActiTarg-K960 
small molecule library in the presence, or absence of irradiation (4 Gy). The fluorescence in the single 
wells as measured by the Acumen is represented as relative intensities of the color green, where black 
corresponds with little cells and green with many cells. When using Gluc as a read-out, cell viability was 
measured by luciferase activity and corrected for the toxicity of the solvent, 0.1% DMSO (set to 100%). 
A reduction of >75% of cell growth was considered to be significant, as indicated by a dashed line. Each 
dot represents a single well; in position F05 a cytotoxic agent is identified, in position C09 a 
radiosensitizer. A representative 96-well plate is shown. B, structure formulae of compounds that 
induce cell death in DAOY medulloblastoma cells but show limited cytotoxicity on primary human 
fibroblasts and on C17.2 neuronal precursor cells (NPCs). Two radiosensitizing agents and three 
compounds that induce cell death independently of irradiation have been identified. C, graphic 
representation of relative cell survival in DAOY medulloblastoma cells (left panel), primary human 
fibroblasts (PHF, middle panel), or neural precursor cells (NPC, right panel) after quercetin (QC) 
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treatment and/or irradiation (IR), as extracted from the small molecule screen. Data are presented as 
means ± SD (n=3). ** p<0.005, Mann-Whitney U test. 
 
 
Figure 2 (legend on previous page) 
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Table 1. Overview of compounds that induce cell death in DAOY medulloblastoma cells, as 
identified by a small molecule screen. Chemical compounds that repetitively induced cell 
death (upper panel) or functioned as radiosensitizers (lower panel) are represented.  
NPC=neural precursor cells; OK= no cell death as compared to control, +/- = ≤ 50% cell 
death. 
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Figure 3. Quercetin sensitizes towards irradiation in a panel of medulloblastoma cells. A, graphic 
representation of relative cell survival of DAOY, D283-med, and D458-med cells after 4 days of 
quercetin treatment in the presence or absence of irradiation (4 Gy). Cell numbers were determined 
by visual counts, using a Bürker hemacytometer. Vehicle treated cells are set at 100%. Data are 
presented as means ± SD (n=3). ** p<0.005, Mann-Whitney U test. B, clonogenic survival of D283-med 
(left panel) and D458-med (right panel) medulloblastoma cells, 14 days after irradiation (0-3Gy). Cells 
were treated with 0 µM (-●-), 0,5 µM (-○-), or 1 µM (-▼-) quercetin 30 minutes prior to irradiation. A 
representative experiment is shown. C, graphic representation of relative cell survival of VU371 and 
ICb-1299MB cells after 4 days of quercetin treatment in the presence or absence of irradiation (0.7 Gy). 
Cell viability was determined by Cell Titer Glo assay. Vehicle treated cells are set at 100%. Data are 
presented as means ± SD. D, molecular subgroup classification of DAOY, D283-med, D458-med, VU371, 
and ICb-1299MB cells. Expression levels of subgroup classifiers WIF1, SFRP1, NPR3, and KCNA were 
determined by qRT-PCR to determine to which subgroups the used medulloblastoma cells belong. 
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Figure 4. Effect of quercetin treatment in combination with irradiation on survival in a xenograft mouse 
model. A, Kaplan-Meier survival analysis of medulloblastoma-bearing mice treated with quercetin (blue 
line), vehicle (5% DMSO – black line), vehicle and irradiation (green line), and quercetin in combination 
with irradiation (red line). A significant survival extension of the group that received ionizing radiation 
in combination with quercetin as compared to the vehicle-treated group (p=0.0052), the quercetin 
group (p<0.0001), or the group that only received radiotherapy (p=0.002) was observed. B, graphical 
representation of survival in days; medians are indicated as horizontal lines.  
 
 
 
  
0 10 20 30 40 50
0
50
100
days after radiation
%
 su
rv
iv
al
A B
Veh IR+Veh QC QC+IR
0
10
20
30
40
50
D
ay
ss
ur
vi
va
l
QUERCETIN 
97 
 
    ____________________________________ 
In the past decade, a better understanding of 
the biology and heterogeneity of childhood 
medulloblastomas has allowed an improved 
patient stratification and risk-adapted 
treatment strategies. However, despite these 
novel insights, therapy still fails in approximately 30% of patients and is often accompanied 
by severe long-term sequelae. Thus, there still is a need for alternative therapies that allow 
to lower the total dose of irradiation, reducing the long-term side effects, and/or increase 
the radiation efficacy. We show here that the flavonoid quercetin can sensitize 
medulloblastoma cells to irradiation, and that administration of quercetin during 
radiotherapy significantly improves survival in mice harboring medulloblastoma.  
 
Quercetin was identified as a ‘ready-to-use’ radiosensitizer in a small molecule screen for 
medulloblastoma cells, using two independent read-out systems. The small molecule screen 
consisted of 960 compounds with a diversity of chemical structures that have been reported 
to exert kinase inhibitory properties. In this screen 23 compounds were repeatedly identified 
that could inhibit cell growth (n=12), or sensitize towards irradiation (n=11).  Strikingly, two 
of the compounds that induced cell death independently of irradiation had similar structures, 
as did three of the 11 compounds that functioned as a radiosensitizer (nitrophenes, 
Supplementary Fig. S1). However, most of those drugs also induced cell death in primary 
human fibroblasts or neuronal progenitor cells, rendering them unfit for the development of 
novel and tumor-specific therapies. Unlike those compounds, quercetin did not affect the 
proliferation of neuronal precursor cells or normal human fibroblasts, nor showed any 
toxicity in the absence of ionizing radiation. This is in concordance with previous studies that 
report selective activity of quercetin as a sensitizer to chemotherapeutics on cancer cells, but 
not in normal cells, even though higher quercetin concentrations (ranging from 5-200 µM) 
were used in these studies 305–307. Importantly, the low micromolar concentrations used in 
our experiments are in the range of the plasma concentrations that can be reached in 
humans and are considered to be safe 308. Quercetin is found in a broad range of fruits and 
vegetables such as apples, onions and tomatoes, and present in plasma at the nanomolar 
range (<100 nM) through our dietary intake, but micromolar concentrations have been 
reported after supplementation 309,310.  
 
The observation that the concentrations needed for therapeutic benefit can be easily 
achieved by oral administration, and the fact that quercetin is cheap and readily available, 
renders this flavonoid an interesting option for the treatment of children with 
medulloblastoma. Another motive to consider quercetin as a radiosensitizer for this type of 
brain tumors, is the previously reported observation that quercetin can pass the blood-brain 
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barrier (BBB)311,312. The BBB is a natural boundary between circulating blood and 
cerebrospinal fluid that protects the brain from toxins and potentially harmful substances 
(reviewed by Agarwal et al. 313). Although beneficial under normal circumstances, the 
presence of this BBB constitutes a major obstacle for drug delivery in the treatment of brain 
tumors. Importantly, quercetin has not only been shown to pass the BBB in in vitro systems, 
but has also been shown to accumulate in the brain after oral administration in rats 303. 
Moreover, quercetin has been shown to function as a neuroprotective agent, both in vitro 
and in vivo following ischemia, trauma, or other forms of induced brain damage 303,314–316. Of 
particular interest in the context of medulloblastoma treatment is the observation that 
administration of quercetin can improve learning and memory deficits in animals that were 
subjected to brain damaging agents 317–319. 
 
 The neuroprotective effect of quercetin has been suggested to be due to its anti-oxidative 
properties. Quercetin is a potent anti-oxidant that can scavenge free radicals and bind 
transition metal ions. However, alternative mechanisms, such as modulation of signal 
transduction pathways or effects on gene expression have also been reported. Quercetin can 
modulate the activity of many kinases and other enzymes (reviewed by Russo et al. 320), which 
may explain the diversity of its actions. Besides neuroprotective properties, quercetin has 
been described to prevent cardiovascular diseases 321, to function as a chemopreventive 
agent 322, to have anti-proliferative and growth-suppressing effects 323, to induce senescence 
and autophagy 324,325, and to have anti-inflammatory and anti-angiogenic activities 326,327. 
Each property or action appears to depend on the dose and model system used. Of note are 
the inhibition of the Wnt/β-catenin pathway, which plays an important role in one of the four 
medulloblastoma subgroups 10, and the inhibition of the Hepatocyte Growth Factor (HGF)-
induced cell migration in medulloblastoma by quercetin 328. Furthermore, quercetin has been 
reported to induce radiosensitization in tumor cells other than medulloblastoma by targeting 
the ATM-mediated pathway, which is critical in the DNA damage response 37. Which pathway 
or mechanism is involved in the radiosensitization of medulloblastoma cells by quercetin is 
not exactly known at the moment. 
 
Four distinct molecular subtypes of medulloblastoma have been identified 10. 
Subclassification of the cell lines used in this study showed that the SHH and group 3 subtypes 
were represented. DAOY was identified as a SHH medulloblastoma, which was also suggested 
by Pambid et al. 329. D283-med and D458-med belong to the group 3 medulloblastomas as 
was reported before for D458-med 9,330. We observed radiosensitization after treatment with 
quercetin in DAOY and D283-med and, to a lesser extent, in D458-med cells. This indicates 
that the mechanism underlying the improved radiation response caused by quercetin may 
represent a general effect on medulloblastoma cells and, thus, is likely to be subtype-
independent. The primary cell cultures used in this study belong to the group 3 and group 4 
QUERCETIN 
99 
 
subtypes. We did not detect a radiosensitizing effect of quercetin in these cells, since these 
cells are highly radiosensitive in vitro and there is no window in which quercetin can exert its 
effect. This was also seen in D458-med cells, which show high sensitivity to radiation. It would 
be of interest to examine the efficacy of quercetin in radioresistant primary medulloblastoma 
cell cultures. In addition, the response of primary cell cultures in vitro may not necessarily 
represent the response in the cerebellar environment. Therefore, we are setting up more 
primary cell lines of the different subtypes and use these to develop orthotopic mouse 
models to study the effect of quercetin as a radiosensitizer in medulloblastoma in an 
environment that is more comparable to that of the original tumor. However, the results 
presented here indicate that quercetin functions as a potent radiosensitizer in 
medulloblastoma cells at easily achievable concentrations, providing a promising lead for 
treatment of children with this type of brain tumor.   
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Supplementary Figures 
 
 
Supplementary Figure S1. Structure formulae of compounds that induce cell death in DAOY 
medulloblastoma cells, as identified by a small molecule screen. Chemical compounds that repetitively 
induced cell death (upper twelve) or functioned as radiosensitizers (lower structures) are represented. 
 
(4-methoxyphenyl)(2-methylbenzo[h]quinolin-4-
yl)amine, chloride
(5-bromo-4-(4-cyclohexyl-5-phenyl(1,2,4-triazol-3-ylthio))-
2-phenyl-2-hydropyri dazin-3-one
6-amino-4-(9-ethylcarbazol-3-yl)-3-methyl-
4H-pyrano[3,2-d]pyrazole-5-carbonitrile
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3-[((1E)-2-(2-pyridyl)-1-azavinyl)amino]-6-methyl-
4H-1,2,4-triazin-5-one
3-[((1E)-2-(2-pyridyl)-1-azavinyl)amino]-4H-
1,2,4-triazin-5-one
4,5-dichloro-2-[(4-fluorophenyl)methyl]
-2-hydropyridazin-3-one
[(5-nitro-2-thienyl)methylene]methane-
1,1-dicarbonitrile
1-cyclohexylazoline-2,5-dione
5-((2E)-5,5-dichloropenta-2,4-dienoyl)-6-
methylpyran-2-one
(8-chloro(4H-benzo[e]1,3-thiazolo[5,4-c]thiin-2-
yl))naphthylamine
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
(quercetin)
3-[(tert-butyl)amino]-1-(5-methyl-
2,3-diphenylindolyl)propan-2-ol
5-(4,6-dimethylpyrimidin-2-ylthio)
-4-nitrobenzo[c]1,2,5-thiadiazole
3-(indol-3-ylmethylene)benzo[b]pyran-2,4-dione
5-[(1E)-2-(4-bromo-3-chlorophenyl)-2-azavinyl]-2-nitrothiophene 5-[(1E)-2-(2,4-dichlorophenyl)-2-azavinyl]-2-nitrothiophene 5-[(1E)-2-(4-iodophenyl)-2-azavinyl]-2-nitrothiophene
6-(tert-butyl)-2-[3-(tert-butyl)-5-bromo
-2-hydroxyphenylthio]-4-bromophenol
di2,3,4,5,6-pentafluorophenyl ketone9-((1E)-2-nitrovinyl)anthracene
3-amino-1-(4-fluorophenyl)
-1H-benzo[f]chromene-2-carbonitrile
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Supplementary Figure S2. Expression levels of subgroup classifiers WIF1, SFRP1, NPR3, and KCNA in 
medulloblastoma cells compared to normal cerebellum. A, expression levels of WIF1, SFRP1, NPR3, and 
KCNA in DAOY, D283-med, and D458-med compared to normal cerebellum. DAOY was identified as a 
SHH medulloblastoma, D283-med and D458-med were identified as group 3 medulloblastomas. B, 
expression levels of WIF1, SFRP1, NPR3, and KCNA in VU371 cells from a xenograft tumor and VU371 
cells from the original tumor as compared to expression in normal cerebellum. VU371 was identified 
as a group 3 medulloblastoma. The subgroup type was preserved after serial transplantation of tumor 
cells in the cerebellum of mice. 
 
  
A
B
W
IF
1
S
FR
P
1
N
P
R
3
K
C
N
A
0.001
0.01
0.1
1
10
100
1000
10000 cerebellum
DAOY
D283-med
D458-med
fo
ld
ch
an
ge
m
R
N
A
le
ve
l
W
IF
1
S
FR
P
1
N
P
R
3
K
C
N
A
0.1
1
10
100
1000
cerebellum
VU371-X
VU371-P
fo
ld
ch
an
ge
m
R
N
A
le
ve
l
 102 
 
 
  
 103 
 
 
CHAPTER 6 |  
Glioblastoma-derived extracellular 
vesicles induce proliferation and 
temozolomide resistance via 
chemokine receptor CCR8 
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___________________________________ 
Cancer cells release extracellular vesicles (EVs) 
that contain functional biomolecules such as 
RNA and proteins. EVs are transferred to 
recipient cancer cells and can promote tumor 
progression and therapy resistance. In contrast to most viral uptake mechanisms, EV uptake 
mechanisms are currently poorly understood. Through RNAi screening we have discovered a 
novel EV uptake mechanism involving a triple interaction between the chemokine receptor 
CCR8 on the cells, glycans exposed on EVs and the soluble ligand CCL18. This ligand acts as 
bridging molecule, connecting EVs to cancer cells. We show that glioblastoma EVs promote 
cell proliferation and resistance to the alkylating agent temozolomide (TMZ). Using in vitro 
and in vivo stem-like glioblastoma models we demonstrate that EV-induced phenotypes are 
neutralized by the small molecule CCR8 inhibitor R243. Interference with chemokine 
receptors may offer therapeutic opportunities against EV-mediated cross-talk in 
glioblastoma, and perhaps other diseases in which EV glycosylation plays a role.  
  
ABSTRACT 
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Intracellular vesicles (EVs), including exosomes 
and shed microvesicles, are membranous 
vesicles released by most, if not all, cell types. 
EVs contain active molecules such as proteins, 
lipids and nucleic acids, that can exert biological functions once taken up by recipient cells. 
EV-mediated communication is of particular importance in tumor progression and therapy 
resistance. For several cancer types it was demonstrated that migratory and metastatic 
potential can be phenocopied from one cell to another by EVs 125,331–335, and that tumor 
growth is enhanced by EVs in many cancer types, including glioblastoma (GBM) 336–339. EVs 
are involved in many aspects of the communication between tumors and their 
microenvironment, such as cell migration and homing, EV-mediated propagation of GBM 
heterogeneity and MGMT promotor methylation status-dependent TMZ resistance 340–343. 
Tumor EVs also exert a protective effect against several chemotherapeutic agents by 
delivering a variety of resistance-inducing molecules such as P-glycoprotein (P-gp), TrpC5, 
and non-coding RNAs 344–348  
Despite the promising therapeutic potential of blocking EV uptake in cancer, this approach is 
not extensively exploited due to the scarce knowledge of EV uptake mechanisms. EV uptake 
is considered to depend on the EV donor and recipient cell type, their physiological state, 
and the presence or absence of interfering molecules in the extracellular microenvironment 
349–351. Although direct fusion of EVs and plasma membranes has been reported for 
melanoma cells 352, multiple studies point to interactions involving endocytic pathways. 
Proteinase K treatment of either recipient cells or EVs strongly reduces EV uptake in several 
cell types, implying a role of membrane proteins in the internalization process 353–355. EV 
uptake is also inhibited at 4oC, indicating an active, energy-dependent process 353,356,357. Co-
localization studies and assays employing pathway-specific inhibitors revealed involvement 
of both clathrin-dependent and clathrin-independent endocytosis, including caveolin-
mediated endocytosis, macropinocytosis and phagocytosis 351.  These observations seem 
compatible with receptor-mediated EV uptake mechanisms, similar as for many enveloped 
viruses 358,359. To date only few specific cellular receptors for EVs have been proposed. In an 
early study, Tim1 and Tim2 receptors were proposed to bind phosphatidylserine exposed on 
EV membranes on pre-B cells overexpressing these receptors 360. Integrins have also been 
shown to act as EV receptors by binding lysophosphatidic acid from the EV surface 361. 
Furthermore, heparan sulfate proteoglycans (HSPGs) on the plasma membrane were 
reported to function as EV receptors, in a mechanism in which fibronectin acts as a bridging 
molecule that interacts with both cellular and exosomal HSPGs 362,363.  
GBM is the most common primary malignant tumor of the central nervous system in adults 
and known to release large amounts of EVs 339,364,365. Affected patients have an extremely 
poor prognosis with a median survival of only 15 months following treatment 366. Standard 
INTRODUCTION 
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of care currently consists of tumor resection combined with radiotherapy and concomitant 
and adjuvant chemotherapy with the alkylating agent temozolomide (TMZ). Although tumors 
may initially respond to this regimen, recurrences are inevitable and occur even while 
patients are still receiving adjuvant TMZ 49. Here we show that GBM EVs are inducers of cell 
proliferation and capable of triggering TMZ resistance in recipient GBM cells. Using RNAi 
screening we identified the chemokine receptor CCR8 as a receptor for EVs, allowing for 
binding and entry of EVs decorated with glycans that interact with the chemokine CCL18.  
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Animal models 
Animal experiments were performed in 
accordance with the European Community 
Council Directive 2010/63/EU. The 
experimental protocol was validated and approved by the local committee on animal 
experimentation of the VU University medical center or The Netherlands Cancer Institute . 
Athymic Nude-Fox1nu mice were purchased from Harlan/Envigo (Horst, The Netherlands). 
They were kept under filter top conditions and received food and water ad libitum. 
Antibodies and chemicals 
MC148 was purchased from B-Bridge international and was dissolved in PBS. R243 was 
custom synthesized by MercaChem (Nijmegen, The Netherlands) and was dissolved in 
dimethyl-sulfoxide (DMSO). Temozolomide (dissolved in DMSO), 4',6-diamidino-2-
phenylindole (DAPI), Dynasore, heparin, heparinase III, Dynasore and PKH67 were obtained 
from Sigma. BrdU was from Life Technologies and recombinant CCL18 and human Epidermal 
Growth Factor (hEGF) were from R&D. Basic-Fibroblast Growth Factor (b-FGF) was purchased 
from PeproTech. The antibodies used in this work were obtained from the following 
manufacturers: mouse anti-CD63 (Clone NKI/C3) from Fisher Scientific. Mouse anti-Alix and 
mouse anti-β-Actin were purchased from Santa Cruz. Mouse anti-Cre and gold-conjugated 
rabbit anti-goat are from Sigma. Rabbit anti-BrdU from Rockland. Rabbit anti-CCR8 and rabbit 
anti-GFP from Abcam. Goat anti-CCL18 from Origene. Rabbit anti phospho-ERK (Phospho-
p44/42 MAPK (Erk1/2) (Thr202/Tyr204)) from Cell Signaling. HRP-conjugated goat anti-
mouse, HRP-conjugated goat anti-rabbit and HRP-conjugated rabbit anti-goat used as 
secondary antibodies in Western blots were from Dako. IRDYE 800CW mouse anti-rabbit and 
IRDYE® 680RD goat anti-mouse also employed for Western blot were from Li Cor. Alexa Fluor 
405 and goat anti-rabbit Alexa Fluor 594 from Life Technologies. Protein A-gold (purchased 
from Cell Microscopy Core, University Medical Center Utrecht), goat-anti-biotin-Gold 
(Aureon). Phage display antibodies (kindly provided by Van Kuppevelt, Nijmegen) to detect 
three types of glycosaminoglycans: VSV-tagged anti-heparan sulfate (HS4E4), VSV-tagged 
anti-chondroitin sulfate (1O3H10) and VSV-tagged anti-dermatan sulfate (GD3A12). 
Western blot analysis 
For Western blot analysis on p-ERK, cells 5 x 105 cells were seeded in 24-well plates and 
isolated EVs (or PBS in the control wells) were added at a final concentration of 100 ng/µl at 
the moment of seeding and once more 18 h later. At 12 h after second EV addition, the cells 
were harvested, washed with PBS and lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl 
(pH 8.0), 1% NP-40, 0.5% deoxycholate, 0.1% SDS) supplemented with Protease Inhibitor 
Cocktail (Roche Applied Sciences). For Alix, CD63 and CCL18 analysis, 40 µg of EVs were 
MATERIALS and 
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directly lysed in RIPA buffer supplemented with protease inhibitor cocktail. After lysis, cell or 
EV samples were loaded in SDS-PAGE gels using NuPAGE® Novex 4–12% Bis-Tris 1.0 mm gel 
(Life Technologies) and the NuPAGE® system from Life Technologies and were transferred 
onto 0.45 µm pore-Immobilon-P PVDF Membrane (Millipore). After blotting, membranes 
were blocked for 30 min in 5% milk (Campina) for CCL18, Alix, and CD63 analyses and in 
Rockland Blocking Buffer (Rockland) for phospho-ERK and β-Actin and incubated overnight 
with primary antibodies (diluted in blocking buffer) at 4°C. After three washes with Tris-
Buffered Saline + 0.1% Tween (TBS-T), membranes were incubated with secondary 
antibodies (diluted in blocking buffer) for 1.5 h and washed again three times with TBS-T 
before being developed using Amersham ECL Plus Western Blotting Detection System (GE 
Healthcare) (CCL-18, Alix, and CD63) or scanned in a LI-COR Odyssey scanner (Biosciences) 
according to the manufacturers’ instructions (phospho-ERK and β-actin). 
 
Transmission electron microscopy 
GBM8 EVs were diluted 1:1 with PBS and coated for a minimum of 10 min on Formfar coated 
copper grids (Electron Microscopy Sciences (EMS)). For the analysis of size distribution, grids 
were washed five times after coating, fixed in 1% glutaraldehyde (EMS), and incubated in 
0.5% uranil acetate (SPI Supplies) / 2% methyl cellulose (SIGMA). A total of nine images (three 
images per grid from three separate grids) were acquired using a transmission electron 
microscope (Philips CM100 Bio Twin), connected to a CCD camera (Olympus, Morada G2) 
and analyzed in iTEM version 5.2 software. Diameters of all EVs found on these images were 
measured in iTEM, resulting in a total of 944 measurements. For immuno-gold stainings, 
grids were coated with EVs 1:1 diluted in PBS, washed five times with PBS supplemented with 
1% BSA (PBA), blocked for 5 min in PBA and 10 min in a commercial blocking reagent (Aureon) 
or 10% rabbit serum (obtained from the Animal facility VU University medical center). After 
a minimum of 30 min incubation with primary antibodies, grids were washed again five times 
with PBA before incubation for 20 min with secondary reagents. Lastly grids were washed, 
fixed in 1% glutaraldehyde, and incubated in 0.5% uranil acetate/2% methyl cellulose before 
imaging. Image acquisition was performed using a transmission electron microscope 
connected to a CCD camera and iTEM software. 
 
EV interaction analysis 
For EV interaction experiments, subconfluent cultures were incubated with 10 ng/µl of 
PKH67-labeled EVs (if not stated otherwise) for 18 hours. Although it is firmly established 
that uptake of EVs is rapid and becomes saturated at 2-3 after incubation, we have incubated 
overnight (18 hours), because we were not only interested in EV binding, but also in 
subsequent processes such as internalization, accumulation, and cellular distribution where 
interference could potentially prevent EV function.  When indicated, cells or EVs were 
treated with recombinant CCL18, anti-CCL18 neutralizing antibody, heparin (25 µg/ml), 
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heparinase III, MC148 or R243 (20 µM unless indicated otherwise) for 1 h before EV addition, 
except for heparinase III, treatment (2 miU every 2 h for 6 h at 37°C). After overnight 
incubation with labeled EVs, cells were washed with PBS before fluorescence analysis. 
PKH67+ cells were either directly quantified in a Leica DM6000 microscope or analyzed by 
flow cytometry. Since GBM8 medium contains heparin, GBM8 uptake experiments were 
carried out in heparin-reduced medium (0.2 µg/ml). 
 
RNA isolation and RT-PCR 
A total of 5 x 105 cells or 40 µg of EVs were lysed in lysis/binding buffer and RNA was isolated 
using the total RNA extraction protocol from the MiRVANA kit (Ambion) following 
manufacturer’s indications. After isolation, RNA integrity and concentration were 
determined on an Agilent 2100 Bioanalyzer using Agilent Small RNA kit (Agilent Technologies, 
Germany), concentration of the samples was adjusted to the minimum concentration of the 
samples analyzed and cDNA was synthesized using Omniscript RT kit for RNA samples above 
50 ng or with Sensiscript RT kit when RT reactions contained less than 50 ng (both kits were 
from Qiagen) following manufacturer’s instructions. 
 
Small RNA sequencing and data analysis 
The RNA quality from GBM cell lines and matched EVs was analyzed on Agilent 2100 
Bioanalyzer using Agilent Small RNA kit (Agilent Technologies, Germany). Maximum sample 
input (6 µl) was prepared for sequencing using the Illumina TruSeq small RNA Preparation Kit 
according to the manufacturer (Illumina). RNAseq was performed on a HiSeq 2500 (Illumina) 
pair-end 125 nucleotide length read, using equimolar amounts for each sample. Sequencing 
reads analysis was done by using the sRNAbench analysis package as described previously 
(Barturen et al., 2014; Koppers-Lalic et al., 2014). Briefly after adapter trimming and unique 
reads grouping, reads were aligned to the human genome (UCSC hg19) using the Bowtie 
1.1.2. To provide annotations for RNA elements that mapped to human genome, several 
databases were used, including miRBase (version 21) for mature and pre-miRNA sequences 
and NCBI Reference Sequences (RefSeq Release 69, January 2nd 2015). Apart from the main 
sRNAbench program, a differential expression module based on edgeR (Robinson et al., 
2010) was used to generate an expression matrix of all miRNAs detected. Note that by using 
edgeR, sRNAbench applies implicitly TMM normalization in the detection of differentially 
expressed small RNAs, which was reported to be among the most stable methods (Dillies et 
al., 2013; Maza et al., 2013). 
 
Relative cell number quantifications 
Relative number of cells in GBM8 spheres were estimated by calculating GBM8 sphere 
volumes, assuming the volume of a neurosphere to be proportional to the number of cells 
comprising it. When seeded at low density in round-bottom, cell-repellent 96-well plates 
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(Greiner Bio-One), GBM8 cells form a single, nearly perfectly spherical neurosphere. Using a 
Leica DM 3000B motorized microscope equipped with a Pulnix JAI RMC-1327GE camera, 
pictures of individual spheres were taken and the area covered by the sphere was calculated 
using ImageJ software. Radius of the sphere was calculated as the square root of the area 
divided by Pi, and relative sphere volume was calculated by taking four thirds of Pi multiplied 
by the third power of the calculated radius. When stated, R243 and/or TMZ (20 µM or 
otherwise indicated concentrations) were directly added to the culture medium immediately 
after seeding the cells. EVs were added at a final concentration of 100 ng/µl once 30 min 
after drug treatments and again 24 h later. Spheres were measured between from 5 to 7 
days after treatments. IC 50  value determination for R243 on GBM8 cells, as well as 
TMZ/R243 synergy studies were performed using CellTiter-Glo kit (Promega), and GBM-FM 
relative cell numbers in Figure 2D were estimated by luciferase assay (Promega). Both assays 
were performed following manufacturer’s recommendations.  
 
Development of Cre and mTmG lines and in vitro Cre-mT/mG EV transfer studies 
The Cre-expressing GBM8 cell line was generated by lentiviral transduction of the plasmid 
Puro.Cre empty vector (Addgene #17408), followed by puromycin selection for one month. 
Homogeneity of Cre expression in GBM8-Cre cells was verified by immunocytochemistry. 
GBM8 mT/mG cells were generated by releasing the entire (linearized) mT/mG cassette from 
ROSA26 mT/mG plasmid (Addgene #17787) by restriction with AscI, AccI and PmeI (New 
England Biolabs), band purification and electroporation with a microporator MP-100 (Digital 
Bio, Seoul, South Korea) following manufacturer’s instructions with a single pulse of 1400 V 
for 40 milliseconds. After 1 month in culture, cells still expressing mTomato protein were 
sorted by flow cytometry in a FACSARIA instrument (BD Biosciences). Functionality of the 
mT/mG cassette was verified by incubating the lenti Puro.Cre virus directly on GBM8-mT/mG 
cells and observing appearance of mG+ cells 96 h later. For EV transfer studies, 1 x 104 GBM8-
mT/mG cells were seeded in 6-well plates and Cre-donor EV isolates were added at a final 
concentration of 10 and 40 ng/µl. An equivalent volume of PBS was added as negative 
control. Alternatively, a total 104 GBM8-mT/mG and GBM8-Cre cells were co-cultured at 1/10 
and 1/100 ratios of mT/mG vs Cre cells. As a negative control, GBM8-mT/mG cells were co-
cultured with parental Cre- cells. After 12 days in culture, wells were inspected for the 
presence of spheres with GFP+ cells in a Leica DM IL microscope equipped with a DFC345 FX 
camera. Results were expressed as % of GFP+ spheres relative to the total spheres. 
 
In vivo Cre-mT/mG EV transfer studies 
Shortly before intracranial injection, GBM8-mTmG were washed once with phosphate 
buffered saline (PBS) and concentrated to 1.2 x 105 cells per µl. Mice were stereotactically 
injected with 6 x 105 cells in a final volume of 5 µl into the striatum. All intracranial injections 
were performed using isoflurane inhalation anesthesia (1.5 L O 2 /min; 2% isoflurane) and 
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appropriate systemic and topical analgesia. Coordinates used for intracranial injections were 
0.5 mm X, 2 mm Y, -2.5 mm Z from the bregma (1). Three days after injection of GBM8-mTmG 
tumor cells, 10 µl vesicle suspension (15 µg) was injected into the tumor, using the same 
coordinates. Vesicles were harvested by ultracentrifugation from Cre-containing GBM8 cells 
of from parental cells. For tumor-to-tumor crosstalk, GBM8-mTmG cells, GBM8-Cre cells and 
GBM8 parental cells were prepared and concentrated as indicated above. GBM8-mTmG cells 
were injected in the striatum of the left hemisphere, whereas GBM8-Cre (n = 6) or GBM8 
parental cells (n = 6) were injected in the right hemisphere. Three weeks after tumor 
injection, mice were sacrificed and cryosections (8 µm thick) of brains were prepared. 
Fluorescence of endogenous mTomato and/or GFP in the left hemisphere was imaged in 
DAPI stained cryosections using a Zeiss Fluorescence microscope. 
 
GPCR siRNA screening 
For the GPCR siRNA screening, HEK-293T cells were plated in 96-well plates at a density of  5 
x 104 cells/ml. After an overnight incubation, cells were transfected with a siGENOME 
Smartpool siRNA library-G Protein-Coupled Receptors (50 nM, Dharmacon) using 
Lipofectamine 2000 as a transfection reagent following manufacturer’s indications. This 
library contains siRNAs against 512 individual GPCRs and GPCR-associated genes.  After 48 h, 
20 ng/µl of PKH67-labeled EVs were added to the plates. As controls for EV uptake reduction, 
every plate was loaded with a standard curve of labeled EVs (20, 10, 5 and 0 ng/µl) on 
untransfected cells. After overnight incubation with stained EVs, plates were washed twice 
with PBS, nuclei were stained with DAPI and plates were scanned in an Acumen eX3 (TTP 
LabTech, Melbourne, UK) microplate cytometer. After this overnight incubation time, the 
fluorescence signal represents the sum of multiple EV interactions and processes, including 
cell-surface bound EVs and intracellular EVs.  Fluorescence levels were normalized by mean 
fluorescence intensity of all the plates excluding controls and divided by the number of nuclei 
determined by DAPI staining. 
 
siRNA validation transfection 
For siRNA screening validation on top-8 EV uptake-inhibiting GPCRs, new siRNAs against 
them were obtained from another manufacturer (Qiagen FlexiTube siRNAS: PTGIR_1: 
SI00019250, C5R1_1: SI00027412, TRAR3_1 (TAAR9): SI00159208, ADORA2A_1: 
SI00013874, MRGX2_1: SI00147994, CXCL3_1: SI00032662, CCR8_7: SI03027843, 
GPR172B_1: SI00120295). siRNAs were transfected in HEK-293T cells with Lipofectamine 
2000 following manufacturer’s instructions. Efficient mRNA knock-down of target genes was 
verified by quantitative real-time PCR (data not shown). siRNA screening results were also 
validated in GBM8 cells by electroporation of Qiagen’s siRNAs with a microporator MP-100 
(Digital Bio, Seoul, South Korea) following manufacturer’s instructions with a single pulse of 
1400 V for 40 milliseconds. At 48 h after transfection, HEK-293T and GBM8 cells were 
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incubated overnight with 20 ng/µl of PKH67-labeled EVs, washed twice with PBS and 
subjected to fluorescent EV uptake analysis. As a control for EV uptake inhibition in GBM8 
cells, siRNA control cells were treated with Dynasore (80 µM), a Dynamin2 inhibitor know to 
impair EV uptake (Mulcahy et al., 2014Mulcahy et al., 2014) for 30 min before incubation 
with labelled EVs. 
 
Flow cytometry 
For FACS analysis, cells were washed in PBS, resuspended in PBS supplemented with 1% BSA 
(PBS-BSA) and analyzed with FACSDiva software in a BD Fortessa instrument. Collected data 
was processed with flowJoX software. CCR8 expression analysis was carried out by incubating 
cells with anti CCR8 antibody for 30 min on ice, washing them three times with PBS-BSA and 
incubating them with an Alexa Fluor 405-coupled secondary antibody for another 30 min. 
Cells were analyzed after three more washes with PBS-BSA. For the BrdU incorporation assay, 
cells were seeded at a density of 4 x 105 cells/ml and EVs (or PBS in the control wells) were 
added at a final concentration of 100 ng/µl at the moment of seeding and once more 18 h 
later. At 12 h after second EV addition, cells were incubated for 2 h with BrdU and washed 
with PBS prior fixation with 4% paraformaldehyde (PFA) for 15 min. Membranes were 
permeabilized with 100% cold methanol and cells were washed with DNAse buffer (10 mM 
Tris, 2.5 mM MgCl 2 , 0.1 mM CaCl 2 ) and treated with DNAseI diluted in DNAse buffer 
at RT for 20 min. Cells were washed in ICC wash buffer (1x PBS, 0.1% Triton TX-100, 0.05% 
Azida, 1% BSA), blocked in wash buffer containing 10% fetal bovine serum (FBS) for 20 min 
at room temperature and incubated overnight with anti-BrdU primary antibody at 4°C. After 
three wash steps, Alexa Fluor 405-coupled secondary antibody was incubated at RT for 2 h. 
Before analysis by flow cytometry, samples were washed three times in ICC wash buffer. 
 
CCR8 and CCL18 expression and patient survival analysis 
Expression and Kaplan Meier analyses were performed using the R2 online platform 
(R2.amc.nl). To distinguish expression levels of GBM versus normal brain tissue, MAS5.0 
normalized, u133p2 microarray data of the (1) French Tumor Glioma Dataset  (GSE16011,) 
containing 276 glioma samples of all histology and 8 control samples 115  (2) The Sun Tumor 
Glioma dataset (GSE4290) containing 157 tumor samples including 26 astrocytomas, 50 
oligodendrogliomas and 81 glioblastomas, (3) Hegi Tumor Glioblastoma  dataset (GSE7696), 
containing 80 glioblastoma specimens of patients were compared to (4) Eight normal 
samples present in the French dataset; (5) the Berchtold Normal Brain regions dataset 
(GSE11882) containing 176 samples from  hippocampus, entorhinal cortex, superior-frontal 
gyrus, and postcentral gyrus brain tissues) and (6) the Harris Normal Brain PFC dataset 
(GSE13564), containing 44 prefrontal cortex brain tissues. Kaplan Meier analyses were 
performed using the French dataset. The significance of the difference in expression levels 
of CCR8 and CCL18 between tumor versus normal brain tissues was determined using a t-
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test. The significance of the Kaplan analyses was tested using a Mann-Whitney test. For this, 
the most optimal expression threshold point was determined. 
 
Immunocytochemistry, Immunohistochemistry, tissue microarray and chemokine array 
For immunocytochemistry, attachment of cells to glass coverslips was induced by adding 10% 
FBS for 2 h. Then, coverslips were washed with PBS, fixed with 4% PFA for 15 min and treated 
with cold methanol. After a wash in ICC wash buffer, coverslips were blocked in ICC wash 
buffer containing 10% FBS for 20 min at room temperature and incubated overnight with 
anti-Cre or anti-CCR8 primary antibodies at 4°C. After three wash steps, Alexa Fluor 488-
coupled (Cre) or Alexa Fluor 594-coupled (CCR8) secondary antibodies were incubated at RT 
for 2 h. Slides were washed three times before and after DAPI counterstain and mounted 
with Vectashield (Vector Laboratories) on glass slides. For analysis of GBM8 mT/mG 
xenografts, brain cryosections (10 µm thick) were fixed in 4% PFA, washed three times with 
PBS for 10 min before and after counterstaining with DAPI and mounted on glass coverslips 
with Vectashield. Pictures were taken with a Leica DM6000 microscope and processed with 
ImageJ software. GFP Immunohistochemistry was performed on cryopreserved tissue slides 
following standard procedures. Slides were scanned using Aperio Scanscope and processed 
with ImageScope software (Leica) (Abcam; ab 6556; 1:1000). Tissue micro array – GL805a 
(TMA) containing glioblastoma samples and control tissues was purchased from US Biomax 
Inc. After deparaffination and microwave induced antigen retrieval (Tris-EDTA pH9.0), TMA’s 
were stained with anti-CCR8 antibody (E77, Abcam) and anti-rabbit/mouse EnVision-HRP 
(DAKO). For negative staining, the first antibody was omitted. CCR8 expression was 
calculated based on the stained area (0-4) and staining intensity (0-4), thus resulting in a 
maximal value of 16. To detect chemokines secreted by GBM8 cells, Proteome Profiler™ 
Human Chemokine Array Kit (R&D Systems) was used to detect secreted chemokines in 
GBM8 conditioned medium following manufacturer’s instructions. Briefly, array membranes 
were blocked and incubated for 2 h with conditioned medium collected from cells growing 
at 2.5 x 105 cells/ml for 24 h and diluted 1:1 in blocking buffer. After washing, membranes 
were incubated with a cocktail of biotinylated human chemokine antibodies in blocking 
buffer at RT for 2 h and then incubated with horseradish peroxidase (HRP)-conjugated 
streptavidin in blocking buffer overnight at 4°C following further washes, After three washes, 
membranes were developed using Chemi Reagent Mix and visualized on X-ray film (GE 
healthcare). 
 
Enzyme-linked immunosorbent assay  
To detect EV-associated molecules, a fixed concentration of 5 ng/µl or serial dilutions of 
isolated EVs were coated overnight at 4°C in coating buffer (0.2 M NaHCO 3 , pH 9.2) on 
ELISA plates. Plates were washed twice with TSM buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 
1 mM CaCl 2 , 2 mM MgCl 2 ) and blocked with 1% BSA in TSM for 1 h at room 
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temperature. Plates were then incubated with primary antibodies at a fixed concentration (1 
µg/ml) or in serial dilutions (from 4 µg/ml to 62.5 ng/ml) in TSM buffer with 1% BSA for 1 h 
at room temperature. After three washes with TSM buffer, plates were incubated with 
secondary antibodies at RT for 1 h, washed again three times, and the reaction was 
developed, using 3,3’,5,5’-tetramethylbenzidine (TMB) as a substrate (Sigma Aldrich). Signal 
intensities were acquired with a Biotek Synergy HT microplate reader. 
 
In vivo R243 + TMZ treatment  
Treatment with R243 (1.0 mg/kg, i.p. once daily) or vehicle (1% DMSO in PBS) was started at 
day 4 after tumor injection and continued until day 8.  At day 5, animals were treated once 
with 10 mg/kg TMZ, i.p.,  or vehicle (4% DMSO in PBS). Stocks of R243 (100 µM; 35.7 mg/ml) 
were prepared in DMSO and stored at -20°C. Working solutions were prepared freshly before 
each administration by diluting R243 stock solution in PBS. 
 
Bioluminescence imaging 
Tumor progression was followed by measuring firefly luciferase (Fluc) signal by a charge-
coupled device (CCD) camera, using the Xenogen-IVIS Lumina system under isoflurane 
anesthesia. Mice were injected intraperitoneally with 150 µl D-luciferin (100 mg/kg). Regions 
of interest were defined on the head of the mice. The photon flux (p/s) in these regions were 
used as a total measurement of Fluc activity. Photon flux was normalized to the group means 
at day 8 (Figure 5E). Disease progression was defined as the time point at which for two 
consecutive measurements an increase in BLI was observed. 
 
Pharmacokinetic studies 
WT FVB mice and transgenic Abcg2-/-, Abcb1a/b-/- and Abcg2; Abcb1a/b-/- FVB mice were used 
in pharmacokinetic studies. R243 was administered i.v. at a dose of 10 mg/kg in a formulation 
containing 2 mg/ml R243 in DMSO:Cremophor EL:saline (1:1:8). Blood and brains were 
collected 1 h after administration. Plasma was obtained by centrifugation (5 min, 5000 rpm, 
4°C) and brains were weighed and homogenized using a FastPrep®-24 (MP-Biomedicals, NY, 
USA) in 1% (w/v) bovine serum albumin in water. R243 was extracted by liquid-liquid 
extraction using ethyl acetate and measured using LC-MS/MS. 
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In vitro translocation assays 
Conventional bidirectional translocation assays were performed using parental MDCK cells 
as described previously (Lin et al., 2013Lin et al., 2013)￼. R243 was added to either the 
apical or basolateral side of a Transwell microporous polycarbonate membrane filters (3.0 
µm pore size, 24 mm diameter; Costar Corning, Corning, NY, USA) at a concentration of 100 
nM and translocation over time was measured using LC-MS/MS. Complete R243 
translocation was reached when an equilibrium between both compartments was 
established. 
 
Supplemental information 
Supplemental Figures and Table are available online. 
 
Accession numbers 
The raw sequencing data are deposited at a public database. The NCBI SRA accession number 
for the small RNA sequencing by Illumina Hi-Seq 2500 reported in this paper is SRP092232. 
Small RNA sequencing data used in the analysis for supplementary Fig. 9 is presented in 
Supplementary Table S1 with the list of human miRNAs detected in GBM8 cells and their 
paired EVs. Individual miRNA sequencing reads mapped to human miRNAs are detected in 
cells and their paired EVs. Highlighted in yellow are miRNAs represented in supplementary 
Fig. 9. RPM, reads per million of normalized reads (relative expression). 
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____________________________________ 
GBM EVs induce a proliferative phenotype in 
recipient GBM cells. 
To confirm the pro-tumoral capacity of EVs on 
GBM cells we isolated EVs from GBM-
conditioned media by differential 
ultracentrifugation 367,368. EVs isolated from stem-like GBM8 cells (a primary stem-like GBM 
cell type) had a diameter ranging from 30 to 200 nm as measured by EM (Fig. 1a), similarly 
as EVs isolated from U87 and U251 GBM cells (Supplementary Fig. 1a, b), and expressed the 
EV markers Alix and CD63 (Fig. 1b and Supplementary Fig. 1c). GBM8 cells were incubated 
with isolated and PKH67-labeled GBM8 EVs, resulting in a dotted fluorescent pattern, 
indicating efficient EV binding (Fig. 1c), similar results were obtained for U251 and U87 
(Supplementary Fig. 1d). Using FACS analysis, the proportion of PKH67+ cells after incubation 
with labeled EVs showed a sigmoidal log-linear dose-response relationship with the amount 
of PKH67-labeled EVs added (R=0.9998). Co-incubation of PKH67-labeled EVs with increasing 
concentrations of unlabeled EVs resulted in a dose-dependent reduction in mean 
fluorescence intensity (Supplementary Figs 1e, f)(39,40). These results prompted us to 
quantify EV-mediated proliferation. We incubated GBM8 cells with fresh EV-depleted 
medium or with medium supplemented with isolated GBM EVs, resulting in enlarged stem-
like GBM8 neurospheres and an increase in total cell number in cells supplemented with 
exogenous EVs (Fig. 1d). The EV-mediated induction of proliferation was significant and dose-
dependent, increasing GBM8 stem-like cell numbers by 2.4-fold when cells were incubated 
with 250 ng/µl of isolated EVs (Fig. 1f). Addition of exogenous EVs resulted in a 1.5-fold 
increase in 5-bromo-2'-deoxyuridine (BrdU) incorporation, indicating that the observed 
increase in cell number is at least partially due to an enhanced proliferation rate (Fig. 1g). EV 
exposure also induced activation of the MAPK-ERK pathway, as evidenced by an increase in 
phospho-ERK levels (Fig. 1e). Because MAPK-ERK activation also is implicated in TMZ 
resistance in GBM cells 369, we validated the effects of TMZ treatment in the presence of EVs. 
After determining the IC 50  value of TMZ on GBM8 cells (~20 µM, Supplementary Fig. 3), 
we treated cells with 20 µM TMZ in the presence or absence of 100 ng/µl of purified EVs. As 
shown in Fig. 1h, addition of exogenous EVs indeed resulted in strong protection against 
TMZ-mediated cell kill, although a partial contribution of a concomitant induction of cellular 
proliferation is not excluded.  
RESULTS 
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Figure 1. GBM cells can exchange functional RNA via EVs. (a) EM image of GBM8 EVs isolated by 
differential centrifugation (scale bar: 100 nm). (b) Western blot analysis of EV markers CD63 and Alix 
on EVs isolated from GBM8 cells. Control: Supernatant from the 70,000 x g centrifugation step. (c) 
GBM8 cells incubated overnight with PKH67-labeled GBM8 EVs. Arrows indicate PKH67+ cells which 
have taken up EVs (scale bar: 10 µm). (d) GBM8 cells incubated with 100 ng/µl of isolated EVs show 
enlarged neurospheres (right picture) as compared with cells incubated with control supernatant from 
the last centrifugation step (left picture) (scale bars: 100 µm). (e) Western blot analysis of phospho-ERK 
on cells incubated as in (g), β-actin was used as a loading control. Numbers above blot represent relative 
phospho-ERK band intensities. (f) Luciferase assay on GBM8-FM cells incubated with increasing 
concentrations of isolated EVs indicates dose-dependent increase in cell number. The bar graphs show 
the means ± standard deviation (SD) of three independent experiments. ***indicates p-value ≤0.001 
and **** indicates p-value ≤0.0001 as determined by one-way analysis of variance (ANOVA). (g) BrdU 
incorporation assay reveals increased proliferation rate in cells incubated with 100 ng/µl as compared 
to control-incubated cells. (h) GBM8 spheres were treated with TMZ for 96 h in the presence or absence 
of 100 ng/µl of GBM8 isolated EVs and relative cell numbers were estimated by calculating sphere 
volume. The data is normalized to control-treated cells (100%) and bar graphs show the means ± SD of 
four independent experiments. ** indicates p-value ≤0.01, *** indicates p-value ≤0.001 as determined 
by ANOVA. 
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To determine whether functional transfer by EVs occurs at physiologically relevant levels, we 
used a color switch system based on EV-mediated Cre recombinase mRNA transfer 125. 
Reporter mT/mG cells contain a floxed copy of membrane-tagged Tomato (mT). Upon Cre-
mediated recombination the mT sequence is excised allowing expression of a membrane-
tagged GFP (mG) located immediately downstream, resulting in a color switch from mT+ (red) 
to mG+ (green) (Supplementary Fig. 2a). Cre protein expression in stably transduced EV donor 
cells was confirmed by immunocytochemistry (Supplementary Fig. 2b), and RT-PCR analysis 
revealed presence of Cre mRNA in EVs isolated from these donor cells (Supplementary Fig. 
2c). Next, addition of purified Cre+ EVs isolated from Cre donor cells induced patches of mG+ 
cells in recipient GBM8-mT/mG stem-like neurospheres (Supplementary Fig. 2d), and Cre 
activity was also transferred from Cre donor cells to mT/mG recipient cells in co-culture 
experiments in which no exogenous EVs were added (Supplementary Fig. 2e).  
Altogether these results indicate that GBM EVs can transfer cargo, and that EV interaction 
results in activation of the MAPK-ERK pathway, induces proliferation and that EVs can reverse 
TMZ sensitivity.  
 
CCR8 acts as an EV receptor  
To identify cellular receptors involved in EV uptake we performed siRNA screening using 
PKH67-labelled EV uptake by HEK-293T cells as readout. HEK-293T cells were selected 
because the conditions for siRNA screening of these cells were considered more favorable as 
compared to primary stem-like GBM neurospheres. We selected a siRNA library against G-
protein coupled receptors (GPCRs) because of the highly versatile roles of GPCRs in many 
cellular processes, including viral entry, and because many GPCRs are potentially druggable. 
After testing that GBM EVs are efficiently taken up by HEK-293T cells and that EV uptake is 
dose-dependent (Supplementary Fig. 4a, b), we transfected the GPCR siRNA library. At 48 h 
after transfection, cells were incubated overnight with labeled EVs and fluorescent cells were 
recorded (Supplementary Fig. 4c). A total of 65 of 512 siRNAs caused a reduction in 
fluorescent signal stronger than 30% from which we selected the top-8 for further validation 
with an independent set of siRNAs (Fig. 2a). CCR8 inhibition caused a strong and consistent 
reduction in EV uptake in both HEK-293T and GBM8 cells and therefore was selected for 
further studies (Fig. 2b and Supplementary Fig. 4d).  
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Figure 2. CCR8 acts as an EV receptor (a) GPCR siRNA screening result on HEK-293T cells. Normalized 
PKH67 fluorescence is displayed on the Y-axis, and each dot represents a siRNA against an individual 
GPCR Top-8 EV uptake-reducing siRNAs are highlighted in orange and indicated at the right side. (b) 
siRNA screening validation on GBM8 cells with an independent set of siRNAs. Normalized PKH67 
fluorescence (EV uptake) is displayed on the Y-axis. Treatment of cells with Dynasore served as a control 
for EV uptake reduction. (c) CCR8 inhibitor MC148 reduces EV uptake in a dose-dependent fashion. (d) 
FACS analysis of CCR8 expression in GBM8 cells. Negative control: No anti-CCR8 primary antibody (e) 
PKH67 fluorescence (representative of EV uptake) of CCR8- (green) compared to CCR8+ (orange) GBM8 
cells. Negative control (grey): GBM8 cells not incubated with PKH67 EVs.  
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CCR8 is a beta chemokine receptor with a known role in induction of chemotaxis in Th2 cells 
via its two ligands CCL1 and CCL18 370, and functions as a co-receptor for enveloped viruses 
including HIV 371,372. The CCR8 axis has been found to be activated in urothelial and renal 
carcinomas resulting in immune response impairment, and it is responsible for apoptosis 
inhibition in lymphoma 373,374. Furthermore, CCR8 function in melanoma cells is essential for 
the entry of metastatic cells into lymph nodes 375. We show the relevance of CCR8  on EV 
uptake in GBM8 cells by the dose-dependent reduction of uptake in the presence of 
increasing concentrations of MC148, a highly selective virus-encoded CCR8 antagonist 376 
(Fig. 2c). According to the CCR8 expression levels, GBM8 cells can be divided in two 
populations. One population expresses undetectable levels of CCR8 (CCR8- cells), whereas 
the other population shows significant CCR8 immunoreactivity (CCR8+ cells) (Fig. 2d and 
Supplementary Fig. 4e). In several independent experiments, we have observed variable 
proportions of CCR8+ GBM cells, ranging from 20-80%. Interestingly, when we combined 
labeled EV uptake with CCR8 immunostaining, we observed that a significantly larger 
proportion of CCR8+ cells take up PKH67-labeled EVs than do CCR8- cells (Fig. 2e), strongly 
suggesting that CCR8 participates in the uptake process. 
 
CCR8 inhibition neutralizes EV-induced phenotypes in vitro 
R243 is a small molecule which functionally inhibits CCR8 both in vivo and in vitro 377. We 
therefore synthesized a batch of R243 to test its effect on inhibiting EV uptake (chemical 
synthesis scheme in Supplementary Fig. 5a). As expected, R243 treatment strongly impaired 
EV uptake (Fig. 3a, b). We then tested whether R243 could counteract EV-induced 
phenotypes on recipient GBM cells. After determining the IC 50  value of R243 on GBM8 
cells (44 µM, Supplementary Fig. 5b), we pre-treated GBM8 cells with R243 (20 µM) for 30 
min, incubated the cells with isolated EVs and measured the total number of GBM cells after 
96 h. As shown in Fig. 3c, R243 alone had no measurable effect on GBM cell growth, whereas 
R243 pre-treatment was able to completely block EV-induced GBM cell growth. Next, we 
studied whether TMZ and R243 have synergistic effects. Combined treatment of GBM cells 
resulted in enhanced potency of TMZ, with combination indexes 378 down to 0.8 (Fig. 3d). We 
studied the effects of R243 on GBM cells treated with TMZ in the presence of isolated EVs. 
Interestingly, although EV supplementation alone restored cell-numbers after TMZ 
treatment, R243 treatment partially prevented this EV-induced resistance to TMZ (Fig. 3e). 
As shown in Supplementary Fig. 5c-g, R243 reduced EV uptake by three different GBM lines 
tested, although with variable potency. We also observed a significant effect of the drug on 
A375 cells (malignant melanoma), but not on A549 cells (lung carcinoma). These results 
suggest that CCR8 may also function as an EV receptor on certain non-GBM cell types. 
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Figure 3. CCR8 inhibition neutralizes EV-induced phenotypes in vitro. (a) PKH67 uptake analysis of cells 
treated with vehicle (green) or with R243 (orange). Control: No PKH67 EVs (grey). (b) Representative 
pictures of cells incubated as in (a) (scale bars: 25 µm). (c) Relative cell number of cells incubated with 
and without GBM8 EVs in the presence or absence of R243. Values are normalized to control (vehicle, 
no EVs) and bar graphs show the means ± SD of six independent experiments. (d) CellTiter-Glo viability 
assay (Promega) on GBM8 cells treated with variable concentrations of TMZ and R243. Darker orange 
represents less viability. (e) Relative cell number of GBM8 spheres incubated with or without 100 ng/µl 
of GBM8 EVs and treated with TMZ in combination with R243 (orange bars) or vehicle (grey bars). Bars 
show the means ± SD of 4 independent experiments. For all experiments * indicates p-value ≤0.05, ** 
indicates p-value ≤0.01, *** indicates p-value ≤0.001 as determined by ANOVA. 
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CCR8 and CCL18 expression levels are increased in GBM and are an indicator of poor prognosis 
To determine whether CCR8 expression has implications in tumor progression in GBM 
patients, we performed immunostaining against CCR8 on a tissue microarray (TMA) from 
glioma samples of patients with different glioma grades, including grade IV GBM. Tumor cells 
exhibited different immunoreactivity patterns which we scored depending on the intensity 
of the staining. Blinded classification of array specimens revealed a significant increase in 
CCR8 expression in grade IV GBM as compared to normal (non-tumoral) brain tissues (Fig. 
4a, b and Supplementary Fig. 6). We also performed metadata analysis on publicly available 
microarray data using the R2 Analysis and Visualization Platform (http://r2.amc.nl). Results 
showed increased mRNA levels of both CCR8 and its natural ligand CCL18 in GBM as 
compared to normal brain samples (Fig. 4c, d). Moreover, survival analyses indicate that both 
CCR8 and CCL18 are indicators of poor prognosis in GBM patients (Fig. 4e, f).  
 
Figure 4. CCR8 and CCL18 expression levels are increased in GBM and are an indicator of poor prognosis. 
(a) Representative pictures of a GBM TMA immunostained against CCR8 (scale bar: 200 µm). (b) Scoring 
of CCR8 immunoreactivity on TMA of GBM of different grades and healthy tissue. * indicates p-value 
≤0.05 (t-test). (c,d) CCR8 and CCL18 mRNA expression analysis on datasets using R2 Analysis and 
Visualization Platform. X axis shows the dataset used. (e,f) Survival analysis of patients expressing high 
and low levels of CCR8 and CCL18 mRNA, respectively. For expression and Kaplan-Meyer analyses R2 
online platform (R2.amc.nl) was used. Differential expression was tested by t-test and significance of 
Kaplan analysis by Mann-Whitney test. P values for CCR8 expression were 10-10 (Sun / Bechtold), 9-9 
(Hegi / Harris) and ˃0.05 for the French dataset. P values for CCL18 expression were 0.004 (Sun / 
Bechtold), 0.05 (Hegi / Harris) and 0.0003 for the French dataset. 
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Pharmacological inhibition of CCR8 delays tumor growth after TMZ treatment 
A common problem in the development of drugs for GBM treatment is the blood-brain 
barrier (BBB). Therefore, we first verified that R243 is capable of reaching the brain. Specific 
transporter proteins, which are present on the BBB, are known for their role in blocking drug 
delivery to the brain 63. By using wildtype mice and transgenic mice deficient for the 
transporters Abcg2 and Abcb1a/b, we show that these drug transporters have no meaningful 
impact on the brain penetration of R243 (Fig. 5a-c). Intriguingly, the brain-to-plasma ratio of 
R243 was 35 in wildtype mice, unusually high, pointing to a remarkable accumulation of R243 
into the brain (Fig. 5d). Next, to test the effects of R243 on GBM in vivo, we employed a 
version of GBM8 cells (GBM8-FM) stably expressing mCherry protein and firefly luciferase, 
which allows monitoring of tumor growth bioluminescence imaging. Subsequently, we tested 
with the Cre-mT/mG EV reporter system the ability of in vivo transfer of EV cargo. We 
orthotopically injected GBM8-mT/mG recipient cells in the brain of nude mice (n = 6). Three 
days after implantation of the recipient reporter cells, we injected EVs isolated from Cre+ (n 
= 3) or Cre- (n = 3) donor cells in the brains of these mice. Two weeks later the mice were 
sacrificed, and the brains were resected, sliced and analyzed by fluorescent microscopy. The 
tumor tissues consisted mostly of red mT+ cells, but tumor areas with abundant mG+ cells 
were also observed in 3 out of 3 mice injected with Cre+ EVs, in contrast to the brains of the 
3 mice injected with Cre- control EVs, where no mG+ cells were detected (Supplementary Fig. 
7a). Next, we investigated whether physiological levels of locally produced Cre+ EVs - by co-
injection of GBM8-Cre donor cells with GBM8-mT/mG recipient cells - can also result in 
functional transfer of Cre. Hence, we co-injected mice with mT/mG recipient cells and Cre+ 
or Cre- donor cells in opposite hemispheres of the brain in order to minimize the risk of cell 
contact-dependent Cre transfer. Again, the brains of 3 out of 3 mice co-injected with Cre+ 
cells displayed patches of mG+ cells in mT/mG tumors, in contrast to mice co-injected with 
Cre- GBM cells which resulted only in mT+ cells (Supplementary Fig. 7b, c).  The presence of 
mG+ cells was further validated by anti-GFP immunostaining of mouse brain slices 
(Supplementary Fig. 7d). These results demonstrate that EVs can indeed provide functional 
transfer of RNA molecules in orthotopic brain tumors, albeit that the efficiency of the Cre–
mT/mG reporter system under these conditions is relatively low. We than tested if we could 
inhibit the EV mediated protumoral effects in vivo, by the administration of the CCR8 
inhibitor R243. As shown in Fig. 5e, f, R243 administration did show a trend in reducing 
primary GBM stem-like xenograft growth in nude mice (n = 6), although no significant effects 
were measured. However, when we administered R243 before and after TMZ treatment in 
nude mice (n = 6), the effect of TMZ was significantly enhanced, and tumor recurrence was 
significantly delayed as compared to TMZ treatment in the absence of R243 (Fig. 5e, f). In 
conclusion, under these conditions R243 only showed a minor non-significant effect when 
administered alone, and perhaps repeated dosing and/or earlier treatment would be more 
beneficial. However, administration of R243 in combination with TMZ did demonstrate a 
124 
significant delay of recurrence after TMZ treatment and warrants further preclinical testing 
(Fig. 5g).  
Figure 5. Pharmacological inhibition of CCR8 delays tumor growth after TMZ treatment. (a) R243 
transwell translocation assay for the drug transporter P-gp using MDCK cells. Percentage of R243 
translocation from basolateral to apical (grey line) and from apical to basolateral (orange line) is plotted 
in Y-axis. (b-d) R243 levels were measured in plasma (b) and in brain (c) 1 h after i.v. injection of the 
drug, and brain-to-plasma ratio was calculated (d). No statistical differences were measured by ANOVA. 
(e-g) BLI tumor growth analysis of GBM8 mouse xenografts treated with vehicle (grey); R243, 1.0 mg/kg 
(green); TMZ, 10 mg/kg (blue) or R243 and TMZ combined (orange). Mice were treated with R243 once 
daily from day 4 to day 8 after tumor injection and TMZ was administered a single time at day 5. The y-
axis represents the median BLI normalized to day 8. The p-value was determined by t-test on the area 
under the curve for TMZ vs. TMZ+R243. Representative BLI images are shown in (f) and progression-
free survival is calculated in (g). P-value on median progression-free survival was determined by the 
Log-rank (Mantel-Cox) test.  
CCL18 acts as a bridging molecule between GAGs on EVs and cellular CCR8 
We performed uptake analyses in the presence of CCL1 and CCL18, the two known ligands 
of CCR8, as well as with neutralizing antibodies directed against these chemokines. Whereas 
CCL1 or its neutralizing antibody had no effect on EV uptake (data not shown), recombinant 
CCL18 addition significantly increased EV uptake, and the CCL18 neutralizing antibody 
decreased uptake (Fig. 6a, b). These results suggest that CCL18 plays a mediating role in the 
EV uptake via CCR8. Chemokine arrays were used to determine that GBM8 cells secrete many 
chemokines, including CCL18 (Supplementary Fig. 8a). Given that EV membranes are highly 
glycosylated 379,380, and that chemokines bind with high affinity to glycans 381,382, we 
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considered the possibility that CCL18 could be acting as a bridging molecule between glycans 
on the EV membrane and the cellular receptor CCR8. We incubated isolated EVs with 
recombinant CCL18 overnight, washed the EVs with PBS and purified them again. Western 
blot analysis revealed that CCL18 can be detected in the EV pellet but not in the supernatant, 
confirming effective binding of CCL18 to EVs (Supplementary Fig. 8b). We incubated ELISA 
plates with isolated GBM8 EVs and confirmed proper vesicle coating by detection with the 
marker CD63 (Fig. 6c and Supplementary Fig. 8c). This system also allowed us to detect 
endogenous CCL18 on GBM8 EVs (Fig. 6d and Supplementary Fig. 8d). To further confirm 
CCL18 presence on GBM8 EVs, we performed immunogold EM on isolated EVs, observing 
exosome-like vesicles with strong immunoreactivity against CCL18 and CD63 (Fig. 6f, g).  
 
Next, we validated the presence of glycans on GBM EV membranes. As shown in Fig. 7a-c, 
GBM8 EVs are rich in heparan sulfate, chondroitin sulfate and dermatan sulfate, the main 
GAGs produced by eukaryotic cells 383–385. Chemokine-glycan interactions occur mainly by 
electrostatic forces and heparin. Heparin is a soluble and highly sulfated GAG, capable of 
displacing chemokine-glycan interactions due to its high negative charge density 381,382,386. 
We reasoned that if CCL18 binding to EVs is needed for cellular uptake, pretreatment of EVs 
with heparin should cause CCL18 to be displaced from the EV membrane consequently, 
resulting in diminished uptake. Indeed, heparin pretreatment reduced EV uptake by 80% (Fig. 
7d). This result is in agreement with a previous report from Paggetti and colleagues in which 
heparin treatment of chronic lymphoid leukemia-derived EVs caused a strong reduction in 
EV uptake 355. Furthermore, heparin has been shown to efficiently bind and capture EVs 387. 
To further demonstrate the involvement of GAGs in the uptake process, we treated purified 
EVs with Heparinase III (H’se III), which cleaves 1-4 linkages between hexosamine and 
glucuronic acid residues in heparan sulfate molecules. H’se III treatment reduced EV uptake 
by approximately 40%, confirming that glycans exposed on the EV membrane facilitate EV 
uptake (Fig. 7e). Collectively, these results reveal an EV uptake model in which CCL18 acts as 
a “connectokine” between glycans decorated on the EV membrane and the cellular receptor 
CCR8 (Fig. 7f). 
 
126 
Figure 6. CCL18 enhances EV uptake. (a) EV uptake analysis on GBM8 cells incubated 
with recombinant CCL18 prior PKH67-EV addition. (b) EV uptake analysis on EVs 
pre-incubated with CCL18 neutralizing antibody. In both (a) and (b), * indicates p-
value ≤0.05, ** indicates p-value ≤0.01, *** indicates p-value ≤0.001 as 
determined by ANOVA. (c,d) ELISA results on EVs plates coated with dilutions of 
isolated EVs and incubated with anti-CD63 (c) or anti-CCL18 (d). Both incubations 
displayed dose-dependent signal. (e) Immunogold EM pictures showing GBM EVs 
with strong reactivity against endogenous CCL18. (f) Positive control: Immunogold 
staining against the exosomal marker CD63. Ab control: No primary antibody (Scale 
bars: 25 µm). 
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Figure 7. CCL18 acts as a bridging molecule between GAGs on EVs and cellular CCR8 (a-c) Heparan sulfate 
(a), dermatan sulfate (b) and chondroitin sulfate (c) GAGs are present on EV membranes, as determined 
by ELISA. (d) EV uptake is prevented by heparin (25 µg/ml) and by (e) Heparinase III (H’se III) (2 miU 
every 2 h for 6 h at 37ºC) treatment of EV isolates. *** indicates p-value ≤0.001 as determined by t-
test. (f) Proposed model: GAGs present on the EV membrane bind CCL18 which connects with cellular 
CCR8 promoting EV uptake. Error bars represent SD of three independent experiments.  
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___________________________________ 
We present three main findings related to EV 
uptake by GBM cells: i) GBM EVs can be 
transferred between GBM cells in vitro and in 
vivo, stimulating GBM cell growth and 
protecting against TMZ; ii) CCR8 acts as an EV receptor on GBM cells and binds to CCL18, 
which acts as a bridging molecule to GAGs exposed on EVs, and iii) Pharmacological inhibition 
of CCR8 with the small molecule R243 inhibits EV uptake by GBM cells, resulting in 
sensitization of GBM cells to TMZ in vitro and in vivo. 
 
Uptake of GBM EVs can induce cell growth in recipient cells, confirming previous reports 
338,339, but seemed to have even stronger phenotypic effects on TMZ resistance in GBM, in 
particular in vivo. Tumor-derived EVs have been implicated in resistance to other types of 
therapy in various tumor types 344–348. The Cre-based color switch model allowed us to 
demonstrate that GBM-derived EVs are capable of transferring active Cre mRNA molecules 
at physiological levels in vitro and in vivo. We identified a set of miRNAs in GBM EVs that have 
strong implications in the process of TMZ resistance. Among the most abundant miRNAs in 
GBM EVs we observed a majority of pro-tumoral, proliferation-inducing miRNAs, such as miR-
10b-5p, miR-92 and miR-21( Supplementary Fig. 9a, b) 388–391. Although this is an interesting 
observation,  more research is needed to fully understand the mechanisms involved in the 
capacity of GBM EVs to induce TMZ resistance. TMZ is an alkylating agent that transfers a 
methyl group to purine bases in cellular DNA, causing incorrect pairing and triggering the 
mismatch repair system (MMR), resulting in cell cycle arrest and apoptosis in proliferating 
cells 392–394. Tumor cells become resistant to TMZ by different mechanisms, including 
overexpression of DNA repair mechanisms and multidrug efflux transporters such as P-gp, 
mutations in p53 and phosphatase and tensin homolog (PTEN), and altered RNA expression 
patterns 395–397. The main inducer of TMZ resistance is the DNA repair enzyme O6-methyl-
guanidine methyltransferase (MGMT). MGMT counteracts TMZ effects by direct removal of 
the O6-methyl group from alkylated guanines 398. Interestingly, it was reported that GBM EVs 
from cell lines resistant to TMZ as well as from treatment-refractory patients carry elevated 
levels of MGMT mRNA and these levels are predictive for patient outcome 399, and we do not 
exclude that EV transfer of MGMT mRNA molecules at least partly facilitates the TMZ 
resistance observed. (60–63).  
 
Here we propose a model in which the chemokine CCL18, a natural ligand of the CCR8 
receptor, connects glycans exposed on the EV membrane to the CCR8 receptor expressed on 
GBM cells. Virus and EVs can have similar biophysical characteristics and routes of biogenesis 
and uptake 358,359,400. For instance, it was reported that certain strains of HIV can bind 
oligomers of CCL5 via glycans exposed on the viral envelope, allowing viral attachment to the 
DISCUSSION 
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plasma membrane of the target cell. CCL5 was also shown to strongly induce uptake of 
(cellular, non-viral) EVs from uninfected T lymphocytes  401. Of note, it was reported that 
enveloped viruses, like HIV, can use chemokine receptors as co-receptors, including CCR8 
371,402–404. Moreover, natural ligands can compete with these viruses for the co-receptors, 
inhibiting viral uptake 405,406. Exploring other viral co-receptors as potential EV receptors 
could be of interest. 
 
Myanishi et al. demonstrated that Tim1 and Tim4 can act as EV receptors by binding to 
phosphatidylserine exposed on EVs. However, EV uptake by a certain cell may not only 
depend on the presence of specific cellular receptors, but in the case of bridging uptake 
mechanisms also on the availability of adaptor ligands, either secreted by the recipient or 
donor cell, or by other cells in the microenvironment. Here we show that CCL18 functions as 
bridging adaptor for GBM EVs, and CCL18 expression has been identified as an important 
prognostic factor in GBM 407. Recently it was shown that EVs can also be decorated by 
autotaxin resulting in binding to integrins expressed on cell surfaces 361. Similarly it was 
reported that heparan sulfates exposed on EVs can bind to fibronectin, serving as a bridging 
molecule to heparan sulfates expressed on cell membranes 363. Christianson et al. previously 
showed that heparan sulfate molecules expressed on cell surfaces can function as EV 
receptors on GBM cells 362, and others demonstrated that heparin treatment reduces EV 
uptake by recipient cells, including GBM cells 355,363,408–411. Here we observed that 
pretreatment of cells with heparin reduces EV uptake to a lesser extent than pretreatment 
of EVs with heparin (data not shown), suggesting that both mechanisms (direct heparin 
sulfate- and CCR8-mediated endocytosis) can occur simultaneously. An important 
consequence of the “connectokine” model is that it implies a complex level of regulation of 
EV transfer, perhaps similarly as observed for decoration of EVs with autotoxin 361 or 
fibronectin.  
 
Interfering with selective EV uptake may be a promising approach to attack cancer cells, given 
the numerous potential protumoral effects EVs can exert. Here, we show that R243, a small 
molecule inhibitor of CCR8, inhibits EV uptake and counteracts EV-induced responses in 
recipient GBM cells in vitro and in vivo. R243 did not only influence the interaction of EVs and 
the GBM8 cell line, but had similar effects in 2 other GBM cell lines and in a melanoma cell 
line, suggesting a general role of CCR8-EV interaction, although the exact role of CCR8 
expression on other non-cancerous cells – remains to be investigated. For instance, Th2 
lymphocytes are known to express high levels of CCR8 370,412–414, which we were not able to 
analyze in our nude mouse xenograft models with primary human GBM stem-like brain 
tumors. Also, we do not exclude that other receptors can function in the uptake of GBM EVs, 
and perhaps additional chemokine/chemokine receptor pairs play a role in the tropism 
determination of EVs. Complex networks of chemokine/chemokine receptor pairs are known 
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to induce tumor cell survival, angiogenesis, invasion as well as recruitment to metastatic 
niches. These networks act in both autocrine and paracrine fashion, establishing virtual 
reciprocal dialogues between the tumor and its environment. The CCR8 axis has been related 
to several cancer progression-related processes in lymphoma, urothelial and renal 
carcinomas, breast, and pancreatic cancers 373,374,415–418. Noteworthy, in melanoma, where 
EV-mediated communication has been shown to be key for metastasis 334,419, highly 
malignant cells express elevated levels of CCR8 and migrate to the lymph node in response 
to the secretion of the ligand by lymphatic endothelial cells. Blocking of the CCR8 axis 
resulted in strong reduction of metastatic transit through the lymph node in xenograft 
models 375, suggestive of a potential role of EV uptake via CCR8 during melanoma metastasis.  
 
In summary, we describe a mechanism of EV uptake involving a chemokine receptor and its 
natural ligand acting as a bridging adaptor. Inhibition of CCR8 decreased EV-induced 
phenotypes in GBM in vitro and in vivo models, opening the door to new anticancer 
approaches based on chemokine-receptor targeting of tumor EV crosstalk. 
 
ACKNOWLEDGEMENTS  
The authors would like to thank M. H. Meel for his help with FACS sorting and J. W. van 
Weering for his assistance with electron microscopy. The plasmids Puro.Cre (Addgene 
plasmid # 17408) and ROSA26 mT/mG (Addgene plasmid # 17787) were a kind gift from Dr. 
T. Jacks and Dr. L. Luo. Financial support was provided by European Research Council 336540 
(TW) and Stichting STOPhersentumoren.nl (JB and TW). This work is part of the research 
program Vernieuwingsimpuls with project number 016.116.366 financed by the Netherlands 
Organization for Scientific Research (TW). 
 
  
EXTRACELLULAR VESICLES 
131 
 
Supplementary Figures 
 
Supplementary Fig 1. (a) EM image of EVs isolated from U87 (left) and U251 (right) cells (scale bar: 100 
nm). (b) Size distribution of isolated GBM8 EVs as determined by manual measuring of EVs on EM 
images. Bars represent the mean of three independent preparations. Error bars represent the standard 
deviation of the three measurements. (c) Western blot analysis of CD63 and Alix on EVs isolated from 
U87 (left) and U251 cells (right). Control: supernatant from the 70000g centrifugation. (d) U87 (left) 
and U251 (right) cells incubated with overnight with PKH67-labelled EVs from the same cell lines (scale 
bars: 10 µm). (e) FACS analysis of GBM8 cells incubated with increasing concentrations of PKH67-
labelled GBM8 EVs. Left panel: scatterplots. Right graph: Dose-response curve of PKH67 fluorescence 
with the amount of EVs added showing saturation around 20 ng/µl of pKH67-labelled EVs. (f) FACS 
analysis of GBM8 cells incubated with a fixed concentration of stained EVs (7.5 ng/µl) and increasing 
concentrations of unstained EVs. Left: scatterplots. Right bar graphs showing the percentage of PKH67+ 
cells.  
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Supplementary Fig 2. (a) Schematic of Cre-mT/mG EV transfer reporter system. (b) 
Immunocytochemistry against Cre protein (green) on control (parental cells, left) or Cre-transduced 
GBM8 cells (right). DAPI (4',6-diamidino-2-phenylindole, blue) was used to stain the nuclei (scale bars: 
10 µm). (c) Cre RT-PCR on Cre donor cells and their isolated EVs (d) Addition of EVs isolated from Cre+ 
donor cells resulted in appearance of mG+ patches in mT/mG spheres, as compared with addition of 
vesicles from non-Cre-expressing cells (left: representative pictures (scale bars: 25 µm); right: 
quantification of mG+ spheres). (e) Co-culture of mT/mG cells with Cre donor cells (left: representative 
pictures (scale bars: 25 µm); right: quantification of mG+ spheres). Bar graphs in (e) and (f) show the 
means ± SD of three independent experiments. * indicates p-value ≤0.05, ** indicates p-value ≤0.005. 
(t-test). 
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Supplementary Fig 3. TMZ IC 50  determination on GBM8 cells (17 µM). Relative cell number was 
determined by calculating GBM8 sphere volumes (see methods). 
 
Supplementary Fig 4. (a) Image of uptake of PKH67-labelled GBM EVs by HEK-293T cells (scale bar: 25 
µm). (b) EV uptake assay showing dose-dependent uptake of PKH67 GBM EVs by HEK-293T. ** indicates 
p-value ≤0.01 and **** indicates p-value ≤0.0001, as determined by ANOVA. (c) Experimental setup of 
the GPCR siRNA screening. At day 0, 5 x 103 HEK-293T cells were seeded in 96-well plates. The day after, 
a GPCR siRNA library was transfected and 48 h later cells were incubated with 20 ng/µl of fluorescent 
EVs. The day after, cell nuclei were stained with Hoechst dye and fluorescence was read with an 
automated plate reader. (d) siRNA screen validation on HEK-293T cells with an independent set of 
siRNAs on the 8 siRNAs which caused the strongest reduction in PKH67 fluorescence. * indicates p-
value ≤0.05 as determined by ANOVA. (e) Immunocytochemistry against CCR8 (red) on GBM8 cells. 
Nuclei were stained with DAPI (blue) (scale bars: 50 µm). 
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Supplementary Fig 5.  (a) Chemical synthesis scheme of R243. (b) R243 IC 50  determination on GBM8 
cells (44 µM). Cell viability was estimated by CellTiter-Glo ssay (Promega). (c-g) EV uptake analysis in 
the presence of R243 on GBM8, U251, U87, A375 and A549cell lines * indicates p-value ≤0.05, ** 
indicates p-value ≤0.01 and *** indicates p-value ≤0.001 as determined by t-tests. 
 
Supplementary Fig 6. Glioma TMA immunostained against CCR8 (scale bar: 5 mm). Specimens are 
included in a colored circle to indicate sample type and tumor grade, as indicated in the legend on the 
right. 
0
20
40
60
80
100
120
CTRL R243
GBM8
0
20
40
60
80
100
120
CTRL R243
U251
*
0
20
40
60
80
100
120
CTRL R243
***
U87
****
%
 E
V
 u
pt
ak
e
%
 E
V
 u
pt
ak
e
%
 E
V
 u
pt
ak
e
0
20
40
60
80
100
120
140
CTRL R243
A549
n.s.
%
 E
V
 u
pt
ak
e
A375
*
%
 E
V
 u
pt
ak
e
0
20
40
60
80
100
120
140
CTRL R243
R243
R243 chemical synthesis scheme
a
100
50
0.0
%
 c
el
ls
0.5 1.0 1.5 2.0
IC50 = 44 µM
Log [R243] (µM)
25
0
75
2.5
  
 
 
b
c d e gf
G
lio
m
a
N
N
B
`
`
`
`
`
`
Normal brain
Grade 2
Grade 3-4
Grade 4
GBM necrotic tissue
Adrenal gland
EXTRACELLULAR VESICLES 
135 
 
 
Supplementary Fig 7. (a) Functionality test of GBM8 mG/mT reporter cells: mG/mT cells were incubated 
with a lentivirus expressing Cre recombinase (LV-CRE) or non-Cre-expressing lentivirus (LV-CTRL). 
Images were taken after 24 h incubation. (scale bars: 25 µm). (b) Direct injection of Cre+ EVs (bottom), 
but not control EVs (top) resulted in mT to mG color switch in GBM8-mT/mG mouse xenografts (scale 
bars: 50 µm). (c) Orthotopic injection of mT/mG cells combined with injection of Cre+ cells (bottom), 
but not Cre- cells (top) in opposite hemispheres resulted in mT to mG color switch in mT/mG cells (scale 
bars: 50 µm). For all experiments 1 x 105 cells resuspended in PBS were injected. (d) GFP 
immunostaining confirming presence of recombined GBM8 mG+ cells in mouse injected with mT/mG 
recipient cells co-injected either with Cre donor cells  or with Cre+ EVs.Negative control: mT/mG Cells 
co-injected with non-Cre expressing GBM8 cells. Positive control  in vitro recombined GBM8 mT/mG 
cells as in Supplementary Fig. 1g. Squares in pictures on the top indicate the magnified areas shown in 
the pictures at the bottom. Scale bars: 200 µm (top), 20 µm (bottom). 
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Supplementary Fig 8. (a) Chemokine array of overnight GBM8 conditioned medium (left). Non-
conditioned medium was used as a negative control (right). Red square indicates the position of the 
anti-CCL18 antibody. Fold increase in band signal is indicated in the table below. (b) Western blot 
analysis against CCL18 on the 70,000 x g pellet or the supernatant derived from GBM8 EVs incubated 
overnight with recombinant CCL18, washed with PBS and re-pelleted. Positive control: Recombinant 
CCL18. (c) ELISA results on plates coated with a fixed concentration of EVs (5 ng/µl) incubated with 
serial dilutions of anti-CD63 antibody. (d) ELISA results on plates coated with a fixed concentration of 
EVs (5 ng/µl) incubated with serial dilutions anti-CCL18 antibody. 
Supplementary Fig 9. (a) small RNA sequencing data of GBM8 cells and EVs. Over-represented miRNAs 
in GBM8 cells and EVs previously described as inducers of proliferation. Bars represent reads per 
million (RPM) in cells (grey bars) and in EVs (orange bars). (b) references relating miRNA sequencing 
results with induction of proliferation in GBM (left) and chemo resistance in several types of cancer 
(right). n.a: not applicable.
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Three-dimensional visualization of the brain
vasculature and its interactions with 
surrounding cells may shed light on diseases 
where aberrant microvascular organization is 
involved, including glioblastoma (GBM). Intravital confocal imaging allows 3D visualization of 
microvascular structures and migration of cells in the brain of mice, however, with limited 
imaging depth. To enable comprehensive analysis of GBM and the brain microenvironment, 
in-depth 3D imaging methods are needed. Here we employed methods for optical tissue 
clearing prior to 3D microscopy to visualize the brain microvasculature and routes of invasion 
of GBM cells.  
We present a workflow for ex vivo imaging of optically-cleared brain tumor tissues, and 
subsequent computational modeling. This workflow was used for quantification of the 
microvasculature in relation to nuclear or cellular density in healthy mouse brain tissues and 
in human orthotopic, infiltrative GBM8 and E98 glioblastoma models. 
Ex vivo cleared mouse brain tissues had a >10-fold increased imaging depth as compared to 
intravital imaging of mouse brain in vivo. Imaging of optically-cleared brain tissue allowed 
quantification of the 3D microvascular characteristics in healthy mouse brains and in tissues 
with diffuse, infiltrative growing GBM8 brain tumors. Detailed 3D visualization revealed the 
organization of tumor cells relative to the vasculature, in both grey- and white matter 
regions, and patterns of multicellular GBM networks collectively invading the brain 
parenchyma.  
Optical tissue clearing opens new avenues for combined quantitative and 3D microscopic 
analysis of the topographical relationship between GBM cells and their microenvironment.  
ABSTRACT 
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Glioblastomas (GBMs) remain incurable, partly 
because of extensive, diffuse infiltration of the 
GBM cells into their surrounding 
microenvironment. GBM cell invasion and 
proliferation leads to changes in the microvasculature, tissue perfusion, and brain 
architecture. Increased awareness of spatial heterogeneity of the GBM cells, in relation to 
the microvasculature, and intervascular tissue microenvironment 67,420–422, has raised the 
need for 3D analyses of brain tumor tissues.  
 
Optical 3D analysis allows imaging of brain structures at cellular resolution and may serve as 
a bridge between CT, PET, or MRI and classical microscopic histology and 
immunohistochemistry 165,423. Intravital confocal microscopy enables 3D fluorescence 
imaging on a cellular level 131,424, but its use is hampered by sedation time of the animal, 
limited imaging depth, small field of view, and limitations associated with fluorescent labeling 
131. These limitations do not apply to ex vivo optical imaging. For a long time, optical imaging 
of 3D structures was dependent on histological sectioning 147,148,421. This sectioning is, 
however, a laborious and challenging task, since at least several dozens of histological slices 
have to be obtained and properly aligned for the creation of an informative 3D image. To 
avoid these laborious and error-prone approach, optical slicing methods were developed. 
Optical slicing involves clearing of tissues to make them transparent, thus enabling deep 
tissue fluorophore excitation and detection. Although optical clearing techniques were 
described already more than a century ago 425, the interest in this approach was boosted by 
the development of more advanced clearing techniques such as 3DISCO/iDISCO/uDISCO, 
Scale, SeeDB and CLARITY 156,161,426–432, which all have their specific advantages and 
disadvantages156,158.  Besides new clearing techniques, other major contributions to optical 
slicing methods were the development and improvement of equipment such as multi-photon 
microscopes and lightsheet microscopes. Furthermore, numerous relevant software tools 
have been developed, including ImageJ, VAA3D, FARSIGHT, NeuronStudio, AMIRA and 
IMARIS 433–436.  
 
Here we employed optical clearance methods to study GBM cells in the mouse brain 
microenvironment. We demonstrate that optically-cleared tissues can be imaged up to at 
least 2000 μm depth, at subcellular resolution. This allowed detailed 3D visualization of the 
brain tumor microenvironment and revealed patterns of networks of collectively invading 
GBM cells. 
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Animal care guidelines
All animal experiments were approved by the 
VU University Medical Center Animal Welfare
review board. Female, specific pathogen-free, 
athymic nude-Foxn1nu mice (6-8 weeks; 
Harlan/Envigo, The Netherlands) were kept in filter top cages and received food and water 
ad libitum.  
Intravital confocal imaging 
Application of a cranial window for intravital imaging of the mouse brain was based on the 
method as described by Mostany et al.126. Three mice were anesthetized by isoflurane 
inhalation and received temgesic (0.05 mg/kg) pre-operatively and dexamethasone (0.2 
mg/kg) with carprufen (5 mg/kg) post-operatively to prevent edema. With a 0.8 mm cutter, 
an area with a diameter of 5 mm in the skull was opened at the designated location. After 
hemostasis, a drop of silicon oil was placed onto the dura and a glass coverslip was glued on 
top of the craniotomy. Blood vessels were fluorescently stained by intravenous injection of 
Lycopersicon esculentum (tomato) lectintomato-FITC. Images with a diameter of 350 µm were 
captured at 50 µm depth intervals.  
Orthotopic GBM xenograft models 
Human GBM8 glioblastoma cells 437 and human E98 glioblastoma cells were lentivirally 
transduced with a lentivirus vector to stably express the mCherry fluorescent protein and 
firefly luciferase (Fluc) 111. GBM8-FM cells were cultured as neurospheres in serum-free 
medium, supplemented with growth factors (2% of B27 supplement, 1% of N2 supplement, 
2 µg/ml heparin, 20 ng/ml recombinant human EGF, 10 ng/ml recombinant human bFGF). 
E98-FM cells were injected subcutaneously in a donor mouse. When the tumor reached a 
diameter of 1 cm, the tumor was removed and a single cell suspension was prepared. The 
harvested GBM cells were washed once with PBS and concentrated by centrifugation to a 
concentration of 1x105 cells per µl. Mice were stereotactically injected with 5x105 tumor cells 
into the striatum.  Intracranial injections were performed under isoflurane anesthesia and 
systemic and topical analgesia (buprenophine, 0.1 mg/kg; lidocaine 0.5%). The coordinates 
used for injections were 0.5 mm X, 2 mm Y, and -3 mm Z from the bregma 200 Tumor 
progression was confirmed by Fluc in vivo bioluminescence imaging (BLI) after i.p. injection 
of  D-luciferin (100 mg/kg) and acquiring the photon flux (p/s) using the Xenogen-IVIS Lumina 
system under isoflurane anesthesia. 
MATERIALS and 
METHODS 
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Photoacoustic Imaging (PAI) 
Three mice with GBM8-FM tumors were used to evaluate photoacoustic imaging.  PAI was 
performed on a Vevo LAZR imaging station (FUJIFILM Visualsonics Inc. Toronto, ON, Canada) 
which features a hybrid ultrasound and photoacoustic transducer with a tunable nanosecond 
pulsed laser. Photoacoustic oxygenation signals were collected at 750 and 850 nm and with 
the provided FIJIFILM Visualsonics imaging analysis software the average oxygen saturation 
of the hemoglobulin was calculated and visualized 438. 
 
CLARITY optical clearing and immunolabeling  
Mice were perfused with CLARITY hydrogel according to the protocol described by Chung et 
al. 429. Animals were deeply anesthetized with an overdose of ketamin/xylazin, and perfused 
with ice-cold PBS to remove highly auto-fluorescent hemoglobin, followed by perfusion with 
hydrogel solution (4% PFA, 4% acrylamide, 0.05% bis-acrylamide, 0.25% VA044 initiator in 
PBS). Brains were incubated for 24-72 hours in hydrogel at 4°C, and polymerization of the 
hydrogel was accomplished by deoxygenation, followed by thermal initiation of the 
polymerization reaction. Polymerized mouse brains were cut into 3-5 mm slices and washed 
to remove free monomers and PFA. An electrophoretic tissue chamber (ETC) was made, 
based on reported specifications 149 (Supplementary Figure S2A). SDS-clearing buffer (200 
mM sodium borate, 4% SDS, pH8.5), was kept at 37ºC and pumped through the ETC chamber 
at a speed of 0.6-1.2 l/min. Tissues were electrophorized during 3-5 days at a constant 
voltage of 20V. The SDS-clearing solution was replaced if pH dropped below pH 8. After 
electrophoretic lipid removal, tissues were washed for 24 hours in PBS containing 0.1% 
Triton-X100 at 37°C. Tissue samples were stained, depending on their sizes, for 1-7 days in 
PBS containing DAPI and lectintomato-Dylight488 or lectintomato-Dylight594 (Vector 
Laboratories, dilution 1:500) or lectintomato-FITC (Vector Laboratories, dilution 1:500). 
Subsequently, samples were washed 24 hours in PBS and finally incubated for 6-24 hours in 
80% glycerol to match refractive indices, resulting in transparency of the samples.  
 
iDISCO immunolabeling and optical clearing  
Brains of mice with established tumor progression were fixed and stored in 4% buffered 
formalin for at least 24 hours, up to more than two years. These brains were sliced into 3-5 
mm thick sections and processed for immunolabeling and optical clearing with the methanol 
iDISCO procedure 439. Samples were permeabilized with increasing methanol concentrations 
to a final concentration of 100% methanol. Next, the brain sections were bleached overnight 
at 4°C in hydrogen peroxide:methanol (ratio of 1:5), after which tissues were gradually 
rehydrated to PBS and washed in PBS with 0.2% Triton-X100. To block residual binding sides, 
tissues were incubated for three days at room temperature (RT) with antibody diluent 
(DAKO). Following blocking, the samples were stained for seven days with primary antibody 
(anti-RFP, which binds the mCherry reporter protein expressed in tumor cells) and Dylight488 
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conjugated lectintomato at RT. Excess primary antibodies or lectins were washed away during 
three days. Tissues were incubated with the secondary antibody (AlexaFluor594 conjugated 
anti-rabbit) for seven days. Unbound antibody was washed away with PBS-Triton during 
three days, after which tissues were dehydrated by gradually increasing methanol 
concentrations to a final solution of 100% methanol. Next, remaining lipids were removed 
by incubation in dichloromethane (DCM)/methanol and one hour incubation with 100% 
DCM. To make the samples transparent, samples were incubated in dibenzyl ether (DBE) for
refractive index matching. It is important to use fresh DCM and DBE as oxidation of these
reagents may result in suboptimal clearing and a brownish color of the tissues. Transparent
samples were stored in the dark in a closed vial completely filled with DBE until image
acquisition for a period up to 6 months.
3D Image acquisition 
Intravital imaging was performed on a custom-built two-photon laser scanning microscope 
using Olympus objectives 153. Ex vivo two-photon images were captured on a LaVision BioTec 
microscope system, based on an Olympus BX51WI microscope, connected to a pulsed 
tunable (740-1070 nm) laser (Chameleon, Coherent). CLARITY-cleared tissues were mounted 
in an imaging chamber filled with 80% glycerol whereas iDISCO-cleared tissues were 
mounted in a flexible imaging chamber, created with adhesive poster pads, which was filled 
with DBE (Supplementary Figure 3B). Images were acquired with a water immersion 
objective (20x magnification, NA 1.00, maximum working distance 2000 µm) at a voxel size 
of 0.54x0.54x1-5 µm. Epifluorescence signals were separated by dichroic mirrors and filters 
(DAPI: 420/50, FITC/Dylight488: 525/50), and collected by a photomultiplier tube (PMT). 
Laser power was set with an automatic laser power increment, which increased laser power 
gradually from 5 to 20% over a depth of maximum 2000 µm. Lectintomato labeled 
microvasculature and DAPI-stained nuclei were imaged at an excitation wavelength of 800 
nm, which simultaneously excites all fluorophores. Alternatively, images were acquired with 
a Leica SP8 confocal microscope, equipped with a pulsed white light laser and a 10x 0.4NA 
air objective or a NIKON A1R confocal microscope with a 20x 0.8NA air objective.  These 
images were taken with a voxel size of 1 µm3 and fluorescent signals were recorded using 
gated hybrid detectors.   
Data processing 
Image reconstruction of the 2-photon images was performed using FIJI with the “Stitch 
Sequence of Grids of Images” plugin of FIJI 440. Background subtraction was performed by 
application of a Gaussian filter. Images obtained with the other microscopes were imported 
directly into IMARIS software (version 7, Bitplane) and stitched automatically. 
OPTICAL CLEARING 
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Quantification of signal intensity  
Quantification of signal intensity was performed using FIJI. Epifluorescent signal intensity as 
a function of imaging depth was determined by measurement of median signal intensity at 
all imaging depths. Median fluorescence was normalized to the intensity of the most 
superficial slide.  
 
3D-modeling of the vasculature and cell density 
Fluorescently-stained vessel surfaces were detected and converted into a mask. This mask 
was used to create a new, binary, channel in which the voxels outside the mask were set to 
zero and inside the mask to a fixed value. This binary mask was used to trace blood vessels 
by the ’Filaments Tracer’ option of IMARIS, which is a tool developed for the automatic 
detection of filament-like structures. Although this ‘Filaments Tracer’ tool is not completely 
compatible for the detection of vessel structures, as it does not allow the formation of loops, 
the detected structures co-localized with most of the fluorescently labeled vessels. During 
the detection process, vascular modeling required assignment of minimal (2 µm) and 
maximal (10 µm) vessel diameter, and manual definition of the thresholds for starting points 
and seeding points. Nuclei or RFP-positive cells were rendered using the “Spots Rendering” 
application of IMARIS. This application visualized the nuclei or cells as artificial solid objects, 
enabling quantification of number of nuclei per ROI and distance of the cells to the nearest 
blood vessel. All computational modeling was done ‘unbiased’, e.g. without additional 
improvement of the modeling by manual deletion or insertion of vessel parts. 
 
2D Immunohistochemistry 
Sections of 5 µm FFPE tumor containing brain tissues were processed after heat-induced 
antigen retrieval with Tris-EDTA (pH 9.0). Sections were stained with Dylight488-labeled 
lectintomato together with rabbit anti-CD31 antibody (Abcam, ab 28364; dilution 1:1000) or 
rabbit anti-RFP antibody (Tebu-Bio, cat. no. 600-901-397; dilution 1:500). The rabbit 
antibodies were detected with AlexaFluor594 labeled anti-rabbit as secondary antibody. 
Alternatively, slides were stained with hematoxylin/eosin. Image acquisition was done with 
a Zeiss Axio Scan Z1 slide scanner. 
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software). Data were 
presented as mean ± SD. Unpaired student t-tests were used to test differences between 
spatial characteristics of different ROIs. P-values <0.05 were considered statistically 
significant.  
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High-resolution intravital imaging of the mouse
brain vasculature is limited to a depth of 200 µm 
Intravital imaging of the mouse cerebral 
vasculature was performed by two-photon 
imaging through a cranial window as schematically shown in Figure 1A. Through this window 
the superficial blood vessels, which can be used for orientation, are easily recognized (Fig. 
1B).  Blood vessels, fluorescently-stained with lectintomato-FITC, were imaged at 50 µm 
intervals. Under these conditions the maximal imaging depth was limited to 200 µm (Fig. 
1C,H). Because this imaging depth was insufficient to image relevant locations deep into the 
brain, we decided to further explore ex vivo imaging methods for the visualization and 
quantification of the relation between tumor cells and the brain microenvironment, with a 
focus on the brain tumor vasculature.  
Ex vivo two-photon imaging of optically-cleared brain tissue 
In order to microscopically visualize regions throughout the entire mouse brain, optically 
clearing methods of mouse brain tissue were employed. Brains were stained and cleared by 
either the CLARITY 429 procedure or the methanol-based iDISCO method 439. Brain slides of 3-
5 mm thickness were processed to render transparent tissue, as shown for the iDISCO 
procedure in Figures 1D and 1E. Whereas iDISCO leads to a stable shrinkage of approximately 
1.2x of the original tissue diameter (Fig. 1E), the CLARITY procedure resulted in an expansion 
of approximately 1.5x the tissue size. This tissue expansion continued after prolonged 
storage of the tissue in 80% glycerol, which complicates re-analysis of CLARITY cleared 
tissues, whereas tissues which were previously cleared and stained could be re-imaged for 
subsequent analyses months later (data not shown).  Within the parietal cortex, lectintomato -
stained microvessels could be imaged by 2-photon-microscopy down to a depth of 2000 µm 
after CLARITY optical clearing (Fig. 1F-H, Supplementary Fig. S1 and Supplementary Movie 
S1). In contrast to the rapid loss of signal intensity at increasing depth during intravital 
imaging, fluorescent signal intensity was well maintained in optically-cleared tissues. In 
optically-cleared tissues, signal intensity remained above 65% of superficial signal intensity 
along the complete working distance of the lens of 2000 µm (Fig. 1H).   
RESULTS 
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Figure 1. Intravital and ex vivo two-photon imaging of mouse cerebral microvasculature. (A) Schematic 
representation of intravital two-photon imaging setup. (B) Superficial blood vessels of the dura mater, 
observed through a cranial window. (C) 2D x-y plains obtained by intravital two-photon-imaging of 
lectin-FITC-labeled cerebral mouse vasculature at 50 µm depth intervals (n=1). Scale bars 100 µm. (D) 
3mm thick slide of mouse brain, before optical clearing. (E) Transparent mouse brain after optical 
clearing with the iDISCO-procedure. (F) 2-photon imaging of lectin-FITC-labeled brain tissue, cleared 
with the CLARITY-procedure. Lateral view of a 3D-reconstruction of composed of 1001 pictures, starting 
at the parietal cortical surface to 2000 µm below, see also Supplementary Movie S1. (G) 2D x-y plains 
of ex vivo two-photon imaging of vasculature in CLARITY-cleared mouse brain tissue at 400 µm depth 
intervals. Scale bars 100 µm. (H) Relative fluorescence intensity as a function of imaging depth for 
intravital 2-photon imaging (n=1) and ex vivo two-photon-imaging of CLARITY-cleared mouse cerebral 
microvasculature (n=1). 
 
Computational modeling of vasculature in healthy mouse brain tissue  
Understanding the relation between glioblastoma cells and the vasculature would benefit 
from quantification of different aspects of their relationship. With the use of healthy mouse 
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brain tissue, a workflow for the quantification of the vasculature was developed 
(Supplementary Fig. S2).  In a stack of lectintomato –FITC-stained vessels (Fig. 2A, green), 
different regions of interest (ROIs) were selected for computational modeling (Fig. 2A, red 
regions). Fluorescently-stained blood vessels (Fig. 2B, green, upper panel) were converted to 
computationally-modeled vessels (Fig. 2B, red, middle panel). Because these computational 
models were unbiased, i.e. without manual post-processing, the overlay of the modeled 
vessels showed a high degree of concordance, but was not perfect. (Fig. 2B overlay, bottom 
panel). By using 2D-orthogonal planes we estimated the concordance of the fluorescently 
labeled vasculature with the computational modeled vasculature to be approximately 80% 
(Fig. 2C, Supplementary Fig. S4). Next, the combination of lectintomato-FITC-labeled 
microvasculature and counter-stained nuclei (DAPI) was imaged using two-photon 
microscopy (Fig. 2D). These large, tiled image files show a striking vignetting at the borders 
of each acquired imaging field. This vignetting is due to the fact that standard water 
immersion or air objectives - which are not corrected for the high refractive indexes of the 
embedding medium - were used for the acquisition. Because this could potentially result in 
artifacts in the stitching and consequent quantification, selected ROIs were centered within 
the tiles. ROIs were selected within the granular layer (GL, green rectangles) and in the 
molecular layer (ML, blue rectangles) of the cerebellum (Fig. 2D). The obtained 3D stack with 
lectintomato-stained microvessels and DAPI-stained nuclei enabled detailed fluorescently 
imaging (Fig. 2E), and allowed computational modeling (Fig. 2F).  After such computational 
modeling, the number of DAPI-stained nuclei, and quantitative data of the vasculature, such 
as number of branches, total vessel length, volume, area, and diameter of single segments 
per volume of 100x100x100 µm (=106 µm3), were calculated. These analyses revealed large 
differences in the vasculature of the GL versus the ML of the cerebellum (Fig. 2G, 
Supplementary Movie S2). These observed differences corroborates findings of previous 
studies reporting that, within different brain regions, large differences in vasculature are 
present 441. Thus emphasizing that only identical, anatomically well-defined, areas should be 
compared to evaluate spatial relations between cells and their brain microenvironment. 
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Figure 2. 3D representation and computational reconstruction of cerebral microvasculature and 
surrounding cells. (A) Computational modeling (red) of 3D cerebral-vasculature fluorescently labeled 
with lectintomato-Dylight488 (green). Scale bars 100 µm. (B) Upper panel: Fluorescently labeled 
vasculature (green), mid panel: computational reconstruction modeled with IMARIS Filaments tool 
(red), bottom: overlay of the fluorescent signal with the computational reconstruction. Scale bar: 
25µm. (C) 2D orthogonal images of computational reconstruction (red) and fluorescent signal (green). 
(D) Areas in the granular layer of the cerebellum (gl, green rectangles) and the molecular layer of the 
cerebellum (ml, blue rectangles) are selected for quantification. Scale bar 100 µm. (E) Detail of a 
granular layer region, showing the spatial relation of the nuclei (blue) to the vessels (green). Scale bar 
25 µm.(F) Computational modeling of vasculature (red) and nuclei (blue) of the microvascular and 
surrounding cells. Scale bars 10 µm. (G) Quantification of number of nuclei, number of vessel branches, 
total vessel length, total surface area, mean vessel diameter and total vessel volume in the granular 
layer and molecular layer regions of the cerebellar cortex. All quantifications are normalized to a 
volume of 106 um3. ** p<0.01, *** p<0.001, t-test. 
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The lectintomato-staining pattern of the microvasculature is not affected by GBM cells 
Because tumor cells are known to alter the endothelial glycocalyx 442, we confirmed the 
binding of lectintomato to blood vessels in tumor containing tissue. Brain tumors were induced 
by orthotopic xenograft transplantation of human GBM8-FM cells into nude mice. First, the 
presence of a GBM8-FM tumor was detected by photoacoustic imaging, which revealed 
increased oxygenation levels in the tumor areas, indicative for a change in the vasculature 
(Fig. 3A). Tumor growth was confirmed by bioluminescence imaging (Fig. 3B), and H&E 
staining of the brain clearly indicated the presence of tumor in the striatum (Fig. 3C). 
Furthermore, tumor was easily identified on tissue slides stained with lectintomato and anti-
RFP antibody, which stains the GBM8-FM cells (Fig. 3D). Combined staining with lectintomato 
and anti-CD31 (Fig. 3E-G) demonstrated overlay of lectintomato-stained and CD31-stained 
microvasculature, indicating that tumor growth does not significantly influence the lectin-
binding pattern of brain microvasculature. 
Computational modeling of the GBM vasculature in mouse brain 
As the iDISCO method allowed easy processing of already formalin-fixed materials, this 
method was employed for optically clearing of the formalin fixed tumor bearing brain tissues. 
The optically clearing procedures were performed with GBM8-FM xenografted brain tissues 
which were fixed for less than 2 months and with E98-FM xenografted brain tissues which 
were fixed for over two years.  Tissue stained for tumor cells (anti-RFP-Ax594, red) and 
vasculature (lectintomato-DL488, green) revealed the presence of large, diffuse infiltrative 
tumors in the GBM8-FM glioblastoma xenograft models (Fig. 4A, Supplementary Movie S3). 
GBM cells have migrated away from the tumor core (TC) into the deep grey (DGM), and white 
(WM) matter areas, and even to the contralateral side (CL). Also, migration into the 
subarachnoid space was observed (arrow). Figure 4B shows that large numbers of GBM cells 
migrated collectively through white matter tracts such as the corpus callosum (CC), but both 
in the hemisphere where the tumor was transplanted as in the contralateral hemisphere, 
solitary cells can be identified, especially in close proximity to blood vessels (arrows). In the 
tumor core, changes in the vasculature where shown (Fig. 4C) as compared to the 
vasculature in the corresponding region on the contralateral side (Fig. 4D). Striking is the 
binding of lectintomato on cell-like structures in the tumor core (Fig. 4C), where these lectin-
stained cells are virtually absent in the contralateral side (Fig. 4D). Computational modeling 
of the vasculature in these lectin-positive cell-rich areas was feasible, because the filament 
tracer detects tube-like structures (Supplemental Fig. S6). Quantifications of GBM8 and E98 
tumors was performed by comparing contralateral brain areas within the same brain. The 
control area was normalized to 100% to allow a pair-wise comparison of the tumor versus 
control area. The quantifications revealed an increase in the number of vessel branches, 
increase in total vessel length and an increase in surface area of these vessels within the 
tumor regions. The mean vessel diameter was slightly lower in the tumor core as compared 
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to the same region of the contralateral side, resulting in comparable vessel volume in both 
areas for both the GBM8 tumor and the E98FM tumor (Fig. 4E). 
 
 
Figure 3. Lectintomato binding 
to the microvasculature in the 
presence of tumor cells. (A) 
Photoacoustic coronal image 
of an intracranial GBM8-FM 
tumor with highly-
oxygenated, vascular regions 
indicated in red. (B) BLI image 
showing the presence of the 
GBM8-FM tumor. (C) 
Hematoxylin/eosin stained 
section of the same tumor as 
depicted in (A) and (B) 
showing the association 
between highly-vascularized/ 
oxygenated areas and the 
presence of tumor. (D) Brain 
tissue with GBM8-FM tumor 
stained with lectintomato-
Dylight488 (green) directed 
against blood vessels, and 
with an anti-RFP-
AlexaFluor594 antibody 
directed against the GBM8-
FM cells. (E-G) Details of (D) 
showing that in the presence 
of tumor, lectintomato (green) 
and anti-CD31 antibody (red) 
stain the same microvessels. 
Scale bars A, C, D: 700 µm; 
Scale bars E, F, G: 10 µm. 
 
 
 
GBM cell distribution in the brain microenvironment 
We quantified the number of GBM cells in three different anatomical areas (TC, DGM, WM), 
as illustrated in Fig. 4A. The number of GBM8 cells per 106 µm3 in the tumor core was 
significantly higher as compared to the infiltrative fronts in both the deep grey and the white 
matter regions (Fig. 5A). Similar as shown in Fig. 2G, large differences in vessel characteristics 
were observed between distinct anatomical regions, as shown for the number of vessel 
branches (Fig. 5B), and other parameters (Supplementary Fig. S7). 
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Next, we calculated the distance of the GBM8 tumor cells to the microvessels in the three 
anatomical areas. In the observed E98-FM tumor xenografts, infiltration was less pronounced 
as compared to the GBM8 tumors (Supplementary Fig. 5), which limited the quantitation of 
the E98 tumor cells to the tumor core and the grey matter areas. In the tumor core, 29.8% 
of the GBM8 tumor cells were located at a distance of >20 µm from the nearest blood vessel. 
Tumor cells in the infiltrative front within the deep grey matter were more closely located to 
the blood vessels; in this grey matter area, only 9.5% of the GBM8 tumor cells was located 
at a distance of >20 µm from their nearest blood vessel (Fig. 5C). The E98 tumor cells were 
even more closely associated to the vasculature, with >99% of the invasive GBM cells in the 
deep grey matter located at a distance of <20 µm from the nearest blood vessel (Fig. 5C).  
Figure 4. Microvascular reconstruction in GBM infiltrated areas. (A) Typical example of a diffuse, 
invasively growing GBM8-FM tumor (anti-RFP-Ax594, red) with its microvasculature (lectintomato-
Dylight488, green). Tumor cells have migrated into the healthy brain parenchyma, away from the tumor 
core (TC) into the contralateral (CL) hemisphere, into the deep gray matter (DGM), and into the 
subarachnoid space (arrows). (B) Detail of (A) showing the abundant presence of GBM-cells in the 
corpus callosum (CC). (C) Detail of the TC, with tumor cells (red) in close proximity to blood vessels 
(green). (D) Detail of (A) showing distantly migrated solitary tumor cells (red) in close proximity to blood 
vessels (green). (E) Quantification of number of vessel branches, vessel length, surface, diameter and 
vessel volume in the tumor core of GBM8 tumors (n=7) and E98 (n=2) tumors. Values are normalized 
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to comparable control areas (CL) within the same brain where no evident tumor formation was 
detected. * p<0.05, ** p<0.01, *** p<0.001, t-test. Scale bars A: 700 µm; B: 250 µm;  C, D:  50 µm. 
 
 
These results may suggest some preference for perivascular migration of GBM cells in the 
deep grey matter, whereas in the tumor core use of alternative migration routes, such as 
through the brain parenchyma, are used. An alternative explanation is that proliferation of 
the GBM cells in the tumor core has resulted in an expansion of the intervascular 
compartment, thus resulting in larger distances of the tumor cells from the microvasculature. 
Interestingly, in the white matter regions, the distance distribution of the GBM cells to the 
nearest blood vessels was comparable to the tumor core regions, suggesting that tumor cell 
migration in the white matter area does not solely depend on blood vessel co-option, but 
may also occur via white matter tracts. Another striking observation is the presence of a 
subset of tumor cells that are interconnected by cellular processes similar as the multicellular 
networks as postulated by Osswald et al. 443. Groups of approximately 4-6 cells were 
interconnected by tubular, ‘dendrite-like’ structures (Fig. 5D, arrows). These results 
demonstrate that optically cleared tissues can be used to detect subtle changes in the brain 
tumor microvasculature, allow visualization and quantitation of GBM cells, and quantitation 
of the relative position of GBM cells to the brain microvasculature. The proposed workflow 
(Supplementary Fig. S2) offers an attractive additional method for 3D histology 
(Supplementary Movie S3), complementary to traditional histological methods. 
 
Figure 5. Topographical characteristics of GBM cells distant from the tumor core. (A) GBM cell density 
(per volume of 106 µm3) was calculated in the tumor core (TC, n=7), and invasive fronts within the deep 
grey matter (DGM, n=7) and white matter (WM, n=4) of GBM8 tumors. (B) Number of vessel branches 
(per volume of 106 µm3 in the three aforementioned areas in GBM8 xenografted brains. (C) Proportion 
of GBM8 and E98 cells at indicated distance (µm) of the nearest vessel at distribution intervals of 2.5 
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µm. (D) GBM8 cells are interconnected via cell processes (arrows).  * p<0.05, ** p<0.01, *** p<0.001, 
t-test. Scale bars 10 µm. Samples were cleared with iDISCO. 
 
 
____________________________________ 
In the present study, we show the use of 
optically-cleared brain tissues to allow 
visualization of cerebral microvasculature and 
the organization of nuclei or tumor cells in the 
brain tumor microenvironment. For this, we developed an effective workflow, which was 
explored to quantify subtle changes in the vasculature, and moreover, to visualize and 
measure the topographical relationship between GBM cells and their microenvironment in 
an invasive orthotopic GBM model in mice. Transparent adult mouse brain tissues were 
prepared with the CLARITY-protocol or the iDISCO-procedure. Both methods allowed 
detailed optical imaging and 3D-reconstruction of the microvasculature and distribution of 
cells or nuclei. Computational modeling allowed quantitative analysis, showing differences in 
the GBM cell distribution in distinct regions of the brain. 
Intravital imaging was not suitable to image relevant regions of intracranial tumor due to its 
limited imaging depth and small fields of view. Therefore, we extended our methods to study 
the tumor microenvironment to ex vivo 3D imaging of transparent brain tissues. Ex vivo 3D 
whole tissue imaging has become a maturing field of research 444 and many tissue-clearing 
protocols have been developed recently. Most of these clearing protocols focus on 
improvement of fluorescence signal intensity because conventional clearing protocols 
caused quenching of fluorescence signal. CLARITY- and iDISCO-procedures have been 
reported to be compatible with  fluorescently stained tissues 156,429,432,439. Both procedures 
remove the highly abundant lipids in myelin rich brain tissue 155, which is an important step 
to obtain optically-transparent tissues, but also improves antibody penetration. 
Improvement of antibody penetration is important because immunofluorescent staining of 
large tissues is still a challenge 162,445. Furthermore, we noticed that certain antibodies require 
further optimization for staining of large tissues. For example, anti-vimentin staining, which 
was successfully used to visualize E98FM tumor cells on traditional 5 µm sections446, did not 
result in detection of tumor cells in our iDISCO processed samples, and the CD31 staining 
was hampered by low signal to noise ratio (data not shown). For the use of antibodies for 
additional markers, optimization steps such as titration of the antibody concentrations, and 
tissue pre-treatment, needs to be validated for each antibody 156. Besides the use of 
antibodies to obtain clear structure information, these antibodies could also be validated for 
their use to provide functional information. These could include the staining of IgG leakiness 
447 or the use of other proteins which leak out of the vasculature after BBB disruption.   To 
ensure complete and consistent tissue staining, we limited the thickness of the tissue slides 
to approximately 3-5 mm and explored the use of lectins, which have a low molecular weight 
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(71 kD), as compared to antibodies (150 kD). The used lectin, isolated from 
Lycopersiconesculentum (tomato), has a high affinity for glycan epitopes on endothelial cells 
447–449, and on ramified and activated microglia448,450, which might explain the observed 
binding of lectintomato to non-endothelial cells within the brain tumor. In addition, to quantify 
the cerebral vasculature and surrounding cells, we have extended the possibilities of 3D-
visualization of cleared brain tissue by the addition of computational modeling with the 
commercial software package IMARIS.  
For imaging of optically cleared tissues, numerous microscopical techniques have been 
developed, including two-photon imaging, light-sheet microscopy and confocal imaging, 
which all have their own advantages and limitations (Supplementary Fig. S8). All used 
microscopes in this manuscript were equipped with standard air or water lenses. Hence, 
vignetting is visible on the edges of all acquired images which leads to artifacts in the stitching 
of the tiled images. To prevent these artifacts, special lenses tailored for CLARITY are 
developed which could further improve the quality of tiled images 451. 
The whole process, from tissue collection to sample preparation, image acquisition, 
reconstruction, post-processing, analysis and 3D-image acquisition takes approximately one 
month for both the CLARITY procedure and the iDISCO procedure (Figure 6). This processing 
time is highly influenced by the thickness of the tissue as diffusion of antibodies through the 
tissue is a time-consuming process. However, although these methods to prepare tissue for 
optical-sectioning are still time-consuming, they are not as labor-intensive as compared to 
traditional methods of mechanically, histological sectioning. 
GBM is still incurable, partly because of its invasive character, but also because interactions 
with its microenvironment and intra-tumoral communication. The invasive character of GBM 
was already thoroughly described in the 1930’s. In that work, four pathways of glioma cell 
invasion were recognized: through the brain parenchyma, along pre-existing blood vessels, 
through white matter tracts and via the subarachnoid space 452,453. The distribution of GBM 
cells we observed are fully compatible with those four migratory patterns. We hypothesized 
that these migration patterns will be reflected by the distance of the tumor cells to the 
microvasculature. Indeed, we found that in grey areas, tumor cells migrated mainly in close 
proximity of the vasculature. In contrast, in the white matter a bigger proportion of the GBM 
cells were located at a larger distance from the microvasculature, suggestive for migration 
following the tracts of the white matter. In GBM, intra-tumoral communication may take 
place via secreted factors, including exosomes 454, or by direct cell-cell contact of the tumor 
cells via an interconnected GBM cell network 125,443,455. In line with this, we observed the 
presence of interconnected GBM cells, similar as suggested by Osswald et al.443. These cell 
clusters were present in the tumor core, but also in the infiltrative fronts in the deep grey 
matter and the white matter.  
In conclusion, we demonstrate the use of optically-cleared, transparent tissues to study in 
3D the architecture of the brain microvasculature as well as the topographical relationship 
156 
of GBM cells to the microvasculature. Detailed 3D-visualization and quantitation revealed 
differences in organization of tumor cells relative to the vasculature in grey matter regions 
versus white matter regions, and patterns of GBM cell networks collectively invading the 
brain parenchyma. This deep-fluorescence-imaging and 3D quantitative approach opens new 
avenues to study the pathobiology of brain cancer cells and their microenvironment. 
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Figure 6. Timelines for the process from tissue collection to data analysis. This figure represents typical 
timelines for tissue of 5 mm thickness, which requires approximately one week for each antibody or 
lectin staining. Because the incubation steps are not very labor-intensive, it is feasible to process several 
tissues simultaneously. 
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Supplementary Figures. 
Supplementary Figure S1. (A) Two-photon imaging of lectintomato-Dylight594 labeled 
brain tissue, cleared with the CLARITY-procedure. Lateral view of a 3D-
reconstruction of composed of 1850 pictures acquired at 1 µm interval. (B) 2D x-y 
plains of ex vivo two-photon imaging of vasculature in CLARITY-cleared mouse brain 
tissue at 200 µm depth intervals.  
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Supplementary Figure S2.  Graphical abstract illustrating the workflow to quantify vessel and tumor 
characteristics in optically-cleared, transparent, tissues. 
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Supplementary Figure S3.  (A) Design of CLARITY-electrophoresis chamber. (B) 
Example of a flexible imaging chamber. 
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Supplementary Figure S4. 2D orthogonal representation of XY, XZ and YZ planes in iDISCO cleared tissues 
to illustrate the concordance between the computational vessel model and imaged fluorescence signal. 
This figures also illustrates the poor resolution in the Z-direction in relation to the XY resolution. 
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Supplementary Figure S5. (A) Example of an E98-FM tumor, this tumor has 
engrafted in the 3d ventricle and shows a more compact phenotype as 
compared to GBM8 tumors. (B) Detail of (A), arrows indicate infiltrating 
E98-FM cells. Scale bar: 30 µm 
Online supplementary movies  
Supplementary Movie S1. Vasculature of healthy mouse brain. 
Supplementary Movie S2. Computational modeling of the mouse brain vasculature 
Supplementary Movie S3. Vasculature and tumor cell distribution in human orthotopic GBM8 
glioblastoma mouse model. 
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Supplementary Figure S6. Computational vessel reconstruction. (A) 
Tumor cells are stained with anti-RFP antibody (red, red arrows). 
The vasculature is stained with lectin (green), but also distinct cells 
are stained with this lectin (green arrow). (B) When a mask is 
applied to the green channel, these lectin stained cells are also 
included in the mask (arrow). (C). After use of the ‘filament tracer’ 
tool, most of the vessels are correctly identified while cell like 
structures are ignored. (D). 2D Orthogonal cross planes showing the 
vessel reconstruction in GBM infiltrated tissue. 
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Supplementary Figure S7.  Quantification of vessel length, surface 
area, diameter and volume within a ROI of 106 µm3 in tumor core 
(TC), deep grey matter (DGM) and white matter (WM).  
Supplementary Figure S8. Characteristics of suitable imaging techniques for advanced 3D-microscopy. 
Lightsheet microscopy offers the highest speed and imaging depth, but is very dependent on successful 
clearing efficacy and has limited magnification. Two-photon imaging has the lowest imaging speed but 
high magnification, good resolution, and good imaging depth. Because of the high wavelengths, 2-
photon microscopy is less dependent on clearing efficacy. Confocal microscopes are available at many 
research labs. They allow reasonable to good imaging speed, good resolution but their imaging depth 
is limited.                                          .
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Currently, the most effective treatment
regimens for primary high-grade brain tumors 
include surgical resection and radiotherapy, 
often supplemented with chemotherapy such 
as temozolomide for the treatment of GBM 49,456. But, despite these therapeutic strategies, 
the relative survival estimates for GBM remain low with a median survival of only 5.5% five 
years post diagnosis 14.  This poor patient outcome is related to several reasons which are 
discussed in this thesis, such as the tumor location within the brain, the blood-brain-barrier 
(BBB) which limits the effective dose of the therapeutic agents, the infiltrative properties of 
these tumors, which prevents the complete resection of the tumor, and the tumor-
heterogeneity that causes drug resistance.  
Drug delivery across the BBB 
Drug discovery programs have identified many therapeutic agents aimed against tumor cells. 
However, most of these therapeutics are not useful for the treatment of brain tumors 
because the compounds do not reach their targets within the brain 457. This is due to several 
factors including metabolic instability of the drug, and the rate and extent of transport across 
the BBB 458. In normal situations, the BBB protects the brain by limiting the access of micro-
organisms and large molecules, and by actively pumping out foreign agents. In brain cancer 
however, the BBB also prevents therapeutic agents to reach sufficient high concentrations 
at the tumor site. To reach clinically effective concentrations of active drugs at the tumor 
location within the brain, several strategies are explored. These strategies involve either the 
increase of transport rate over the BBB into the brain, or the prevention of removal of the 
compound from the brain, bypassing the BBB, or combinations of these strategies.  
To increase transport over the BBB, pharmaceutical characteristics including the polarity and 
molecular size of the compound are important. Because the BBB prevents large compounds 
to enter the brain, small-molecule drugs, with a molecular mass under a 400- to 500-Da 
threshold, are more likely to pass the BBB than larger drugs 312,457,459. But, even if the drugs 
can pass the BBB, many will not reach pharmacologically relevant dosages at the tumor 
location because the drugs are actively pumped out of the brain. This drug removal is 
achieved by a range of ATP-binding cassette (ABC) efflux transporters such as ABCB1 (also 
known as multidrugresistance protein1 (MDR1) or P-glycoprotein) 63,460. Therefore, inhibition 
of these drug efflux pumps would be a logical step to increase the drug concentration at the 
target location.  
Inhibition of drug efflux pumps has been studied in the context of overcoming multidrug 
resistance (MDR). MDR is associated with the overexpression of efflux transporters on the 
tumor cells. Inhibition of these transporters could reverse the poor treatment outcome in 
the therapy resistant cancers, but so far clinical trials of inhibitors of ABCB1 have only been 
Brain tumors and 
therapy 
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moderately successful. The first and second generations of these inhibitors suffered from 
severe systemic toxicity, because efflux pumps are also present in tissues such as the liver 
and have important physiologic roles.  In the third generation of ABCB1 modulators, the 
systemic toxicity of the inhibitors themselves is low. But these inhibitors are so effective that 
they frequently necessitate a reduction in the dose of anticancer agents 461. Thus, although 
efflux transporter inhibitors efficiently increase drug concentrations within the brain in 
laboratory settings, animal models, and even in clinical studies, common practice of their use 
in combination therapies is still limited, due to concerns previously raised by these MDR 
studies.   
If transport across the intact BBB after systemic administration is ineffective, other ways to 
deliver the drugs to the brain tumor are needed. One approach to bypass the BBB is local 
delivery of the compound directly into the brain, or even the tumor. This could be done by 
intracavitary chemotherapy such as the insertion of carmustine wafers in the resection area 
194,462, intrathecal- or lumbar injections, or the  intratumorally delivery by convection-
enhanced delivery (CED). CED is the continuous infusion of the infusate by a positive-
pressure. This technique allows distribution of the infusate into the tumor and its 
surrounding micro-environment. This infusion results in pharmaceutical relevant drug 
concentrations within the tumor, orders of magnitudes greater than systemic levels. Because 
drug distribution is not diffusion-mediated, there is not a steep concentration gradient 
required, thus limiting local toxicity of the initial dose 176. With this convected delivery into 
the tumor, or tumor region, compounds can exert their effects locally on the tumor, without 
the severe systemical toxicity associated to systemic administration.  
Besides the choice of therapeutic agents, therapy outcome via CED is also largely dependent 
on distribution and composition of the infusate. This distribution volume should cover the 
complete tumor area, including the invasive cells, to prevent tumor regrowth by untreated 
cells. This distribution volume of the infusate is highly dependent on technical variables, such 
as placement and design of the catheters, volume of infusion (Vi) and the infusion rate. But 
also properties, such as polarity and lipophilicity, of the drug.  
 
In Chapter 2 and Chapter 3, we employed CED for the administration of carmustine and 
doxorubicin in the treatment of diffuse intrinsic pontine glioma (DIPG). The intraparenchymal 
delivery approach resulted in locally high, but systemically low, concentrations of these 
chemotherapeutics. Unfortunately, although systemic toxicity was not observed with this 
administration route, the effects on survival in our animal tumor models were only modest. 
This because CED treatment resulted in only a temporary remission of the tumor 
progression, and moreover, damage to the surrounding brain tissue. Other therapeutics 
which have less effect on the healthy brain tissue might therefore be more suitable for the 
treatment of high-grade brain tumors.  
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Tumor biology and anti-cancer treatment 
To avoid local toxicity as we observed with the broad-spectrum therapeutics which were 
used in our projects, such as carmustine and doxorubicin, more specific therapeutics could 
be used. Attractive candidate are drugs against specific epigenetic dysregulations which are 
found frequently in DIPG and GBM patients. In this approach, therapies are targeted against 
enzymes which affect the use of genes by histone modification. Recent studies suggest that 
EZH2 (enhancer of zeste homolog 2) and bromodomain proteins are promising therapeutic 
targets for DIPG and GBM treatment strategies 463–466. EZH2 participates in DNA methylation, 
and bromodomain proteins recognize acetylated lysine residues on the N-terminal tails of 
histones, thus affecting gene activity and expression. However, systemic administration of 
these compounds for the treatment of brain tumors is not very effective, as the EZH2 
inhibitors show restricted brain penetration, due to interaction with the drug efflux 
transporters ABCB1 and ABCG2 464. These drug characteristics -specific inhibition of the DIPG-
targets and limited BBB-passage- make these drugs attractive candidates for CED 
administration. Besides these specific epigenetic dysregulations, also other cancer specific 
therapies could be explored for the treatment of brain tumors, such as the targeting of cell-
cycle specific processes by interfering with the centrosome 467, MPS1 468, WEE1 kinase 38,262, 
or Ape1 469. 
Another attractive approach, is the local delivery of immune-checkpoint inhibitors such as 
programmed death cell receptor (PD1/PDL1), cytotoxic T lymphocyte associated antigen 4 
(CTLA-4) of indoleamine 2,3-dioxygenase (IDO) 81,470. This could result in an alteration of the 
local immune system thereby limiting the tumor-promoting effects of the microenvironment 
and might even result in an anti-tumor response of the immune system.  
Tumor heterogeneity and drug resistance 
Even if the drug distribution to the tumor is adequate and the drug reaches clinically effective 
concentrations, treatment-effects are often only temporarily. These short-lived effects could 
partly be contributed to heterogeneity of brain tumors. This heterogeneity is due to the fact 
that cancer is not a single disease entity, but rather a whole family of diseases. The main 
characteristic of cancer is the pathological proliferation of cells. This uncontrolled growth of 
cells starts typically in a single cell due to genetic or epigenetic mutations caused by 
environmental factors, heredity or deviant cell division 471. In normal situations, these 
mutations are corrected by the cells’ repair machinery or the mutated cells are removed by 
the immune system. However, some mutations might escape these cell-cycle checkpoints or 
immune-cycle checkpoints which could result in initiation of cancer 472. When these mutated 
cells start to multiply, every generation goes through a little evolutionary cycle, resulting in 
more evolved cells. These relentless cycles of mutation, selection and survival of cancer cells 
results in the generation of new cancer cells with the capacity to resist death signals, incite 
growth of blood vessels and ability to invade tissues.  
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Although the main tumor characteristic of uncontrolled proliferation of cells suggest a high 
commonality between cancers, most cancers, and thus most cancer patients are unique 471. 
For high grade brain tumors, the situation is even more complex because tumor 
heterogeneity is not only observed between patients but also within the tumor of an 
individual patient. The strongest example of this is GBM where each cell might bear varying 
degrees of cellular and nuclear polymorphisms, as shown by the establishment of several 
subclones from a single tumor 473. This indicates the presence of  heterogeneous populations 
of cells within the tumor, where each cell may present its own potential target for 
therapeutic intervention 64. This tumor heterogeneity contributes largely to the therapy 
resistance of brain tumors as the therapeutic agent initially kills only a proportion of the 
tumor cells. But after the initial therapeutic effect, remaining resistant cells, which have a 
different molecular identity, will continue to proliferate, thus resulting in recurrence of a 
therapy resistant tumor.  To optimize current therapies, we evaluated the use different 
therapeutic strategies via three distinct mechanisms, namely 1) to improve radiotherapy, 2) 
anti-VEGF treatment for DIPG and 3) by diminishing cell-to-cell communication. 
 
Radiotherapy 
Radiotherapy is still an important aspect in the treatment of brain tumor patients. Radiation 
will not only affect the tumor tissue but also surrounding non-neoplastic tissues 47. Because 
the brain of children under 3 years of age is still under development these brains are very 
sensitive to radiation, thus limiting the radiation dose is crucial in the treatment of young 
children. Therefore, methods to improve radiation efficiency and thus limiting the radiation 
are needed, especially for this group of young patients.  
Sensitization of the tumor cells to radiotherapy could be a way to reduce the radiation dose 
as demonstrated in Chapter 5 with the radio-sensitizing effect of quercetin. The role of 
quercetin in the treatment of brain tumor patients is probably not only limited to the 
radiotherapy, but could also be of value in the enhancement of chemotherapy, as quercetin 
has also been reported to exert synergistic effects when combined with temozolomide 
(TMZ), a FDA-approved drug for brain cancer treatment 474–479.   
 
Angiogenesis inhibition 
Treatment such as chemotherapy and radiotherapy are mainly aimed to kill the tumor cells 
directly. However, besides the direct attack of the tumor cells, it was hypothesized already 
in the 1970s that anti-angiogenic treatments could result in shrinkage of solid tumors. This 
led to development of anti-angiogenic agents, such as bevacizumab, which are directed 
against the vascular endothelial growth factor (VEGF) 253,480. Targeting VEGF inhibits the 
process of new blood vessel formation and promotes regression of existing vessels. As high-
grade brain tumors are highly vascularized 481, and VEGF is overexpressed in GBM, anti-
angiogenic therapies were widely explored for these patients. These anti-VEGF therapies 
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resulted in inhibition of endothelial outgrow, which led to vascular normalization, and 
apparent improvement on contrast-enhanced MRI (pseudoresponse) 482–484. However, this 
improvement of progression free survival was not reflected by an increase of the overall 
survival. 
In chapter 4, we have demonstrated that in GBM this lack of efficacy of treatment with anti-
VEGF antibodies can be partly explained by an absent VEGF upregulation on diffuse 
infiltrative tumor cells, and the inability of the antibody against VEGF to pass the BBB. These 
results, strengthened by a clinical study performed in children with DIPG 485, shows the 
importance of drug imaging to avoid treatment with compounds which are irrelevant for that 
specific type of tumor or for that specific patient.  
Cell-to-cell communication 
Intercellular communication might play a role in therapy resistance. This communication can 
be via direct cell-cell contact or via communication via excreted components. Examples for 
the role for direct cell-cell contact include the observation that clustered cancer cells are 
more resistant than single cells to apoptosis and that circulating tumor cell (CTC) clusters 
have increased metastatic potential compared to single CTCs 486,487. Cell-cell contact of GBM 
stem cells was also demonstrated after xenografting in a mouse brain. In this study by 
Osswald et al. they showed that GBM cells formed multicellular networks by ultra-long 
cellular protrusions (length > 500 um). These multicellular networks were resistant to 
selective single cell ablation by application of a fatal laser dose 443. 
Besides direct cell-cell contact, cells can communicate with each other via excreted 
components, including extracellular vesicles (EVs). EVs are membrane surrounded structures 
released by cells in an evolutionally conserved manner 488. Tumor cells, including GBMs, are 
known to release vast amount of heterogenous populations of EVs, but also normal  cells can 
produce significant amounts of EVs 339,489. These EVs have the potential to migrate 
throughout the body and they are taken up by other cells. The uptake of the EV cargo could 
result in phenocopying tumor characteristics or alterations of the micro-environment 125,340 
which result in the transfer of therapy resistance from one cell to another (Chapter 6).  
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Animal models for brain tumors 
Research into the mechanisms behind the 
onset and progression of brain tumors needs 
complex test systems, which should represent 
important aspects such as the BBB, tumor 
heterogeneity and the tumor micro-
environment. Currently most in vitro assays -including advanced assays such as the culture 
of organoids or ‘lab-on-a-chip’ devices-  are not sufficient to represent all these aspects. This 
lack of in vitro systems justifies the use of animal experiments to study brain tumors 490–493. 
Before employing these complex animal experiments, data about efficacy, feasibility, and 
drug safety data are collected by iterative in vitro assays. Often, such in vitro tests start by 
administration of the compounds of interest to established cell lines to validate their effect 
on these cells. However, one cell line never reflects all the characteristics of a heterogeneous 
tumor. Therefore, to cover a large part of GBM heterogeneity, initiatives like the Human 
Glioblastoma Cell Culture (HGCC) resource were initiated. This HGCC collection aims to 
represent the four main GBM subtypes, namely proneural, neural, classical and 
mesenchymal 494. Obtained cell lines can thus be used to identify novel therapeutics against 
the different GBM subclones. By screening drug libraries on cultured tumor cell lines in 
comparison with a range of normal –healthy- cells, compounds can be identified which have 
a toxic effect towards the tumor cells whilst normal cells are not, or minimally, affected.  
 
Animal disease models are still crucial to study complex interactions such as the role of the 
immune system; the role of the BBB on brain tumor progression; to study the interaction of 
a tumor cell with its micro-environment, and to study the dependency of tumor cells on a 
wide range of physiological stimuli including cells, proteins and RNAs. Moreover, besides the 
need of animal experiments to advance scientific knowledge, the use of animal models is 
often demanded by regulatory authorities to identify adverse effects of therapies. 
 
In our studies, we used xenograft models to study brain tumors. To enable the intracranial 
injection of human tumor cells, these cells were cultured in vitro. Many of these cell lines, 
including GBM lines U87MG, U251, and medulloblastoma lines DAOY and D283-med were 
established already decades ago 495–497. Although these cell lines are generally used, their 
clinical relevance is questionable because the lack of infiltrative growth of the GBM cells and 
their relative sensitivity towards many drugs. Also, the authenticity of the cell lines with 
respect to the tumor where they were obtained from is questionable for a number of these 
cell lines.  
 
PRECLINICAL 
RESEARCH and 
IMAGING 
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Although not many cell lines can be authenticated with their original tumor anymore, it was 
shown for the widely used U87MG glioma cell line, that the DNA profile of the cell line was 
different from that of the original tumor 498. Furthermore, established cell lines have evolved 
from their primary cell line. Every in vitro passage of the cell line represents a selection 
pressure on the cell line, resulting in a genetic drift in the cancer cells and even loss of typical 
GBM profiles in long-term subclones 499. The authentication and characterization of the used 
cell lines, prior to start of the animal models would improve the translation of the obtained 
results. Further refinement of the xenograft models could be achieved by the use of primary 
cells which better reflect the tumor heterogeneity than established cell lines.  
But not only the tumor should represent the human situation, also treatment options should 
reflect clinical practice closely. Although efforts are being made to treat mice similar as 
human patients 97, this is rarely the case as explained by some examples: Firstly, surgery is 
an important treatment option in human patients. Although tumor resection of intracranial 
tumors is feasible both in mice 500 and rats 115, not many studies consider the use of surgical 
resection of the brain tumor within preclinical settings of rodent studies. Secondly, for 
preclinical radiation therapy, often the whole head is irradiated 39 as opposed to localized, 
field  radiation as used in the clinic. Thirdly, when novel treatments against human specific 
targets are being tested in xenograft models, these human targets might be absent in the 
animal tissues, thereby underestimating unwanted systemic side effects. But also wanted 
effects might be missed due to the species differences: Although a tumor microenvironment 
is present in the animal models, this microenvironment is of rodent origin and therefore not 
the same as in human patients. Finally, in preclinical research, therapy is often started at 
early time points at which the tumor is hardly detectable, whereas in humans the tumors are 
often at a much more advanced stage before therapy is started. Because now the tumors are 
small and not well-evolved yet, treatment is relatively easy at this time.  
Imaging tools 
Since cancer cells evolve during their relentless cycles of mutation and selection, anti-tumor 
therapies are most effective when a tumor is detected early after its initiation. For this early 
detection, imaging of tumor biomarkers is indispensable in current clinical oncology practice. 
Biomarkers are defined as 'characteristics that are objectively measured and evaluated as in 
indicators of normal biological processes, pathological processes or pharmaceutical 
responses to a therapeutic intervention' 501. In contrast to previous definitions, these markers 
are not limited to biological molecules, as the FDA-NIH Biomarker Working Group explicitly 
states that 'molecular, histologic, radiographic, or physiologic characteristics are types of 
biomarkers' 502. Imaging biomarkers are important to test hypotheses in vitro and on tissues; 
but their real value is in imaging of whole organisms during in vivo research and subsequently 
in early phase clinical trials 503. 
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Grading of brain tumors is mainly based on histological characteristics such as the presence 
of mitotic activity, nuclear atypia, microvascular, proliferation, and coagulation or 
pseudopalisading necrosis. All these observations are done ex vivo on tissue pieces or 
biopsies, as microscopical evaluation in living tissues is still at its infancy. In humans, intravital 
microscopy is feasible in only superficial tissues, as demonstrated by confocal 
endomicroscopy 504, in which microscopy is combined with colonoscopy. Intravital imaging 
has also been demonstrated on in vivo cleared skin tissues. These skin tissues were made 
somewhat transparent with the use of hyperosmotic agents 505,506. For brain imaging, 
intravital imaging through a cranial window is feasible in preclinical animal research 128,507 
and techniques to visualize unstained tissues with the use of second and third harmonic 
signaling are being explored for utilization in clinical practice 120. Although microscopical 
techniques have their specific advantages, especially with respect to resolution, the 
availability of many specific stainings, and the cultivated histopathological knowledge, a 
major disadvantage of all these techniques is that only small fields of view or thin histological 
slides can be imaged. Imaging of optical cleared tissues allows imaging of larger tissues and 
is not restricted to 5 - 10 µm slides as commonly used for diagnosis by a pathologist. We 
employed these optically clearing techniques to visualize the tumor micro-environment and 
the topological orientation of tumor cells relative to the vasculature (Chapter 7). 
 
A wide variety of preclinical imaging tools are available to detect a tumor, to monitor tumor 
growth, and to get insight in the processes involved in tumor progression. Obviously, mice 
are much smaller than men. This implicates that preclinical imaging equipment needs high-
resolution to detect alterations in mice. For preclinical PET-scanners, a three-fold reduction 
of the spatial resolution was obtained as compared to clinical scanners. But this improvement 
is still insufficient to reach an equal sampling size as in humans, because a mouse brain is 
approximately 3000 times smaller than a human. Many of these imaging techniques which 
are used for preclinical research, such as PET, CT, and MRI, have proven their use in clinical 
practice, which simplifies translation of preclinically obtained results to the clinic. Others, like 
bioluminescent imaging and 3D-microscopy are still limited to preclinical research. In 
preclinical research, bioluminescent imaging is a valuable tool to establish the engraftment 
of tumor cells, tumor progression and the formation of distant metastasis. While 
bioluminescence imaging is widely used in a laboratory setting, the challenge to translate this 
imaging technique to the clinic is still unattainable due to the potential toxicity of luciferin as 
well as the potential immunogenicity of luciferases 508.  
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Early detection of cancer will save lives. By the
time symptoms appear, cancer might already 
have spread and evolved, thus complicating 
effective treatment. Imaging remains a 
powerful, non-invasive tool to positively impact the management of patients with a brain 
tumor. Detection of the tumor is often dependent on imaging tools such as MR and CT. For 
some brain tumors, such as DIPG, even the diagnosis could be solely based on these imaging 
methods. But these conventional imaging methods are not very sensitive and have significant 
limitations in assessing treatment response and monitoring of disease progression. Both 
‘pseudoprogression’ after chemoradiation and ‘pseudoresponse’ after anti-angiogenesis 
treatments are well-known radiological entities which are difficult to dissect from actual 
tumor progression  509.  Liquid biopsies could be a way to detect tumors even before a patient 
has symptoms. Techniques which enable these screening methods include the detection of 
circulating tumor cells, circulating biomarkers, or profiling of tumor-educated platelets 481,510–
514. Furthermore, these techniques might provide molecular subtyping of the tumor, thus
allowing a personalized based targeted therapy.
Nowadays cancer treatment is not limited to chemotherapy and radiation, but also 
immunotherapy plays a limited, but increasingly important role in treatment of cancer. 
Cancer immunotherapies make use of the body’s own immune system to attack and remove 
the cancer cells as it is based on stimulation of the body’s own immune system in order to 
amplify both a humoral and cytotoxic immune response to target tumor cells 515. 
Immunotherapies for brain cancer include the use of cancer vaccines, where tumor-
associated antigens are used to elicit an immune response to attack cancer cells with these 
antigens 516–519; skewing the immune response from tumor promoting to antitumoral, for 
example with anti-PD-1 and anti-CTLA-4 antibodies 520–522; therapy with oncolytic viruses to 
cause lysis of the tumor cells and consequently generate an immune response against this 
cancer 523–525; adoptive cell therapy where immune cells from the patient are activated or 
modified in vitro and re-injected into the patient to result in an anti-cancer response 526–531; 
adjuvant immunotherapies and monoclonal antibodies 532.  
Initially immunotherapy was not considered to be an option for brain cancer due to the BBB 
as well as the absence of the conventional lymphatic drainage system 533. However, these 
opinions changed after demonstration that active immunotherapy with autologous dendritic 
cells (DCs) loaded with autologous tumor cells or lysates did improve median overall survival 
for both recurrent- and newly diagnosed GBM patients as compared to non-DC treated GBM 
patients 527. Novel approaches, specifically aimed at the treatment of brain cancer are to 
adapt the innate immunity-mediated inflammation by depletion of tumor associated 
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microglia/macrophages (TAMs). TAMs are tumor promoting and can form up to 30% of the 
tumor mass in GBM. Moreover, TAMs can inhibit adaptive anti-tumor responses by the 
expression of cytokines and certain receptors. Targeting the CSF-1 receptor (CSF-1R) results 
both in removal of TAMs and skewing of TAMs to elicit an anti-tumor response 76,80,534.  
 
As stated before, immunosuppressive checkpoints, including IDO, CTLA-4 and PD1/PDL1, 
have critical roles in tumor progression. Unfortunately, the efficacy of immune-checkpoint 
inhibitors is still limited for the treatment of brain tumors. This is illustrated by the treatment 
with nivolumab, an anti-PD-1 monoclonal antibody. Although this offers a superior survival 
benefit over docetaxel treatment in patients with non-small-cell lung cancer (NSCLC), the 
effect of nivolumab on brain tumor metastasis is limited.  
Although the promising results and ongoing trials with CED 535, other approaches to pass the 
BBB are being explored.  One of such approaches is the use of targeted ultrasound together 
with microbubbles 59–61. The high energetic movement of the microbubbles results in a 
temporary opening of the BBB, thus allowing systemically administered therapeutics to enter 
the brain and exerts their effects onto the tumor cells. The main advantage of this ultrasound 
technique as compared to CED is the lack of invasive placement of catheters. However, due 
to the systemic administration of the compound, relatively high systemic concentrations of 
the therapeutic are needed, thus limiting the use of this technique to compounds with low 
systemic toxicity.  
 
The procedures described in this thesis could be employed to improve the efficacy of these 
immune-checkpoint inhibitor treatments. CED could be a way to pass the BBB; PET-imaging 
to visualize the uptake of the compound in the brain tumor; 3D imaging to analyze changes 
in the tumor micro-environment and a change in the immune cell composition.  The 
described techniques are not only useful to study brain tumors, but could also be extended 
to other tumor types as we have shown for the preclinically visualization and quantification 
of tumor progression in xenograft models of pancreatic ductal adenocarcinoma (PDAC), 
osteosarcoma, and prostate cancer 340,467,536. 
 
Concluding remarks 
Despite continuing advances in radiation therapy, neurosurgical techniques and 
chemotherapies, prognosis of high-grade primary brain tumor patients remains poor. In this 
thesis, we show the feasibility of CED to deliver pharmaceutical compounds into the brain, 
the use of a radiosensitizer to limit the radiation dose in pediatric patients and a novel target 
to inhibit the interaction of EVs with tumor cells. Furthermore, PET-imaging revealed that 
bevacizumab, an antibody against VEGF, does not reach its target within the brain. Finally, 
we have used 3D-microscopical techniques to visualize the topological orientation of tumor 
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cells and the brain vasculature.  These insights and techniques could be a start of many new 
research projects, aiming at the improvement of brain tumor patients.  
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CHAPTER 9 | 
SUMMARY 
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In the human brain, a wide variety of primary
tumors can be encountered, both in adults and 
in children. Due the infiltrative growth pattern 
of many of these tumors, complete surgical 
resection is often impossible. Furthermore, eradication of tumor cells by chemotherapy and 
radiotherapy without damaging the surrounding brain parenchyma is difficult to achieve, and 
these therapies often result in severe treatment-related side effects. The main obstacles 
which impair treatment efficacy in these patients are the presence of the blood-brain-barrier 
(BBB), which prevents drugs to reach clinically-effective concentrations at the tumor 
location, and the resistance to therapy. In this thesis, we aim to evaluate novel therapeutic 
strategies to improve the treatment of high grade brain tumors. We explored the use of 
convection-enhanced delivery (CED) to circumvent the BBB, the use of radiosensitizers to 
improve radiotherapy and the use of CCR8 inhibition to prevent therapy resistance. 
Furthermore, we employed a wide range of preclinical imaging techniques to monitor tumor 
progression. 
In chapter 2 we developed a method to perform CED into the murine brainstem, and to test 
this method using the chemotherapeutic agent carmustine. We designed a stepped CED-
catheter for the delivery of compounds into the brainstem of mice. This CED-catheter was 
used to treat mice with VUMC-DIPG-3 and E98FM brainstem tumors. Administration of the 
vehicle solutions (5% dextrose water, or 10% ethanol) into the brainstem was well tolerated. 
CED of carmustine increased median survival of the tumor bearing mice.  
Chapter 3 describes the use of this CED method for local delivery of the anthracycline 
doxorubicin to treat pediatric DIPG and thalamic high-grade gliomas. First, the sensitivity of 
the tumor cells to a panel of anthracyclines was tested in vitro. From this panel, doxorubicin 
was selected for further evaluation. Doxorubicin was formulated either as free doxorubicin 
(i.e. dissolved directly in the vehicle solution) or in PEGylated liposomes (PEGylated liposomal 
doxorubicin, PLD). The maximum tolerated dose of these compounds into the thalamus was 
10-times higher as compared to delivery into the brainstem.  Local delivery of both
doxorubicin formulations into the brainstem caused severe toxicity, even at concentrations
which were safe when administered into the thalamus.
In chapter 4, we show by PET-imaging and distribution studies in orthotopically (intracranial) 
and heterotopic (subcutaneous) DIPG and high-grade glioma animal models that VEGF 
expression is dependent on the tumor microenvironment.  Tumor cells were injected into 
different locations, and tumor progression was monitored by bioluminescence imaging and 
MRI. Although the tumors which were placed subcutaneously showed high accumulation of 
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89Zr-bevacizumab, an antibody against VEGF, no accumulation of 89Zr-bevacizumab was 
observed in any of the orthotopically located tumors. In situ hybridization demonstrated the 
presence of VEGF in the perinecrotic regions of subcutaneous E98-FM tumors whereas the 
VEGF-expression in the intracranial tumors was below detection limit.  
 
In chapter 5, screening of a library of small-molecule compounds identified the flavonoid 
quercetin as a radiosensitizer. Radiosensitizing effects were confirmed on medulloblastoma 
cell lines D283 and D458. Quercetin was shown to sensitize these cells to radiation at low 
micromolar concentrations. Moreover, quercetin did not affect proliferation of normal 
human fibroblasts or neural precursor cells. In an orthotopic xenograft model for 
medulloblastoma, we confirmed that administration of quercetin around the time of 
radiation increases the radiation efficacy and increased survival of the tumor bearing mice.  
 
Chapter 6 focuses on the role of extracellular vesicles (EVs). We show that glioblastoma EVs 
are transferred to recipient tumor cells and can promote tumor progression and resistance 
to the alkylating agent temozolomide (TMZ). Through RNAi screening, we identified that 
chemokine receptor CCR8 is involved in EV interaction. We discovered a novel EV-uptake 
mechanism which involves a triple interaction between the chemokine receptor CCR8 on the 
cell, glycans exposed on EVs and the soluble ligand CCL18. We demonstrate that EV-induced 
phenotypes are neutralized by the R243, a small-molecule inhibitor of CCR8. Administration 
of this compound R243 in combination with TMZ, to mice with orthotopically transplanted 
glioblastoma, prolongs progression-free survival and prevents TMZ resistance. 
 
In chapter 7, we describe the use of optically-cleared, transparent tissues to study the 
topographical relationship between GBM cells and their microenvironment. We present a 
workflow for ex vivo imaging of optically-cleared brain tumor tissues, and subsequent 
computational modeling. This workflow was used for quantification of the microvasculature 
in relation to tumor-cell location in infiltrative GBM models. The detailed 3D-visualization 
revealed differences of organization of tumor cells relative to the vasculature between grey- 
and white matter regions. We identified GBM cells co-opting the brain vasculature, cells 
invading along white matter tracts, and groups of infiltrative, interconnected GBM cells. 
 
In chapter 8, we discuss the results of these studies and the relevance of the use of preclinical 
animal models and imaging techniques in the field of brain tumor research. The insights and 
techniques described in this thesis could be a start of many new research projects, aiming at 
the improved treatment of brain tumor patients. 
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SAMENVATTING 
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___________________________________ 
Er zijn vele vormen van kwaadaardige
hersentumoren, zowel bij volwassenen als ook 
bij kinderen. Deze tumoren zijn vaak slecht te 
behandelen, onder andere omdat de 
tumorcellen de hersenen infiltreren. Hierdoor zijn ze onbereikbaar voor de chirurg waardoor 
er na een operatie altijd tumorcellen achterblijven. Om deze achtergebleven tumorcellen te 
verwijderen, kan er gebruik gemaakt worden van chemotherapie en bestraling. Deze 
therapieën beschadigen echter ook vaak het omliggende hersenweefsel. Met name bij jonge 
kinderen kan bestraling daarom niet worden toegepast. Maar ook bij volwassenen zijn de 
behandelingsmethoden niet efficiënt en leiden ze vaak tot ernstige bijwerkingen. Eén van de 
factoren die de behandeling van hersentumoren bemoeilijkt, is de aanwezigheid van de 
bloed-hersen-barrière. Deze barrière voorkomt normaal gesproken dat schadelijke stoffen 
de hersenen bereiken. Bij de behandeling van hersentumoren voorkomen ze echter ook dat 
de geneesmiddelen de tumor bereiken. Hierdoor zijn hersentumoren vaak niet gevoelig voor 
behandeling met geneesmiddelen die wel bij andere tumoren effectief zijn gebleken. 
In dit proefschrift testen we de mogelijkheid van ‘convection-enhanced delivery’ (CED) om 
geneesmiddelen toch bij de tumor te krijgen. CED wil zeggen dat je onder een lichte druk, 
het geneesmiddel direct in het tumorgebied injecteert. Met deze techniek hoeft het 
geneesmiddel dus niet in staat te zijn om zelfstandig over de bloed-hersen-barrière te gaan, 
maar wordt het geneesmiddel direct op de juiste locatie geïnjecteerd. Door deze manier van 
toedienen zijn de bijwerkingen vaak minder dan wanneer het geneesmiddelen via een infuus 
of als pil wordt toegediend.  
Verder wordt in dit proefschrift een methode beschreven om de effecten van bestraling te 
versterken en we beschrijven hoe we een nieuw principe hebben gevonden dat we kunnen 
gebruiken om te voorkomen dat een tumor ongevoelig wordt voor behandeling met 
chemotherapeutica. 
Voor al deze onderzoeken hebben we gebruik gemaakt van proefdiermodellen. Om te 
kunnen vaststellen of de therapie effectief was, hebben we gebruik gemaakt van 
beeldvormende technieken zoals bioluminescentie (waarbij we cellen voorzien hebben van 
een enzym uit een vuurvliegje zodat de tumor licht geeft), MRI, PET (injectie van radio-actieve 
signaalstoffen) en geavanceerde microscopische technieken. 
In hoofdstuk 2 beschrijven we de techniek om CED in de hersenstam van de muis te kunnen 
uitvoeren. Omdat deze hersenstam heel klein is, hebben we zelf een CED-catheter 
ontwikkeld. Deze catheter hebben we vervolgens gebruikt om de chemotherapie, 
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carmustine, toe te dienen in de hersenstamtumor. Eerst hebben we bepaald of de techniek 
veilig was. Dit hebben we gedaan door alleen het oplosmiddel toe te dienen. Nadat dit veilig 
was gebleken hebben we vervolgens carmustine toegediend. Het bleek dat dieren die met 
de CED-methode met carmustine waren behandeld langer in leven bleven dan de dieren die 
alleen het oplosmiddel toegediend hadden gekregen.  
Hoofdstuk 3 beschrijft vervolgens het gebruik van dezelfde CED-techniek om een ander 
geneesmiddel toe te dienen. In dit hoofdstuk wordt bepaald of de toediening van 
doxorubicine effectief is voor de behandeling van twee verschillende soorten hersentumoren 
die veel bij kinderen voorkomen, namelijk diffuus intrinsiek pons glioom (DIPG) welke in de 
hersenstam ontstaat en hoog-gradige gliomen (hGG) welke in de grote hersenen ontstaan. 
Eerst hebben we met behulp van een panel van geneesmiddelen bepaald voor welke 
behandelingen deze tumorcellen gevoelig zijn. Doxorubicine kwam uit deze testen naar 
voren als een geschikt geneesmiddel voor deze vormen van kanker. Doxorubicine kan 
toegediend worden als ‘vrij-doxorubicine’ -direct opgelost in het oplosmiddel- of in 
‘PEGylated liposomes’ -hierbij zit het doxorubicine verpakt in liposomen, een soort kleine 
blaasjes.  We toonden aan dat beide toedieningsvormen van doxorubicine zeer schadelijk 
waren wanneer het middel toegediend werd in de hersenstam. Wanneer dezelfde 
middelen werden toegediend in de grote hersenen, waren de bijwerkingen milder. 
Hierdoor kon er in de grote hersenen een 10x hogere dosis worden toegediend. Door 
deze schadelijke bijwerkingen was de effectiviteit van doxorubicine afwezig in de 
hersenstamtumoren en waren de gunstige effecten in hGG-tumoren in de grote hersenen 
zeer beperkt. 
In hoofdstuk 4 beschrijven we het gebruik van een PET-scan. Dit is een positron emitting 
tomography; je kunt hiermee zien waar een radioactieve signaalstof aanwezig is. We hebben 
deze techniek gebruikt om vast te stellen of bevacizumab, een geneesmiddel gericht 
tegen VEGF -een signaalstof waarmee de tumor zorgt dat er nieuwe bloedvaten worden 
gevormd-, aankomt bij de tumorcellen. We konden vaststellen dat de hoeveelheid 
VEGF die tumorcellen produceren afhankelijk is van de locatie waarin deze tumor zich 
bevindt. Hiervoor hadden we tumorcellen onderhuids geïnjecteerd, of dezelfde 
tumorcellen in de hersenen. De radioactieve signaalstof, 89Zr-bevacizumab, was 
aantoonbaar in de onderhuids geïnjecteerde tumoren, maar niet in de tumoren welke in de 
hersenen zaten.  Vervolgens hebben we met een in situ hybridisatie techniek vastgesteld 
dat in de onderhuids geïnjecteerde tumoren het VEGF aanwezig was, maar dat in de 
tumoren in de hersenen dit VEGF niet geproduceerd werd. In deze experimenten 
hebben we gebruik gemaakt van diverse beeldvormende technieken zoals MRI om 
te zien of de bloed-hersen-barrière nog intact was en bioluminescentie om de 
tumorgroei te kunnen vaststellen. 
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In hoofdstuk 5 hebben we van 960-verschillende stoffen getest of ze in staat zijn om de 
effecten van bestraling te versterken. Uit deze testen kwam de stof quercetine naar voren 
als een effective ‘radiosensitizer’. Dit ‘radiosensitizerende’ effect werd bevestigd in een 
aantal andere cellijnen voor een kinderhersentumor: medulloblastoma cellijnen D283 en 
D458. Het bleek dat quercetine al in zeer lage concentraties in staat was om de cellen te 
sensitiseren voor bestraling. Bovendien bleek dat quercetine geen invloed had op de 
celdeling van normale humane fibroblast cellen of neurale precursor cellen. Met behulp van 
een proefdiermodel, waarbij we menselijke medulloblastome tumorcellen in de hersenen 
van een muis hadden geïnjecteerd, hebben we vervolgens vastgesteld dat wanneer je 
quercetine toedient rondom het moment van bestraling, dit een versterking van het 
bestralingseffect geeft en de dieren langer blijven leven dan een controle groep die geen 
quercetine heeft gehad. 
Hoofdstuk 6 behandelt de rol van 'extracellular vesicles' (EVs). EVs zijn kleine blaasjes die door 
alle cellen worden uitgescheiden. Eerst tonen we aan dat glioblastoma EVs van de ene cel, 
kunnen worden opgenomen door een andere cel. Deze opname van EVs zorgt voor een 
toename van het aantal tumorcellen en dat de tumorcellen minder gevoelig worden voor 
behandeling met temozolomide chemotherapie. Vervolgens hebben we een RNAi screenings 
techniek gebruikt om te bepalen via welke receptoren de tumorcellen EVs kunnen binden. 
Uit deze screenings techniek kwam het chemokine CCR8 naar voren als een effectieve 
receptor voor EVs. We hebben vastgesteld dat deze binding van EVs verloopt via een drie-
staps interactie tussen het CCR8 op de tumorcellen, glycanen op de EVs en het chemokine 
CCL18 wat uitgescheiden wordt door de tumorcellen en hun omgeving. Deze interactie kan 
worden geremd met een stof genaamd R243. Dit is een ‘small-molecule inhibitor’ van CCR8. 
Wanneer we R243 toedienden in combinatie met temozolomide in een muismodel werd 
voorkomen dat de tumor ongevoelig werd voor temozolomide behandeling en leefden de 
dieren langer dan wanneer ze maar één van de middelen toegediend kregen.  
In hoofdstuk 7 beschrijven we het gebruik van doorzichtig weefsel om de topografische 
relatie tussen tumorcellen en hun omgeving te bestuderen. We presenteren eerst een 
schema waarbij we weefsels doorzichtig kunnen maken, structuren kunnen bestuderen met 
behulp van geavanceerde microscopische technieken en de verschillende structuren kunnen 
detecteren met behulp van computermodellen. Deze proefopzet hebben we gebruikt om 
de afstand tussen tumorcellen en bloedvaten te kunnen meten in verschillende delen van 
de hersenen, namelijk de witte- en de grijze stof gebieden.  Ook hebben we met deze 
techniek kunnen bevestigen dat glioblastoma tumorcellen voor hun migratie door de 
hersenen gebruik maken van de bloedvaten en de witte stof banen. Ook hebben we 
waargenomen dat er groepen van onderling met elkaar verbonden glioblastoma cellen 
aanwezig zijn. 
SAMENVATTING 
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In hoofdstuk 8 bespreken we de resultaten van de studies uit dit proefschrift en de relevantie 
van proefdiermodellen en beeldvormende technieken in het veld van hersentumor 
onderzoek. De verkregen inzichten en technieken vormen een mooi startpunt voor nieuwe 
onderzoeksprojecten gericht op de verbetering van de behandeling van hersentumor 
patiënten. 
. 
 
190 
 191 
 
 
 
 
 
 
CHAPTER 11 | 
REFERENCES 
  
192 
1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous
system. Acta Neuropathol. 2007;114(2):97-109. doi:10.1007/s00401-007-0243-4. 
2. McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human
glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8. doi:10.1038/nature07385. 
3. Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant
subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 
2010;17(1):98-110. doi:10.1016/j.ccr.2009.12.020. 
4. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and 
biological subgroups of glioblastoma. Cancer Cell 2012;22(4):425-37. doi:10.1016/j.ccr.2012.08.024. 
5. Sturm D, Bender S, Jones DTW, et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits 
emerge. Nat. Rev. Cancer 2014;14(2):92-107. doi:10.1038/nrc3655. 
6. Schwartzentruber J, Korshunov A, Liu X-Y, et al. Driver mutations in histone H3.3 and chromatin
remodelling genes in paediatric glioblastoma. Nature 2012;482(7384):226-31. doi:10.1038/nature10833. 
7. Rushing EJ, Wesseling P. Towards an integrated morphological and molecular WHO diagnosis of central
nervous system tumors: a paradigm shift. Curr. Opin. Neurol. 2015;28(6):628-32. 
doi:10.1097/WCO.0000000000000258. 
8. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of 
the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20. doi:10.1007/s00401-
016-1545-1. 
9. Northcott PA, Shih DJH, Peacock J, et al. Subgroup-specific structural variation across 1,000
medulloblastoma genomes. Nature 2012;488(7409):49-56. doi:10.1038/nature11327. 
10. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: The current
consensus. Acta Neuropathol. 2012;123(4):465-472. doi:10.1007/s00401-011-0922-z. 
11. Inda M, Bonavia R, Mukasa A, et al. Tumor heterogeneity is an active process maintained by a mutant
EGFR-induced cytokine circuit in glioblastoma. 2010:1731-1745. doi:10.1101/gad.1890510.themselves. 
12. Sottoriva A, Spiteri I, Piccirillo SGM, et al. Intratumor heterogeneity in human glioblastoma reflects cancer 
evolutionary dynamics. Proc. Natl. Acad. Sci. U. S. A. 2013;110(10). doi:10.1073/pnas.1219747110. 
13. Singh AK, Arya RK, Maheshwari S, et al. Tumor heterogeneity and cancer stem cell paradigm: Updates in 
concept, controversies and clinical relevance. Int. J. Cancer 2015;136(9):1991-2000. 
doi:10.1002/ijc.28804. 
14. Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical report: Primary brain and other central nervous 
system tumors diagnosed in the United States in 2009-2013. Neuro. Oncol. 2016;18(suppl_5):v1-v75. 
doi:10.1093/neuonc/now207. 
15. Merchant TE, Pollack IF, Loeffler JS. Brain Tumors Across the Age Spectrum: Biology, Therapy, and Late
Effects. Semin. Radiat. Oncol. 2010;20(1):58-66. doi:10.1016/j.semradonc.2009.09.005. 
16. Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and decline in intelligence: the influence of 
dose and age on IQ score. J. Clin. Oncol. 1992;10(9):1390-6. 
17. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose 
radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. J. 
Clin. Oncol. 2001;19(15):3470-6. 
18. Palmer SL, Reddick WE, Gajjar A. Understanding the cognitive impact on children who are treated for
medulloblastoma. J. Pediatr. Psychol. 2007;32(9):1040-9. doi:10.1093/jpepsy/jsl056. 
19. Kallappagoudar S, Yadav RK, Lowe BR, Partridge JF. Histone H3 mutations--a special role for H3.3 in
tumorigenesis? Chromosoma 2015;124(2):177-89. doi:10.1007/s00412-015-0510-4. 
20. Veldhuijzen van Zanten SEM, Jansen MHA, Sanchez Aliaga E, van Vuurden DG, Vandertop WP, Kaspers
GJL. A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The 
Netherlands. Expert Rev. Anticancer Ther. 2015;15(2):157-64. doi:10.1586/14737140.2015.974563. 
21. Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J. Clin. 
Oncol. 2006;24(8):1266-72. doi:10.1200/JCO.2005.04.6599. 
22. Hargrave D, Chuang N, Bouffet E. Conventional MRI cannot predict survival in childhood diffuse intrinsic 
pontine glioma. J. Neurooncol. 2008;86(3):313-319. doi:10.1007/s11060-007-9473-5. 
23. Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic
pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 2012;44(3):251-3. doi:10.1038/ng.1102. 
24. Grasso CS, Tang Y, Truffaux N, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine
glioma. Nat. Med. 2015;21(6):555-9. doi:10.1038/nm.3855. 
REFERENCES 
193 
 
25.  Castel D, Philippe C, Calmon R, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups 
of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 
2015;130(6):815-827. doi:10.1007/s00401-015-1478-0. 
26.  Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the 
molecular era: the current consensus. Acta Neuropathol. 2016;131(6):821-31. doi:10.1007/s00401-016-
1569-6. 
27.  Pizer B, Clifford S. Medulloblastoma: new insights into biology and treatment. Arch. Dis. Child. Educ. Pract. 
Ed. 2008;93(5):137-44. doi:10.1136/adc.2007.136655. 
28.  Tamayo-Orrego L, Swikert SM, Charron F. Evasion of cell senescence in SHH medulloblastoma. Cell Cycle 
2016:1-6. doi:10.1080/15384101.2016.1189044. 
29.  de Haas T, Hasselt N, Troost D, et al. Molecular Risk Stratification of Medulloblastoma Patients Based on 
Immunohistochemical Analysis of MYC, LDHB, and CCNB1 Expression. Clin. Cancer Res. 2008;14(13):4154-
4160. doi:10.1158/1078-0432.CCR-07-4159. 
30.  Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-
analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 
medulloblastomas. Acta Neuropathol. 2012;123(4):473-84. doi:10.1007/s00401-012-0958-8. 
31.  Gottardo NG, Gajjar A. Chemotherapy for malignant brain tumors of childhood. J. Child Neurol. 
2008;23(10):1149-59. doi:10.1177/0883073808321765. 
32.  Lafay-Cousin L, Smith A, Chi SN, et al. Clinical, Pathological, and Molecular Characterization of Infant 
Medulloblastomas Treated with Sequential High-Dose Chemotherapy. Pediatr. Blood Cancer 
2016;63(9):1527-34. doi:10.1002/pbc.26042. 
33.  Palmer SL, Goloubeva O, Reddick WE, et al. Patterns of intellectual development among survivors of 
pediatric medulloblastoma: a longitudinal analysis. J. Clin. Oncol. 2001;19(8):2302-8. 
34.  Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic 
approaches. Neurotherapeutics 2009;6(3):570-86. doi:10.1016/j.nurt.2009.04.006. 
35.  von Bueren AO, von Hoff K, Pietsch T, et al. Treatment of young children with localized medulloblastoma 
by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic 
impact of histology. Neuro. Oncol. 2011;13(6):669-79. doi:10.1093/neuonc/nor025. 
36.  Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of 
glioblastoma multiforme. Clin. Adv. Hematol. Oncol. 2007;5(11):894-915. 
37.  Lin C, Yu Y, Zhao H-G, Yang A, Yan H, Cui Y. Combination of quercetin with radiotherapy enhances tumor 
radiosensitivity in vitro and in vivo. Radiother. Oncol. 2012;104(3):395-400. 
doi:10.1016/j.radonc.2011.10.023. 
38.  Caretti V, Hiddingh L, Lagerweij T, et al. WEE1 kinase inhibition enhances the radiation response of diffuse 
intrinsic pontine gliomas. Mol. Cancer Ther. 2013;12(2):141-50. doi:10.1158/1535-7163.MCT-12-0735. 
39.  Markowitz D, Powell C, Tran NL, et al. Pharmacological inhibition of the protein kinase MRK/ZAK 
radiosensitizes medulloblastoma. Mol. Cancer Ther. 2016. doi:10.1158/1535-7163.MCT-15-0849. 
40.  Kleihues P, Burger PC, Scheithauer BW. The New WHO Classification of Brain Tumours. Brain Pathol. 
1993;3(3):255-268. doi:10.1111/j.1750-3639.1993.tb00752.x. 
41.  Li B, Senbabaoglu Y, Peng W, Yang M-L, Xu J, Li JZ. Genomic estimates of aneuploid content in glioblastoma 
multiforme and improved classification. Clin. Cancer Res. 2012;18(20):5595-605. doi:10.1158/1078-
0432.CCR-12-1427. 
42.  Mizoguchi M, Yoshimoto K, Ma X, et al. Molecular characteristics of glioblastoma with 1p/19q co-deletion. 
Brain Tumor Pathol. 2012;29(3):148-53. doi:10.1007/s10014-012-0107-z. 
43.  Leone PE, González MB, Elosua C, et al. Integration of global spectral karyotyping, CGH arrays, and 
expression arrays reveals important genes in the pathogenesis of glioblastoma multiforme. Ann. Surg. 
Oncol. 2012;19(7):2367-79. doi:10.1245/s10434-011-2202-5. 
44.  Li L, Chakraborty S, Yang C-R, et al. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the 
activation of EGFRvIII. Oncogene 2014;33(33):4253-64. doi:10.1038/onc.2013.400. 
45.  Montano N, Cenci T, Martini M, et al. Expression of EGFRvIII in glioblastoma: prognostic significance 
revisited. Neoplasia 2011;13(12):1113-21. 
46.  Eskilsson E, Rosland G V, Talasila KM, et al. EGFRvIII mutations can emerge as late and heterogenous 
events in glioblastoma development and promote angiogenesis through Src activation. Neuro. Oncol. 
2016. doi:10.1093/neuonc/now113. 
47.  Adamson C, Kanu OO, Mehta AI, et al. Glioblastoma multiforme: a review of where we have been and 
where we are going. Expert Opin. Investig. Drugs 2009;18(8):1061-83. doi:10.1517/13543780903052764. 
194 
48. Stupp R, Taillibert S, Kanner AA, et al. Maintenance Therapy With Tumor-Treating Fields Plus
Temozolomide vs Temozolomide Alone for Glioblastoma. JAMA 2015;314(23):2535. 
doi:10.1001/jama.2015.16669. 
49. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide 
for glioblastoma. N. Engl. J. Med. 2005;352(10):987-96. doi:10.1056/NEJMoa043330. 
50. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in
glioblastoma. N. Engl. J. Med. 2005;352(10):997-1003. doi:10.1056/NEJMoa043331. 
51. Cominelli M, Grisanti S, Mazzoleni S, et al. EGFR amplified and overexpressing glioblastomas and
association with better response to adjuvant metronomic temozolomide. J. Natl. Cancer Inst. 2015;107(5). 
doi:10.1093/jnci/djv041. 
52. Yin D, Forsayeth J, Bankiewicz KS. Optimized cannula design and placement for convection-enhanced 
delivery in rat striatum. J. Neurosci. Methods 2010;187(1):46-51. doi:10.1016/j.jneumeth.2009.12.008. 
53. Lonser RR, Warren KE, Butman JA, et al. Real-time image-guided direct convective perfusion of intrinsic
brainstem lesions. Technical note. J. Neurosurg. 2007;107(1):190-7. doi:10.3171/JNS-07/07/0190. 
54. Chen X, Astary GW, Sepulveda H, Mareci TH, Sarntinoranont M. Quantitative assessment of
macromolecular concentration during direct infusion into an agarose hydrogel phantom using contrast-
enhanced MRI. Magn. Reson. Imaging 2008;26(10):1433-41. doi:10.1016/j.mri.2008.04.011. 
55. Sugiyama S, Yamashita Y, Kikuchi T, Saito R, Kumabe T, Tominaga T. Safety and efficacy of convection-
enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor models. J. Neurooncol. 
2007;82(1):41-7. doi:10.1007/s11060-006-9247-5. 
56. Rip J, Chen L, Hartman R, et al. Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo 
across the blood-brain barrier in rats. J. Drug Target. 2014;22(5):460-7. 
doi:10.3109/1061186X.2014.888070. 
57. Kang Y-S, Jung H-J, Oh J-S, Song D-Y. Use of PEGylated Immunoliposomes to Deliver Dopamine Across the 
Blood-Brain Barrier in a Rat Model of Parkinson’s Disease. CNS Neurosci. Ther. 2016;22(10):817-23. 
doi:10.1111/cns.12580. 
58. Fu H, McCarty DM. Crossing the blood-brain-barrier with viral vectors. Curr. Opin. Virol. 2016;21:87-92. 
doi:10.1016/j.coviro.2016.08.006. 
59. Shen Y, Guo J, Chen G, et al. Delivery of Liposomes with Different Sizes to Mice Brain after Sonication by 
Focused Ultrasound in the Presence of Microbubbles. Ultrasound Med. Biol. 2016;42(7):1499-511. 
doi:10.1016/j.ultrasmedbio.2016.01.019. 
60. Sheikov N, McDannold N, Vykhodtseva N, Jolesz F, Hynynen K. Cellular mechanisms of the blood-brain 
barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med. Biol. 
2004;30(7):979-89. doi:10.1016/j.ultrasmedbio.2004.04.010. 
61. Alonso A. Ultrasound-induced blood-brain barrier opening for drug delivery. Front. Neurol. Neurosci. 
2015;36:106-115. doi:10.1159/000366242. 
62. Connell JJ, Chatain G, Cornelissen B, et al. Selective permeabilization of the blood-brain barrier at sites of 
metastasis. J. Natl. Cancer Inst. 2013;105(21):1634-43. doi:10.1093/jnci/djt276. 
63. Van Tellingen O, Yetkin-Arik B, De Gooijer MC, Wesseling P, Wurdinger T, De Vries HE. Overcoming the
blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist. Updat. 2015;19:1-12. 
doi:10.1016/j.drup.2015.02.002. 
64. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74. 
doi:10.1016/j.cell.2011.02.013. 
65. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic
requirements of cell proliferation. Science 2009;324(5930):1029-33. doi:10.1126/science.1160809. 
66. Leenders WPJ, Küsters B, de Waal RMW. Vessel co-option: how tumors obtain blood supply in the absence 
of sprouting angiogenesis. Endothelium 2002;9(2):83-87. doi:10.1080/10623320290016537. 
67. Lu K V, Chang JP, Parachoniak CA, et al. VEGF inhibits tumor cell invasion and mesenchymal transition
through a MET/VEGFR2 complex. Cancer Cell 2012;22(1):21-35. doi:10.1016/j.ccr.2012.05.037. 
68. Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects 
and escape mechanisms. Expert Opin. Ther. Targets 2009;13(4):455-68. 
doi:10.1517/14728220902806444. 
69. Ziegler J, Pody R, Coutinho de Souza P, et al. ELTD1, an effective anti-angiogenic target for gliomas:
preclinical assessment in mouse GL261 and human G55 xenograft glioma models. Neuro. Oncol. 
2016:now147. doi:10.1093/neuonc/now147. 
REFERENCES 
195 
 
 
70.  Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, 
delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 
2006;9(3):157-73. doi:10.1016/j.ccr.2006.02.019. 
71.  Rood BR, Zhang H, Cogen PH. Intercellular heterogeneity of expression of the MGMT DNA repair gene in 
pediatric medulloblastoma. Neuro. Oncol. 2004;6(3):200-7. doi:10.1215/S1152851703000565. 
72.  Munoz JL, Rodriguez-Cruz V, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. Temozolomide resistance 
in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of 
connexin 43. Cell Death Dis. 2014;5:e1145. doi:10.1038/cddis.2014.111. 
73.  Hirata E, Girotti MR, Viros A, et al. Intravital imaging reveals how BRAF inhibition generates drug-tolerant 
microenvironments with high integrin β1/FAK signaling. Cancer Cell 2015;27(4):574-88. 
doi:10.1016/j.ccell.2015.03.008. 
74.  Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as 
a minor clone in non-small cell lung cancer. Cancer Res. 2006;66(16):7854-8. doi:10.1158/0008-
5472.CAN-06-1951. 
75.  Bodogai M, Moritoh K, Lee-Chang C, et al. Immune suppressive and pro-metastatic functions of myeloid-
derived suppressive cells rely upon education from tumor-associated B cells. Cancer Res. 
2015;75(17):3456-65. doi:10.1158/0008-5472.CAN-14-3077. 
76.  Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks 
glioma progression. Nat. Med. 2013;19(10):1264-72. doi:10.1038/nm.3337. 
77.  Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 
2013;19(11):1423-37. doi:10.1038/nm.3394. 
78.  Zhou W, Ke SQ, Huang Z, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-
associated macrophages and promotes malignant growth. Nat. Cell Biol. 2015;17(November 2014):170-
182. doi:10.1038/ncb3090. 
79.  Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma 
maintenance and progression. Nat. Neurosci. 2015;19(1). doi:10.1038/nn.4185. 
80.  Coniglio SJ, Eugenin E, Dobrenis K, et al. Microglial stimulation of glioblastoma invasion involves epidermal 
growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol. Med. 
2012;18:519-27. doi:10.2119/molmed.2011.00217. 
81.  Patel MA, Kim JE, Ruzevick J, Li G, Lim M. The future of glioblastoma therapy: synergism of standard of 
care and immunotherapy. Cancers (Basel). 2014;6(4):1953-85. doi:10.3390/cancers6041953. 
82.  de Jong M, Essers J, van Weerden WM. Imaging preclinical tumour models: improving translational power. 
Nat. Rev. Cancer 2014;14(7):481-93. doi:10.1038/nrc3751. 
83.  Dickinson PJ, LeCouteur RA, Higgins RJ, et al. Canine spontaneous glioma: A translational model system 
for convection-enhanced delivery. Neuro. Oncol. 2010;12(9):928-940. doi:10.1093/neuonc/noq046. 
84.  Warnock G, Turtoi A, Blomme A, et al. In vivo PET/CT in a human glioblastoma chicken chorioallantoic 
membrane model: a new tool for oncology and radiotracer development. J. Nucl. Med. 2013;54(10):1782-
8. doi:10.2967/jnumed.112.117150. 
85.  Lokman NA, Elder ASF, Ricciardelli C, Oehler MK. Chick chorioallantoic membrane (CAM) assay as an in 
vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. 
Int. J. Mol. Sci. 2012;13(8):9959-70. doi:10.3390/ijms13089959. 
86.  Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin. 
Cancer Res. 2006;12(18):5288-97. doi:10.1158/1078-0432.CCR-06-0438. 
87.  Lesniak MS. Development of preclinical models for immunogene therapy of brain cancer: it’s not monkey 
business! Mol. Ther. 2014;22(2):247-9. doi:10.1038/mt.2013.298. 
88.  Lee H. Genetically engineered mouse models for drug development and preclinical trials. Biomol. Ther. 
(Seoul). 2014;22(4):267-74. doi:10.4062/biomolther.2014.074. 
89.  Kucherlapati R. Genetically modified mouse models for biomarker discovery and preclinical drug testing. 
Clin. Cancer Res. 2012;18(3):625-30. doi:10.1158/1078-0432.CCR-11-2021. 
90.  Anderson A. Oncomouse released. Nature 1988;336(6197):300. 
91.  de Vries NA, Bruggeman SW, Hulsman D, et al. Rapid and Robust Transgenic High-Grade Glioma Mouse 
Models for Therapy Intervention Studies. Clin. Cancer Res. 2010;16(13):3431-3441. doi:10.1158/1078-
0432.CCR-09-3414. 
92.  Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of 
bacteriophage P1. Proc. Natl. Acad. Sci. U. S. A. 1988;85(14):5166-70. 
196 
93. Huijbers IJ, Del Bravo J, Bin Ali R, et al. Using the GEMM-ESC strategy to study gene function in mouse
models. Nat. Protoc. 2015;10(11):1755-85. doi:10.1038/nprot.2015.114. 
94. Ren Y, Qiu L, Lü F, et al. TALENs-directed knockout of the full-length transcription factor Nrf1α that 
represses malignant behaviour of human hepatocellular carcinoma (HepG2) cells. Sci. Rep. 2016;6:23775. 
doi:10.1038/srep23775. 
95. Uhrbom L, Hesselager G, Nister M, Westermark B. Induction of Brain Tumors in Mice Using a Recombinant 
Platelet-derived Growth Factor B-Chain Retrovirus. Cancer Res. 1998;58(23):5275-5279. 
96. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 
and CNS-1 gliomas. J. Neurooncol. 1998;36(1):91-102. 
97. Townsend EC, Murakami MA, Christodoulou A, et al. The Public Repository of Xenografts Enables
Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell 2016;29(4):574-586. 
doi:10.1016/j.ccell.2016.03.008. 
98. Cekanova M, Rathore K. Animal models and therapeutic molecular targets of cancer: utility and limitations. 
Drug Des. Devel. Ther. 2014;8:1911-21. doi:10.2147/DDDT.S49584. 
99. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: 
better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2003;2(4 Suppl 1):S134-9. 
doi:213 [pii]. 
100. Teicher BA. Tumor models for efficacy determination. Mol. Cancer Ther. 2006;5(10):2435-2443. 
doi:10.1158/1535-7163.MCT-06-0391. 
101. Shapiro WR, Basler GA, Chernik NL, Posner JB. Human brain tumor transplantation into nude mice. J. Natl. 
Cancer Inst. 1979;62(3):447-53. 
102. Horten BC, Basler GA, Shapiro WR. Xenograft of human malignant glial tumors into brains of nude mice. A 
histopatholgical study. J. Neuropathol. Exp. Neurol. 1981;40(5):493-511. 
103. Garcia C, Dubois L, Xavier A, et al. The orthotopic xenotransplant of human glioblastoma successfully
recapitulates glioblastoma-microenvironment interactions in a non-immunosuppressed mouse model.
BMC Cancer 2014;14(1):923. doi:10.1186/1471-2407-14-923. 
104. Borges AR, Lopez-Larrubia P, Marques JB, Cerdan SG. MR imaging features of high-grade gliomas in murine 
models: how they compare with human disease, reflect tumor biology, and play a role in preclinical trials. 
AJNR. Am. J. Neuroradiol. 2012;33(1):24-36. doi:10.3174/ajnr.A2959. 
105. Oh T, Fakurnejad S, Sayegh ET, et al. Immunocompetent murine models for the study of glioblastoma
immunotherapy. J. Transl. Med. 2014;12(1):107. doi:10.1186/1479-5876-12-107. 
106. Wang H, Cai S, Bailey BJ, et al. Combination therapy in a xenograft model of glioblastoma: enhancement 
of the antitumor activity of temozolomide by an MDM2 antagonist. J. Neurosurg. 2016;13(13):1-14. 
doi:10.3171/2016.1.JNS152513. 
107. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat. Rev. 
Immunol. 2007;7(2):118-30. doi:10.1038/nri2017. 
108. Cunha L, Horvath I, Ferreira S, et al. Preclinical imaging: an essential ally in modern biosciences. Mol. Diagn. 
Ther. 2014;18(2):153-73. doi:10.1007/s40291-013-0062-3. 
109. Richmond J. Refinement, reduction, and replacement of animal use for regulatory testing: future
improvements and implementation within the regulatory framework. ILAR J. 2002;43 Suppl:S63-8. 
110. Medvedeva SE, Boyandin A, Lankin Y, Kotov D, Rodicheva E, Popova L. BIOLUMBASE - The database of
natural and transgenic bioluminescent organisms. Luminescence 2005;20(2):90-96. 
111. Wurdinger T, Badr C, Pike L, et al. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat. 
Methods 2008;5(2):171-173. doi:10.1038/nmeth.1177. 
112. de Wet JR, Wood K V, DeLuca M, Helinski DR, Subramani S. Firefly luciferase gene: structure and
expression in mammalian cells. Mol. Cell. Biol. 1987;7(2):725-37. 
113. Edinger M, Cao Y -a., Hornig YS, et al. Advancing animal models of neoplasia through in vivo
bioluminescence imaging. Eur. J. Cancer 2002;38(16):2128-2136. doi:10.1016/S0959-8049(02)00410-0. 
114. Dinca EB, Voicu R V., Ciurea A V. Bioluminescence imaging of invasive intracranial xenografts: implications 
for translational research and targeted therapeutics of brain tumors. Neurosurg. Rev. 2010;33(4):385-394. 
doi:10.1007/s10143-010-0275-4. 
115. Sweeney KJ, Jarzabek MA, Dicker P, et al. Validation of an imageable surgical resection animal model of
Glioblastoma (GBM). J. Neurosci. Methods 2014;233:99-104. doi:10.1016/j.jneumeth.2014.05.006. 
116. Rehemtulla A, Stegman LD, Cardozo SJ, et al. Rapid and quantitative assessment of cancer treatment
response using in vivo bioluminescence imaging. Neoplasia 2000;2(6):491-495. 
doi:10.1038/sj.neo.7900121. 
REFERENCES 
197 
 
117.  Ray P, Wu AM, Gambhir SS. Optical bioluminescence and positron emission tomography imaging of a novel 
fusion reporter gene in tumor xenografts of living mice. Cancer Res. 2003;63(6):1160-5. 
118.  Heuveling DA, Visser GWM, de Groot M, et al. Nanocolloidal albumin-IRDye 800CW: a near-infrared 
fluorescent tracer with optimal retention in the sentinel lymph node. Eur. J. Nucl. Med. Mol. Imaging 
2012;39(7):1161-8. doi:10.1007/s00259-012-2080-5. 
119.  van den Berg NS, Miwa M, KleinJan GH, et al. (Near-Infrared) Fluorescence-Guided Surgery Under Ambient 
Light Conditions: A Next Step to Embedment of the Technology in Clinical Routine. Ann. Surg. Oncol. 2016. 
doi:10.1245/s10434-016-5186-3. 
120.  Kuzmin N V, Wesseling P, Hamer PC de W, et al. Third harmonic generation imaging for fast, label-free 
pathology of human brain tumors. Biomed. Opt. Express 2016;7(5):1889-904. doi:10.1364/BOE.7.001889. 
121.  Li JL, Goh CC, Keeble JL, et al. Intravital multiphoton imaging of immune responses in the mouse ear skin. 
Nat. Protoc. 2012;7(2):221-34. doi:10.1038/nprot.2011.438. 
122.  Egawa G, Kabashima K. In Vivo Imaging of Cutaneous DCs in Mice. Methods Mol. Biol. 2016;1423:269-74. 
doi:10.1007/978-1-4939-3606-9_19. 
123.  Uchugonova A, Hoffman RM, Weinigel M, Koenig K. Watching stem cells in the skin of living mice 
noninvasively. Cell Cycle 2011;10(12):2017-20. doi:10.4161/cc.10.12.15895. 
124.  Pineda CM, Park S, Mesa KR, et al. Intravital imaging of hair follicle regeneration in the mouse. Nat. Protoc. 
2015;10(7):1116-30. doi:10.1038/nprot.2015.070. 
125.  Zomer A, Maynard C, Verweij FJ, et al. In Vivo Imaging Reveals Extracellular Vesicle-Mediated 
Phenocopying of Metastatic Behavior. Cell 2015;161(5):1046-1057. doi:10.1016/j.cell.2015.04.042. 
126.  Mostany R, Portera-Cailliau C. A craniotomy surgery procedure for chronic brain imaging. J. Vis. Exp. 
2008;5(12):2-3. doi:10.3791/680. 
127.  Tozer GM, Ameer-Beg SM, Baker J, et al. Intravital imaging of tumour vascular networks using multi-
photon fluorescence microscopy. Adv. Drug Deliv. Rev. 2005;57(1):135-52. 
doi:10.1016/j.addr.2004.07.015. 
128.  Holtmaat A, Bonhoeffer T, Chow DK, et al. Long-term, high-resolution imaging in the mouse neocortex 
through a chronic cranial window. Nat. Protoc. 2009;4(8):1128-44. doi:10.1038/nprot.2009.89. 
129.  Bayerl SH, Niesner R, Cseresnyes Z, et al. Time lapse in vivo microscopy reveals distinct dynamics of 
microglia-tumor environment interactions - a new role for the tumor perivascular space as highway for 
trafficking microglia. Glia 2016. doi:10.1002/glia.22994. 
130.  Lohela M, Casbon A-J, Olow A, et al. Intravital imaging reveals distinct responses of depleting dynamic 
tumor-associated macrophage and dendritic cell subpopulations. Proc. Natl. Acad. Sci. U. S. A. 
2014;111(47):E5086-95. doi:10.1073/pnas.1419899111. 
131.  Kobat D, Horton NG, Xu C. In vivo two-photon microscopy to 1.6-mm depth in mouse cortex. J. Biomed. 
Opt. 2011;16(10):106014. doi:10.1117/1.3646209. 
132.  Horton NG, Wang K, Kobat D, et al. In vivo three-photon microscopy of subcortical structures within an 
intact mouse brain. Nat. Photonics 2013;7(3). doi:10.1038/nphoton.2012.336. 
133.  Bloomfield PM, Rajeswaran S, Spinks TJ, et al. The design and physical characteristics of a small animal 
positron emission tomograph. Phys. Med. Biol. 1995;40(6):1105-26. 
134.  Watanabe M, Uchida H, Okada H, et al. A high resolution PET for animal studies. IEEE Trans. Med. Imaging 
1992;11(4):577-80. doi:10.1109/42.192694. 
135.  Cutler PD, Cherry SR, Hoffman EJ, Digby WM, Phelps ME. Design features and performance of a PET system 
for animal research. J. Nucl. Med. 1992;33(4):595-604. 
136.  Kenny L. The Use of Novel PET Tracers to Image Breast Cancer Biologic Processes Such as Proliferation, 
DNA Damage and Repair, and Angiogenesis. J. Nucl. Med. 2016;57 Suppl 1:89S-95S. 
doi:10.2967/jnumed.115.157958. 
137.  Puttick S, Bell C, Dowson N, Rose S, Fay M. PET, MRI, and simultaneous PET/MRI in the development of 
diagnostic and therapeutic strategies for glioma. Drug Discov. Today 2015;20(3):306-17. 
doi:10.1016/j.drudis.2014.10.016. 
138.  Das NM, Hatsell S, Nannuru K, et al. In Vivo Quantitative Microcomputed Tomographic Analysis of 
Vasculature and Organs in a Normal and Diseased Mouse Model. PLoS One 2016;11(2):e0150085. 
doi:10.1371/journal.pone.0150085. 
139.  Varoquaux A, Rager O, Poncet A, et al. Detection and quantification of focal uptake in head and neck 
tumours: (18)F-FDG PET/MR versus PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2014;41(3):462-75. 
doi:10.1007/s00259-013-2580-y. 
  
198 
140. Baumann BC, Benci JL, Santoiemma PP, et al. An integrated method for reproducible and accurate image-
guided stereotactic cranial irradiation of brain tumors using the small animal radiation research platform. 
Transl. Oncol. 2012;5(4):230-7. 
141. Radaelli E, Ceruti R, Patton V, et al. Immunohistopathological and neuroimaging characterization of
murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features 
of human disease. Histol. Histopathol. 2009;24(7):879-91. 
142. Ramasawmy R, Johnson SP, Roberts TA, et al. Monitoring the Growth of an Orthotopic Tumour Xenograft 
Model: Multi-Modal Imaging Assessment with Benchtop MRI (1T), High-Field MRI (9.4T), Ultrasound and 
Bioluminescence. PLoS One 2016;11(5):e0156162. doi:10.1371/journal.pone.0156162. 
143. Nagy K, Toth M, Major P, et al. Performance Evaluation of the Small-Animal nanoScan PET/MRI System. J. 
Nucl. Med. 2013;54(10):1825-32. doi:10.2967/jnumed.112.119065. 
144. De Souza R, Spence T, Huang H, Allen C. Preclinical imaging and translational animal models of cancer for 
accelerated clinical implementation of nanotechnologies and macromolecular agents. J. Control. Release 
2015;219:313-30. doi:10.1016/j.jconrel.2015.09.041. 
145. Stein EW, Maslov K, Wang L V. Noninvasive, in vivo imaging of blood-oxygenation dynamics within the
mouse brain using photoacoustic microscopy. J. Biomed. Opt. 2009;14(2):20502. doi:10.1117/1.3095799. 
146. Griffini P, Smorenburg SM, Verbeek FJ, van Noorden CJ. Three-dimensional reconstruction of colon
carcinoma metastases in liver. J. Microsc. 1997;187(Pt 1):12-21. 
147. Gijtenbeek JMM, Wesseling P, Maass C, Burgers L, van der Laak JAWM. Three-dimensional reconstruction 
of tumor microvasculature: simultaneous visualization of multiple components in paraffin-embedded 
tissue. Angiogenesis 2005;8(4):297-305. doi:10.1007/s10456-005-9019-4. 
148. Gilhuis HJ, van der Laak JAWM, Pomp J, Kappelle AC, Gijtenbeek JMM, Wesseling P. Three-dimensional 
(3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and
ependymoma subtypes. Angiogenesis 2006;9(4):201-8. doi:10.1007/s10456-006-9054-9. 
149. Chung K, Wallace J, Kim S-Y, et al. Structural and molecular interrogation of intact biological systems
(supp). Nature 2013;497(7449):332-7. doi:10.1038/nature12107. 
150. Chieco P, Jonker A, De Boer BA, Ruijter JM, Van Noorden CJF. Image Cytometry: Protocols for 2D and 3D 
Quantification in Microscopic Images. Prog. Histochem. Cytochem. 2013;47(4):211-333. 
doi:10.1016/j.proghi.2012.09.001. 
151. Weissleder R, Nahrendorf M. Advancing biomedical imaging. Proc. Natl. Acad. Sci. U. S. A. 
2015;112(47):14424-8. doi:10.1073/pnas.1508524112. 
152. Mauch CP, Dodt H, Leischner U, et al. Ultramicroscopy : three-dimensional visualization of neuronal
networks in the whole mouse brain. Nat. Methods 2007;4(4):331-336. doi:10.1038/NMETH1036. 
153. Negrean A, Mansvelder HD. Optimal lens design and use in laser-scanning microscopy. Biomed. Opt.
Express 2014;5(5):1588. doi:10.1364/BOE.5.001588. 
154. Susaki E a, Tainaka K, Perrin D, et al. Whole-Brain Imaging with Single-Cell Resolution Using Chemical
Cocktails and Computational Analysis. Cell 2014;157(3):726-739. doi:10.1016/j.cell.2014.03.042. 
155. Yang B, Treweek JB, Kulkarni RP, et al. Single-Cell Phenotyping within Transparent Intact Tissue through
Whole-Body Clearing. Cell 2014:1-14. doi:10.1016/j.cell.2014.07.017. 
156. Renier N, Wu Z, Simon DJ, Yang J, Ariel P, Tessier-lavigne M. Resource iDISCO : A Simple , Rapid Method 
to Immunolabel Large Tissue Samples for Volume Imaging. Cell 2014;Im:1-15. 
doi:10.1016/j.cell.2014.10.010. 
157. Lee E, Choi J, Jo Y, et al. ACT-PRESTO: Rapid and consistent tissue clearing and labeling method for 3-
dimensional (3D) imaging. Sci. Rep. 2016;6:18631. doi:10.1038/srep18631 
158. Azaripour A, Lagerweij T, Scharfbillig C, Jadczak AE, Willershausen B, Van Noorden CJF. A survey of clearing 
techniques for 3D imaging of tissues with special reference to connective tissue. Prog. Histochem.
Cytochem. 2016. doi:10.1016/j.proghi.2016.04.001. 
159. Panchuk-Voloshina N, Haugland RP, Bishop-Stewart J, et al. Alexa dyes, a series of new fluorescent dyes
that yield exceptionally bright, photostable conjugates. J. Histochem. Cytochem. 1999;47(9):1179-1188. 
doi:10.1177/002215549904700910. 
160. Chen AK, Cheng Z, Behlke MA, Tsourkas A. Assessing the sensitivity of commercially available fluorophores 
to the intracellular environment. Anal. Chem. 2008;80(19):7437-44. doi:10.1021/ac8011347. 
161. Liu H, Kao WWY. A novel protocol of whole mount electro-immunofluorescence staining. Mol. Vis. 
2009;15(7449):505-517. doi:10.1038/nature12107. 
REFERENCES 
199 
 
162.  Kim S-Y, Cho JH, Murray E, et al. Stochastic electrotransport selectively enhances the transport of highly 
electromobile molecules. Proc. Natl. Acad. Sci. U. S. A. 2015;112(46):E6274-83. 
doi:10.1073/pnas.1510133112. 
163.  Strack R. Protein labeling in cells. Nat. Methods 2015;13(1):33-33. doi:10.1038/nmeth.3702. 
164.  Lyons SK. Advances in imaging mouse tumour models in vivo. J. Pathol. 2005;205(2):194-205. 
doi:10.1002/path.1697. 
165.  Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev. Cancer 2002;2(1):11-
8. doi:10.1038/nrc701. 
166.  Massoud TF, Gambhir SS. Molecular imaging in living subjects: Seeing fundamental biological processes in 
a new light. Genes Dev. 2003;17(5):545-580. doi:10.1101/gad.1047403. 
167.  Kherlopian AR, Song T, Duan Q, et al. A review of imaging techniques for systems biology. BMC Syst. Biol. 
2008;2(1):74. doi:10.1186/1752-0509-2-74. 
168.  Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: Critical review of clinical trials. 
Lancet Oncol. 2006;7(3):241-248. doi:10.1016/S1470-2045(06)70615-5. 
169.  Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJL. Diffuse intrinsic pontine gliomas: A systematic 
update on clinical trials and biology. Cancer Treat. Rev. 2012;38(1):27-35. doi:10.1016/j.ctrv.2011.06.007. 
170.  Veringa SJE, Biesmans D, van Vuurden DG, et al. In Vitro Drug Response and Efflux Transporters Associated 
with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma. Ulasov I, ed. 
PLoS One 2013;8(4):e61512. doi:10.1371/journal.pone.0061512. 
171.  Bradley KA, Pollack IF, Reid JM, et al. Motexafin gadolinium and involved field radiation therapy for intrinsic 
pontine glioma of childhood: a Children’s Oncology Group phase I study. Neuro. Oncol. 2008;10(5):752-8. 
doi:10.1215/15228517-2008-043. 
172.  Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW. Patterns of Contrast Enhancement 
in the Brain and Meninges. RadioGraphics 2007;27(2):525-551. doi:10.1148/rg.272065155. 
173.  Deeken JF, Löscher W. The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses. 
Clin. Cancer Res. 2007;13(6). 
174.  Bartels U, Hawkins C, Vézina G, Kun L, Souweidane M, Bouffet E. Proceedings of the diffuse intrinsic 
pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in 
DIPG. J. Neurooncol. 2011;105(1):119-125. doi:10.1007/s11060-011-0704-4. 
175.  Song DK, Lonser RR. Convection-enhanced delivery for the treatment of pediatric neurologic disorders. J. 
Child Neurol. 2008;23(10):1231-7. doi:10.1177/0883073808321064. 
176.  Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of 
macromolecules in the brain. Proc. Natl. Acad. Sci. U. S. A. 1994;91(6):2076-80. 
177.  Groothuis DR, Ward S, Itskovich AC, et al. Comparison of 14C-sucrose delivery to the brain by intravenous, 
intraventricular, and convection-enhanced intracerebral infusion. J Neurosurg 1999;90(2):321-331. 
doi:10.3171/jns.1999.90.2.0321. 
178.  Bidros DS, Liu JK, Vogelbaum MA. Future of convection-enhanced delivery in the treatment of brain 
tumors. Futur. Oncol. 2010;6(1):117-125. doi:10.2217/fon.09.135. 
179.  Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug 
delivery. Neuro. Oncol. 2000;2(1):45-59. 
180.  Pardridge WM. Drug Delivery to the Brain. J. Cereb. Blood Flow Metab. 1997:713-731. 
doi:10.1097/00004647-199707000-00001. 
181.  Sandberg DI, Edgar MA, Souweidane MM. Convection-enhanced delivery into the rat brainstem. J. 
Neurosurg. 2002;96(5):885-891. doi:10.3171/jns.2002.96.5.0885. 
182.  Thomale UW, Tyler B, Renard VM, et al. Local chemotherapy in the rat brainstem with multiple catheters: 
a feasibility study. Childs. Nerv. Syst. 2009;25(1):21-8. doi:10.1007/s00381-008-0684-7. 
183.  Lonser RR, Walbridge S, Garmestani K, et al. Successful and safe perfusion of the primate brainstem: in 
vivo magnetic resonance imaging of macromolecular distribution during infusion. J. Neurosurg. 
2002;97(4):905-913. doi:10.3171/jns.2002.97.4.0905 
184.  Yin D, Richardson RM, Fiandaca MS, et al. Cannula placement for effective convection-enhanced delivery 
in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J. 
Neurosurg. 2010;113(2):240-248. doi:10.3171/2010.2.JNS091744. 
185.  Murad GJA, Walbridge S, Morrison PF, et al. Image-guided convection-enhanced delivery of gemcitabine 
to the brainstem. J. Neurosurg. 2007;106(2):351-356. doi:10.3171/jns.2007.106.2.351. 
  
200 
186. Anderson RCE, Kennedy B, Yanes CL, et al. Convection-enhanced delivery of topotecan into diffuse intrinsic 
brainstem tumors in children. J. Neurosurg. Pediatr. 2013;11(3):289-295. 
doi:10.3171/2012.10.PEDS12142. 
187. Barua NU, Lowis SP, Woolley M, O’Sullivan S, Harrison R, Gill SS. Robot-guided convection-enhanced 
delivery of carboplatin for advanced brainstem glioma. Acta Neurochir. (Wien). 2013;155(8):1459-1465. 
doi:10.1007/s00701-013-1700-6. 
188. Saito R, Sonoda Y, Kumabe T, Nagamatsu K, Watanabe M, Tominaga T. Regression of recurrent
glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride. J. 
Neurosurg. Pediatr. 2011;7(5):522-6. doi:10.3171/2011.2.PEDS10407. 
189. Becher OJ, Hambardzumyan D, Walker TR, et al. Preclinical Evaluation of Radiation and Perifosine in a
Genetically and Histologically Accurate Model of Brainstem Glioma. Cancer Res. 2010;70(6). 
190. Monje M, Mitra SS, Freret ME, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic
pontine glioma. Proc. Natl. Acad. Sci. U. S. A. 2011;108(11):4453-8. doi:10.1073/pnas.1101657108. 
191. Silvani A, Gaviani P, Lamperti EA, et al. Cisplatinum and BCNU chemotherapy in primary glioblastoma
patients. J. Neurooncol. 2009;94(1):57-62. doi:10.1007/s11060-009-9800-0. 
192. Buonerba C, Di Lorenzo G, Marinelli A, et al. A comprehensive outlook on intracerebral therapy of
malignant gliomas. Crit. Rev. Oncol. Hematol. 2011;80(1):54-68. doi:10.1016/j.critrevonc.2010.09.001. 
193. Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg. 
Neurol. 2000;53(5):458-64. 
194. Sardi I, Sanzo M, Giordano F, et al. Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for 
recurrent anaplastic ependymoma. Oncol. Rep. 2008;19(5):1219-23. 
195. Layton PB, Greenberg HS, Stetson PL, Ensminger WD, Gyves JW. BCNU solubility and toxicity in the
treatment of malignant astrocytomas. J. Neurosurg. 1984;60(6):1134-1137. 
doi:10.3171/jns.1984.60.6.1134. 
196. Caretti V, Sewing ACPCP, Lagerweij T, et al. Human pontine glioma cells can induce murine tumors. Acta 
Neuropathol. 2014;127(6):897-909. doi:10.1007/s00401-014-1272-4. 
197. Caretti V, Zondervan I, Meijer DH, et al. Monitoring of tumor growth and post-irradiation recurrence in a 
diffuse intrinsic pontine glioma mouse model. Brain Pathol. 2011;21(4):441-451. doi:10.1111/j.1750-
3639.2010.00468.x. 
198. Chen Z-J, Gillies GT, Broaddus WC, et al. A realistic brain tissue phantom for intraparenchymal infusion
studies. J. Neurosurg. 2004;101(2):314-322. doi:10.3171/jns.2004.101.2.0314. 
199. Caretti V, Bugiani M, Freret M, et al. Subventricular spread of diffuse intrinsic pontine glioma. Acta 
Neuropathol. 2014;128(4):605-607. doi:10.1007/s00401-014-1307-x. 
200. Paxinos GKF. The Mouse Brain in Stereotaxic Coordinates, Compact, 3rd Edition | George Paxinos, Keith
Franklin | ISBN 9780123742445. Mouse Brain Stereotaxic Coord. Compact. 3rd Ed. 2008. 
201. Saito R, Krauze MT, Noble CO, et al. Tissue affinity of the infusate affects the distribution volume during 
convection-enhanced delivery into rodent brains: Implications for local drug delivery. J. Neurosci. Methods 
2006;154(1):225-232. doi:10.1016/j.jneumeth.2005.12.027. 
202. Caretti V, Jansen MHA, Van Vuurden DG, et al. Implementation of a Multi-Institutional Diffuse Intrinsic
Pontine Glioma Autopsy Protocol and Characterization of a Primary Cell Culture. Neuropathol. Appl.
Neurobiol. 2012. doi:10.1111/j.1365-2990.2012.01294.x. 
203. Occhiogrosso G, Edgar MA, Sandberg DI, Souweidane MM. Prolonged Convection-enhanced Delivery into 
the Rat Brainstem. Neurosurgery 2003;52(2):388-394. doi:10.1227/01.NEU.0000043696.83722.8D. 
204. Solomon DA, Wood MD, Tihan T, et al. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series 
of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. Brain 
Pathol. 2016;26(5):569-580. doi:10.1111/bpa.12336. 
205. Eisenstat DD, Pollack IF, Demers A, et al. Impact of tumor location and pathological discordance on survival 
of children with midline high-grade gliomas treated on Children’s Cancer Group high-grade glioma study 
CCG-945. J. Neurooncol. 2015;121(3):573-581. doi:10.1007/s11060-014-1669-x. 
206. Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, et al. Survival prediction model of children with 
diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro. Oncol. 2015;17(1):160-
166. doi:10.1093/neuonc/nou104. 
207. Buczkowicz P, Hoeman C, Rakopoulos P, et al. Genomic analysis of diffuse intrinsic pontine gliomas
identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 
2014;46(5):451-456. doi:10.1038/ng.2936. 
REFERENCES 
201 
 
208.  Buczkowicz P, Hawkins C. Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine 
Glioma. Front. Oncol. 2015;5:147. doi:10.3389/fonc.2015.00147. 
209.  Morales La Madrid A, Hashizume R, Kieran MW. Future Clinical Trials in DIPG: Bringing Epigenetics to the 
Clinic. Front. Oncol. 2015;5:148. doi:10.3389/fonc.2015.00148. 
210.  Salloum R, DeWire M, Lane A, et al. Patterns of progression in pediatric patients with high-grade glioma 
or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis. J. Neurooncol. 
2014;121:591-598. doi:10.1007/s11060-014-1671-3. 
211.  Kaspers GJ, Jansen MH. A new era for children with diffuse intrinsic pontine glioma: hope for cure? Expert 
Rev. Anticancer Ther. 2012;12(9):1109-1112. doi:10.1586/era.12.95. 
212.  van Dalen EC, Raphaël MF, Caron HN, Kremer LC. Treatment including anthracyclines versus treatment 
not including anthracyclines for childhood cancer. In: van Dalen EC, ed. Cochrane Database of Systematic 
Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2014. doi:10.1002/14651858.CD006647.pub4. 
213.  Lipshultz SE, Karnik R, Sambatakos P, Franco VI, Ross SW, Miller TL. Anthracycline-related cardiotoxicity in 
childhood cancer survivors. Curr. Opin. Cardiol. 2014;29(1):103-112. 
doi:10.1097/HCO.0000000000000034. 
214.  Austin Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP 
(ABCG2). Oncogene 2003;22(47):7340-7358. doi:10.1038/sj.onc.1206938. 
215.  Qosa H, Miller DS, Pasinelli P, Trotti D. Regulation of ABC efflux transporters at blood-brain barrier in health 
and neurological disorders. Brain Res. 2015;1628:298-316. doi:10.1016/j.brainres.2015.07.005. 
216.  Chittiboina P, Heiss JD, Warren KE, Lonser RR. Magnetic resonance imaging properties of convective 
delivery in diffuse intrinsic pontine gliomas. J. Neurosurg. Pediatr. 2014;13(3):276-82. 
doi:10.3171/2013.11.PEDS136. 
217.  Barua NU, Gill SS, Love S. Convection-Enhanced Drug Delivery to the Brain: Therapeutic Potential and 
Neuropathological Considerations. Brain Pathol. 2014;24(2):117-127. doi:10.1111/bpa.12082. 
218.  Lonser RR, Sarntinoranont M, Morrison PF, Oldfield EH. Convection-enhanced delivery to the central 
nervous system. J. Neurosurg. 2015;122(3):697-706. doi:10.3171/2014.10.JNS14229. 
219.  Allard E, Passirani C, Benoit J-P. Convection-enhanced delivery of nanocarriers for the treatment of brain 
tumors. Biomaterials 2009;30(12):2302-2318. doi:10.1016/j.biomaterials.2009.01.003. 
220.  Kikuchi T, Saito R, Sugiyama S, et al. Convection-enhanced delivery of polyethylene glycol–coated 
liposomal doxorubicin: characterization and efficacy in rat intracranial glioma models. J. Neurosurg. 
2008;109(5):867-873. doi:10.3171/JNS/2008/109/11/0867. 
221.  Krauze MT, Noble CO, Kawaguchi T, et al. Convection-enhanced delivery of nanoliposomal CPT-11 
(irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. 
Neuro. Oncol. 2007;9(4):393-403. doi:10.1215/15228517-2007-019. 
222.  Zhou J, Patel TR, Sirianni RW, et al. Highly penetrative, drug-loaded nanocarriers improve treatment of 
glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 2013;110(29):11751-6. doi:10.1073/pnas.1304504110. 
223.  Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations 
as predictive markers in node-positive breast cancer patients randomly treated either with an 
anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer 
Res. 2002;8(5):1107-16. 
224.  Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M, Larsimont D. Topoisomerase II alpha as a marker 
predicting anthracyclines’ activity in early breast cancer patients: Ready for the primetime? Eur. J. Cancer 
2008;44(18):2791-2798. doi:10.1016/j.ejca.2008.09.014. 
225.  Paugh BS, Broniscer A, Qu C, et al. Genome-wide analyses identify recurrent amplifications of receptor 
tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J. Clin. Oncol. 
2011;29(30):3999-4006. doi:10.1200/JCO.2011.35.5677. 
226.  Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas 
reveals key differences with the adult disease. J. Clin. Oncol. 2010;28(18):3061-3068. 
doi:10.1200/JCO.2009.26.7252. 
227.  Harris LW, Lockstone HE, Khaitovich P, Weickert CS, Webster MJ, Bahn S. Gene expression in the prefrontal 
cortex during adolescence: implications for the onset of schizophrenia. BMC Med. Genomics 2009;2:28. 
doi:10.1186/1755-8794-2-28. 
228.  Gravendeel L a M, Kouwenhoven MCM, Gevaert O, et al. Intrinsic gene expression profiles of gliomas are 
a better predictor of survival than histology. Cancer Res. 2009;69(23):9065-9072. doi:10.1158/0008-
5472.CAN-09-2307. 
  
202 
229. Boult JKR, Taylor KR, Vinci M, et al. Abstract 3271: Novel orthotopic pediatric high grade glioma xenografts 
evaluated with magnetic resonance imaging mimic human disease. Cancer Res. 2015;75(15 
Supplement):3271-3271. doi:10.1158/1538-7445.AM2015-3271. 
230. Jansen MHA, Lagerweij T, Sewing ACP, et al. Bevacizumab targeting diffuse intrinsic pontine glioma: results 
of 89Zr-bevacizumab PET imaging in brain tumor models. Mol. Cancer Ther. 2016;15(September):2166-
2174. doi:10.1158/1535-7163.MCT-15-0558. 
231. Gaillard PJ, Appeldoorn CCM, Dorland R, et al. Pharmacokinetics, Brain Delivery, and Efficacy in Brain
Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101). Velasco G, ed. PLoS One 
2014;9(1):e82331. doi:10.1371/journal.pone.0082331. 
232. Barenholz Y (Chezy). Doxil® — The first FDA-approved nano-drug: Lessons learned. J. Control. Release 
2012;160(2):117-134. doi:10.1016/j.jconrel.2012.03.020. 
233. Claes A, Schuuring J, Boots-Sprenger S, et al. Phenotypic and genotypic characterization of orthotopic
human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol. 2008;18(3):423-
433. doi:10.1111/j.1750-3639.2008.00141.x. 
234. Sewing ACPCP, Caretti V, Lagerweij T, et al. Convection Enhanced Delivery of Carmustine to the Murine
Brainstem: a feasibility study. J. Neurosci. Methods 2014;238:88-94. doi:10.1016/j.jneumeth.2014.09.020. 
235. Chastagner P, Sudour H, Mriouah J, Barberi-Heyob M, Bernier-Chastagner V, Pinel S. Preclinical Studies of 
Pegylated- and Non-Pegylated Liposomal Forms of Doxorubicin as Radiosensitizer on Orthotopic High-
Grade Glioma Xenografts. Pharm. Res. 2015;32(1):158-166. doi:10.1007/s11095-014-1452-x. 
236. Lippens RJ. Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors. 
Pediatr. Hematol. Oncol. 16(2):131-9. 
237. Wagner S, Peters O, Fels C, et al. Pegylated-liposomal doxorubicin and oral topotecan in eight children
with relapsed high-grade malignant brain tumors. J. Neurooncol. 2008;86(2):175-181. 
doi:10.1007/s11060-007-9444-x. 
238. Wolff JE, Trilling T, Mölenkamp G, Egeler RM, Jürgens H. Chemosensitivity of glioma cells in vitro: a meta 
analysis. J. Cancer Res. Clin. Oncol. 125(8-9):481-6. 
239. Chan K-M, Fang D, Gan H, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27
methylation and gene expression. Genes Dev. 2013;27(9):985-990. doi:10.1101/gad.217778.113. 
240. Fontebasso AM, Liu X-Y, Sturm D, Jabado N. Chromatin Remodeling Defects in Pediatric and Young Adult 
Glioblastoma: A Tale of a Variant Histone 3 Tail. Brain Pathol. 2013;23(2):210-216. 
doi:10.1111/bpa.12023. 
241. Pang B, Qiao X, Janssen L, et al. Drug-induced histone eviction from open chromatin contributes to the
chemotherapeutic effects of doxorubicin. Nat. Commun. 2013;4:1908. doi:10.1038/ncomms2921. 
242. Zhang R, Saito R, Mano Y, et al. Concentration rather than dose defines the local brain toxicity of agents 
that are effectively distributed by convection-enhanced delivery. J. Neurosci. Methods 2014;222:131-137. 
doi:10.1016/j.jneumeth.2013.11.004. 
243. Kakee A, Terasaki T, Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the 
blood-brain barrier. J. Pharmacol. Exp. Ther. 1996;277(3):1550-9. 
244. Zhou Z, Ho SL, Singh R, Pisapia DJ, Souweidane MM. Toxicity evaluation of convection-enhanced delivery 
of small-molecule kinase inhibitors in naïve mouse brainstem. Child’s Nerv. Syst. 2015;31(4):557-562. 
doi:10.1007/s00381-015-2640-7. 
245. Siepmann J, Siepmann F, Florence AT. Local controlled drug delivery to the brain: Mathematical modeling 
of the underlying mass transport mechanisms. Int. J. Pharm. 2006;314(2):101-119. 
doi:10.1016/j.ijpharm.2005.07.027. 
246. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 
2004;25(4):581-611. doi:10.1210/er.2003-0027. 
247. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in
angiogenesis. J. Biochem. Mol. Biol. 2006;39(5):469-478. doi:10.5483/BMBRep.2006.39.5.469. 
248. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in
recurrent glioblastoma. J. Clin. Oncol. 2009;27(28):4733-40. doi:10.1200/JCO.2008.19.8721. 
249. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent 
malignant glioma. Clin. Cancer Res. 2007;13(4):1253-1259. doi:10.1158/1078-0432.CCR-06-2309. 
250. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma
multiforme. J. Clin. Oncol. 2007;25(30):4722-4729. doi:10.1200/JCO.2007.12.2440. 
251. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed
REFERENCES 
203 
 
glioblastoma. N. Engl. J. Med. 2014;370(8):709-22. doi:10.1056/NEJMoa1308345. 
252.  Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed 
glioblastoma. N. Engl. J. Med. 2014;370(8):699-708. doi:10.1056/NEJMoa1308573. 
253.  Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Antiangiogenic therapy for high-grade 
glioma. Cochrane database Syst. Rev. 2014;9:CD008218. doi:10.1002/14651858.CD008218.pub3. 
254.  Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children 
with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. 
J. Clin. Oncol. 2010;28(18):3069-3075. doi:10.1200/JCO.2009.26.8789. 
255.  Aguilera DG, Mazewski C, Hayes L, et al. Prolonged survival after treatment of diffuse intrinsic pontine 
glioma with radiation, temozolamide, and bevacizumab: report of 2 cases. J. Pediatr. Hematol. Oncol. 
2013;35(1):e42-6. doi:10.1097/MPH.0b013e318279aed8. 
256.  Zaky W, Wellner M, Brown RJ, Blüml S, Finlay JL, Dhall G. Treatment of children with diffuse intrinsic 
pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and 
bevacizumab. Pediatr. Hematol. Oncol. 2013;30(7):623-32. doi:10.3109/08880018.2013.829895. 
257.  Hummel TR, Salloum R, Drissi R, et al. A pilot study of bevacizumab-based therapy in patients with newly 
diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. J. Neurooncol. 2016;127(1):53-61. 
doi:10.1007/s11060-015-2008-6. 
258.  Roodink I, Van Der Laak J, Kusters B, et al. Development of the tumor vascular bed in response to hypoxia-
induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. Int. J. Cancer 
2006;119(9):2054-2062. doi:10.1002/ijc.22072. 
259.  Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen G a MS. 89Zr immuno-
PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 
2003;44(8):1271-1281. 
260.  Taylor KR, Mackay A, Truffaux N, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine 
glioma. Nat. Genet. 2014;46(5):457-61. doi:10.1038/ng.2925. 
261.  Bernsen HJJ a, Rijken PFJW, Peters H, Bakker H, van der Kogel  a. J. The effect of the anti-angiogenic agent 
TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J. 
Neurooncol. 1998;38(1):51-57. doi:10.1023/A:1005957201431. 
262.  Mir SE, De Witt Hamer PC, Krawczyk PM, et al. In silico analysis of kinase expression identifies WEE1 as a 
gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010;18(3):244-57. 
doi:10.1016/j.ccr.2010.08.011. 
263.  de Weger RA, Tilanus MG, Scheidel KC, van den Tweel JG, Verdonck LF. Monitoring of residual disease and 
guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis 
with short tandem repeats. Br. J. Haematol. 2000;110(3):647-53. 
264.  Verel I, Visser GWM, Boellaard R, et al. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled 
monoclonal antibodies in xenograft-bearing nude mice. J. Nucl. Med. 2003;44(10):1663-1670. 
265.  de Jong HWAM, van Velden FHP, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA. Performance evaluation 
of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys. Med. Biol. 
2007;52(5):1505-26. doi:10.1088/0031-9155/52/5/019. 
266.  Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol. 
Imaging 2003;2(3):131-7. 
267.  Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor 
(VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15(2):171-
185. doi:10.1007/s10456-011-9249-6. 
268.  Jacobs VL, Valdes PA, Hickey WF, De Leo JA. Current review of in vivo GBM rodent models: emphasis on 
the CNS-1 tumour model. ASN Neuro 2011;3(3):e00063. doi:10.1042/AN20110014. 
269.  Johansson M, Brännström T, Bergenheim  a T, Henriksson R. Spatial expression of VEGF-A in human 
glioma. J. Neurooncol. 2002;59(1):1-6. 
270.  Navis AC, Hamans BC, Claes A, et al. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic 
glioma models. J. Pathol. 2011;223(5):626-634. doi:10.1002/path.2836. 
271.  Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: A reassessment. Investig. 
Ophthalmol. Vis. Sci. 2008;49(2):522-527. doi:10.1167/iovs.07-1175. 
272.  Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas 
reveals key differences with the adult disease. J. Clin. Oncol. 2010;28(18):3061-8. 
doi:10.1200/JCO.2009.26.7252 
  
204 
. 
273. Zhao L, Yang Z, Liu Y, Ying H, Zhang H, Xue Y. Vascular endothelial growth factor increases permeability of 
the blood-tumor barrier via caveolae-mediated transcellular pathway. J. Mol. Neurosci. 2011;44(2):122-9. 
doi:10.1007/s12031-010-9487-x. 
274. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to 
increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31. 
doi:10.1016/j.ccr.2009.01.027. 
275. Gomez-Manzano C, Holash J, Fueyo J, et al. VEGF Trap induces antiglioma effect at different stages of
disease. Neuro. Oncol. 2008;10(6):940-945. doi:10.1215/15228517-2008-061. 
276. Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors; pathobiological and clinical aspects. J. 
Neurooncol. 1997;32(3):253-65. 
277. Gagner J-P, Law M, Fischer I, Newcomb EW, Zagzag D. Angiogenesis in gliomas: imaging and experimental 
therapeutics. Brain Pathol. 2005;15(4):342-363. doi:10.1111/j.1750-3639.2005.tb00119.x. 
278. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet. Oncol. 
2010;11(12):1172-83. doi:10.1016/S1470-2045(10)70232-1. 
279. Jubb AM. Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and 
Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer. J. Clin.
Oncol. 2005;24(2):217-227. doi:10.1200/JCO.2005.01.5388. 
280. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. 
Ther. 2006;28(11):1779-802. doi:10.1016/j.clinthera.2006.11.015. 
281. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous
system tumors diagnosed in the United States in 2006-2010. Neuro. Oncol. 2013;15 Suppl 2(suppl 2):ii1-
56. doi:10.1093/neuonc/not151. 
282. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins.
Nature 2010;468(7327):1095-9. doi:10.1038/nature09587. 
283. Grammel D, Warmuth-Metz M, von Bueren AO, et al. Sonic hedgehog-associated medulloblastoma arising 
from the cochlear nuclei of the brainstem. Acta Neuropathol. 2012;123(4):601-14. doi:10.1007/s00401-
012-0961-0. 
284. Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with
medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology
Group trial A9961. Neuro. Oncol. 2013;15(1):97-103. doi:10.1093/neuonc/nos267. 
285. Massimino M, Cefalo G, Riva D, et al. Long-term results of combined preradiation chemotherapy and age-
tailored radiotherapy doses for childhood medulloblastoma. J. Neurooncol. 2012;108(1):163-71. 
doi:10.1007/s11060-012-0822-7. 
286. Gajjar A, Packer RJ, Foreman NK, Cohen K, Haas-Kogan D, Merchant TE. Children’s Oncology Group’s 2013 
blueprint for research: central nervous system tumors. Pediatr. Blood Cancer 2013;60(6):1022-6. 
doi:10.1002/pbc.24427. 
287. Toogood AA. Endocrine consequences of brain irradiation. Growth Horm. IGF Res. 2004;14 Suppl A:S118-
24. doi:10.1016/j.ghir.2004.03.038. 
288. Armstrong GT, Whitton JA, Gajjar A, et al. Abnormal timing of menarche in survivors of central nervous
system tumors: A report from the Childhood Cancer Survivor Study. Cancer 2009;115(11):2562-70. 
doi:10.1002/cncr.24294. 
289. Kieffer-Renaux V, Viguier D, Raquin M-A, et al. Therapeutic schedules influence the pattern of intellectual 
decline after irradiation of posterior fossa tumors. Pediatr. Blood Cancer 2005;45(6):814-9. 
doi:10.1002/pbc.20329. 
290. Miralbell R, Lomax A, Russo M. Potential role of proton therapy in the treatment of pediatric
medulloblastoma/primitive neuro-ectodermal tumors: spinal theca irradiation. Int. J. Radiat. Oncol. Biol. 
Phys. 1997;38(4):805-11. 
291. Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma,
medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int. J. 
Radiat. Oncol. Biol. Phys. 2005;63(2):362-72. doi:10.1016/j.ijrobp.2005.01.060. 
292. Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: toxicity of current treatment and potential
role of protontherapy. Cancer Treat. Rev. 2009;35(1):79-96. doi:10.1016/j.ctrv.2008.09.002. 
293. Luttjeboer M, Kaspers GJL. Medulloblastoma: need for targeted treatment. Expert Rev. Anticancer Ther. 
2006;6(5):649-52. doi:10.1586/14737140.6.5.649. 
REFERENCES 
205 
 
294.  Vuurden DG Van, Hulleman E, Meijer OLM, et al. PARP inhibition sensitizes childhood high grade 
medulloblastoma and ependymoma to radiation. Oncotarget 2011;2(12):984-996. 
295.  Zhao X, Liu Z, Yu L, et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-
based orthotopic xenograft mouse models of medulloblastoma. Neuro. Oncol. 2012;14(5):574-83. 
doi:10.1093/neuonc/nos061. 
296.  Pollastri MP. Overview on the Rule of Five. Curr. Protoc. Pharmacol. 2010;Chapter 9:Unit 9.12. 
doi:10.1002/0471141755.ph0912s49. 
297.  Badr CE, Wurdinger T, Tannous BA. Functional drug screening assay reveals potential glioma therapeutics. 
Assay Drug Dev. Technol. 2011;9(3):281-9. doi:10.1089/adt.2010.0324. 
298.  Zhao X, Liu Z, Yu L, et al. Global gene expression profiling confirms. 2012. 
299.  Paxinos G, Franklin K. The Mouse Brain in Stereotaxic Coordinates: Second Edition (Deluxe). Academic 
Press, New York; 2001. 
300.  Zhang J, Chung T, Oldenburg K. A Simple Statistical Parameter for Use in Evaluation and Validation of High 
Throughput Screening Assays. J. Biomol. Screen. 1999;4(2):67-73. 
301.  van Rijn J, van den Berg J. Flavonoids as enhancers of x-ray-induced cell damage in hepatoma cells. Clin. 
Cancer Res. 1997;3(10):1775-9. 
302.  Luttjeboer M, Lafleur MVM, Kwidama ZJ, et al. Strategies for the analysis of in vitro radiation sensitivity 
and prediction of interaction with potential radiation modifying agents. Int. J. Radiat. Biol. 2010;86(6):458-
66. doi:10.3109/09553000903568019. 
303.  Ishisaka A, Ichikawa S, Sakakibara H, et al. Accumulation of orally administered quercetin in brain tissue 
and its antioxidative effects in rats. Free Radic. Biol. Med. 2011;51(7):1329-36. 
doi:10.1016/j.freeradbiomed.2011.06.017. 
304.  Ferrer P, Asensi M, Segarra R, et al. Association between pterostilbene and quercetin inhibits metastatic 
activity of B16 melanoma. Neoplasia 2005;7(1):37-47. 
305.  Aghdassi A, Phillips P, Dudeja V, et al. Heat shock protein 70 increases tumorigenicity and inhibits 
apoptosis in pancreatic adenocarcinoma. Cancer Res. 2007;67(2):616-25. doi:10.1158/0008-5472.CAN-
06-1567. 
306.  Aalinkeel R, Bindukumar B, Reynolds JL, et al. The dietary bioflavonoid, quercetin, selectively induces 
apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate 
2008;68(16):1773-89. doi:10.1002/pros.20845. 
307.  Lugli E, Ferraresi R, Roat E, et al. Quercetin inhibits lymphocyte activation and proliferation without 
inducing apoptosis in peripheral mononuclear cells. Leuk. Res. 2009;33(1):140-50. 
doi:10.1016/j.leukres.2008.07.025. 
308.  Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of 
the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of 
genotoxic/carcinogenic properties. Food Chem. Toxicol. 2007;45(11):2179-205. 
doi:10.1016/j.fct.2007.05.015. 
309.  Conquer JA, Maiani G, Azzini E, Raguzzini A, Holub BJ. Supplementation with quercetin markedly increases 
plasma quercetin concentration without effect on selected risk factors for heart disease in healthy 
subjects. J. Nutr. 1998;128(3):593-7. 
310.  Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols 
in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 2005;81(1 Suppl):230S-242S. 
311.  Faria A, Pestana D, Teixeira D, et al. Flavonoid transport across RBE4 cells: A blood-brain barrier model. 
Cell. Mol. Biol. Lett. 2010;15(2):234-41. doi:10.2478/s11658-010-0006-4. 
312.  Yang Z-H, Sun X, Mei C, Sun X-B, Liu X-D, Chang Q. An in vitro transport model for rapid screening and 
predicting the permeability of candidate compounds at blood-brain barrier. J. Asian Nat. Prod. Res. 
2011;13(12):1087-97. doi:10.1080/10286020.2011.599958. 
313.  Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. Delivery of molecularly targeted therapy to 
malignant glioma, a disease of the whole brain. Expert Rev. Mol. Med. 2011;13:e17. 
doi:10.1017/S1462399411001888. 
314.  Schültke E, Kamencic H, Zhao M, et al. Neuroprotection following fluid percussion brain trauma: a pilot 
study using quercetin. J. Neurotrauma 2005;22(12):1475-84. doi:10.1089/neu.2005.22.1475. 
315.  Pu F, Mishima K, Irie K, et al. Neuroprotective effects of quercetin and rutin on spatial memory impairment 
in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats. J. 
Pharmacol. Sci. 2007;104(4):329-34. 
  
206 
316. Lu J, Wu D-M, Zheng Y-L, et al. Quercetin activates AMP-activated protein kinase by reducing PP2C
expression protecting old mouse brain against high cholesterol-induced neurotoxicity. J. Pathol. 
2010;222(2):199-212. doi:10.1002/path.2754. 
317. Singh A, Naidu PS, Kulkarni SK. Reversal of aging and chronic ethanol-induced cognitive dysfunction by
quercetin a bioflavonoid. Free Radic. Res. 2003;37(11):1245-52. 
318. Tota S, Awasthi H, Kamat PK, Nath C, Hanif K. Protective effect of quercetin against intracerebral
streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav. Brain 
Res. 2010;209(1):73-9. doi:10.1016/j.bbr.2010.01.017. 
319. Tongjaroenbuangam W, Ruksee N, Chantiratikul P, Pakdeenarong N, Kongbuntad W, Govitrapong P.
Neuroprotective effects of quercetin, rutin and okra (Abelmoschus esculentus Linn.) in dexamethasone-
treated mice. Neurochem. Int. 2011;59(5):677-85. doi:10.1016/j.neuint.2011.06.014. 
320. Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and 
therapy: facts and fancies. Biochem. Pharmacol. 2012;83(1):6-15. doi:10.1016/j.bcp.2011.08.010. 
321. Perez-Vizcaino F, Duarte J. Flavonols and cardiovascular disease. Mol. Aspects Med. 2010;31(6):478-94. 
doi:10.1016/j.mam.2010.09.002. 
322. Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A. Chemoprotective mechanism of the 
natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and
cardiovascular diseases. Curr. Med. Chem. 2009;16(12):1451-62. 
323. Lamson DW, Brignall MS. Antioxidants and cancer, part 3: quercetin. Altern. Med. Rev. 2000;5(3):196-208. 
324. Zamin LL, Filippi-Chiela EC, Dillenburg-Pilla P, Horn F, Salbego C, Lenz G. Resveratrol and quercetin
cooperate to induce senescence-like growth arrest in C6 rat glioma cells. Cancer Sci. 2009;100(9):1655-
62. doi:10.1111/j.1349-7006.2009.01215.x. 
325. Wang K, Liu R, Li J, et al. Quercetin induces protective autophagy in gastric cancer cells: involvement of
Akt-mTOR- and hypoxia-induced factor 1α-mediated signaling. Autophagy 2011;7(9):966-78. 
326. Donnini S, Finetti F, Lusini L, et al. Divergent effects of quercetin conjugates on angiogenesis. Br. J. Nutr. 
2006;95(5):1016-23. 
327. Chirumbolo S. The role of quercetin, flavonols and flavones in modulating inflammatory cell function.
Inflamm. Allergy Drug Targets 2010;9(4):263-85. 
328. Labbé D, Provençal M, Lamy S, Boivin D, Gingras D, Béliveau R. The flavonols quercetin, kaempferol, and 
myricetin inhibit hepatocyte growth factor-induced medulloblastoma cell migration. J. Nutr. 
2009;139(4):646-52. doi:10.3945/jn.108.102616. 
329. Pambid MR, Berns R, Adomat HH, et al. Overcoming resistance to Sonic Hedgehog inhibition by targeting 
p90 ribosomal S6 kinase in pediatric medulloblastoma. Pediatr. Blood Cancer 2014;61(1):107-15. 
doi:10.1002/pbc.24675. 
330. Diaz R, Golbourn B, Faria C, et al. Mechanism of action and therapeutic application of aurora kinase B
inhibition in c-MYC overexpressing medulloblastoma. Oncotarget 2015;6(5):i1-i51. 
331. Wang Y, Yi J, Chen X, Zhang Y, Xu M, Yang Z. The regulation of cancer cell migration by lung cancer cell-
derived exosomes through TGF-β and IL-10. Oncol. Lett. 2016;11(2):1527-1530. 
doi:10.3892/ol.2015.4044. 
332. Liao J, Liu R, Shi YJ, Yin LH, Pu YP. Exosome-shuttling microRNA-21 promotes cell migration and invasion-
targeting PDCD4 in esophageal cancer. Int. J. Oncol. 2016;48(6):2567-2579. doi:10.3892/ijo.2016.3453. 
333. Hoshino A, Costa-Silva B, Shen T-L, et al. Tumour exosome integrins determine organotropic metastasis. 
Nature 2015;527(7578):329-35. doi:10.1038/nature15756. 
334. Peinado H, Alečković M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells 
toward a pro-metastatic phenotype through MET. Nat. Med. 2012;18(6):883-91. doi:10.1038/nm.2753. 
335. Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche
formation in the liver. Nat Cell Biol 2015;17(6):816-826. doi:10.1038/ncb3169. 
336. Hosseini-Beheshti E, Choi W, Weiswald LB, et al. Exosomes confer pro-survival signals to alter the
phenotype of prostate cells in their surrounding environment. Oncotarget 2016;7(12):14639-14658. 
doi:10.18632/oncotarget.7052. 
337. Rodríguez M, Silva J, Herrera A, et al. Exosomes enriched in stemness/metastatic-related mRNAS promote 
oncogenic potential in breast cancer. Oncotarget 2015;6(38):40575-87. doi:10.18632/oncotarget.5818. 
338. Setti M, Osti D, Richichi C, et al. Extracellular vesicle-mediated transfer of CLIC1 protein is a novel
mechanism for the regulation of glioblastoma growth. Oncotarget 2015;6(31):31413-27. 
doi:10.18632/oncotarget.5105. 
REFERENCES 
207 
 
339.  Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote 
tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008;10(12):1470-6. 
doi:10.1038/ncb1800. 
340.  Baglio SR, Lagerweij T, Pérez Lanzón M, et al. Blocking tumor-educated MSC paracrine activity halts 
osteosarcoma progression. Clin. Cancer Res. 2017. 
341.  Wendler F, Favicchio R, Simon T, Alifrangis C, Stebbing J, Giamas G. Extracellular vesicles swarm the cancer 
microenvironment: from tumor–stroma communication to drug intervention. Oncogene 2017;36(7):877-
884. doi:10.1038/onc.2016.253. 
342.  Godlewski J, Krichevsky AM, Johnson MD, Chiocca EA, Bronisz A. Belonging to a network--microRNAs, 
extracellular vesicles, and the glioblastoma microenvironment. Neuro. Oncol. 2015;17(5):652-62. 
doi:10.1093/neuonc/nou292. 
343.  Godlewski J, Ferrer-Luna R, Rooj AK, et al. MicroRNA Signatures and Molecular Subtypes of Glioblastoma: 
The Role of Extracellular Transfer. Stem cell reports 2017;8(6):1497-1505. 
doi:10.1016/j.stemcr.2017.04.024. 
344.  Bebawy M, Combes V, Lee E, et al. Membrane microparticles mediate transfer of P-glycoprotein to drug 
sensitive cancer cells. Leuk.  Off. J. Leuk. Soc. Am. Leuk. Res. Fund, U.K 2009;23(9):1643-1649. 
doi:10.1038/leu.2009.76. 
345.  Corcoran C, Rani S, O’Brien K, et al. Docetaxel-Resistance in Prostate Cancer: Evaluating Associated 
Phenotypic Changes and Potential for Resistance Transfer via Exosomes. PLoS One 2012;7(12). 
doi:10.1371/journal.pone.0050999. 
346.  Ma X, Chen Z, Hua D, et al. Essential role for TrpC5-containing extracellular vesicles in breast cancer with 
chemotherapeutic resistance. Proc. Natl. Acad. Sci. U. S. A. 2014;111(17):6389-94. 
doi:10.1073/pnas.1400272111. 
347.  Takahashi K, Yan IK, Kogure T, Haga H, Patel T. Extracellular vesicle-mediated transfer of long non-coding 
RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio 2014;4:458-467. 
doi:10.1016/j.fob.2014.04.007. 
348.  Sousa D, Lima RT, Vasconcelos MH. Intercellular Transfer of Cancer Drug Resistance Traits by Extracellular 
Vesicles. Trends Mol. Med. 2015;21(10):595-608. doi:10.1016/j.molmed.2015.08.002. 
349.  Wiklander OPB, Nordin JZ, O’Loughlin A, et al. Extracellular vesicle in vivo biodistribution is determined by 
cell source, route of administration and targeting. J. Extracell. vesicles 2015;4(2015 SRC-GoogleScholar 
FG-0):26316. doi:10.3402/jev.v4.26316. 
350.  Prada I, Meldolesi J. Binding and fusion of extracellular vesicles to the plasma membrane of their cell 
targets. Int. J. Mol. Sci. 2016;17(8). doi:10.3390/ijms17081296. 
351.  Mulcahy LA, Pink RC, Carter DRF. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. 
vesicles 2014;3(2014 SRC-GoogleScholar FG-0):1-14. doi:10.3402/jev.v3.24641. 
352.  Parolini I, Federici C, Raggi C, et al. Microenvironmental pH is a key factor for exosome traffic in tumor 
cells. J. Biol. Chem. 2009;284(49):34211-34222. doi:10.1074/jbc.M109.041152. 
353.  Escrevente C, Keller S, Altevogt P, Costa J. Interaction and uptake of exosomes by ovarian cancer cells. 
BMC Cancer 2011;11(2011 SRC-GoogleScholar FG-0):108. doi:10.1186/1471-2407-11-108. 
354.  Smyth TJ, Redzic JS, Graner MW, Anchordoquy TJ. Examination of the specificity of tumor cell derived 
exosomes with tumor cells in vitro. Biochim. Biophys. Acta 2014;1838(11):2954-2965. 
doi:10.1016/j.bbamem.2014.07.026. 
355.  Paggetti J, Haderk F, Seiffert M, et al. Exosomes released by chronic lymphocytic leukemia cells induce the 
transition of stromal cells into cancer-associated fi broblasts. Blood 2015;126(9):1106-1118. 
doi:10.1182/blood-2014-12-618025.The. 
356.  Lässer C, Alikhani VS, Ekström K, et al. Human saliva, plasma and breast milk exosomes contain RNA: 
uptake by macrophages. J. Transl. Med. 2011;9(1):9. doi:10.1186/1479-5876-9-9. 
357.  Svensson KJ, Christianson HC, Wittrup A, et al. Exosome uptake depends on ERK1/2-heat shock protein 27 
signaling and lipid raft-mediated endocytosis negatively regulated by caveolin-1. J. Biol. Chem. 
2013;288(24):17713-17724. doi:10.1074/jbc.M112.445403. 
358.  van Dongen HM, Masoumi N, Witwer KW, Pegtel DM. Extracellular Vesicles Exploit Viral Entry Routes for 
Cargo Delivery. Microbiol. Mol. Biol. Rev. 2016;80(2):369-86. doi:10.1128/MMBR.00063-15. 
359.  Wurdinger T, Gatson NN, Balaj L, Kaur B, Breakefield XO, Pegtel DM. Extracellular Vesicles and Their 
Convergence with Viral Pathways. Adv. Virol. 2012;2012(2012 SRC-GoogleScholar FG-0). 
doi:10.1155/2012/767694. 
  
208 
360. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4 as a
phosphatidylserine receptor. Nature 2007;450(7168):435-439. doi:10.1038/nature06307. 
361. Jethwa SA, Leah EJ, Zhang Q, et al. Exosomes bind autotaxin and act as a physiological delivery mechanism 
to stimulate LPA receptor signalling in cells. J. Cell Sci. 2016;129(August):3948-3957. 
doi:10.1242/jcs.184424. 
362. Christianson HC, Svensson KJ, van Kuppevelt TH, Li J-P, Belting M. Cancer cell exosomes depend on cell-
surface heparan sulfate proteoglycans for their internalization and functional activity. Proc. Natl. Acad.
Sci. U. S. A. 2013;110(43):17380-5. doi:10.1073/pnas.1304266110. 
363. Purushothaman A, Bandari SK, Liu J, Mobley JA, Brown EA, Sanderson RD. Fibronectin on the surface of
myeloma cell-derived exosomes mediates exosome-cell interactions. J. Biol. Chem. 2016;291(4):1652-
1663. doi:10.1074/jbc.M115.686295. 
364. Al-Nedawi K. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from
tumour cells. Nat. Cell Biol. 2008;10:619-624. 
365. Antonyak MA, Li B, Boroughs LK, et al. Cancer cell-derived microvesicles induce transformation by
transferring tissue transglutaminase and fibronectin to recipient cells. Proc. Natl. Acad. Sci. 
2011;108(12):4852-4857. doi:10.1073/pnas.1017667108. 
366. Johnson DR, O’Neill BP. Glioblastoma survival in the United States before and during the temozolomide
era. J. Neurooncol. 2012;107(2):359-364. doi:10.1007/s11060-011-0749-4. 
367. Théry C, Amigorena S. Isolation and characterization of exosomes from cell culture supernatants and
biological fluids. In: Current Protocols in Cell Biology.Vol supplement.; 2006:1-29. 
368. Livshts MA, Khomyakova E, Evtushenko EG, et al. Isolation of exosomes by differential centrifugation:
Theoretical analysis of a commonly used protocol. Sci. Rep. 2015;5(2015 SRC-GoogleScholar FG-0). 
doi:10.1038/srep17319. 
369. Sato A, Sunayama J, Matsuda K, et al. MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and 
Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis. Stem Cells 
2011;29(12):1942-1951. doi:10.1002/stem.753. 
370. Islam SA, Ling MF, Leung J, Shreffler WG, Luster AD. Identification of human CCR8 as a CCL18 receptor. J. 
Exp. Med. 2013;210 SRC-:1889-1898. 
371. Lee S, Tiffany HL, King L, et al. CCR8 on Human Thymocytes Functions as a Human Immunodeficiency Virus 
Type 1 Coreceptor CCR8 on Human Thymocytes Functions as a Human Immunodeficiency Virus Type 1
Coreceptor. J. Virol. 2000;74 SRC-:6946-6952. doi:10.1128/JVI.74.15.6946-6952.2000.Updated. 
372. Calado M. Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine
receptor as an alternative coreceptor. Virology 2010;408:174-182. 
373. Eruslanov E. Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal 
carcinomas. Clin. cancer Res.  an Off. J. Am. Assoc. Cancer Res. 2013;19 SRC-:1670-1680. 
374. Louahed J. CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-
309/CCL1 and vMIP-I. Eur. J. Immunol. 2003;33:494-501. 
375. Das S. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node 
lymphatic sinuses. J. Exp. Med. 2013;210 SRC-:1509-1528. 
376. Lüttichau HR, Stine J, Boesen TP, et al. A highly selective CC chemokine receptor (CCR)8 antagonist
encoded by the poxvirus molluscum contagiosum. J. Exp. Med. 2000;191(1):171-80. 
377. Oshio T, Kawashima R, Kawamura YI, Hagiwara T, Mizutani N. Chemokine Receptor CCR8 Is Required for 
Lipopolysaccharide-Triggered Cytokine Production in Mouse Peritoneal Macrophages. 2014;9(4).
doi:10.1371/journal.pone.0094445. 
378. Chou T, Talalay P. C. & Quantitative analysis of dose-effect relationships: the combined effects of multiple 
drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984;22:27-55. 
379. Escrevente C, Grammel N, Kandzia S, et al. Sialoglycoproteins and N-Glycans from Secreted Exosomes of 
Ovarian Carcinoma Cells. PLoS One 2013;8(10). doi:10.1371/journal.pone.0078631. 
380. Batista BS, Eng WS, Pilobello KT, Mahal LK. Hendricks-Muñoz, K.D. & Identification of a Conserved Glycan 
Signature for Microvesicles. J. Proteome Res. 2011;10:4624-4633. 
381. Fukui S, Feizi T, Galustian C, Lawson AM, Chai W. Oligosaccharide microarrays for high-throughput 
detection and specificity assignments of carbohydrate-protein interactions. Nat. Biotechnol. 
2002;20:1011-1017. 
382. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE. Regulation of protein function by
glycosaminoglycans-as exemplified by chemokines. Annu. Rev. Biochem. 2005;74 SRC-:385-410. 
REFERENCES 
209 
 
383.  Raedts J, Kengen SW, der Oost J. van Occurrence of L-iduronic acid and putative D-glucuronyl C5-
epimerases in prokaryotes. Glycoconj. J. 2011;28:57-66. 
384.  Bülow HE, Hobert O. The Molecular Diversity of Glycosaminoglycans Shapes Animal Development. Annu. 
Rev. Cell Dev. Biol. 2006;22(1):375-407. doi:10.1146/annurev.cellbio.22.010605.093433. 
385.  Hook M, Kjellen L, Johansson S. Cell-surface glycosaminoglycans. Annu. Rev. Biochem. 1984;53:847-869. 
386.  Kuschen GS V, Coulin F, Power CA, et al. Glycosaminoglycans interact selectively with chemokines and 
modulate receptor binding and cellular responses. Biochemistry 1999;38(39):12959-12968. 
doi:10.1021/bi990711d. 
387.  Balaj L. Heparin affinity purification of extracellular vesicles. Sci Rep 5 10266(2015 SRC-GoogleScholar FG-
0). 
388.  Gabriely G, Yi M, Narayan RS, et al. Human glioma growth is controlled by microRNA-10b. Cancer Res. 
2011;71(10):3563-72. doi:10.1158/0008-5472.CAN-10-3568. 
389.  Chan JA, Krichevsky AM, Kosik KS, Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 Is an Antiapoptotic 
Factor in Human Glioblastoma Cells MicroRNA-21 Is an Antiapoptotic Factor in Human. Cancer Res. 
2005;65(14):6029-6033. doi:10.1158/0008-5472.CAN-05-0137. 
390.  Wang K, Wang X, Zou J, et al. MiR-92b controls glioma proliferation and invasion through regulating 
Wnt/beta-catenin signaling via Nemo-like kinase. Neuro. Oncol. 2013;15(5):578-588. 
doi:10.1093/neuonc/not004. 
391.  Niu H, Wang K, Zhang A, et al. miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with 
inverse expression of BCL2L11. Oncol. Rep. 2012;28(5):1771-1777. doi:10.3892/or.2012.1970. 
392.  Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack J a. NMR and molecular modeling investigation of 
the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. 
Biochemistry 1994;33:9045-9051. doi:10.1021/bi00197a003. 
393.  Drabløs, F. Alkylation damage in DNA and RNA—repair mechanisms and medical significance. 2004;3 SRC-
G:1389-1407. 
394.  Friedman HS, Kerby T, Calvert H. Temozolomide and Treatment of Malignant Glioma. Clin. Cancer Res. 
2000;6 SRC-G:2585-2597. 
395.  Messaoudi K, Clavreul A, Lagarce F. Toward an effective strategy in glioblastoma treatment. Part I: 
resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug 
Discov. Today 2015;20(7):899-905. doi:10.1016/j.drudis.2015.02.011. 
396.  Hiddingh L. EFEMP1 induces gamma-secretase/Notch-mediated temozolomide resistance in 
glioblastoma. Oncotarget 2014;5 SRC-G:363-374. 
397.  Hiddingh L, Raktoe RS, Jeuken J, et al. Identification of temozolomide resistance factors in glioblastoma 
via integrative miRNA/mRNA regulatory network analysis. Sci. Rep. 2014;4(2014 SRC-GoogleScholar FG-
0):5260. doi:10.1038/srep05260. 
398.  Kaina B, Christmann M, Naumann S, Roos WP. MGMT: Key node in the battle against genotoxicity, 
carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst). 2007;6(8):1079-1099. 
doi:10.1016/j.dnarep.2007.03.008. 
399.  Shao H, Chung J, Lee K, et al. Chip-based analysis of exosomal mRNA mediating drug resistance in 
glioblastoma. Nat. Commun. 2015;6(May):6999. doi:10.1038/ncomms7999. 
400.  Meckes DG, Raab-Traub N. Microvesicles and viral infection. J. Virol. 2011;85(24):12844-54. 
doi:10.1128/JVI.05853-11. 
401.  Trkola A, Gordon C, Matthews J, et al. The CC-chemokine RANTES increases the attachment of human 
immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal 
transduction pathway that enhances viral infectivity. J Virol 1999;73(8):6370-6379. 
402.  Dragic T. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381 
SRC-:667-673. 
403.  Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 Entry Cofactor: Functional cof a Seven-Transmembrane, 
Receptor. Science   . 1996;272 SRC-:872-877. 
404.  Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 
1996;381(6584):661-666. doi:10.1038/381661a0. 
405.  Cocchi F, Devico AL, Garzinodemo A, Arya SK, Gallo RC, Lusso P. Identification of Rantes, Mip-1-Alpha, and 
Mip-1-Beta As the Major Hiv-Suppressive Factors Produced By Cd8(+) T-Cells. Science (80-. ). 
1995;270(5243):1811-1815. 
406.  Trkola A, Paxton WA, Monard SP, et al. Genetic subtype-independent inhibition of human 
immunodeficiency virus type 1 replication by CC and CXC chemokines. J Virol 1998;72(1):396-404. 
210 
407. Cheng W. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology 
2016;86:2226-2234. 
408. Atai NA, Balaj L, Van Veen H, et al. Heparin blocks transfer of extracellular vesicles between donor and
recipient cells. J. Neurooncol. 2013;115(3):343-351. doi:10.1007/s11060-013-1235-y. 
409. Franzen CA, Simms PE, Van Huis AF, Foreman KE, Kuo PC, Gupta GN. Characterization of uptake and
internalization of exosomes by bladder cancer cells. Biomed Res. Int. 2014;2014(2014 SRC-GoogleScholar 
FG-0). doi:10.1155/2014/619829. 
410. Sento S, Sasabe E, Yamamoto T, LoS ONE. Application of a Persistent Heparin Treatment Inhibits the
Malignant Potential of Oral Squamous Carcinoma Cells Induced by Tumor Cell-Derived Exosomes. P11 e 
148454(2016 SRC-GoogleScholar FG-0). 
411. Sukreet S, Zhang H, Adamec J, Cui J, Zempleni J. Identification of Glycoproteins on the Surface of Cow’s
Milk Exosomes that Mediate the Uptake of Exosomes into Human Colon Carcinoma Caco-2 Cells. 30 125 
1(2016 SRC-GoogleScholar FG-0). 
412. Soler D, Chapman TR, Poisson LR, et al. CCR8 Expression Identifies CD4 Memory T Cells Enriched for
FOXP3+ Regulatory and Th2 Effector Lymphocytes. J. Immunol. 2006;177(10):6940-6951. 
doi:10.4049/jimmunol.177.10.6940. 
413. Connolly S, Skrinjar M, Rosendahl A. Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T 
cell and eosinophil migration. Biochem. Pharmacol. 2012;83(6):778-787. doi:10.1016/j.bcp.2011.12.021. 
414. De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-
associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. 
J. Exp. Med. 2011;208(3):469-78. doi:10.1084/jem.20101876. 
415. Hoelzinger DB, Smith SE, Mirza N, Dominguez AL, Manrique SZ, Lustgarten J. Blockade of CCL1 Inhibits T 
Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses. 
J. Immunol. 2010;184(12). 
416. Chen J, Yao Y, Gong C, et al. CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer 
Metastasis via PITPNM3. Cancer Cell 2011;19(4):541-555. doi:10.1016/j.ccr.2011.02.006. 
417. Li D, Duell EJ, Yu K, et al. Pathway analysis of genome-wide association study data highlights pancreatic
development genes as susceptibility factors for pancreatic cancer. Carcinogenesis 2012;33(7):1384-1390. 
doi:10.1093/carcin/bgs151. 
418. Burkholder B, Huang R-Y, Burgess R, et al. Tumor-induced perturbations of cytokines and immune cell
networks. Biochim. Biophys. Acta - Rev. Cancer 2014;1845(2):182-201. doi:10.1016/j.bbcan.2014.01.004. 
419. Hood JL, San Roman S, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes 
for tumor metastasis. Cancer Res. 2011;71(11):3792-3801. doi:10.1158/0008-5472.CAN-10-4455. 
420. Achyut BR, Shankar A, Iskander ASM, et al. Chimeric Mouse model to track the migration of bone marrow 
derived cells in glioblastoma following anti-angiogenic treatments. Cancer Biol. Ther. 2016;17(3):280-90. 
doi:10.1080/15384047.2016.1139243. 
421. Wu J, He Y, Yang Z, et al. 3D BrainCV: simultaneous visualization and analysis of cells and capillaries in a
whole mouse brain with one-micron voxel resolution. Neuroimage 2014;87:199-208. 
doi:10.1016/j.neuroimage.2013.10.036. 
422. Wälchli T, Mateos JM, Weinman O, et al. Quantitative assessment of angiogenesis, perfused blood vessels 
and endothelial tip cells in the postnatal mouse brain. Nat. Protoc. 2015;10(1):53-74. 
doi:10.1038/nprot.2015.002. 
423. Helmchen F, Denk W. Deep tissue two-photon microscopy. Nat. Methods 2005;2(12):932-940. 
doi:10.1038/nmeth818. 
424. Kobat D, Durst ME, Nishimura N, Wong AW, Schaffer CB, Xu C. Deep tissue multiphoton microscopy using 
longer wavelength excitation. Opt. Express 2009;17(16):13354. doi:10.1364/OE.17.013354. 
425. Spalteholz W. Über Das Durchsichtigmachen von Menschlichen Und Tierischen Präparaten Und Seine
Theoretischen Bedingungen. Leipzig: Hierzel S, Leipzig; 1914. 
426. Hama H, Hioki H, Namiki K, et al. ScaleS: an optical clearing palette for biological imaging. Nat. Neurosci. 
2015;18(10):1518-1529. doi:10.1038/nn.4107. 
427. Ertürk A, Becker K, Jährling N, et al. Three-dimensional imaging of solvent-cleared organs using 3DISCO. 
Nat. Protoc. 2012;7(11):1983-95. doi:10.1038/nprot.2012.119. 
428. Ke M-T, Fujimoto S, Imai T. SeeDB: a simple and morphology-preserving optical clearing agent for neuronal 
circuit reconstruction. Nat. Neurosci. 2013;16(8):1154-61. doi:10.1038/nn.3447. 
429. Chung K, Deisseroth K. CLARITY for mapping the nervous system. Nat. Methods 2013;10(6):508-13. 
doi:10.1038/nmeth.2481. 
REFERENCES 
211 
 
430.  Tang JCY, Szikra T, Kozorovitskiy Y, et al. A Nanobody-Based System Using Fluorescent Proteins as Scaffolds 
for Cell-Specific Gene Manipulation. Cell 2013;154(4):928-939. 
431.  Costantini I, Ghobril J-P, Di Giovanna AP, et al. A versatile clearing agent for multi-modal brain imaging. 
Sci. Rep. 2015;5:9808. doi:10.1038/srep09808. 
432.  Pan C, Cai R, Quacquarelli FP, et al. Shrinkage-mediated imaging of entire organs and organisms using 
uDISCO. Nat. Methods 2016. doi:10.1038/nmeth.3964. 
433.  Peng H, Bria A, Zhou Z, Iannello G, Long F. Extensible visualization and analysis for multidimensional images 
using Vaa3D. Nat. Protoc. 2014;9(1):193-208. doi:10.1038/nprot.2014.011. 
434.  Bjornsson CS, Lin G, Al-Kofahi Y, et al. Associative image analysis: a method for automated quantification 
of 3D multi-parameter images of brain tissue. J. Neurosci. Methods 2008;170(1):165-78. 
doi:10.1016/j.jneumeth.2007.12.024. 
435.  de Chaumont F, Dallongeville S, Chenouard N, et al. Icy: an open bioimage informatics platform for 
extended reproducible research. Nat. Methods 2012;9(7):690-6. doi:10.1038/nmeth.2075. 
436.  Kutzing MK, Langhammer CG, Luo V, Lakdawala H, Firestein BL. Automated Sholl analysis of digitized 
neuronal morphology at multiple scales. J. Vis. Exp. 2010;(45). doi:10.3791/2354. 
437.  Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of 
invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 
2009;69(8):3472-81. doi:10.1158/0008-5472.CAN-08-3886. 
438.  Scheepbouwer C, Meyer S, Burggraaf MJ, Jose J, Molthoff CFM. A Multimodal Imaging Approach for 
Longitudinal Evaluation of Bladder Tumor Development in an Orthotopic Murine Model. PLoS One 
2016;11(8). doi:10.1371/journal.pone.0161284. 
439.  Renier N, Adams EL, Kirst C, et al. Mapping of Brain Activity by Automated Volume Analysis of Immediate 
Early Genes. Cell 2016;165(7):1789-1802. doi:10.1016/j.cell.2016.05.007. 
440.  Preibisch S, Saalfeld S, Tomancak P. Globally optimal stitching of tiled 3D microscopic image acquisitions. 
Bioinformatics 2009;25(11):1463-5. doi:10.1093/bioinformatics/btp184. 
441.  Wesseling P, van der Laak JA, de Leeuw H, Ruiter DJ, Burger PC. Quantitative immunohistological analysis 
of the microvasculature in untreated human glioblastoma multiforme. Computer-assisted image analysis 
of whole-tumor sections. J. Neurosurg. 1994;81(6):902-9. doi:10.3171/jns.1994.81.6.0902. 
442.  Rai S, Nejadhamzeeigilani Z, Gutowski NJ, Whatmore JL. Loss of the endothelial glycocalyx is associated 
with increased E-selectin mediated adhesion of lung tumour cells to the brain microvascular endothelium. 
J. Exp. Clin. Cancer Res. 2015;34. doi:10.1186/s13046-015-0223-9. 
443.  Osswald M, Jung E, Sahm F, et al. Brain tumour cells interconnect to a functional and resistant network. 
Nature 2015;528(7580):93-98. doi:10.1038/nature16071. 
444.  Vogt N. Transparency in large tissue samples. Nat. Methods 2015;12(1):2015. 
445.  Hiromitsu S, Jin K, Emiko S, et al. Novel method for immunofluorescence staining of mammalian eggs using 
non-contact alternating-current electric-field mixing of microdroplets. Sci. Rep. 2015;5:15371. 
doi:10.1038/srep15371. 
446.  Caretti V, Sewing ACP, Lagerweij T, et al. Human pontine glioma cells can induce murine tumors. Acta 
Neuropathol. 2014;127(6):897-909. doi:10.1007/s00401-014-1272-4. 
447.  Michalak Z, Lebrun A, Miceli M Di, et al. IgG Leakage May Contribute to Neuronal Dysfunction in Drug-
Refractory Epilepsies With Blood-Brain Barrier Disruption. J. Neuropathol. Exp. Neurol. 2012;71(9):826-
838. doi:10.1097/NEN.0b013e31826809a6. 
448.  Jährling N, Becker K, Dodt H. 3D-reconstruction of blood vessels by ultramicroscopy. Organogenesis 
2009;5(4):227-230. doi:10.4161/org.5.4.10403. 
449.  Minamikawa T, Miyake T, Takamatsu T, Fujita S. A new method of lectin histochemistry for the study of 
brain angiogenesis - Lectin angiography. Histochemistry 1987;87(4):317-320. doi:10.1007/BF00492584. 
450.  Robertson RT, Levine ST, Haynes SM, et al. Use of labeled tomato lectin for imaging vasculature structures. 
Histochem. Cell Biol. 2014;143(2):225-234. doi:10.1007/s00418-014-1301-3. 
451.  Villacampa N, Almolda B, González B, Castellano B. Tomato lectin histochemistry for microglial 
visualization. Methods Mol. Biol. 2013;1041:261-79. doi:10.1007/978-1-62703-520-0_23. 
452.  Marx V. Microscopy: seeing through tissue. Nat. Methods 2014;11(12):1209-1214. 
doi:10.1038/nmeth.3181. 
453.  Scherer HJ. Structural Development in Gliomas. Am. J. Cancer 1938;34(3). 
454.  Cuddapah VA, Robel S, Watkins S, Sontheimer H. A neurocentric perspective on glioma invasion. Nat. Rev. 
Neurosci. 2014;15(7):455-465. doi:10.1038/nrn3765. 
  
212 
455. Osswald M, Solecki G, Wick W, Winkler F. A malignant cellular network in gliomas: potential clinical 
implications. Neuro. Oncol. 2016;18(4):479-85. doi:10.1093/neuonc/now014. 
456. Landelijke-Werkgroep-Neuro-Oncologie. Oncoline - richtlijnen oncologische zorg. 2017. Available at:
www.oncoline.nl/gliomen. 
457. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2(1):3-14. 
doi:10.1602/neurorx.2.1.3. 
458. Hoosain FG, Choonara YE, Tomar LK, et al. Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible
Applications in Pharmacoresistant Schizophrenia Therapy. Biomed Res. Int. 2015;2015. 
doi:10.1155/2015/484963. 
459. Martins IF, Teixeira AL, Pinheiro L, Falcao AO. A Bayesian approach to in Silico blood-brain barrier
penetration modeling. J. Chem. Inf. Model. 2012;52:1686-1697. doi:10.1021/ci300124c. 
460. de Gooijer MC, Zhang P, Thota N, et al. P-glycoprotein and breast cancer resistance protein restrict the
brain penetration of the CDK4/6 inhibitor palbociclib. Invest. New Drugs 2015;33(5):1012-9. 
doi:10.1007/s10637-015-0266-y. 
461. Callaghan R, Luk F, Bebawy M. Special Section on Transporters in Toxicity and Disease—Minireview 
Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy? DRUG Metab.
Dispos. Drug Metab Dispos 2014;42:623-631. doi:10.1124/dmd.113.056176. 
462. Chae GS, Lee JS, Kim SH, et al. Enhancement of the stability of BCNU using self-emulsifying drug delivery 
systems (SEDDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer. Int. J. Pharm. 
2005;301(1-2):6-14. doi:10.1016/j.ijpharm.2005.03.034. 
463. Ridler C. Neuro-oncology: New therapeutic targets for diffuse intrinsic pontine glioma. Nat. Rev. Neurol. 
2017. doi:10.1038/nrneurol.2017.39. 
464. Mohammad F, Weissmann S, Leblanc B, et al. EZH2 is a potential therapeutic target for H3K27M-mutant 
pediatric gliomas. Nat. Med. 2017;23(4):483-492. doi:10.1038/nm.4293. 
465. Piunti A, Hashizume R, Morgan MA, et al. Therapeutic targeting of polycomb and BET bromodomain
proteins in diffuse intrinsic pontine gliomas. Nat. Med. 2017;23(4):493-500. doi:10.1038/nm.4296. 
466. deVries NA, Hulsman D, Akhtar W, et al. Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch 
in Cell Fate Resulting in Tumor Progression. Cell Rep. 2015;10(3):383-397. 
doi:10.1016/j.celrep.2014.12.028. 
467. Bijnsdorp I V, Hodzic J, Lagerweij T, et al. miR-129-3p controls centrosome number in metastatic prostate 
cancer cells by repressing CP110. Oncotarget 2016. doi:10.18632/oncotarget.7572. 
468. Tannous BABA, Kerami M, Van Der Stoop PMPM, et al. Effects of the selective MPS1 inhibitor MPS1-IN-3 
on glioblastoma sensitivity to antimitotic drugs. J. Natl. Cancer Inst. 2013;105(17):1322-1331. 
doi:10.1093/jnci/djt168. 
469. Montaldi AP, Godoy PRD V, Sakamoto-Hojo ET. APE1/REF-1 down-regulation enhances the cytotoxic
effects of temozolomide in a resistant glioblastoma cell line. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 
2015;793:19-29. doi:10.1016/j.mrgentox.2015.06.001. 
470. De Felice F, Musio D, Cassese R, Gravina GL, Tombolini V. New approaches in glioblastoma multiforme:
the potential role of immune-check point inhibitors. Curr. Cancer Drug Targets 2016. 
471. Mukherjee S. The Emperor of All Maladies. First edit. London: Fourth Estate, HarperCollins publishers;
2011. 
472. Vogelstein B, Kinzler KW. The Path to Cancer --Three Strikes and You’re Out. N. Engl. J. Med. 
2015;373(20):1895-8. doi:10.1056/NEJMp1508811. 
473. Soeda A, Hara A, Kunisada T, Yoshimura S, Iwama T, Park DM. The Evidence of Glioblastoma
Heterogeneity. Sci. Rep. 2015;5:7979. doi:10.1038/srep07979. 
474. Jakubowicz-Gil J, Langner E, Rzeski W. Kinetic studies of the effects of Temodal and quercetin on
astrocytoma cells. Pharmacol. Rep. 2011;63(2):403-16. 
475. Hu J, Wang J, Wang G, Yao Z, Dang X. Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric 
liposomes loaded with quercetin and temozolomide: Analysis of their effectiveness in enhancing the
chemosensitization of drug-resistant glioma cells. Int. J. Mol. Med. 2016;37(3):690-702. 
doi:10.3892/ijmm.2016.2458. 
476. Matias D, Balça-Silva J, Dubois LG, et al. Dual treatment with shikonin and temozolomide reduces
glioblastoma tumor growth, migration and glial-to-mesenchymal transition. Cell. Oncol. 2017:1-15. 
doi:10.1007/s13402-017-0320-1. 
REFERENCES 
213 
 
477.  Xavier CPR, Lima CF, Rohde M, Pereira-Wilson C. Quercetin enhances 5-fluorouracil-induced apoptosis in 
MSI colorectal cancer cells through p53 modulation. Cancer Chemother. Pharmacol. 2011;68(6):1449-
1457. doi:10.1007/s00280-011-1641-9. 
478.  Siegelin MD, Reuss DE, Habel A, Rami A, von Deimling A. Quercetin promotes degradation of survivin and 
thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro. Oncol. 2009;11(2):122-31. 
doi:10.1215/15228517-2008-085. 
479.  Kim EJ, Choi CH, Park JY, Kang SK, Kim YK. Underlying mechanism of quercetin-induced cell death in human 
glioma cells. Neurochem. Res. 2008;33(6):971-979. doi:10.1007/s11064-007-9416-8. 
480.  Sherwood LM, Parris EE, Folkman J. Tumor Angiogenesis: Therapeutic Implications. N. Engl. J. Med. 
1971;285(21):1182-1186. doi:10.1056/NEJM197111182852108. 
481.  Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular 
mechanisms and markers. Acta Neuropathol. 2015;129(6):829-48. doi:10.1007/s00401-015-1432-1. 
482.  Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS. Bevacizumab in high-grade gliomas: a review 
of its uses, toxicity assessment, and future treatment challenges. Onco. Targets. Ther. 2013;6:371-89. 
doi:10.2147/OTT.S38628. 
483.  Wilson TA, Karajannis MA, Harter DH. Glioblastoma multiforme: State of the art and future therapeutics. 
Surg. Neurol. Int. 2014;5:64. doi:10.4103/2152-7806.132138. 
484.  Jain RK. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science 
(80-. ). 2005;307(5706):58-62. doi:10.1126/science.1104819. 
485.  Veldhuijzen van Zanten SEM, Jansen M, van Vuurden DG, et al. HG-009. MOLECULAR DRUG IMAGING: 
PIONEERING WORK IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro. Oncol. 2014;16 
(Suppl:i40-59. 
486.  Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat. Rev. Mol. 
Cell Biol. 2009;10(7):445-457. doi:10.1038/nrm2720. 
487.  Aceto N, Bardia A, Miyamoto DT, et al. Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast 
Cancer Metastasis. Cell 2014;158(5):1110-1122. doi:10.1016/j.cell.2014.07.013. 
488.  Extracellular Vesicles. Available at: www.extracellularvesicles.org. Accessed June 20, 2012. 
489.  Nilsson RJA, Balaj L, Hulleman E, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 
2011;118(13):3680-3. doi:10.1182/blood-2011-03-344408. 
490.  Bagley JA, Reumann D, Bian S, L?vi-Strauss J, Knoblich JA. Fused cerebral organoids model interactions 
between brain regions. Nat. Methods 2017. doi:10.1038/nmeth.4304. 
491.  Lancaster MA, Corsini NS, Wolfinger S, et al. Guided self-organization and cortical plate formation in 
human brain organoids. Nat. Biotechnol. 2017. doi:10.1038/nbt.3906. 
492.  Gruionu G, Bazou D, Maimon N, et al. Implantable tissue isolation chambers for analyzing tumor dynamics 
in vivo. Lab Chip 2016;16(10):1840-51. doi:10.1039/c6lc00237d. 
493.  Griep LM, Wolbers F, de Wagenaar B, et al. BBB ON CHIP: microfluidic platform to mechanically and 
biochemically modulate blood-brain barrier function. Biomed. Microdevices 2013;15(1):145-150. 
doi:10.1007/s10544-012-9699-7. 
494.  Xie Y, Bergström T, Jiang Y, et al. The Human Glioblastoma Cell Culture Resource: Validated Cell Models 
Representing All Molecular Subtypes. EBioMedicine 2015;2(10):1351-63. 
doi:10.1016/j.ebiom.2015.08.026. 
495.  Jacobsen PF, Jenkyn DJ, Papadimitriou JM. Establishment of a human medulloblastoma cell line and its 
heterotransplantation into nude mice. J. Neuropathol. Exp. Neurol. 1985;44(5):472-85. 
496.  Friedman HS, Burger PC, Bigner SH, et al. Establishment and characterization of the human 
medulloblastoma cell line and transplantable xenograft D283 Med. J. Neuropathol. Exp. Neurol. 
1985;44(6):592-605. 
497.  Pontén J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol. Microbiol. 
Scand. 1968;74(4):465-86. 
498.  Allen M, Bjerke M, Edlund H, Nelander S, Westermark B. Origin of the U87MG glioma cell line: Good news 
and bad news. Sci. Transl. Med. 2016;8(354):354re3-354re3. doi:10.1126/scitranslmed.aaf6853. 
499.  Torsvik A, Stieber D, Enger PØ, et al. U-251 revisited: genetic drift and phenotypic consequences of long-
term cultures of glioblastoma cells. Cancer Med. 2014;3(4):812-24. doi:10.1002/cam4.219. 
500.  Hingtgen S, Figueiredo J-L, Farrar C, et al. Real-time multi-modality imaging of glioblastoma tumor 
resection and recurrence. J. Neurooncol. 2013;111(2):153-61. doi:10.1007/s11060-012-1008-z. 
501.  Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and 
conceptual framework. Clin. Pharmacol. Ther. 2001;69(3):89-95. doi:10.1067/mcp.2001.113989. 
214 
502. Group F-NBW. BEST (Biomarkers, EndpointS, and Other Tools) Resource. Food and Drug Administration
(US); 2016. 
503. Skwarski M, Higgins GS. A new roadmap to improve translation of imaging biomarkers. Br. J. Cancer 
2016;115(12):1443-1444. doi:10.1038/bjc.2016.374. 
504. Ussui VM, Wallace MB, Ussui VM, Wallace MB. Confocal Endomicroscopy of Colorectal Polyps.
Gastroenterol. Res. Pract. 2012;2012:1-6. doi:10.1155/2012/545679. 
505. Yeh AT, Choi B, Nelson JS, Tromberg BJ. Reversible Dissociation of Collagen in Tissues. J. Invest. Dermatol. 
2003;121(6):1332-1335. doi:10.1046/j.1523-1747.2003.12634.x. 
506. Genina E a., Bashkatov AN, Tuchin V V. Glucose-Indused Optical Clearing Effects in Tissues and Blood.
Handb. Opt. Sens. Glucose Biol. Fluids Tissues Ser. Med. Phys. Biomed. Eng. 2009:657-692. 
507. Wilson CM, Gaber MW, Sabek OM, Zawaski J a, Merchant TE. Radiation-induced astrogliosis and blood-
brain barrier damage can be abrogated using anti-TNF treatment. Int. J. Radiat. Oncol. Biol. Phys. 
2009;74(3):934-41. doi:10.1016/j.ijrobp.2009.02.035. 
508. Badr C. Bioluminescence imaging in glioblastoma: monitoring of biological processes and novel
therapeutics. In: PhD Thesis.; 2010:10-29. 
509. Hyare H, Thust S, Rees J. Advanced MRI Techniques in the Monitoring of Treatment of Gliomas. Curr. Treat. 
Options Neurol. 2017;19(3):11. doi:10.1007/s11940-017-0445-6. 
510. Lombard A, Goffart N, Rogister B, Lombard A, Goffart N, Rogister B. Glioblastoma Circulating Cells: Reality, 
Trap or Illusion? Stem Cells Int. 2015;2015:182985. doi:10.1155/2015/182985. 
511. Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic
inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 2012;109(31):E2110-6. 
doi:10.1073/pnas.1209414109. 
512. Best MG, Sol N, Kooi I, et al. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, 
Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell 2015;28(5):666-676. 
doi:10.1016/j.ccell.2015.09.018. 
513. Saadatpour L, Fadaee E, Fadaei S, et al. Glioblastoma: exosome and microRNA as novel diagnosis
biomarkers. Cancer Gene Ther. 2016;23(12):415-418. doi:10.1038/cgt.2016.48. 
514. Lamb LS, Bowersock J, Dasgupta A, et al. Engineered drug resistant γδ T cells kill glioblastoma cell lines
during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PLoS One 
2013;8(1):e51805. doi:10.1371/journal.pone.0051805. 
515. Schuster M, Nechansky A, Kircheis R. Cancer immunotherapy. Biotechnol. J. 2006;1(2):138-147. 
doi:10.1002/biot.200500044. 
516. Kindy MS, Yu J, Zhu H, Smith MT, Gattoni-Celli S. A therapeutic cancer vaccine against GL261 murine
glioma. J. Transl. Med. 2016;14(1):1. doi:10.1186/s12967-015-0757-9. 
517. Renner DN, Malo CS, Jin F, Parney IF, Pavelko KD, Johnson AJ. Improved Treatment Efficacy of
Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model.
Neurotherapeutics 2016;13(1):226-236. doi:10.1007/s13311-015-0407-1. 
518. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating Tumor Antigens into Cancer Vaccines. 
Clin. Vaccine Immunol. 2011;18(1):23-34. doi:10.1128/CVI.00286-10. 
519. Sampson JH, Mitchell DA. Vaccination strategies for neuro-oncology. Neuro. Oncol. 2015;17 Suppl 7(suppl 
7):vii15-vii25. doi:10.1093/neuonc/nov159. 
520. Zeng J, See AP, Phallen J, et al. Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival 
in Mice With Intracranial Gliomas. Int. J. Radiat. Oncol. 2013;86(2):343-349. 
doi:10.1016/j.ijrobp.2012.12.025. 
521. Hardcastle J, Mills L, Malo CS, et al. Immunovirotherapy with measles virus strains in combination with
anti–PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro. Oncol. 
2016:now179. doi:10.1093/neuonc/now179. 
522. Wainwright DA, Chang AL, Dey M, et al. Durable Therapeutic Efficacy Utilizing Combinatorial Blockade
against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors. Clin. Cancer Res. 2014;20(20):5290-5301. 
doi:10.1158/1078-0432.CCR-14-0514. 
523. Verheije MH, Lamfers MLM, Wurdinger T, et al. Coronavirus Genetically Redirected to the Epidermal
Growth Factor Receptor Exhibits Effective Antitumor Activity against a Malignant Glioblastoma. J. Virol. 
2009;83(15):7507-7516. doi:10.1128/JVI.00495-09. 
524. Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front. Biosci. 
2008;13:2060-4. 
REFERENCES 
215 
 
525.  Andreansky S, Soroceanu L, Flotte ER, et al. Evaluation of genetically engineered herpes simplex viruses 
as oncolytic agents for human malignant brain tumors. Cancer Res. 1997;57(8):1502-9. 
526.  Shah AH, Bregy A, Heros DO, Komotar RJ, Goldberg J. Dendritic cell vaccine for recurrent high-grade 
gliomas in pediatric and adult subjects: clinical trial protocol. Neurosurgery 2013;73(5):863-7. 
doi:10.1227/NEU.0000000000000107. 
527.  Bregy A, Wong TM, Shah AH, Goldberg JM, Komotar RJ. Active immunotherapy using dendritic cells in the 
treatment of glioblastoma multiforme. Cancer Treat. Rev. 2013;39(8):891-907. 
doi:10.1016/j.ctrv.2013.05.007. 
528.  Miao H, Choi BD, Suryadevara CM, et al. EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to 
and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma. 
Castro MG, ed. PLoS One 2014;9(4):e94281. doi:10.1371/journal.pone.0094281. 
529.  Gras Navarro A, Kmiecik J, Leiss L, et al. NK Cells with KIR2DS2 Immunogenotype Have a Functional 
Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival. J. Immunol. 
2014;193(12):6192-6206. doi:10.4049/jimmunol.1400859. 
530.  Polyzoidis S, Ashkan K. DCVax®-L—Developed by Northwest Biotherapeutics. Hum. Vaccin. Immunother. 
2014;10(11):3139-3145. doi:10.4161/hv.29276. 
531.  Jarry U, Chauvin C, Joalland N, et al. Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells 
efficiently control the development of human glioblastoma brain tumors. Oncoimmunology 
2016;5(6):e1168554. doi:10.1080/2162402X.2016.1168554. 
532.  Immuno therapy. Available at: www.cancerresearch.org. Accessed December 1, 2016. 
533.  McMahon EJ, Bailey SL, Miller SD. CNS dendritic cells: Critical participants in CNS inflammation? 
Neurochem. Int. 2006;49(2):195-203. doi:10.1016/j.neuint.2006.04.004. 
534.  Huang L, Xu X, Hao Y. The possible mechanisms of tumor progression via CSF-1/CSF-1R pathway activation. 
Rom J Morphol Embryol 2014;55(2):501-506. 
535.  Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev. 
Neurother. 2009;9(10):1519-1527. doi:10.1586/ern.09.99. 
536.  Avan A, Caretti V, Funel N, et al. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven 
pancreatic carcinoma. Cancer Res. 2013;73(22):6745-6756. doi:10.1158/0008-5472.CAN-13-0837. 
 
 
 
216 
 217 
 
ADDENDA | 
CURRICULUM VITAE 
218 
CURRICULUM VITAE 
219 
 
        ____________________________________ 
Tonny Lagerweij is geboren op 10 december 1971 
te Lunteren, gemeente Ede. Zijn jeugd heeft hij 
doorgebracht in het bosrijke Bennekom, waar hij 
zijn lagere school heeft gevolgd op de 
Nassauschool. In 1989 behaalde hij zijn H.A.V.O.-
diploma aan het Christelijk Streeklyceum Ede. In datzelfde jaar begon hij zijn studie H.L.O. 
Biotechnologie aan de Hogeschool Gelderland in Arnhem en Nijmegen.  
Met behulp van een verkregen Erasmus beurs, heeft hij zijn stage/afstudeeropdracht kunnen 
verrichten in het buitenland bij Zeneca Bioproducts in Billingham, Engeland, onder 
begeleiding van dr. Ian Hodgson.  Aansluitend aan het verkrijgen van zijn H.L.O. diploma 
(1993) is hij Biomedische Gezondheidswetenschappen -met als specialisatie toxicologie- 
gaan studeren aan de Katholieke Universiteit Nijmegen. In het kader van zijn 
doctoraalexamen heeft hij zijn afstudeeropdracht gedaan bij de afdeling Longziekten van het 
St. Radboud Ziekenhuis Nijmegen onder supervisie van dr. Pascal Wielders. Tijdens deze 
studie heeft hij zijn aantekening proefdierdeskundige (ex. Art. 9 van de Wet op Dierproeven) 
behaald. Zijn doctoraal heeft hij in 1996 afgerond. 
Van 1997 tot 2000 was hij werkzaam als Research Scientist en Quality Assurance Deputy bij 
de startup van het bedrijf Future Diagnostics in Wijchen. Dit bedrijf stond onder leiding van 
Frans Rosmalen en Mike Martens. Bij Future Diagnostics heeft hij zijn aantekening Internal 
Quality Auditor bij Llods Register in 1997 gehaald en vervolgens het ISO9001-
kwaliteitssysteem bij dit bedrijf mede vormgegeven.  
In 2000 verhuisde hij naar de Randstad en vervolgde zijn carrière in Leiden bij TNO Kwaliteit 
van Leven, afdeling Immunologische en Infectieziekten, onder leiding van Lex Nagelkerken. 
Tijdens zijn werkzaamheden bij TNO, heeft hij zijn certificaat International Project 
Management (IPMA-D) in 2008 behaald. Hij heeft met name gewerkt aan onderzoek naar 
auto-immuunziektes zoals multiple sclerosis en psoriasis en verschillende diermodellen 
opgezet voor chronische darmontstekingen.  
Na 10 jaar met veel plezier bij TNO gewerkt te hebben, veranderde hij in 2010 van werkplek 
en ging werken bij de Neuro-oncologische Research Group van het VUmc te Amsterdam. Na 
eerst vier jaar als research technician gewerkt te hebben aan preklinisch onderzoek naar de 
vorming en behandeling van hersentumoren, is hij in 2014 gestart als promovendus en heeft 
hij in het lab van prof.dr. Tom Wurdinger het in dit proefschrift beschreven onderzoek 
verricht.  
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Het is gedaan! Het werk van bijna vier jaar onderzoek is gebundeld in een boekje en nu kan 
ik het gedeelte gaan schrijven dat wel door iedereen gelezen wordt. Want dit proefschrift 
was niet tot stand gekomen zonder de hulp en steun van een groot aantal mensen. Enkelen 
wil ik hier bij naam noemen. 
 
Allereerst wil ik natuurlijk mijn begeleider en promotor, prof. dr. Wurdinger bedanken. Tom, 
jouw optimisme, enthousiasme en enorme gedrevenheid werken bijzonder stimulerend. 
Besprekingen met jou leveren altijd vele nieuwe ideeën op, waarvan sommigen zelfs 
uitvoerbaar blijken. Deze positieve insteek heeft er dan ook mede aan bijgedragen dat ik 
alsnog de stap heb gezet om een promotietraject te starten. 
 
Ook mijn copromotor, dr, Esther Hulleman, wil ik graag bedanken voor alle hulp de 
afgelopen jaren. Esther, al voor mijn promotietraject begon onze samenwerking met de 
DIPG projecten. Maar gelukkig hebben we ook tijdens mijn AIO-schap nog samen kunnen 
werken en hopelijk blijft dat ook nog zo na mijn promotie. 
. 
Dr. Noske en prof.dr. Vandertop: Bedankt voor jullie kritische noten bij de manuscripten en 
voor alle hulp bij de organisatorische aspecten die zijn komen kijken bij de afronding van dit 
proefschrift. 
 
Ook wil ik de leden van de leescommissie, prof.dr. Van Dongen, prof.dr. Van Noorden, 
prof.dr. Van Beusechem, dr. Wolf en dr. Walenkamp, bedanken voor het aandachtig lezen 
van alle hoofdstukken. Ik kijk uit naar de dag van de promotie, waarop ik met u van 
gedachten kan wisselen over de inhoud van dit proefschrift. 
 
Nadat ik mijn werkzame leven begonnen ben bij Future Diagnostics, en vervolgens bij TNO, 
ben ik in 2010, via een sollicitatiegesprek met Jacqueline Cloos,  als analist begonnen bij de 
Neuro-oncologische researchgroep (NRG). Viola Caretti tried to convince me that I should 
become a doctor, but only after she had left I realized that she was correct. Viola, thanks a 
lot for the nice cooperation during your PhD; and for the fact that you always believed in 
my capacities. And it was an honor to be, together with Marc, your paranymph during your 
promotion.  
 
Tijdens mijn periode bij de NRG was het een komen-en-gaan van AIOs en analisten. Ik denk 
hierbij vooral aan Michiel, Jolien, Ravi, Magda, Dennis, Pepijn, Marcel, Sjoerd, Lotte, Dannis, 
Sharyar, Susanna. Voor de meeste van jullie was de NRG een leuke begin, maar hopelijk 
heeft jullie carrière hierna een echte start gemaakt. 
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Maar ook verschillende postdocs zijn er gepasseerd tijdens mijn verblijf bij de NRG: Petra, 
bedankt dat je vanuit je huidige functie bij de HLO Leiden nog regelmatig nieuwe studenten 
bij ons aanbeveelt. Jordi, and Xi Wen: Such a pity that you have left. We still have to get at 
least one manuscript published, but I hope that even after that we will find a way to 
continue our work together.  
Nik, Myron, Ravi en Lot; Al zijn jullie al vertrokken uit de AIO-kamer, gelukkig komen jullie 
zo af-en-toe nog wel eens langs. Meestal voor borrels, of als er gebak te halen is, maar het 
is in ieder geval altijd gezellig als jullie er zijn. 
Veel van mijn studies zijn voor een groot deel uitgevoerd in locaties buiten het Cancer 
Center Amsterdam. Heel veel tijd heb ik doorgebracht in het RNC. Marijke, Mariska en 
Ricardo waren altijd zeer betrokken bij het welzijn van de dieren. Carla, heeft de organisatie 
van de dierfaciliteit altijd strak in handen gehouden. Tjaard, Gertrude, en de technische 
dienst, met name Fred waren altijd in de buurt als er een probleem opgelost moest worden. 
Maar ook heb ik vrij veel tijd doorgebracht bij de microscopen op het MCBI. Esther, Nanne, 
Jasper, Elga, Jeroen en René hebben me daarbij geholpen met het regelen van toegang tot 
de apparatuur, het instellen van de apparatuur, en met z’n allen hebben we heel veel tijd 
gestoken in het verkrijgen van schitterende microscopische opnames en de analyses 
achteraf.  
Behalve aan de mensen binnen de VU, ben ik ook veel dank verschuldigd aan een groot 
aantal mensen buiten de VU met wie ik heb mogen samenwerken zoals Olaf van Tellingen 
en Mark de Gooijer van het NKI, jullie input was altijd geweldig, zowel qua discussies als met 
alle hulp wanneer ik weer eens iets nodig had; William Leenders, Kiek Verrijp en Anneke 
Navis van het Radboud UMC, Timo ten Hagen van het Erasmus MC. And of course I would 
also would like to thank Bakhos Tannous, for his help on many of our projects. 
Alhoewel mijn proefschrift toegespitst is op hersentumoren, heb ik ook mogen bijdragen 
aan andere research projecten. Eén van de eerst samenwerkingen was in een project gericht 
tegen pancreas tumoren. Elisa, Amir, Rocco, Tessa, it was great to work with you. I was 
always amazed how quickly you were able to organize the projects and finish a paper. 
Another nice collaboration was (and still is) the work on osteosarcoma and extracellular 
vesicles together with Rubina, Maria and Michiel.  Furthermore, I had the pleasure to join a 
project on gingiva together with Adriano, Mo, and Ron. From this project I learned especially 
how nice it is to present your work for an international audience. En ook ben ik blij dat ik 
heb mogen meewerken aan een prostaatkanker project waarbij onder anderen Irene, 
Jasmina en Ab betrokken waren.  
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En nu ga ik dan ook nog toekomen aan mijn huidige, zeer gewaardeerde collega’s. Ten 
eerste natuurlijk Laurine, je organisatie skills zijn onovertroffen, maar ik denk dat vooral het 
feit dat je altijd voor iedereen klaar staat zorgt dat de NRG zo’n hechte club blijft. Piotr, 
fantastisch zoals jij ook altijd alles weet te plannen en klaar staat om alle collega’s van advies 
en hulp te voorzien.  Ed, Heleen, Francios, Aniska, heel erg bedankt voor jullie hulp in het 
lab en de vele verhalen tijdens de lunch. Ida, Jasmina, Wen, Terki, Maxime. Jullie waren 
geweldige buren op de derde verdieping. 
 
Bart en Dani, bedankt voor al jullie support bij het opstellen van mijn eerste 
subsidieaanvragen. Nog niet succesvol, maar dat lag zeker niet aan jullie. Pieter¸ dank voor 
al je kritische noten bij de histologische beoordeling van de verschillende preparaten. Ik heb 
hier veel van geleerd.  
 
Mijn huidige kamergenoten: Chantal, Sjors, Mo, Rianne, Dennis, Adrienne, en Hans. 
Wetenschappelijke discussie met jullie starten vaak op een hoog niveau, en zakken dan snel 
af tot een gesprek waarin ik ook kan meepraten. Door jullie was er een fantastische sfeer in 
de kamer, en tijdens de vele borrels buiten het CCA.  
 
Ook wil ik alle studenten die bij onze afdeling stage liepen, waaronder Thijs, Bart, Sophie, 
Jurrien, Lieke, Jhon, Yanyan, en Naomi, bedanken voor alle gezelligheid. En ik ben stiekem 
toch wel blij dat de meeste van jullie, ondanks mijn advies om het niet te doen, toch hebben 
gekozen voor een carrière binnen de wetenschap.  
 
Natuurlijk wil ik Hilde en Naomi bedanken dat ze mijn paranimfen willen zijn.  
 
Paps en mams, dat hadden jullie toch ook nooit kunnen bedenken dat jullie zoon nog eens 
doctor zou worden.  Bedankt voor al jullie liefde en steun.  
 
Nicolette: Door jouw onvoorwaardelijke liefde was ik in staat om dit af te ronden. Het 
schrijven van dit proefschrift kostte toch wat meer uren dan dat er in een werkdag zaten. 
Al die avonden dat ik achter de computer heb gezeten, had ik liever samen met jou 
doorgebracht. Thijs en Daan, ik hou van jullie.  
 
En dan nog iedereen die niet genoemd is, co-auteurs, medewerkers van andere afdelingen 
waar ik wel eens wat van geleend heb of mee samengewerkt heb, buren, vrienden en 
familie: Bedankt! 
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